0001077183-21-000050.txt : 20210111 0001077183-21-000050.hdr.sgml : 20210111 20210111171316 ACCESSION NUMBER: 0001077183-21-000050 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 38 CONFORMED PERIOD OF REPORT: 20210106 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210111 DATE AS OF CHANGE: 20210111 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEOGENOMICS INC CENTRAL INDEX KEY: 0001077183 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-TESTING LABORATORIES [8734] IRS NUMBER: 742897368 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35756 FILM NUMBER: 21521568 BUSINESS ADDRESS: STREET 1: 12701 COMMONWEALTH DRIVE STREET 2: SUITE 9 CITY: FORT MYERS STATE: FL ZIP: 33913 BUSINESS PHONE: 9419231949 MAIL ADDRESS: STREET 1: 12701 COMMONWEALTH DRIVE STREET 2: SUITE 9 CITY: FORT MYERS STATE: FL ZIP: 33913 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN COMMUNICATIONS ENTERPRISES INC DATE OF NAME CHANGE: 19990120 8-K 1 neo-20210106.htm 8-K neo-20210106
0001077183FALSE00010771832021-01-062021-01-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549 
 
FORM 8-K  
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
January 6, 2021
 
NEOGENOMICS, INC.
(Exact name of registrant as specified in its charter) 
 
Nevada
001-35756
74-2897368
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
 
12701 Commonwealth Drive, Suite 9,Fort Myers,Florida33913
(Address of principal executive offices)(Zip Code)
(239) 768-0600
(Registrant’s telephone number, including area code) 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Title of each classTrading SymbolName of each exchange on which registered
Common stock ($0.001 par value)NEOThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 




Item 1.01
Entry into a Material Definitive Agreement.

Common Stock Underwriting Agreement

On January 6, 2021, NeoGenomics, Inc. (the “Company”), in connection with an offering by the Company of its common stock (the “Common Stock Offering”), entered into an underwriting agreement (the “Common Stock Underwriting Agreement”) with BoA Securities, Inc., Morgan Stanley & Co. LLC, and Goldman Sachs & Co. LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the issuance and sale of 4,081,632 shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”). The price to the public in this offering was $49.00 per share and the Underwriters purchased the shares from the Company at the public offering price, less underwriting discounts and commissions of $2.45 per share. Under the terms of the Common Stock Underwriting Agreement, the Company granted the Underwriters a 30-day option to purchase up to 612,244 additional shares of Common Stock at the public offering price, less underwriting discounts and commissions. The Underwriters exercised in full their option to purchase the additional shares on January 7, 2021. The net proceeds to the Company from the Common Stock Offering are expected to be approximately $218.3 million (including proceeds from the Underwriters' exercise of their option to purchase additional shares), after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

A copy of the Common Stock Underwriting Agreement is filed as Exhibit 1.1 to this Current Report and is incorporated herein by reference. The foregoing description of the terms of the Common Stock Underwriting Agreement is qualified in its entirety by the Common Stock Underwriting Agreement.

Convertible Notes Underwriting Agreement

On January 6, 2021, the Company, in connection with an offering by the Company (the “Convertible Notes Offering” and together with the Common Stock Offering, the “Offerings”) of its 0.25% convertible senior notes due 2028 (the “Notes”), entered into an underwriting agreement (the “Convertible Notes Underwriting Agreement” and together with the Common Stock Underwriting Agreement, the “Underwriting Agreements”) with the Underwriters pursuant to which the Company agreed to issue and sell a total of $300.0 million aggregate principal amount of its Notes to the Underwriters. In addition, pursuant to the Convertible Notes Underwriting Agreement, the Underwriters were granted an option, exercisable within 30 days, to purchase up to an additional $45.0 million aggregate principal amount of the Notes on the same terms and conditions solely to cover over-allotments with respect to the Convertible Notes Offering. The Underwriters exercised in full their option to purchase the additional principal amount of Notes on January 7, 2021. The Notes were priced to investors in the Convertible Notes Offering at 100% of their principal amount, and the Underwriters purchased the Notes from the Company pursuant to the Convertible Notes Underwriting Agreement at a price of 97% of their principal amount. The net proceeds to the Company from the Convertible Notes Offering are expected to be approximately $334.5 million (including proceeds from the Underwriters' exercise of their option to purchase the additional principal amounts of Notes), after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company used a portion of the net proceeds from the Offerings to enter into capped call transactions (as described below under the heading “Capped Call Transactions”).

A copy of the Convertible Notes Underwriting Agreement is filed as Exhibit 1.2 to this Current Report and is incorporated herein by reference. The foregoing description of the terms of the Convertible Notes Underwriting Agreement is qualified in its entirety by the Convertible Notes Underwriting Agreement.

General

Copies of the Underwriting Agreements have been included to provide security holders with information regarding their terms. They are not intended to provide any other factual information about the Company. The representations, warranties and covenants contained in each Underwriting Agreement were made solely for purposes of the applicable Offering and as of specific dates, were solely for the benefit of the parties to the applicable Underwriting Agreement, may be subject to limitations agreed upon by the contracting parties, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to security holders. Security holders are not third-party beneficiaries under either Underwriting Agreement and should not rely on the representations, warranties, and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Underwriting Agreements, which subsequent information may or may not be fully reflected in the Company’s public disclosures.




The Underwriters and certain of their affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The Underwriters and certain of their affiliates have, from time to time, performed, currently are performing, and may in the future perform, various commercial and investment banking and financial advisory services for the Company and its affiliates, for which they received or will receive customary fees and expenses.

Indenture for the Notes

On January 11, 2021, the Company entered into an Indenture (the “Indenture”) with U.S. Bank National Association, as trustee (the “Trustee”), governing the Notes.

The Notes bear interest at a rate of 0.25% per annum, payable semi-annually in arrears on January 15 and July 15 of each year, beginning on July 15, 2021. The Notes mature on January 15, 2028, unless earlier repurchased or converted. Noteholders may convert their Notes at their option prior to the close of business on the business day immediately preceding September 15, 2017, only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021 (and only during such calendar quarter), if the last reported sale price of the Common Stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s Common Stock and the conversion rate on each such trading day; (3) if the Company calls any or all of the Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after September 15, 2027 until the close of business on the business day immediately preceding the maturity date, noteholders may convert their Notes at any time, regardless of the foregoing circumstances.

The conversion rate will initially be 15.1172 shares of the Common Stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $66.15 per share of Common Stock). The conversion rate will be subject to adjustment in certain events but will not be adjusted for accrued and unpaid interest. In addition, if a “make-whole fundamental change” (as defined in the Indenture) occurs or if the Company calls any Notes for redemption, then the Company will in certain circumstances increase the conversion rate for a specified period of time for holders who convert their notes in connection with such fundamental change or during the related redemption period.

The Company may not redeem the Notes prior to January 20, 2025. The Company may redeem for cash all or any portion of the Notes, at its option, on or after January 20, 2025 if the last reported sale price of its Common Stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date of notice by the Company of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes.

If the Company undergoes a “fundamental change” (as defined in Indenture), then noteholders may require the Company to repurchase their Notes at a cash repurchase price equal to the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.

The Notes are the Company’s senior, unsecured obligations and will be equal in right of payment with its existing and future senior, unsecured indebtedness, including its 1.25% convertible senior notes due 2025, senior in right of payment to its existing and future indebtedness that is expressly subordinated to the Notes and effectively junior to any existing and future secured indebtedness to the extent of the value of the collateral securing that indebtedness. The Notes will be structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, of its subsidiaries.

A copy of the Indenture is attached as Exhibit 4.1 and is incorporated herein by reference into this Item 1.01. The above description is qualified in its entirety by reference to such exhibit.

Capped Call Transactions

In connection with the Convertible Notes Offering, on January 11, 2021, the Company has entered into privately negotiated capped call transactions (collectively, the “Capped Call Transactions”) with certain of the Underwriters and/or their respective affiliates pursuant to capped call confirmations in substantially the form filed as Exhibit 10.1 to this Current Report (each a “Confirmation”). The Capped Call Transactions are expected generally to reduce the potential dilution to the Common Stock



upon any conversion of the Notes and/or offset some or all of any cash payments the Company is required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to a cap. The cap price of the Capped Call Transactions is initially $85.75 per share, which represents a premium of 75% over the public offering price of the Common Stock in the Common Stock Offering, which was $49.00 per share, and is subject to certain adjustments under the terms of the Capped Call Transactions.

The foregoing description of the Capped Call Transactions contained herein is qualified in its entirety by reference to the text of the form of Confirmation filed as Exhibit 10.1 to this Current Report and incorporated herein by reference.

Item 2.03
Creation of Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of Registrant.

The information set forth under Item 1.01 of this Current Report on Form 8-K under the heading “Indenture for the Notes” and “Capped Call Transactions” is incorporated by reference into this Item 2.03.

Item 8.01Other Events.

On January 6, 2021, the Company announced the pricing of its underwritten public offering of 4.1 million shares of its Common Stock at a public offering price of $49.00 per share and an underwritten public offering of $300 million aggregate principal amount of 0.25% Convertible Senior Notes due 2028. A copy of this press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.
Item 9.01
Financial Statements and Exhibits.
 
(d) Exhibits.

1.1 
1.2 
4.1 
4.2 
5.1 
5.2 
10.1 
23.1 
23.2 
99.1 
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
NEOGENOMICS, INC.
By:
/s/ Kathryn B. McKenzie
Kathryn B. McKenzie
Chief Financial Officer
January 11, 2021






EX-1.1 2 exhibit11underwritingagree.htm EX-1.1 Document
Exhibit 1.1
NeoGenomics, Inc.
(a Nevada corporation)
4,081,632 Shares of Common Stock
UNDERWRITING AGREEMENT
January 6, 2021
BofA Securities, Inc.
One Bryant Park
New York, New York 10036

Morgan Stanley & Co. LLC
1585 Broadway
New York, New York 10036

Goldman Sachs & Co. LLC
200 West Street
New York, New York 10282

as Representatives of the several Underwriters

Ladies and Gentlemen:
NeoGenomics, Inc., a Nevada corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA Securities”), Morgan Stanley & Co. LLC (“Morgan Stanley”) and Goldman Sachs & Co. LLC (“Goldman Sachs”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for which BofA Securities, Morgan Stanley and Goldman Sachs are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of common stock, par value $0.001 per share, of the Company (“Common Stock”) set forth in Schedule A hereto (the “Initial Securities”) and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 612,244 additional shares of Common Stock (the “Option Securities” and, together with the Initial Securities, the “Securities”).
The Company understands that the Underwriters propose to make a public offering of the Securities as soon as the Representatives deem advisable after this Underwriting Agreement (this “Agreement”) has been executed and delivered.
The Company has filed with the Securities and Exchange Commission (the “Commission”) an automatic shelf registration statement on Form S-3 (No. 333-231608), covering the public offering and sale of certain securities, including the Securities, under the Securities Act of 1933, as amended (the “1933 Act”) and the rules and regulations of the Commission promulgated thereunder (the “1933 Act Regulations”), which automatic shelf registration statement became automatically effective upon filing. The information included in such prospectus that was omitted from such registration statement at the time such registration statement became effective but that is deemed to be part of such registration statement at

    


the time it became effective under Rule 462(e) under the 1933 Act Regulations (“Rule 462(e)”). Such registration statement, as of any time, means such registration statement as amended by any post-effective amendments thereto to such time, including the exhibits and any schedules thereto at such time, the documents incorporated or deemed to be incorporated by reference therein at such time pursuant to Item 12 of Form S-3 under the 1933 Act and the documents otherwise deemed to be a part thereof as of such time pursuant to Rule 430B under the 1933 Act Regulations (“Rule 430B”), is referred to herein as the “Registration Statement;” provided, however, that the “Registration Statement” without reference to a time means such registration statement as amended by any post-effective amendments thereto as of the time of the first contract of sale for the Securities, which time shall be considered the “new effective date” of such registration statement with respect to the Securities within the meaning of paragraph (f)(2) of Rule 430B, including the exhibits and schedules thereto as of such time, the documents incorporated or deemed incorporated by reference therein at such time pursuant to Item 12 of Form S-3 under the 1933 Act and the documents otherwise deemed to be a part thereof as of such time pursuant to the Rule 430B. Each preliminary prospectus used in connection with the offering of the Securities, including the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of Form S-3 under the 1933 Act, are collectively referred to herein as a “preliminary prospectus.” Promptly after execution and delivery of this Agreement, the Company will prepare and file a final prospectus relating to the Securities in accordance with the provisions of Rule 424(b) under the 1933 Act Regulations (“Rule 424(b)”). The final prospectus, in the form first furnished or made available to the Underwriters for use in connection with the offering of the Securities, including the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of Form S-3 under the 1933 Act, are collectively referred to herein as the “Prospectus.” For purposes of this Agreement, all references to the Registration Statement, any preliminary prospectus, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval system (or any successor system) (“EDGAR”).
As used in this Agreement:
“Applicable Time” means 8:00 P.M., New York City time, on January 6, 2021 or such other time as agreed by the Company and the Representatives.
“General Disclosure Package” means any Issuer General Use Free Writing Prospectuses issued at or prior to the Applicable Time, the most recent preliminary prospectus (including any documents incorporated therein by reference) that is distributed to investors prior to the Applicable Time and the information included on Schedule B-1 hereto, all considered together.
“Issuer Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433 of the 1933 Act Regulations (“Rule 433”), including without limitation any “free writing prospectus” (as defined in Rule 405 of the 1933 Act Regulations (“Rule 405”)) relating to the Securities that is (i) required to be filed with the Commission by the Company, (ii) a “road show for an offering that is a written communication” within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Securities or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g).
“Issuer General Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors (other than a “bona fide electronic
    2
    


road show,” as defined in Rule 433 (a “Bona Fide Electronic Road Show”)), as evidenced by its being specified in Schedule B-2 hereto.
“Issuer Limited Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.
“Testing-the-Waters Communication” means any communication with potential investors undertaken in reliance on Section 5(d) or Rule 163B of the Securities Act.
All references in this Agreement to financial statements and schedules and other information which is “contained,” “included” or “stated” (or other references of like import) in the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include all such financial statements and schedules and other information incorporated or deemed incorporated by reference in the Registration Statement, any preliminary prospectus or the Prospectus, as the case may be, prior to the execution and delivery of this Agreement; and all references in this Agreement to amendments or supplements to the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include the filing of any document under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the “1934 Act”), incorporated or deemed to be incorporated by reference in the Registration Statement, such preliminary prospectus or the Prospectus, as the case may be, at or after the execution and delivery of this Agreement.
SECTION 1.Representations and Warranties.
(a)Representations and Warranties by the Company. The Company represents and warrants to each Underwriter as of the date hereof, the Applicable Time, the Closing Time (as defined below) and any Date of Delivery (as defined below), and agrees with each Underwriter, as follows:
(i) Registration Statement and Prospectuses. The Company meets the requirements for use of Form S-3 under the 1933 Act. Each of the Registration Statement and any amendment thereto has become effective under the 1933 Act. No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued by the Commission under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued by the Commission and no proceedings for any of those purposes have been instituted by the Commission or are pending or, to the Company’s knowledge, contemplated by the Commission. The Company has complied with each request (if any) from the Commission for additional information.
Each of the Registration Statement and any post-effective amendment thereto, at the time of its effectiveness and at each deemed effective date with respect to the Underwriters pursuant to Rule 430B(f)(2) under the 1933 Act Regulations, the Applicable Time, the Closing Time and any Date of Delivery complied and will comply in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus, the Prospectus and any amendment or supplement thereto, at the time each was filed with the Commission, and in each case, at the Applicable Time, the Closing Time and any Date of Delivery complied and will comply in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus delivered to the Underwriters for use in connection with the offering and the Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.
    3
    


The documents incorporated or deemed to be incorporated by reference in the Registration Statement, any preliminary prospectus and the Prospectus, when they became effective or at the time they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the 1934 Act and the rules and regulations of the Commission under the 1934 Act (the “1934 Act Regulations”).
The Registration Statement, any preliminary prospectus and the Prospectus, and the filing of the Registration Statement, any preliminary prospectus and the Prospectus with the Commission have been duly authorized by and on behalf of the Company, and the Registration Statement has been duly executed pursuant to such authorization.
(ii) Accurate Disclosure. Neither the Registration Statement nor any amendment thereto, at its effective time, on the date hereof, at the Closing Time or at any Date of Delivery, contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the Applicable Time, neither of (A) the General Disclosure Package nor (B) any individual Issuer Limited Use Free Writing Prospectus and (C) individual Written Testing-the-Waters Communication, when considered together with the General Disclosure Package, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Neither the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b), at the Closing Time or at any Date of Delivery, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, at the time the Registration Statement became effective or when such documents incorporated by reference were filed with the Commission, as the case may be, when read together with the other information in the Registration Statement, the General Disclosure Package or the Prospectus, as the case may be, did not and will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.
The representations and warranties in this subsection shall not apply to statements in or omissions from the Registration Statement (or any amendment thereto), the General Disclosure Package or the Prospectus (or any amendment or supplement thereto, including any prospectus wrapper) made in reliance upon and in conformity with written information furnished to the Company by any Underwriter through the Representatives expressly for use therein. For purposes of this Agreement, the only information so furnished shall be the following: the sixth paragraph (beginning “The representatives have advised us…”), the statements concerning stabilizing transactions and syndicate covering transactions under the caption “Underwriting—Price Stabilization, Short Positions and Penalty Bids” and the sentence under the caption “Electronic Distribution” (beginning “In connection with the offering…”) of the “Underwriting” section of the Prospectus (collectively, the “Underwriter Information”).
(iii) Issuer Free Writing Prospectuses. No Issuer Free Writing Prospectus conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including any document incorporated by reference therein, and any preliminary or other prospectus deemed
    4
    


to be a part thereof that has not been superseded or modified. No filing of any “road show” (as defined in Rule 433(h)) is required in connection with the offering of the Securities. Any Issuer Free Writing Prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the 1933 Act and the 1933 Act Regulations. Each Issuer Free Writing Prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the 1933 Act or that was prepared by or behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Except for the Issuer Free Writing Prospectuses, if any, identified in Schedule B-2 hereto, and electronic road shows, if any, each furnished to the Representatives before first use, the Company has not prepared, used or referred to, and will not, without the prior consent of the Representatives, prepare, use or refer to, any issuer free writing prospectus.
(iv) Well-Known Seasoned Issuer. (A) At the time of the most recent amendment of the Registration Statement for the purposes of complying with Section 10(a)(3) of the 1933 Act (whether such amendment was by post-effective amendment, incorporated report filed pursuant to Section 13 or 15(d) of the 1934 Act or form of prospectus), (B) at the time the Company or any person acting on its behalf (within the meaning, for this clause only, of Rule 163(c) under the 1933 Act) made any offer relating to the Securities in reliance on the exemption of Rule 163 under the 1933 Act, and (C) as of the Applicable Time, the Company was and is a “well-known seasoned issuer” (as defined in Rule 405).
(v) Company Not Ineligible Issuer. At the time of filing the Registration Statement and any post-effective amendments thereto, at the earliest time thereafter that the Company or another offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) of the 1933 Act Regulations) of the Securities and at the date hereof, the Company was not and is not an “ineligible issuer,” as defined in Rule 405, without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible issuer.
(vi) Independent Accountants. Each of the accountants who certified the financial statements and supporting schedules included in or incorporated by reference into the Registration Statement, the General Disclosure Package and the Prospectus are independent public accountants as required by the 1933 Act, the 1933 Act Regulations, the 1934 Act, the 1934 Act Regulations and the Public Company Accounting Oversight Board (United States).
(vii) Financial Statements; Non-GAAP Financial Measures. The financial statements included or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, together with the related schedules and notes, comply as to form in all material respects with Regulation S-X under the 1933 Act and present fairly, in all material respects, the financial position of the Company and its consolidated Subsidiaries (as defined below) at the dates indicated and the statement of operations, stockholders’ equity and cash flows of the Company and its consolidated Subsidiaries for the periods specified; said financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) applied on a consistent basis throughout the periods involved, except, in the case of unaudited, interim financial statements, subject to normal year-end adjustments. The supporting schedules, if any, present fairly, in all material respects, in accordance with GAAP the information required to be stated therein. The selected financial data and the summary financial information included in the Registration Statement, the General Disclosure Package and the
    5
    


Prospectus present fairly, in all material respects, the information shown therein and have been compiled on a basis consistent with that of the audited financial statements included therein. Except as included therein, no other historical or pro forma financial statements or supporting schedules are required to be included or incorporated by reference in the Registration Statement, the General Disclosure Package or the Prospectus under the 1933 Act or the 1933 Act Regulations. All disclosures contained in the Registration Statement, the General Disclosure Package or the Prospectus, or incorporated by reference therein, regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the Commission) comply with Regulation G of the 1934 Act, and Item 10 of Regulation S-K, to the extent applicable. The interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto.
(viii) Compliance with the Sarbanes-Oxley Act of 2002. There is and has been no failure on the part of the Company or any of the Company’s directors or officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith, including Section 402 related to loans and Sections 302 and 906 related to certifications.
(ix) No Material Adverse Change in Business. Except as otherwise stated therein, since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, (A) there has been no material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its Subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business (a “Material Adverse Effect”), (B) there have been no transactions entered into by the Company or its Subsidiaries, other than those in the ordinary course of business, which are material with respect to the Company and its Subsidiaries considered as one enterprise, (C) there have been no material liabilities or obligations, direct or contingent, entered into by the Company or any of its Subsidiaries and (D) there has been no dividend or distribution of any kind declared, paid or made by the Company on any class of its capital stock.
(x) Good Standing of the Company. The Company has been duly organized and is validly existing as a corporation in good standing under the laws of the State of Nevada and has corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and to enter into and perform its obligations under this Agreement; and the Company is duly qualified as a foreign corporation to transact business and is in good standing in each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified or to be in good standing would not result in a Material Adverse Effect.
(xi) Good Standing of the Company’s Subsidiaries. Each subsidiary of the Company (collectively, the “Subsidiaries”) has been duly organized and is validly existing in good standing under the laws of the jurisdiction of its incorporation or organization, has corporate or similar power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct
    6
    


of business, except where the failure to be so qualified or to be in good standing would not result in a Material Adverse Effect. Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, all of the issued and outstanding capital stock of each Subsidiary has been duly authorized and validly issued, is fully paid and non-assessable and is owned by the Company, directly or through Subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance, claim or equity. None of the outstanding shares of capital stock of any Subsidiary was issued in violation of the preemptive or similar rights of any securityholder of such Subsidiary. The only Subsidiaries are the entities listed on Exhibit 21 to the Company’s annual report on Form 10-K, as amended.
(xii) Capitalization. The authorized, issued and outstanding shares of capital stock of the Company are as set forth in the Registration Statement, the General Disclosure Package and the Prospectus. The outstanding shares of capital stock of the Company have been duly authorized and are validly issued, fully paid and non-assessable. None of the outstanding shares of capital stock of the Company was issued in violation of the preemptive or other similar rights of any securityholder of the Company.
(xiii) Authorization of Agreement. This Agreement has been duly authorized, executed and delivered by the Company.
(xiv) Authorization and Description of Securities. The Securities to be purchased by the Underwriters from the Company have been duly authorized for issuance and sale to the Underwriters pursuant to this Agreement and, when issued and delivered by the Company pursuant to this Agreement against payment of the consideration set forth herein, will be validly issued and fully paid and non-assessable; and the issuance of the Securities is not subject to the preemptive or other similar rights of any securityholder of the Company. The Common Stock conforms in all material respects to all statements relating thereto contained in the Registration Statement, the General Disclosure Package and the Prospectus and such description conforms in all material respects to the rights set forth in the instruments defining the same. No holder of Securities will be subject to personal liability by reason of being such a holder.
(xv) Registration Rights. There are no persons with registration rights or other similar rights to have any securities registered for sale pursuant to the Registration Statement or otherwise registered for sale or sold by the Company under the 1933 Act pursuant to this Agreement, other than those rights that have been disclosed in the Registration Statement, the General Disclosure Package and the Prospectus and have been waived.
(xvi) Absence of Violations, Defaults and Conflicts. Neither the Company nor any Subsidiary is (A) in violation of its charter, by-laws or similar organizational document, (B) in default in the performance or observance of any obligation, agreement, covenant or condition contained in any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument to which the Company or any Subsidiary is a party or by which either of them may be bound or to which any of the properties or assets of the Company or any Subsidiary is subject (collectively, “Agreements and Instruments”), except for such defaults that would not, singly or in the aggregate, result in a Material Adverse Effect, or (C) in violation of any law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental body, regulatory body, administrative agency or other authority, body or agency having jurisdiction over the Company or its Subsidiaries or any of their respective properties, assets or operations (each, a “Governmental Entity”), except for such violations that would not,
    7
    


singly or in the aggregate, result in a Material Adverse Effect. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated herein and in the Registration Statement, the General Disclosure Package and the Prospectus (including the issuance and sale of the Initial Securities and the Option Securities and the use of the proceeds from the sale of the Initial Securities and the Option Securities as described therein under the caption “Use of Proceeds”) and compliance by the Company with its obligations hereunder have been duly authorized by all necessary corporate action and do not and will not, whether with or without the giving of notice or passage of time or both, conflict with or constitute a breach of, or default or Repayment Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any properties or assets of the Company or its Subsidiaries pursuant to, the Agreements and Instruments (except for such conflicts, breaches, defaults or Repayment Events or liens, charges or encumbrances that would not, singly or in the aggregate, result in a Material Adverse Effect), nor will such action result in any violation of the provisions of the charter, by-laws or similar organizational document of the Company or its Subsidiaries or any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Entity. As used herein, a “Repayment Event” means any event or condition which gives the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or its Subsidiaries.
(xvii) Absence of Labor Dispute. No labor dispute with the employees of the Company or its Subsidiaries exists or, to the knowledge of the Company, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or its Subsidiaries’ principal suppliers, manufacturers, customers or contractors, which, in either case, would result in a Material Adverse Effect.
(xviii) Absence of Proceedings. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, there is no action, suit, proceeding, inquiry or investigation before or brought by any Governmental Entity (including, without limitation, any action, suit proceeding, inquiry or investigation before or brought by the U.S. Food and Drug Administration (the “FDA”)) now pending or, to the knowledge of the Company, threatened, against or affecting the Company or its Subsidiaries, which would reasonably be expected to result in a Material Adverse Effect, or which would reasonably be expected to materially and adversely affect (A) the possession by any of them of any Governmental Licenses (as defined herein) currently held by any of them, (B) the accreditation of any of their respective laboratories with the College of American Pathologists (“CAP”), (C) any of their qualification to perform services for and receive reimbursement from, Medicaid or Medicare, (D) any of their ability to conduct their clinical testing business in any state or (E) their respective properties or assets or the consummation of the transactions contemplated in this Agreement or the performance by the Company of its obligations hereunder; and the aggregate of all pending legal or governmental proceedings to which the Company or any such Subsidiary is a party or of which any of their respective properties or assets is the subject which are not described in the Registration Statement, the General Disclosure Package and the Prospectus, including ordinary routine litigation incidental to the business, would not reasonably be expected to result in a Material Adverse Effect.
(xix) Accuracy of Exhibits. There are no contracts or documents which are required to be described in the Registration Statement, the General Disclosure Package or the Prospectus or to
    8
    


be filed as exhibits to the Registration Statement which have not been so described and filed as required.
(xx) Absence of Further Requirements. No filing with, or authorization, approval, consent, license, order, registration, qualification or decree of, any Governmental Entity is necessary or required for the performance by the Company of its obligations hereunder, in connection with the offering, issuance or sale of the Securities hereunder or the consummation of the transactions contemplated by this Agreement, except such as have been already obtained or as may be required under the 1933 Act, the 1933 Act Regulations, the rules of the NASDAQ Stock Market LLC, state securities laws or the rules of FINRA.
(xxi) Possession of Licenses and Permits. The Company and its Subsidiaries possess such permits, licenses, approvals, consents and other authorizations required (i) under the Medicare and Medicaid programs, (ii) under the Clinical Laboratories Improvement Act of 1967, as amended (“CLIA”) and (iii) as otherwise necessary to conduct the business now operated by them respectively, issued by United States Centers for Medicare and Medicaid Services (“CMS”), the FDA and each other appropriate federal, state, local or foreign regulatory agencies or bodies including, but not limited to, any foreign regulatory authorities performing functions similar to their respective functions (collectively, “Governmental Licenses”) issued by the appropriate Governmental Entities necessary to conduct the business now operated by them, except where the failure so to possess would not, singly or in the aggregate, result in a Material Adverse Effect. The Company and its Subsidiaries are in compliance with the terms and conditions of all Governmental Licenses, except where the failure so to comply would not, singly or in the aggregate, result in a Material Adverse Effect. All of the Governmental Licenses are valid and in full force and effect, except when the invalidity of such Governmental Licenses or the failure of such Governmental Licenses to be in full force and effect would not, singly or in the aggregate, result in a Material Adverse Effect. Neither the Company nor its Subsidiaries has received any notice of proceedings relating to the revocation or modification of any Governmental Licenses which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Effect, and nor are there, to the knowledge of the Company, any pending or threatened actions, suits, claims or proceedings against the Company or any subsidiary before any court, governmental agency or body including, but not limited to, CMS and the FDA or otherwise that would reasonably be expected to limit, revoke, cancel, suspend or cause not to be renewed any Governmental Licenses, in each case, which would result in a Material Adverse Effect.
(xxii) Title to Property. The Company and its Subsidiaries have good and marketable title to all real property owned by them and good title to all other properties owned by them, in each case, free and clear of all mortgages, pledges, liens, security interests, claims, restrictions or encumbrances of any kind except such as (A) are described in the Registration Statement, the General Disclosure Package and the Prospectus or (B) do not, singly or in the aggregate, materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company or its Subsidiaries; and all of the leases and subleases material to the business of the Company and its Subsidiaries, considered as one enterprise, and under which the Company or its Subsidiaries holds properties described in the Registration Statement, the General Disclosure Package or the Prospectus, are in full force and effect, and neither the Company nor any such Subsidiary has any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or any Subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the
    9
    


Company or such Subsidiary to the continued possession of the leased or subleased premises under any such lease or sublease.
(xxiii) Title to Intellectual Property.  Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, the Company and its Subsidiaries own or have valid, binding and enforceable licenses or other rights under any and all patents, licenses, inventions, copyrights, know how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade names and all other similar intellectual property or proprietary rights throughout the world (including all registrations and applications for registration of, and all goodwill associated with, the foregoing), necessary for, or used in, the conduct, or the proposed conduct, of the business of the Company and its Subsidiaries in the manner described in the Registration Statement, the General Disclosure Package and the Prospectus (collectively, the “Intellectual Property”); the Intellectual Property is valid, enforceable, and subsisting and is owned free and clear of all liens, encumbrances, defects and other restrictions; other than as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, (A) the Company and its Subsidiaries are not obligated to pay a material royalty, grant a license to, or provide other material consideration to any third party in connection with the Intellectual Property, (B) the Company and its Subsidiaries have not received any notice of any claim of infringement, misappropriation or other violation with any rights of others with respect to any of the Company’s products, services, processes or Intellectual Property, (C) neither the sale nor use of any of the discoveries, inventions, products, services or processes of the Company or any Subsidiary referred to in the Registration Statement, the General Disclosure Package or the Prospectus do or will infringe, misappropriate or otherwise violate any rights of any third party, (D) none of the technology employed by the Company has been obtained or is being used by the Company in material violation of any contractual obligation binding on the Company or any of its officers, directors or employees or otherwise in violation of the rights of any persons, (E) no third party has any ownership right in or to any Intellectual Property that is owned by the Company or any Subsidiary, other than any co-owner of any patent constituting Intellectual Property who is listed on the records of the U.S. Patent and Trademark Office (the “USPTO”) and any co-owner of any patent application constituting Intellectual Property who is named in such patent application, and, to the knowledge of the Company, no third party has any ownership right in or to any Intellectual Property in any field of use that is exclusively licensed to the Company or a Subsidiary, other than any licensor to the Company of such Intellectual Property, (F) to the knowledge of the Company, there is no infringement by third parties of any Intellectual Property, (G) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others (x) challenging the Company’s or any Subsidiary’s rights in or to any Intellectual Property, (y) challenging the ownership, validity, enforceability or scope of any Intellectual Property, or (z) alleging that the Company or any Subsidiary has infringed, misappropriated or otherwise violated any rights of any third party, and in the case of each of (x), (y) and (z), the Company is not aware of any facts that would form a reasonable basis for any such action, suit, proceeding or claim, (H) the Company and its Subsidiaries have at all times taken all reasonable steps in accordance with normal industry practice to maintain the confidentiality of all Intellectual Property, the value of which to the Company is contingent upon maintaining the confidentiality thereof, and (I) all founders, current and former employees, contractors, consultants and other parties involved in the development of the Intellectual Property have signed valid and enforceable confidentiality and invention assignment agreements with the Company or a Subsidiary pursuant to which the Company or a Subsidiary has obtained ownership and is the exclusive owner of such Intellectual Property.  The Company and its Subsidiaries are in compliance with the terms of each
    10
    


agreement pursuant to which Intellectual Property has been licensed to the Company or a Subsidiary, and all such agreements are in full force and effect.
(xxiv) Patents and Patent Applications.  All patents and patent applications owned by or, to the knowledge of the Company, licensed to the Company and its Subsidiaries, or under which the Company or any Subsidiary otherwise has rights, have been duly and properly filed and maintained; the parties prosecuting the patent applications owned by or, to the knowledge of the Company, licensed to the Company or any of its Subsidiaries, have complied with their duty of candor and disclosure to the USPTO in connection with such applications; and the Company is not aware of any facts required to be disclosed to the USPTO that were not disclosed to the USPTO and which would preclude the grant of a patent in connection with any such application or would reasonably be expected to form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications.  All patents and patent applications owned by the Company and its Subsidiaries and filed with the USPTO or any foreign or international patent authority (the “Company Patent Rights”) and, to the Company’s knowledge, all patents and patent applications in-licensed by the Company and its Subsidiaries and filed with the USPTO or any foreign or international patent authority (the “In-licensed Patent Rights”) have been duly and properly filed; the Company and its Subsidiaries have complied with their duty of candor and disclosure to the USPTO for the Company Patent Rights and, to the Company’s knowledge, the licensors of the In-licensed Patent Rights have complied with their duty of candor and disclosure to the USPTO for the In-licensed Patent Rights.
(xxv) FDA Compliance. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, the Company: (A) is and at all times has been in material compliance with all statutes, rules or regulations of the FDA and other comparable Governmental Entities applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed by the Company (“Applicable Laws”); (B) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA or any Governmental Authority alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”); (C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and the Company is not in material violation of any term of any such Authorizations; (D) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any Governmental Authority or third party alleging that any product operation or activity is in material violation of any Applicable Laws or Authorizations and has no knowledge that the FDA or any Governmental Authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (E) has not received notice that the FDA or any Governmental Authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has no knowledge that the FDA or any Governmental Authority is considering such action; and (F) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission).
    11
    


(xxvi) Licensing and Accreditation of Laboratories. All of the regional laboratories of the Company and its subsidiaries are eligible for accreditation by CAP and are so accredited, and all of the laboratories of the Company and the Subsidiaries are in compliance, in all material respects, with the standards required by CLIA. Except as disclosed in the General Disclosure Package or as would not reasonably be expected to have a Material Adverse Effect, since January 1, 2015, the Company and its subsidiaries have not had any clinical laboratory test that it performs (“Test”) or laboratory site (whether Company-owned, or Company subsidiary-owned subject to a governmental authority (including the FDA) shutdown, and to the Company’s knowledge, neither the FDA nor any other governmental authority is considering such action.
(xxvii) Safety Notices. Except as would not reasonably be expected to have a Material Adverse Effect, (i) there have been no recalls, field notifications, field corrections, market withdrawals or replacements, warnings, “dear doctor” letters, investigator notices, safety alerts or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Company’s Tests (collectively, “Safety Notices”) since January 1, 2015, (ii) such Safety Notices, if any, were resolved or closed, and (iii) to the Company’s knowledge, there are no material complaints with respect to the Company’s Tests that are currently unresolved; to the Company’s knowledge, there are no facts that would be reasonably likely to result in (x) a material Safety Notice with respect to the Company’s Test candidates, (y) a material change in labeling of any the Company’s Tests, or (z) a termination or suspension of marketing or performing of any of the Company Tests;
(xxviii) Compliance with Health Care Laws. The Company has operated and currently is in compliance with all applicable health care laws, rules and regulations (except where such failure to operate or non-compliance would not, singly or in the aggregate, result in a Material Adverse Effect), including, without limitation, (i) the Federal, Food, Drug and Cosmetic Act (21 U.S.C. §§ 301 et seq.); (ii) all applicable federal, state, local and all applicable foreign healthcare related fraud and abuse laws, including, without limitation, the federal Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)), the U.S. Physician Payments Sunshine Act (42 U.S.C. § 1320a-7h), the civil False Claims Act (31 U.S.C. §§ 3729 et seq.), the criminal False Claims Law (42 U.S.C. § 1320a-7b(a)), all criminal laws relating to healthcare fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287, the healthcare fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) (42 U.S.C. Section 1320d et seq.), the exclusion laws (42 U.S.C. § 1320a-7), Section 1877 of the Social Security Act (42 U.S.C. 1395nn), and the civil monetary penalties law (42 U.S.C. § 1320a-7a); (iii) HIPAA, as amended by the Health Information Technology for Economic Clinical Health Act (42 U.S.C. Section 17921 et seq.); (iv) the regulations promulgated pursuant to such laws; and (v) any other similar local, state, federal, or foreign laws (collectively, the “Health Care Laws”). Neither the Company, nor to the Company’s knowledge, any of its officers, directors, employees or agents have engaged in activities which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other state or federal healthcare program. The Company has not received written notice or other correspondence of any claim, action, suit, audit, survey, proceeding, hearing, enforcement, investigation, arbitration or other action (“Action”) from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care Laws, and, to the Company’s knowledge, no such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is threatened. The Company is not a party to and does not have any ongoing reporting obligations pursuant to any corporate integrity agreement, deferred prosecution agreement, monitoring agreement, consent decree, settlement order, plan of correction or similar agreement imposed by any governmental or regulatory authority.
    12
    


Additionally, neither the Company, nor to the Company’s knowledge, any of its employees, officers or directors, has been excluded, suspended or debarred from participation in any U.S. state or federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.
(xxix) Environmental Laws. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus or would not, singly or in the aggregate, result in a Material Adverse Effect, (A) neither the Company nor any Subsidiary is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products, asbestos-containing materials or toxic mold (collectively, “Hazardous Materials”) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, “Environmental Laws”), (B) the Company and its Subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws for the ownership or operation of their businesses or the occupancy or use of their real property facilities and are each in compliance with their requirements, (C) there are no pending or, to the knowledge of the Company threatened, administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any Subsidiary and (D) to the knowledge of the Company, there are no events or circumstances that would reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or Governmental Entity, against or affecting the Company or any Subsidiary relating to Hazardous Materials or any Environmental Laws.
(xxx) Accounting Controls and Disclosure Controls. The Company and each of its Subsidiaries maintain effective internal control over financial reporting (as defined under Rule 13-a15 and 15d-15 under the rules and regulations of the Commission under the 1934 Act Regulations and a system of internal accounting controls sufficient to provide reasonable assurances that (A) transactions are executed in accordance with management’s general or specific authorization; (B) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (C) access to assets is permitted only in accordance with management’s general or specific authorization; (D) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (E) the interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission’s rules and guidelines applicable thereto. Since the end of the Company’s most recent audited fiscal year, there has been (1) no material weakness in the Company’s internal control over financial reporting (whether or not remediated) and (2) no change in the Company’s internal control over financial reporting that has materially adversely affected, or is reasonably likely to materially adversely affect, the Company’s internal control over financial reporting. The Company and each of its Subsidiaries maintain an effective system of disclosure controls and
    13
    


procedures (as defined in Rule 13a-15 and Rule 15d-15 under the 1934 Act Regulations) that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and is accumulated and communicated to the Company’s management, including its principal executive officer or officers and principal financial officer or officers, as appropriate, to allow timely decisions regarding disclosure.
(xxxi) Payment of Taxes. The Company and each of its Subsidiaries have filed all federal, state, local and foreign tax returns required to be filed through the date of this Agreement or have requested extensions thereof (except where the failure to file would not, individually or in the aggregate, have a Material Adverse Effect) and have paid all taxes required to be paid thereon (except for cases in which the failure to file or pay would not have a Material Adverse Effect, or, except as currently being contested in good faith and for which reserves required by U.S. GAAP have been recorded in the financial statements of the Company), and no tax deficiency has been determined adversely to the Company or any of its Subsidiaries which has had (and none of the Company and its Subsidiaries has any notice or knowledge of any tax deficiency which could reasonably be expected to be determined adversely to the Company or its Subsidiaries and which could reasonably be expected to have) a Material Adverse Effect.
(xxxii) Insurance. The Company and its Subsidiaries carry or are entitled to the benefits of insurance, with financially sound and reputable insurers, in such amounts and covering such risks as is generally maintained by companies of established repute engaged in the same or similar business, and all such insurance is in full force and effect. The Company has no reason to believe that it or its Subsidiaries will not be able (A) to renew its existing insurance coverage as and when such policies expire or (B) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse Effect. Neither of the Company nor its Subsidiaries has been denied any insurance coverage which it has sought or for which it has applied.
(xxxiii) Investment Company Act. The Company is not required, and upon the issuance and sale of the Securities as herein contemplated and the application of the net proceeds therefrom as described in the Registration Statement, the General Disclosure Package and the Prospectus will not be required, to register as an “investment company” under the Investment Company Act of 1940, as amended (the “1940 Act”).
(xxxiv) Absence of Manipulation. Neither the Company nor any affiliate of the Company has taken, nor will the Company or any affiliate take, directly or indirectly, any action which is designed, or would be expected, to cause or result in, or which constitutes, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities or to result in a violation of Regulation M under the 1934 Act.
(xxxv) Foreign Corrupt Practices Act. None of the Company, its Subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other person acting on behalf of the Company or its Subsidiaries is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the “FCPA”), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of
    14
    


any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA and the Company and its Subsidiaries have and, to the knowledge of the Company, its affiliates have conducted their businesses in compliance with the FCPA and applicable anti-corruption laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed to ensure, and which are reasonably expected to continue to ensure, continued compliance with such laws and with the representations and warranties contained herein.
(xxxvi) Money Laundering Laws. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the “Money Laundering Laws”); and no action, suit or proceeding by or before any Governmental Entity involving the Company or its Subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.
(xxxvii)OFAC. None of the Company, its Subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or representative of the Company or its Subsidiaries is an individual or entity (“Person”) is, or is owned or controlled by one or more Persons that are the subject or target of any sanctions administered or enforced by the United States Government, including, without limitation, the U.S. Department of the Treasury’s Office of Foreign Assets Control, the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority (collectively, “Sanctions”), nor is the Company located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, Crimea, Cuba, Iran, North Korea and Syria); and the Company and its Subsidiaries have not knowingly engaged in, are not now knowingly engaged in, and will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions; and the Company will not, directly or indirectly, use the proceeds of the sale of the Securities, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partners or other Person: (i) to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions or (ii) in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise).
(xxxviii) Lending Relationship. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company (i) does not have any material lending or other relationship with any banking or lending affiliate of any Underwriter and (ii) does not intend to use any of the proceeds from the sale of the Securities to repay any outstanding debt owed to any affiliate of any Underwriter.
(xxxix) Statistical and Market-Related Data. Any statistical and market-related data included in the Registration Statement, the General Disclosure Package or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and
    15
    


accurate in all material respects and, to the extent required, the Company has obtained the written consent to the use of such data from such sources.
(xl) Maintenance of Rating. The Company has no debt securities or preferred stock that is rated by any “nationally recognized statistical rating organization” (as that term is defined by the Commission for purposes of Rule 436(g)(2) under the 1933 Act).
(xli) No Broker Fees. Except as disclosed in the General Disclosure Package, there are no contracts, agreements or understandings between the Company and any person that would give rise to a valid claim against the Company or any Underwriter for a brokerage commission, finder’s fee or other like payment in connection with the offering of the Securities contemplated hereby.
(xlii) Cybersecurity. (i)(x) Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, there has been no security breach or other compromise of or relating to any of the information technology and computer systems, networks, hardware, software, data, equipment or technology owned, held or used by or for the Company (including the data of its customers, employees, suppliers, vendors and any third party data maintained by or on behalf of the Company) (collectively, the “IT Systems and Data”) and (y) the Company has not been notified of, and has no knowledge of any event or condition that would reasonably be expected to result in, any security breach or other compromise to the IT Systems and Data; (ii) the Company has complied, and is presently in compliance, with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to (x) the collection, use, transfer, storage, protection, disposal and/or disclosure of personally identifiable information collected from or provided by third parties, (y) the privacy and security of the IT Systems and Data and (z) the protection of the IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, in the case of this clause (ii), individually or in the aggregate, have a Material Adverse Effect; and (iii) the Company has taken commercially reasonable steps to protect the IT Systems and Data, including by implementing backup, security and disaster recovery plans, procedures and technology consistent with industry standards and practices.
(xliii) Testing-the-Waters Materials. The Company (i) has not alone engaged in any Testing-the-Waters Communication with any person other than Testing-the-Waters Communications with the consent of the Representatives with entities that are qualified institutional buyers within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act and (ii) has not distributed any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the Securities Act (a “Written Testing-the-Waters Communication”) other than those listed on Schedule B-3 hereto.
(b)Officer’s Certificates. Any certificate signed by any officer of the Company delivered to the Representatives or to counsel for the Underwriters shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered thereby.
    16
    


SECTION 2.Sale and Delivery to Underwriters; Closing.
(a)Initial Securities. On the basis of the representations and warranties herein contained and subject to the terms and conditions herein set forth, the Company agrees to sell to each Underwriter, severally and not jointly, and each Underwriter, severally and not jointly, agrees to purchase from the Company, at the price per share set forth in Schedule A, that number of Initial Securities set forth in Schedule A opposite the name of such Underwriter, plus any additional number of Initial Securities which such Underwriter may become obligated to purchase pursuant to the provisions of Section 10 hereof, subject, in each case, to such adjustments among the Underwriters as the Representatives in their sole discretion shall make to eliminate any sales or purchases of fractional shares.
(b)Option Securities. In addition, on the basis of the representations and warranties herein contained and subject to the terms and conditions herein set forth, the Company hereby grants an option to the Underwriters, severally and not jointly, to purchase up to an additional 612,244 shares of Common Stock, at the price per share set forth in Schedule A, less an amount per share equal to any dividends or distributions declared by the Company and payable on the Initial Securities but not payable on the Option Securities. The option hereby granted may be exercised for 30 days after the date hereof and may be exercised in whole or in part at any time from time to time upon notice by the Representatives to the Company setting forth the number of Option Securities as to which the several Underwriters are then exercising the option and the time and date of payment and delivery for such Option Securities. Any such time and date of delivery (a “Date of Delivery”) shall be determined by the Representatives, but any Date of Delivery after the Closing Time shall not be later than seven full business days nor earlier than two full business days after the exercise of said option, nor in any event prior to the Closing Time. If the option is exercised as to all or any portion of the Option Securities, each of the Underwriters, acting severally and not jointly, will purchase that proportion of the total number of Option Securities then being purchased which the number of Initial Securities set forth in Schedule A opposite the name of such Underwriter bears to the total number of Initial Securities, subject, in each case, to such adjustments as the Representatives in their sole discretion shall make to eliminate any sales or purchases of fractional shares.
(c)Payment. Payment of the purchase price for, and delivery of certificates or security entitlements for, the Initial Securities shall be made at the offices of Davis Polk & Wardwell LLP, or at such other place as shall be agreed upon by the Representatives and the Company, at 10:00 A.M. (New York City time) on the second (third, if the pricing occurs after 4:30 P.M. (New York City time) on any given day) business day after the date hereof (unless postponed in accordance with the provisions of Section 10), or such other time not later than ten business days after such date as shall be agreed upon by the Representatives and the Company (such time and date of payment and delivery being herein called the “Closing Time”). Delivery of the Initial Securities at the Closing Time shall be made through the facilities of The Depository Trust Company unless the Representatives shall otherwise instruct.
In addition, in the event that any or all of the Option Securities are purchased by the Underwriters, payment of the purchase price for, and delivery of certificates or security entitlements for, such Option Securities shall be made at the above-mentioned offices, or at such other place as shall be agreed upon by the Representatives and the Company, on each Date of Delivery as specified in the notice from the Representatives to the Company. Delivery of the Option Securities on each such Date of Delivery shall be made through the facilities of The Depository Trust Company unless the Representatives shall otherwise instruct.
    17
    


Payment for the Initial Securities and Option Securities, if any, shall be made to the Company by wire transfer of immediately available funds to a bank account designated by the Company, against delivery to the Representatives for the respective accounts of the Underwriters of certificates or security entitlements for the Initial Securities and the Option Securities, if any, to be purchased by them. It is understood that each Underwriter has authorized the Representatives, for their accounts, to accept delivery of, receipt for, and make payment of the purchase price for, the Initial Securities and the Option Securities, if any, which it has agreed to purchase. Each of the Representatives, individually and not as representatives of the Underwriters, may (but shall not be obligated to) make payment of the purchase price for the Initial Securities or the Option Securities, if any, to be purchased by any Underwriter whose funds have not been received by the Closing Time or the relevant Date of Delivery, as the case may be, but such payment shall not relieve such Underwriter from its obligations hereunder.
SECTION 3.Covenants of the Company. The Company covenants with each Underwriter as follows:
(a)Compliance with Securities Regulations and Commission Requests. The Company, subject to Section 3(b), will comply with the requirements of Rule 430B, and will notify the Representatives as soon as practicable, and confirm the notice in writing, (i) when any post-effective amendment to the Registration Statement shall become effective or any amendment or supplement to the Prospectus shall have been filed, (ii) of the receipt of any comments from the Commission, (iii) of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus (including any document incorporated by reference therein) or for additional information, (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment or of any order preventing or suspending the use of any preliminary prospectus or the Prospectus, or of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes or of any examination pursuant to Section 8(d) or 8(e) of the 1933 Act concerning the Registration Statement and (v) if the Company becomes the subject of a proceeding under Section 8A of the 1933 Act in connection with the offering of the Securities. The Company will effect all filings required under Rule 424(b), in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and will take such steps as it deems necessary to ascertain promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company will make every reasonable effort to prevent the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment. The Company shall pay the required Commission filing fees relating to the Securities within the time required by Rule 456(b)(1)(i) under the 1933 Act Regulations without regard to the proviso therein and otherwise in accordance with Rules 456(b) and 457(r) under the 1933 Act Regulations (including, if applicable, by updating the “Calculation of Registration Fee” table in accordance with Rule 456(b)(1)(ii) either in a post-effective amendment to the Registration Statement or on the cover page of a prospectus filed pursuant to Rule 424(b)).
(b)Continued Compliance with Securities Laws. The Company will comply with the 1933 Act, the 1933 Act Regulations, the 1934 Act and the 1934 Act Regulations so as to permit the completion of the distribution of the Securities as contemplated in this Agreement and in the Registration Statement, the General Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172 of the 1933 Act Regulations (“Rule 172”), would be) required by the 1933 Act to be delivered in connection with sales of the Securities, any event shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel for the
    18
    


Underwriters or for the Company, to (i) amend the Registration Statement in order that the Registration Statement will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii) amend or supplement the General Disclosure Package or the Prospectus in order that the General Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in the light of the circumstances existing at the time it is delivered to a purchaser or (iii) amend the Registration Statement or amend or supplement the General Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements of the 1933 Act or the 1933 Act Regulations, the Company will promptly (A) give the Representatives notice of such event, (B) prepare any amendment or supplement as may be necessary to correct such statement or omission or to make the Registration Statement, the General Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representatives with copies of any such amendment or supplement and (C) file with the Commission any such amendment or supplement; provided that the Company shall not file or use any such amendment or supplement to which the Representatives or counsel for the Underwriters shall object. The Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters may reasonably request. The Company has given the Representatives notice of any filings made pursuant to the 1934 Act or the 1934 Act Regulations within 48 hours prior to the Applicable Time; the Company will give the Representatives notice of its intention to make any such filing from the Applicable Time to the Closing Time and will furnish the Representatives with copies of any such documents a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any such document to which the Representatives or counsel for the Underwriters shall reasonably object.
(c)Delivery of Registration Statements. The Company has furnished or will deliver to the Representatives and counsel for the Underwriters, without charge, signed copies of the Registration Statement as originally filed and each amendment thereto (including exhibits filed therewith or incorporated by reference therein and documents incorporated or deemed incorporated by reference therein) and signed copies of all consents and certificates of experts, and will also deliver to the Representatives, without charge, a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) for each of the Underwriters. The copies of the Registration Statement and each amendment thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.
(d)Delivery of Prospectuses. The Company has delivered to each Underwriter, without charge, as many copies of each preliminary prospectus as such Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted by the 1933 Act. The Company will furnish to each Underwriter, without charge, during the period when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, such number of copies of the Prospectus (as amended or supplemented) as such Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.
(e)Blue Sky Qualifications. The Company will use its best efforts, in cooperation with the Underwriters, to qualify the Securities for offering and sale by the Company under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Representatives may designate and to maintain such qualifications in effect so long as required to complete the distribution of
    19
    


the Securities; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.
(f)Rule 158. The Company will timely file such reports pursuant to the 1934 Act as are necessary in order to make generally available to its securityholders as soon as practicable an earning statement for the purposes of, and to provide to the Underwriters the benefits contemplated by, the last paragraph of Section 11(a) of the 1933 Act.
(g)Use of Proceeds. The Company will use the net proceeds received by it from the sale of the Securities in all material respects in the manner specified in the Registration Statement, the General Disclosure Package and the Prospectus under the heading “Use of Proceeds.”
(h)Listing. The Company will use its best efforts to effect and maintain the listing of the Common Stock (including the Securities) on The Nasdaq Capital Market.
(i)Restriction on Sale of Securities. During a period of 90 days from the date of the Prospectus, the Company will not, without the prior written consent of the Representatives, (i) directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or file any registration statement under the 1933 Act with respect to any of the foregoing, (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Common Stock, whether any such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise or (iii) publicly announce an intention to effect any such swap, agreement or other transaction described in clauses (i) and (ii). The foregoing sentence shall not apply to (A) the Securities to be sold hereunder; (B) the Company’s 0.25% Convertible Senior Notes due 2028 (the “Convertible Notes”) to be sold pursuant to that certain underwriting agreement (the “Convertible Notes Underwriting Agreement”) dated on or about the date hereof by and among the Company and the Representatives relating to the sale of the Convertible Notes; (C) entry into, or the consummation of the transactions contemplated by, the Capped Call Confirmations (as defined in the Convertible Notes Underwriting Agreement; (D) any shares of Common Stock issued by the Company upon the exercise of an option or warrant or the conversion of a convertible security outstanding on the date hereof and referred to in the Registration Statement, the General Disclosure Package and the Prospectus, including the Convertible Notes; (E) any shares of Common Stock issued or options to purchase Common Stock granted pursuant to existing employee benefit plans of the Company referred to in the Registration Statement, the General Disclosure Package and the Prospectus; (F) any shares of Common Stock issued pursuant to any existing non-employee director stock plan or dividend reinvestment plan referred to in the Registration Statement, the General Disclosure Package and the Prospectus; (G) the filing by the Company of any registration statement on Form S-8 or a successor form thereto; or (H) the issuance of shares of Common Stock or securities convertible into, exercisable for or exchangeable for Common Stock as full or partial consideration in connection with a merger, acquisition, consolidation or purchase of the securities or assets of a corporation or other entity (or any division or business unit thereof); provided that the number of securities issued (on an as-converted to Common Stock basis) pursuant to this Section 3(i) shall not exceed 10% of the total number of shares of Common Stock outstanding immediately following the public offering of the Securities contemplated hereby, and each recipient of
    20
    


such securities shall execute and deliver to the Representatives, on or prior to the issuance of such securities, a lock-up agreement substantially to the effect set forth in this Section 3(i).
(j)Reporting Requirements. The Company, during the period when a Prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, will file all documents required to be filed with the Commission pursuant to the 1934 Act within the time periods required by the 1934 Act and 1934 Act Regulations.
(k)Issuer Free Writing Prospectuses. The Company agrees that, unless it obtains the prior written consent of the Representatives, it will not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a “free writing prospectus,” or a portion thereof, required to be filed by the Company with the Commission or retained by the Company under Rule 433; provided that the Representatives will be deemed to have consented to the Issuer Free Writing Prospectuses listed on Schedule B-2 hereto and any “road show that is a written communication” within the meaning of Rule 433(d)(8)(i) that has been reviewed by the Representatives. The Company represents that it has treated or agrees that it will treat each such free writing prospectus consented to, or deemed consented to, by the Representatives as an “issuer free writing prospectus,” as defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including timely filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement, any preliminary prospectus or the Prospectus or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.
(l)Testing-the-Waters Materials. If at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs an event or development as a result of which such Written Testing-the-Waters Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such untrue statement or omission.
SECTION 4.Payment of Expenses.
(a)Expenses. The Company will pay or cause to be paid all expenses incident to the performance of its obligations under this Agreement, including (i) the preparation, printing and filing of the Registration Statement (including financial statements and exhibits) as originally filed and each amendment thereto, (ii) the preparation, printing and delivery to the Underwriters of copies of each preliminary prospectus, each Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements thereto and any costs associated with electronic delivery of any of the foregoing by the Underwriters to investors, (iii) the preparation, issuance and delivery of the certificates or security entitlements for the Securities to the Underwriters, including any stock or other transfer taxes and any stamp or other duties payable upon the sale, issuance or delivery of the Securities to the Underwriters, (iv) the fees and disbursements of the Company’s counsel, accountants and other advisors, (v) the
    21
    


qualification of the Securities under securities laws in accordance with the provisions of Section 3(e) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Underwriters in connection therewith and in connection with the preparation of a “Blue Sky Survey” and any supplement thereto, (vi) the fees and expenses of any transfer agent or registrar for the Securities, (vii) the costs and expenses of the Company relating to investor presentations on any “road show” undertaken in connection with the marketing of the Securities, including without limitation, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations, travel and lodging expenses of the representatives and officers of the Company and any such consultants, and the cost of aircraft and other transportation chartered in connection with the road show, (viii) the filing fees incident to, and the reasonable fees and disbursements of counsel to the Underwriters in connection with, the review by FINRA of the terms of the sale of the Securities, (ix) the fees and expenses incurred in connection with the listing of the Securities on The Nasdaq Capital Market, and (x) the costs and expenses (including, without limitation, any damages or other amounts payable in connection with legal or contractual liability) associated with the reforming of any contracts for sale of the Securities made by the Underwriters caused by a breach of the representation contained in the third sentence of Section 1(a)(ii).
(b)Termination of Agreement. If this Agreement is terminated by the Representatives in accordance with the provisions of Section 5, Section 9(a)(i), Section 9(a)(iii) or Section 10 hereof, the Company shall reimburse the Underwriters for all of their reasonably documented out-of-pocket expenses, including the reasonable fees and disbursements of counsel for the Underwriters; provided, however, that if this Agreement is terminated by the Representatives pursuant to Section 10 hereof, the Company shall have no obligation to reimburse any out of pocket expenses of any Underwriter that has failed to purchase the Securities that such Underwriter has agreed to purchase hereunder.
SECTION 5.Conditions of Underwriters’ Obligations. The obligations of the several Underwriters hereunder are subject to the accuracy of the representations and warranties of the Company contained herein or in certificates of any officer of the Company or any of its Subsidiaries delivered pursuant to the provisions hereof, to the performance by the Company of its covenants and other obligations hereunder, and to the following further conditions:
(a)Effectiveness of Registration Statement. The Registration Statement has become effective and, at the Closing Time, no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company’s knowledge, contemplated; and the Company has complied with each request (if any) from the Commission for additional information to the reasonable satisfaction of counsel to the Underwriters.
(b)Opinion of Counsel for Company. At the Closing Time, the Representatives shall have received the opinion and the negative assurance letter, each dated the Closing Time, of (i) K&L Gates LLP, counsel for the Company and (ii) Snell & Wilmer LLP, Nevada counsel for the Company, each in form and substance satisfactory to counsel for the Underwriters, together with signed or reproduced copies of each such letter for each of the other Underwriters to the effect set forth in Exhibits A-1 and A-2 hereto and to such further effect as counsel to the Underwriters may reasonably request.
(c)Opinion of Counsel for Underwriters. At the Closing Time, the Representatives shall have received the opinion, and negative assurance letter, each dated the Closing Time, of Davis Polk & Wardwell LLP, counsel for the Underwriters, together with signed or reproduced copies of such letters for
    22
    


each of the other Underwriters in form and substance satisfactory to the Representatives. In giving such opinion such counsel may rely, as to all matters governed by the laws of jurisdictions other than the law of the State of New York, the General Corporation Law of the State of Delaware and the federal securities laws of the United States, upon the opinions of counsel satisfactory to the Representatives. Such counsel may also state that, insofar as such opinion involves factual matters, they have relied, to the extent they deem proper, upon certificates of officers and other representatives of the Company and its Subsidiaries and certificates of public officials.
(d)Officers’ Certificate. At the Closing Time, there shall not have been, since the date hereof or since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any Material Adverse Effect, and the Representatives shall have received a certificate of the principal executive officer of the Company and of the principal financial officer of the Company, dated the Closing Time, to the effect that (i) there has been no such Material Adverse Effect, (ii) the representations and warranties of the Company in this Agreement are true and correct with the same force and effect as though expressly made at and as of the Closing Time, (iii) the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied at or prior to the Closing Time, and (iv) no stop order suspending the effectiveness of the Registration Statement under the 1933 Act has been issued, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to their knowledge, contemplated.
(e)Accountants’ Comfort Letters. At the time of the execution of this Agreement, the Representatives shall have received from each of (i) Crowe LLP and (ii) Deloitte & Touche LLP, a letter, dated such date, in form and substance satisfactory to the Representatives, together with signed or reproduced copies of such letter for each of the other Underwriters containing statements and information of the type ordinarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial information contained in the Registration Statement, the General Disclosure Package and the Prospectus.
(f)Bring-down Comfort Letters. At the Closing Time, the Representatives shall have received from each of (i) Crowe LLP and (ii) Deloitte & Touche LLP, a letter, dated as of the Closing Time, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection (e) of this Section, except that the specified date referred to shall be a date not more than three business days prior to the Closing Time.
(g)Approval of Listing. At the Closing Time, the Securities shall have been approved for listing on The Nasdaq Capital Market, subject only to official notice of issuance.
(h)No Objection. FINRA has confirmed that it has not raised any objection with respect to the fairness and reasonableness of the underwriting terms and arrangements relating to the offering of the Securities.
(i)Lock-up Agreements. At the date of this Agreement, the Representatives shall have received an agreement substantially in the form of Exhibit B hereto signed by all of the Company’s directors and officers.
(j)Maintenance of Ratings. Neither the Company nor its subsidiaries have any debt securities or preferred stock that are rated by any “nationally recognized statistical rating agency” (as defined in Section 3(a)(62) of the 1934 Act).
    23
    


(k)[Reserved].
(l)Conditions to Purchase of Option Securities. In the event that the Underwriters exercise their option provided in Section 2(b) hereof to purchase all or any portion of the Option Securities, the representations and warranties of the Company contained herein and the statements in any certificates furnished by the Company hereunder shall be true and correct as of each Date of Delivery and, at the relevant Date of Delivery, the Representatives shall have received:
(i)    Officers’ Certificate. A certificate, dated such Date of Delivery, of the principal executive officer of the Company and of the principal financial officer of the Company confirming that the certificate delivered at the Closing Time pursuant to Section 5(d) hereof remains true and correct as of such Date of Delivery.
(ii)    Opinion of Counsel for Company. If requested by the Representatives, the opinion, and negative assurance letter, of (i) K&L Gates LLP, counsel for the Company and (ii) Snell & Wilmer LLP, Nevada counsel for the Company, each in form and substance satisfactory to counsel for the Underwriters, dated such Date of Delivery, relating to the Option Securities to be purchased on such Date of Delivery and otherwise to the same effect as the opinions and negative assurance letter required by Section 5(b) hereof.
(iii)    Opinion of Counsel for Underwriters. If requested by the Representatives, the opinion, and negative assurance letter, of Davis Polk & Wardwell LLP, counsel for the Underwriters, dated such Date of Delivery, relating to the Option Securities to be purchased on such Date of Delivery and otherwise to the same effect as the opinion and negative assurance letter required by Section 5(c) hereof.
(iv)    Bring-down Comfort Letters. If requested by the Representatives, a letter from each of (i) Crowe LLP and (ii) Deloitte & Touche LLP, in form and substance satisfactory to the Representatives and dated such Date of Delivery, substantially in the same form and substance as the letter furnished to the Representatives pursuant to subsection (f) of this Section, except that the “specified date” in the letter furnished pursuant to this paragraph shall be a date not more than three business days prior to such Date of Delivery.
(m)Additional Documents. At the Closing Time and at each Date of Delivery (if any), counsel for the Underwriters shall have been furnished with such documents and opinions as they may reasonably require for the purpose of enabling them to pass upon the issuance and sale of the Securities as herein contemplated, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Securities as herein contemplated shall be reasonably satisfactory in form and substance to the Representatives and counsel for the Underwriters.
(n)Termination of Agreement. If any condition specified in this Section shall not have been fulfilled when and as required to be fulfilled, this Agreement, or, in the case of any condition to the purchase of Option Securities on a Date of Delivery which is after the Closing Time, the obligations of the several Underwriters to purchase the relevant Option Securities, may be terminated by the Representatives by notice to the Company at any time at or prior to Closing Time or such Date of Delivery, as the case may be, and such termination shall be without liability of any party to any other party except as provided in Section 4 and except that Sections 1, 4, 6, 7, 8, 14, 15 and 16 shall survive any such termination and remain in full force and effect.
    24
    


SECTION 6.Indemnification.
(a)Indemnification of Underwriters. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates (as such term is defined in Rule 501(b) under the 1933 Act (each, an “Affiliate”)), its selling agents and each person, if any, who controls any Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act (collectively, the “Underwriters Indemnitees”) as follows:
(i)    against any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading or arising out of any untrue statement or alleged untrue statement of a material fact included (A) in any preliminary prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package, the Prospectus (or any amendment or supplement thereto), or (B) in any Written Testing-the-Waters Communication or any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Securities (“Marketing Materials”), including any roadshow or investor presentations made to investors by the Company (whether in person or electronically), or the omission or alleged omission in any preliminary prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package, the Prospectus (or any amendment or supplement thereto), any Written Testing-the-Waters Communication or in any Marketing Materials of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
(ii)    against any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided that (subject to Section 6(d) below) any such settlement is effected with the written consent of the Company;
(iii)    against any and all expense whatsoever, as incurred (including the reasonable fees and disbursements of counsel chosen by the Representatives), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission, to the extent that any such expense is not paid under (i) or (ii) above;
provided, however, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue statement or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Underwriter Information.
(b)Indemnification of Company, Directors and Officers. Each Underwriter severally agrees to indemnify and hold harmless the Company, its directors, each of its officers who signed the
    25
    


Registration Statement, and each person, if any, who controls the Company within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act (collectively, the “Company Indemnitees”), against any and all loss, liability, claim, damage and expense described in the indemnity contained in subsection (a) of this Section, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Underwriter Information.
(c)Actions against Parties; Notification. Each indemnified party shall give notice as promptly as reasonably practicable to each indemnifying party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying party shall not relieve such indemnifying party from any liability hereunder to the extent it is not materially prejudiced as a result thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement. Upon request of the indemnified party, the indemnifying party shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the indemnifying party may designate in such proceeding and shall pay the fees and disbursements of such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel, (ii) the named parties to any such proceeding (including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them, (iii) the indemnifying party has failed within a reasonable time to retain counsel reasonably satisfactory to the indemnified party or (iv) the indemnified party shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the indemnifying party. It is understood that the indemnifying party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for (i) the fees and expenses of more than one separate firm (in addition to any local counsel) for the Underwriters Indemnitees and (ii) the fees and expenses of more than one separate firm (in addition to any local counsel) for the Company Indemnitees, and that all such fees and expenses shall be reimbursed as they are incurred. In the case of any such separate firm for the Underwriters Indemnitees, such firm shall be designated in writing by the Underwriters. In the case of any such separate firm for the Company Indemnitees, such firm shall be designated in writing by the Company.
No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever in respect of which indemnification or contribution could be sought under this Section 6 or Section 7 hereof (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified party from all liability arising out of such litigation, investigation, proceeding or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.
(d)Settlement without Consent if Failure to Reimburse. If at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by Section 6(a)(ii) effected without its written consent if (i) such settlement is entered into
    26
    


more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall have received notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (iii) such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.
SECTION 7.Contribution. If the indemnification provided for in Section 6 hereof is for any reason unavailable to or insufficient to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such indemnified party, as incurred, (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Securities pursuant to this Agreement or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and of the Underwriters, on the other hand, in connection with the statements or omissions which resulted in such losses, liabilities, claims, damages or expenses, as well as any other relevant equitable considerations.
The relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Securities pursuant to this Agreement (before deducting expenses) received by the Company, on the one hand, and the total underwriting discount received by the Underwriters, on the other hand, in each case as set forth on the cover of the Prospectus, bear to the aggregate initial public offering price of the Securities as set forth on the cover of the Prospectus.
The relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.
The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 7 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to above in this Section 7. The aggregate amount of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section 7 shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement or omission or alleged omission.
Notwithstanding the provisions of this Section 7, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions received by such Underwriter in connection with the Securities underwritten by it and distributed to the public.
No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
    27
    


For purposes of this Section 7, each person, if any, who controls an Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act and each Underwriter’s Affiliates and selling agents shall have the same rights to contribution as such Underwriter, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act shall have the same rights to contribution as the Company. The Underwriters’ respective obligations to contribute pursuant to this Section 7 are several in proportion to the number of Initial Securities set forth opposite their respective names in Schedule A hereto and not joint.
SECTION 8.Representations, Warranties and Agreements to Survive. All representations, warranties and agreements contained in this Agreement or in certificates of officers of the Company or any of its Subsidiaries submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i) any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter, its officers or directors or any person controlling the Company and (ii) delivery of and payment for the Securities.
SECTION 9.Termination of Agreement.
(a)Termination. The Representatives may terminate this Agreement, by notice to the Company, at any time at or prior to the Closing Time (i) if there has been, in the judgment of the Representatives, since the time of execution of this Agreement or since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any Material Adverse Effect, or (ii) if there has occurred any material adverse change in the financial markets in the United States or the international financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or development involving a prospective change in U.S. or international political, financial or economic conditions, in each case the effect of which is such as to make it, in the judgment of the Representatives, impracticable or inadvisable to proceed with the completion of the offering or to enforce contracts for the sale of the Securities, or (iii) if trading in any securities of the Company has been suspended or materially limited by the Commission or The Nasdaq Capital Market, or (iv) if trading generally on the NYSE American or the New York Stock Exchange or in The Nasdaq Capital Market has been suspended or materially limited, or minimum or maximum prices for trading have been fixed, or maximum ranges for prices have been required, by any of said exchanges or by order of the Commission, FINRA or any other governmental authority, or (v) a material disruption has occurred in commercial banking or securities settlement or clearance services in the United States or with respect to Clearstream or Euroclear systems in Europe, or (vi) if a banking moratorium has been declared by either Federal or New York authorities.
(b)Liabilities. If this Agreement is terminated pursuant to this Section, such termination shall be without liability of any party to any other party except as provided in Section 4 hereof, and provided further that Sections 1, 4, 6, 7, 8, 14, 15 and 16 shall survive such termination and remain in full force and effect.
SECTION 10.Default by One or More of the Underwriters. If one or more of the Underwriters shall fail at the Closing Time or a Date of Delivery to purchase the Securities which it or they are obligated to purchase under this Agreement (the “Defaulted Securities”), the Representatives shall have the right, within 24 hours thereafter, to make arrangements for one or more of the non-defaulting Underwriters, or any other underwriters, to purchase all, but not less than all, of the Defaulted Securities in such amounts as may be agreed upon and upon the terms herein set forth; if, however, the Representatives shall not have completed such arrangements within such 24-hour period, then:
    28
    


(i)if the number of Defaulted Securities does not exceed 10% of the number of Securities to be purchased on such date, each of the non-defaulting Underwriters shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions that their respective underwriting obligations hereunder bear to the underwriting obligations of all non-defaulting Underwriters, or
(ii)if the number of Defaulted Securities exceeds 10% of the number of Securities to be purchased on such date, this Agreement or, with respect to any Date of Delivery which occurs after the Closing Time, the obligation of the Underwriters to purchase, and the Company to sell, the Option Securities to be purchased and sold on such Date of Delivery shall terminate without liability on the part of any non-defaulting Underwriter.
No action taken pursuant to this Section shall relieve any defaulting Underwriter from liability in respect of its default.
In the event of any such default which does not result in a termination of this Agreement or, in the case of a Date of Delivery which is after the Closing Time, which does not result in a termination of the obligation of the Underwriters to purchase and the Company to sell the relevant Option Securities, as the case may be, either the (i) Representatives or (ii) the Company shall have the right to postpone Closing Time or the relevant Date of Delivery, as the case may be, for a period not exceeding seven days in order to effect any required changes in the Registration Statement, the General Disclosure Package or the Prospectus or in any other documents or arrangements. As used herein, the term “Underwriter” includes any person substituted for an Underwriter under this Section 10.
SECTION 11.Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted by any standard form of telecommunication. Notices to the Underwriters shall be directed to BofA Securities at One Bryant Park, New York, New York 10036, attention of Syndicate Department (facsimile: (646) 855-3073), with a copy to ECM Legal (facsimile: (212) 230-8730); Morgan Stanley & Co. LLC at 1585 Broadway, New York, New York 10036, Attention: Equity Syndicate Desk, with a copy to the Legal Department; and Goldman Sachs at 200 West Street, New York, New York 10282, Attention: Registration Department and the Legal Department. Notices to the Company shall be directed to it at 12701 Commonwealth Dr., Suite 9, Fort Myers, FL 33913, Facsimile (239) 432-5601, Attention: Kathryn B. McKenzie, CFO, with a copy to K&L Gates LLP at 200 S. Biscayne Blvd., Suite 3900, Miami, FL 33131, Facsimile (305) 538-7095, Attention: Clayton Parker.
SECTION 12.No Advisory or Fiduciary Relationship. The Company acknowledges and agrees that (a) the purchase and sale of the Securities pursuant to this Agreement, including the determination of the initial public offering price of the Securities and any related discounts and commissions, is an arm’s-length commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b) in connection with the offering of the Securities and the process leading thereto, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, any of its Subsidiaries or their respective stockholders, creditors, employees or any other party, (c) no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering of the Securities or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company or any of its Subsidiaries on other matters) and no Underwriter has any obligation to the Company with respect to the offering of the Securities except the obligations expressly set forth in this Agreement, (d) the Underwriters and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of
    29
    


the Company and (e) the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering of the Securities and the Company has consulted its own respective legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.
SECTION 13.Parties. This Agreement shall each inure to the benefit of and be binding upon the Underwriters and the Company and their respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or corporation, other than the Underwriters and the Company and their respective successors and the controlling persons and officers and directors referred to in Sections 6 and 7 and their heirs and legal representatives, any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision herein contained. This Agreement and all conditions and provisions hereof are intended to be for the sole and exclusive benefit of the Underwriters and the Company and their respective successors, and said controlling persons and officers and directors and their heirs and legal representatives, and for the benefit of no other person, firm or corporation. No purchaser of Securities from any Underwriter shall be deemed to be a successor by reason merely of such purchase.
SECTION 14.Waiver of Trial by Jury. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.
SECTION 15.GOVERNING LAW. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.
SECTION 16.Consent to Jurisdiction; Waiver of Immunity. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby shall be instituted in (i) the federal courts of the United States of America located in the City and County of New York, Borough of Manhattan or (ii) the courts of the State of New York located in the City and County of New York, Borough of Manhattan (collectively, the “Specified Courts”), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party’s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.
SECTION 17.TIME. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME.
SECTION 18.Partial Unenforceability. The invalidity or unenforceability of any Section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other Section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.
    30
    


SECTION 19.Recognition of the U.S. Special Resolution Regimes.
(a)In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.
(b)In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.
As used in this Section 19:
BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k).
Covered Entity” means any of the following:
(i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b);
(ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or
(iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b).
Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable.
U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.
SECTION 20.Counterparts. This Agreement may be executed in any number of counterparts (which may include counterparts delivered by any standard form of telecommunication), each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same agreement. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
SECTION 21.Effect of Headings. The Section headings herein are for convenience only and shall not affect the construction hereof.
    31
    


SECTION 22.Entire Agreement. This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and the Underwriters with respect to the subject matter hereof.
[SIGNATURE PAGES FOLLOW]


    32
    


    If the foregoing is in accordance with your understanding of our agreement, please sign and return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts, will become a binding agreement among the Underwriters and the Company in accordance with its terms.

Very truly yours,

NEOGENOMICS, INC.



By:    /s/ Kathryn B. McKenzie
    Name: Kathryn B. McKenzie
    Title: Chief Financial Officer

CONFIRMED AND ACCEPTED
    As of the date first above written:


BOFA SECURITIES INC.



By:    /s/ Omid Ahdieh
    Name: Omid Ahdieh
    Title: Managing Director


MORGAN STANLEY & CO. LLC



By:    /s/Chris Rigoli
    Name: Chris Rigoli
    Title: Vice President


GOLDMAN SACHS & CO. LLC



By: /s/ Bartosz Ostenda
    Name: Bartosz Ostenda
    Title: Managing Director


For themselves and as Representatives of the
other Underwriters named in Schedule A hereto.


    [SIGNATURE PAGE TO UNDERWRITING AGREEMENT]
    


SCHEDULE A
The initial public offering price per share for the Securities shall be $49.00.
The purchase price per share for the Securities to be paid by the several Underwriters shall be $46.55 being an amount equal to the initial public offering price set forth above less $2.45 per share, subject to adjustment in accordance with Section 2(b) for dividends or distributions declared by the Company and payable on the Initial Securities but not payable on the Option Securities.
Name of Underwriter
Number of
Initial Securities
BofA Securities, Inc.1,510,207 
Morgan Stanley & Co. LLC1,102,040 
Goldman Sachs & Co. LLC979,591 
SVB Leerink LLC326,530 
Craig-Hallum Capital Group LLC40,816 
Needham & Company, LLC40,816 
Raymond James & Associates, Inc.40,816 
Stephens Inc.40,816 
Total4,081,632 




    


SCHEDULE B-1
Pricing Terms
1.    The Company is selling 4,081,632 shares of Common Stock.
2.    The Company has granted an option to the Underwriters, severally and not jointly, to purchase up to an additional 612,244 shares of Common Stock.
3.    The initial public offering price per share for the Securities shall be $49.00.


    


SCHEDULE B-2
Free Writing Prospectuses

    


Schedule B-3
Testing-the-Waters Communication
None.

    



Exhibit A-1
K&L Gates LLP Form Opinion
Based on the foregoing, and subject to the foregoing and the additional qualifications and other matters set forth below, it is our opinion that:
1. The Company is qualified, and is in good standing, as a foreign corporation in the State of New York. The Company is qualified as a foreign corporation and is authorized to transact business in the State of Florida.
2. The Registration Statement is an “automatic shelf registration statement” as defined in Rule 405 under the 1933 Act that has been filed with the Commission not earlier than three years prior to the date of the Underwriting Agreement. Based solely on a review of the stop orders issued by the Commission as reflected on the Commission’s website as of [__:__] a.m. (New York City time) on the date hereof, no stop order suspending the effectiveness of the Registration Statement has been issued under the 1933 Act and no proceedings for that purpose have been initiated or threatened by the Commission. The Preliminary Prospectus Supplement has been filed in accordance with Rule 424(b) under the 1933 Act and the Prospectus has been filed in accordance with Rule 424(b) under the 1933 Act.
3. The execution and delivery by the Company of, and the performance by the Company of its obligations under, the Underwriting Agreement will not, as of the date hereof, violate or cause a breach or default under (a) any applicable statute, rule or regulation of the United States, the State of New York or the State of Florida or (b) the terms of any Specified Agreement.
4. The execution and delivery by the Company of, and the performance by the Company of its obligations under, the Underwriting Agreement will not, as of the date hereof, require the Company to obtain any authorization, approval, consent or order of or filing with any court or governmental authority of the United States, the State of New York or the State of Florida, other than as may be required under the 1933 Act and the rules and regulations under the 1933 Act; provided, however, that we express no opinion as to (a) state securities or “blue sky” laws or foreign securities laws of the various jurisdictions in which the Securities are being offered by the Underwriters or your selected dealers, if any, (b) any approval of FINRA of the terms and conditions of the Underwriting Agreement or (c) authorizations, approvals, consents or orders of, or qualification with, any court or governmental authority of any jurisdiction outside of the United States.
5. The Registration Statement, insofar as it pertains to the offering of the Securities, the Time of Sale Disclosure Package and the Prospectus, as of their respective effective or issue dates (other than the financial statements and related notes and schedules and other financial and accounting information included therein or omitted therefrom, as to which we express no opinion), each appears on its face to be appropriately responsive in all material respects to the applicable form requirements for registration statements on Form S-3 of the 1933 Act and the rules and regulations of the Commission thereunder.
6. Based solely on the Company’s Fact Certificate, and except as described in the Time of Sale Disclosure Package and the Prospectus, there are no contracts, agreements or understandings between the Company and any person granting such person registration rights.

    


7. The Company is not required, and upon the sale of the Securities as contemplated in the Underwriting Agreement and the application of the net proceeds as described in the Prospectus will not be required to register as an “investment company” as such term is defined under the Investment Company Act of 1940, as amended.
8. The statements in the Health Care Regulatory Sections of the Time of Sale Package and the Prospectus, insofar as such statements purport to describe or summarize applicable provisions of the Health Care Regulatory Laws including the qualifications set forth therein, are accurate in all material respects and fairly present such provisions of the Health Care Regulatory Laws.
9. The statements set forth in the Time of Sale Package and Prospectus under the caption “Material U.S. Federal Income and Estate Tax Considerations for Non-U.S. Holders”, insofar as they purport to constitute summaries of U.S. federal income tax laws and regulations or conclusions with respect thereto (and subject to the limitations, qualifications, and assumptions set forth therein), are accurate and fairly summarized in all material respects.

    2
    


Exhibit A-2
Snell & Wilmer LLP Form Opinion
Based on the foregoing, and subject to the assumptions, qualifications and limitations stated in this letter, we are of the opinion that:
1.    The Company is a corporation validly existing and in good standing under the laws of the State of Nevada.
2.    The Company has the corporate power to own its properties and conduct its business as currently being carried on as described in the Registration Statement, the General Disclosure Package and the Prospectus Supplement and to enter into and perform its obligations under the Underwriting Agreement.
3.    The capital stock of the Company conforms as to legal matters to the description of the Company’s capital stock contained in the Registration Statement, the General Disclosure Package and the Prospectus Supplement.
4.    The Securities to be issued and sold by the Company under the Underwriting Agreement have been duly authorized for issuance, and, when issued, delivered, and paid for in accordance with the terms of the Underwriting Agreement, will be validly issued, and fully paid, and nonassessable, and the holders of such Securities will not be subject to personal liability solely by reason of being such holders. There are no preemptive rights or other similar rights to subscribe for or to purchase any of the Securities pursuant to the Company’s articles of incorporation or bylaws, or any agreement or other instrument known to us to which the Company is a party or by which the Company is bound.
5.    The Company has full corporate power and authority to enter into the Underwriting Agreement and the Underwriting Agreement has been duly authorized, executed, and delivered by the Company.
6.    The execution, delivery, and performance of the Underwriting Agreement and the consummation of the transactions contemplated in such document will not result in a breach or violation of any of the terms or provisions of, or constitute a default under, (i) any Nevada statute, rule, or regulation, (ii) any agreement known to us to which the Company is a party or by which the Company is bound or to which the Company’s property is subject, (iii) the Company’s articles of incorporation or bylaws, or (iv) any order or decree known to us of any Nevada court or Nevada governmental authority having jurisdiction over the Company or any of it properties.




    


Exhibit B
FORM OF D&O LOCK-UP AGREEMENT


[●], 20[20]
BofA Securities, Inc.
One Bryant Park
New York, New York 10036

Morgan Stanley & Co. LLC
1585 Broadway
New York, New York 10036

Goldman Sachs & Co. LLC
200 West Street New York, New York 10282
as Representatives of the several Underwriters

Re: Proposed Public Offering by NeoGenomics, Inc.
Ladies and Gentlemen:

The undersigned, an officer and/or director of NeoGenomics, Inc., a Nevada corporation (the “Company”), understands that BofA Securities, Inc., Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC (the “Representatives”) propose to enter into an Underwriting Agreement (the “Equity Underwriting Agreement”) with the Company providing for the public offering (the “Equity Offering”) of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The undersigned also understands that the Representatives propose to enter into an Underwriting Agreement (the “Convertible Notes Underwriting Agreement” and, together with the Equity Underwriting Agreement, the “Underwriting Agreements”) with the Company providing for the public offering (the “Convertible Notes Offering” and, together with the Public Equity Offering, the “Public Offering”) of convertible notes.

In recognition of the benefit that such an offering will confer upon the undersigned as a stockholder, an officer and/or a director of the Company, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each underwriter to be named in the Underwriting Agreements (collectively, the “Underwriters”) that, during the period beginning on the date hereof and ending on the date that is 90 days from the date of the Underwriting Agreements (the “Lock-Up Period”), the undersigned will not, without the prior written consent of the Representatives, on behalf of the Underwriters, directly or indirectly, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of, or otherwise dispose of or transfer any shares of Common Stock or any securities convertible into or exchangeable or exercisable for Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (collectively, the “Lock-Up Securities”), or exercise any right with respect to the registration of any of the Lock-Up Securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act of 1933, as amended; (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock-Up Securities, whether any such swap or transaction is to be settled by delivery of Common Stock or other securities, in cash or otherwise; or (iii) publicly disclose the intention to take any of the actions described in the foregoing clauses (i) or (ii) of this paragraph.


    


Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer Lock-Up Securities without the prior written consent of the Representatives, provided, in each case, that (1) the Representatives receive a signed lock-up agreement for the balance of the Lock-Up Period from each donee, trustee, distributee, or transferee, as the case may be, (2) any such transfer shall not involve a disposition for value, (3) such transfers are not required to be reported with the Securities and Exchange Commission on Form 4 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and (4) the undersigned does not otherwise voluntarily effect any public filing or report regarding such transfers (other than a filing on a Form 5 made after the expiration of the Lock-Up Period):

i.as a bona fide gift or gifts;

ii.to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned (for purposes of this lock-up agreement, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin);

iii.as a distribution or other transfer by a partnership to its partners or former partners or by a limited liability company to its members or retired members or by a corporation to its stockholders or former stockholders or to any wholly-owned subsidiary of such corporation;

iv.to the undersigned’s affiliates or to any investment fund or other entity controlled or managed by the undersigned;

v.pursuant to a qualified domestic relations order or in connection with a divorce settlement;

vi.by will or intestate succession upon the death of the undersigned; or

vii.to the Company in satisfaction of any tax withholding obligation.

Furthermore, no provision in this letter shall be deemed to restrict or prohibit (1) the transfer of the undersigned’s Lock-Up Securities to the Company in connection with the termination of the undersigned’s services to the Company, provided that any filing under Section 16 of the Exchange Act made in connection with such transfer shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this clause (1); (2) the exercise or exchange by the undersigned of any option or warrant to acquire any shares of Common Stock or options to purchase shares of Common Stock, in each case for cash or on a “cashless” or “net exercise” basis, pursuant to any stock option, stock bonus or other stock plan or arrangement; provided, however, that any such plan or arrangement is in effect on the date hereof and is described in the prospectus filed with the Securities and Exchange Commission relating to the Public Offering; and provided further, however, that the underlying shares of Common Stock may only be transferred to the Company and shall continue to be subject to the restrictions on transfer set forth in this letter and that any filing under Section 16 of the Exchange Act made in connection with such exercise or exchange shall clearly indicate in the footnotes thereto that (a) the filing relates to the circumstances described in this clause (2) and (b) no shares were sold by the reporting person; (3) the transfer of Lock-Up Securities upon the completion of a bona fide third-party tender offer, merger, consolidation or other similar transaction made to all holders of the Company’s securities involving a “change of control” (as defined below) of the Company; provided, however, that in the event that such tender offer, merger, consolidation or other such transaction is not completed, such securities held by the undersigned shall remain subject to the restrictions on transfer set forth in this letter; and (4) the conversion of outstanding preferred stock of the Company into shares of Common Stock, provided that any such shares received upon such conversion shall be subject to the restrictions on transfer set forth in this letter. “Change of control” means the consummation of any bona fide third-party tender offer, merger, consolidation or other similar transaction the result of which is that any “person” (as
    


defined in Section 13(d)(3) of the Exchange Act), or group of persons, other than the Company, becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the Exchange Act) of more than 50% of total voting power of the voting stock of the Company.

Notwithstanding anything herein to the contrary, nothing herein shall prevent the undersigned from establishing a 10b5-1 trading plan that complies with Rule 10b5-1 under the Exchange Act (“10b5-1 Trading Plan”) or from amending an existing 10b5-1 Trading Plan so long as there are no sales of Lock-Up Securities under any such 10b5-1 Trading Plan during the Lock-Up Period; and provided that, the establishment of a 10b5-1 Trading Plan or the amendment of a 10b5-1 Trading Plan shall only be permitted if (i) the establishment or amendment of such plan is not required to be reported in any public report or filing with the Securities Exchange Commission, or otherwise and (ii) the undersigned or the Company does not otherwise voluntarily effect any public filing or report regarding the establishment or amendment of such plan.

The undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the Lock-Up Securities except in compliance with the foregoing restrictions. This lock-up agreement shall automatically terminate, and the undersigned shall be released from the undersigned’s obligations hereunder, upon the earliest to occur, if any, of (i) prior to the execution of the Underwriting Agreements, the Company advises the Representatives in writing that it has determined not to proceed with the Public Offering; (ii) the Underwriting Agreements are executed but are terminated prior to the closing of the Public Offering (other than the provisions thereof which survive termination), or (iii) February 28, 2021, in the event that the Underwriting Agreements have not been executed by such date.

The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the Underwriters solicited any action from the undersigned with respect to the offering of the securities and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate.
This agreement shall be governed by, and construed in accordance with, the laws of the State of New York.

[SIGNATURE PAGE FOLLOWS]



















    


Very truly yours,

________________________________________
Name of Security Holder (Print exact name)


By:________________________________________
Signature



If not signing in an individual capacity:

________________________________________
Name of Authorized Signatory (Print)

________________________________________
Title of Authorized Signatory (Print)

(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)





























[Signature Page to Lock-Up Agreement]
    
EX-1.2 3 exhibit12underwritingagree.htm EX-1.2 Document
Exhibit 1.2
$300,000,000
NeoGenomics, Inc.
(a Nevada corporation)
0.25% Convertible Senior Notes due 2028
UNDERWRITING AGREEMENT
January 6, 2021

BofA Securities, Inc.
One Bryant Park
New York, New York 10036

Morgan Stanley & Co. LLC
1585 Broadway
New York, New York 10036

Goldman Sachs & Co. LLC
200 West Street
New York, New York 10282

as Representatives of the several Underwriters

Ladies and Gentlemen:
NeoGenomics, Inc., a Nevada corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA Securities”), Morgan Stanley & Co. LLC (“Morgan Stanley”) and Goldman Sachs & Co. LLC (“Goldman Sachs”), as representatives (the “Representatives”) of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective principal amounts set forth on Schedule A hereto of $300,000,000 aggregate principal amount of the Company’s 0.25% Convertible Senior Notes due 2028 (“Initial Securities”) and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase, solely to cover over-allotments, all or any part of an additional $45,000,000 aggregate principal amount of the Company’s 0.25% Convertible Senior Notes due 2028 (the “Option Securities” and, together with the Initial Securities, the “Securities”). The Securities are to be issued pursuant to an indenture (the “Indenture”) between the Company and U.S. Bank National Association, as trustee (the “Trustee”). The Common Stock, par value $0.001 per share, of the Company is hereinafter referred to as the “Common Stock.” The Securities will be convertible into cash, shares of Common Stock (the “Underlying Shares”), or a combination of cash and Underlying Shares at the option of the Company, as set forth in the Indenture.

The Company understands that the Underwriters propose to make a public offering of the Securities as soon as the Representatives deem advisable after this Underwriting Agreement (this “Agreement”) has been executed and delivered and the Indenture has been qualified under the Trust

    


Indenture Act of 1939, as amended (together with the rules and regulations promulgated thereunder, the “1939 Act”).
In connection with the offering of the Initial Securities, the Company is entering into capped call transactions with certain of the Underwriters or their respective affiliates and/or other financial institutions (collectively, the “Option Counterparties”) pursuant to separate capped call transaction confirmations (the “Base Capped Call Confirmations”), each to be dated the date hereof, and in connection with any exercise by the Underwriters of their option to purchase any Option Securities, the Company and the Option Counterparties may enter into additional capped call transactions pursuant to additional capped call transaction confirmations (the “Additional Capped Call Confirmations”) with each of the Option Counterparties, each to be dated the date on which the Underwriters exercise their option to purchase such Option Securities. The Base Capped Call Confirmations and the Additional Capped Call Confirmations are referred to herein collectively as the “Capped Call Confirmations”.
The Company has filed with the Securities and Exchange Commission (the “Commission”) an automatic shelf registration statement on Form S-3 (No. 333-251901), covering the public offering and sale of the Securities, under the Securities Act of 1933, as amended (the “1933 Act”) and the rules and regulations of the Commission promulgated thereunder (the “1933 Act Regulations”), which automatic shelf registration statement became automatically effective upon filing. The information included in such prospectus that was omitted from such registration statement at the time such registration statement became effective but that is deemed to be part of such registration statement at the time it became effective under Rule 462(e) under the 1933 Act Regulations (“Rule 462(e)”). Such registration statement, as of any time, means such registration statement as amended by any post-effective amendments thereto to such time, including the exhibits and any schedules thereto at such time, the documents incorporated or deemed to be incorporated by reference therein at such time pursuant to Item 12 of Form S-3 under the 1933 Act and the documents otherwise deemed to be a part thereof as of such time pursuant to Rule 430B under the 1933 Act Regulations (“Rule 430B”), is referred to herein as the “Registration Statement;” provided, however, that the “Registration Statement” without reference to a time means such registration statement as amended by any post-effective amendments thereto as of the time of the first contract of sale for the Securities, which time shall be considered the “new effective date” of such registration statement with respect to the Securities within the meaning of paragraph (f)(2) of Rule 430B, including the exhibits and schedules thereto as of such time, the documents incorporated or deemed incorporated by reference therein at such time pursuant to Item 12 of Form S-3 under the 1933 Act and the documents otherwise deemed to be a part thereof as of such time pursuant to the Rule 430B. Each preliminary prospectus used in connection with the offering of the Securities, including the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of Form S-3 under the 1933 Act, are collectively referred to herein as a “preliminary prospectus.” Promptly after execution and delivery of this Agreement, the Company will prepare and file a final prospectus relating to the Securities in accordance with the provisions of Rule 424(b) under the 1933 Act Regulations (“Rule 424(b)”). The final prospectus, in the form first furnished or made available to the Underwriters for use in connection with the offering of the Securities, including the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of Form S-3 under the 1933 Act, are collectively referred to herein as the “Prospectus.” For purposes of this Agreement, all references to the Registration Statement, any preliminary prospectus, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval system (or any successor system) (“EDGAR”).
As used in this Agreement:
    2
    


“Applicable Time” means 8:00 P.M., New York City time, on January 6, 2021 or such other time as agreed by the Company and the Representatives.
“General Disclosure Package” means any Issuer General Use Free Writing Prospectuses issued at or prior to the Applicable Time, the most recent preliminary prospectus (including any documents incorporated therein by reference) that is distributed to investors prior to the Applicable Time, all considered together.
“Issuer Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433 of the 1933 Act Regulations (“Rule 433”), including without limitation any “free writing prospectus” (as defined in Rule 405 of the 1933 Act Regulations (“Rule 405”)) relating to the Securities that is (i) required to be filed with the Commission by the Company, (ii) a “road show for an offering that is a written communication” within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Securities or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g) or (iv) the Final Term Sheet (as defined below).
“Issuer General Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors (other than a “bona fide electronic road show,” as defined in Rule 433 (a “Bona Fide Electronic Road Show”)), as evidenced by its being specified in Schedule B hereto.
“Issuer Limited Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.
“Testing-the-Waters Communication” means any communication with potential investors undertaken in reliance on Section 5(d) or Rule 163B of the Securities Act.
All references in this Agreement to financial statements and schedules and other information which is “contained,” “included” or “stated” (or other references of like import) in the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include all such financial statements and schedules and other information incorporated or deemed incorporated by reference in the Registration Statement, any preliminary prospectus or the Prospectus, as the case may be, prior to the execution and delivery of this Agreement; and all references in this Agreement to amendments or supplements to the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include the filing of any document under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the “1934 Act”), incorporated or deemed to be incorporated by reference in the Registration Statement, such preliminary prospectus or the Prospectus, as the case may be, at or after the execution and delivery of this Agreement.
SECTION 1.Representations and Warranties.
(a)Representations and Warranties by the Company. The Company represents and warrants to each Underwriter as of the date hereof, the Applicable Time, the Closing Time (as defined below) and any Date of Delivery (as defined below), and agrees with each Underwriter, as follows:
(i) Registration Statement and Prospectuses. The Company meets the requirements for use of Form S-3 under the 1933 Act. Each of the Registration Statement and any amendment
    3
    


thereto has become effective under the 1933 Act. No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued by the Commission under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued by the Commission and no proceedings for any of those purposes have been instituted by the Commission or are pending or, to the Company’s knowledge, contemplated by the Commission. The Company has complied with each request (if any) from the Commission for additional information.
Each of the Registration Statement and any post-effective amendment thereto, at the time of its effectiveness and at each deemed effective date with respect to the Underwriters pursuant to Rule 430B(f)(2) under the 1933 Act Regulations, the Applicable Time, the Closing Time and any Date of Delivery complied and will comply in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus, the Prospectus and any amendment or supplement thereto, at the time each was filed with the Commission, and, in each case, at the Applicable Time, the Closing Time and any Date of Delivery complied and will comply in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus delivered to the Underwriters for use in connection with the offering and the Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.
The documents incorporated or deemed to be incorporated by reference in the Registration Statement, any preliminary prospectus and the Prospectus, when they became effective or at the time they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the 1934 Act and the rules and regulations of the Commission under the 1934 Act (the “1934 Act Regulations”).
The Registration Statement, any preliminary prospectus and the Prospectus, and the filing of the Registration Statement, any preliminary prospectus and the Prospectus with the Commission have been duly authorized by and on behalf of the Company, and the Registration Statement has been duly executed pursuant to such authorization.
(ii) Accurate Disclosure. Neither the Registration Statement nor any amendment thereto, at its effective time, on the date hereof, at the Closing Time or at any Date of Delivery, contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the Applicable Time, neither (A) the General Disclosure Package nor (B) any individual Issuer Limited Use Free Writing Prospectus, and (C) and individual Written Testing-the-Waters Communication, when considered together with the General Disclosure Package, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Neither the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b), at the Closing Time or at any Date of Delivery, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, at the time the Registration Statement
    4
    


became effective or when such documents incorporated by reference were filed with the Commission, as the case may be, when read together with the other information in the Registration Statement, the General Disclosure Package or the Prospectus, as the case may be, did not and will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.
The representations and warranties in this subsection shall not apply to (i) the Statement of Eligibility (Form T-1) of the Trustee under the 1939 Act or (ii) statements in or omissions from the Registration Statement (or any amendment thereto), the General Disclosure Package or the Prospectus (or any amendment or supplement thereto, including any prospectus wrapper) made in reliance upon and in conformity with written information furnished to the Company by any Underwriter through the Representatives expressly for use therein. For purposes of this Agreement, the only information so furnished shall be the following: the statements concerning stabilizing transactions and syndicate covering transactions under the caption “Underwriting—Price Stabilization and Short Positions” and the statements under the caption “Electronic Prospectus” (beginning “A prospectus in electronic format…”) of the “Underwriting” section of the Prospectus (collectively, the “Underwriter Information”).
(iii) Issuer Free Writing Prospectuses. No Issuer Free Writing Prospectus conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including any document incorporated by reference therein, and any preliminary or other prospectus deemed to be a part thereof that has not been superseded or modified. No filing of any “road show” (as defined in Rule 433(h)) is required in connection with the offering of the Securities. Any Issuer Free Writing Prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the 1933 Act and the 1933 Act Regulations. Each Issuer Free Writing Prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the 1933 Act or that was prepared by or behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Except for the Issuer Free Writing Prospectuses, if any, identified in Schedule B hereto, and electronic road shows, if any, each furnished to the Representatives before first use, the Company has not prepared, used or referred to, and will not, without the prior consent of the Representatives, prepare, use or refer to, any issuer free writing prospectus.
(iv) Well-Known Seasoned Issuer. (A) At the time of the most recent amendment of the Registration Statement for the purposes of complying with Section 10(a)(3) of the 1933 Act (whether such amendment was by post-effective amendment, incorporated report filed pursuant to Section 13 or 15(d) of the 1934 Act or form of prospectus), (B) at the time the Company or any person acting on its behalf (within the meaning, for this clause only, of Rule 163(c) under the 1933 Act) made any offer relating to the Securities in reliance on the exemption of Rule 163 under the 1933 Act, and (C) as of the Applicable Time, the Company was and is a “well-known seasoned issuer” (as defined in Rule 405).
(v) Company Not Ineligible Issuer. At the time of filing the Registration Statement and any post-effective amendments thereto, at the earliest time thereafter that the Company or another offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) of the 1933 Act Regulations) of the Securities and at the date hereof, the Company was not and is not an “ineligible issuer,” as defined in Rule 405, without taking account of any determination by the
    5
    


Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible issuer.
(vi) Independent Accountants. Each of the accountants who certified the financial statements and supporting schedules included in or incorporated by reference into the Registration Statement, the General Disclosure Package and the Prospectus are independent public accountants as required by the 1933 Act, the 1933 Act Regulations, the 1934 Act, the 1934 Act Regulations and the Public Company Accounting Oversight Board (United States).
(vii) Financial Statements; Non-GAAP Financial Measures. The financial statements included or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, together with the related schedules and notes, comply as to form in all material respects with Regulation S-X under the 1933 Act and present fairly, in all material respects, the financial position of the Company and its consolidated Subsidiaries (as defined below) at the dates indicated and the statement of operations, stockholders’ equity and cash flows of the Company and its consolidated Subsidiaries for the periods specified; said financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) applied on a consistent basis throughout the periods involved, except, in the case of unaudited, interim financial statements, subject to normal year-end adjustments. The supporting schedules, if any, present fairly, in all material respects, in accordance with GAAP the information required to be stated therein. The selected financial data and the summary financial information included in the Registration Statement, the General Disclosure Package and the Prospectus present fairly, in all material respects, the information shown therein and have been compiled on a basis consistent with that of the audited financial statements included therein. Except as included therein, no other historical or pro forma financial statements or supporting schedules are required to be included or incorporated by reference in the Registration Statement, the General Disclosure Package or the Prospectus under the 1933 Act or the 1933 Act Regulations. All disclosures contained in the Registration Statement, the General Disclosure Package or the Prospectus, or incorporated by reference therein, regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the Commission) comply with Regulation G of the 1934 Act, and Item 10 of Regulation S-K, to the extent applicable. The interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto.
(viii) Compliance with the Sarbanes-Oxley Act of 2002. There is and has been no failure on the part of the Company or any of the Company’s directors or officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith, including Section 402 related to loans and Sections 302 and 906 related to certifications.
(ix) No Material Adverse Change in Business. Except as otherwise stated therein, since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, (A) there has been no material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its Subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business (a “Material Adverse Effect”), (B) there have been no transactions entered into by the Company or its Subsidiaries, other than those in the ordinary course of business, which are
    6
    


material with respect to the Company and its Subsidiaries considered as one enterprise, (C) there have been no material liabilities or obligations, direct or contingent, entered into by the Company or any of its Subsidiaries and (D) there has been no dividend or distribution of any kind declared, paid or made by the Company on any class of its capital stock.
(x) Good Standing of the Company. The Company has been duly organized and is validly existing as a corporation in good standing under the laws of the State of Nevada and has corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and to enter into and perform its obligations under this Agreement, the Indenture, the Securities and the Capped Call Confirmations (collectively, the “Transaction Agreements”); and the Company is duly qualified as a foreign corporation to transact business and is in good standing in each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified or to be in good standing would not result in a Material Adverse Effect.
(xi) Good Standing of the Company’s Subsidiaries. Each subsidiary of the Company (collectively, the “Subsidiaries”) has been duly organized and is validly existing in good standing under the laws of the jurisdiction of its incorporation or organization, has corporate or similar power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified or to be in good standing would not result in a Material Adverse Effect. Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, all of the issued and outstanding capital stock of each Subsidiary has been duly authorized and validly issued, is fully paid and non-assessable and is owned by the Company, directly or through Subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance, claim or equity. None of the outstanding shares of capital stock of any Subsidiary was issued in violation of the preemptive or similar rights of any securityholder of such Subsidiary. The only Subsidiaries are the entities listed on Exhibit 21 to the Company’s annual report on Form 10-K, as amended.
(xii) Capitalization. The authorized, issued and outstanding shares of capital stock of the Company are as set forth in the Registration Statement, the General Disclosure Package and the Prospectus. The outstanding shares of capital stock of the Company have been duly authorized and are validly issued, fully paid and non-assessable. None of the outstanding shares of capital stock of the Company was issued in violation of the preemptive or other similar rights of any securityholder of the Company.
(xiii) Authorization of Agreement. This Agreement has been duly authorized, executed and delivered by the Company.
(xiv) Authorization of Indenture.    The Indenture has been duly authorized by the Company and duly qualified under the 1939 Act and, when duly executed and delivered by the Company and the Trustee, the Indenture will constitute a valid and binding agreement of the Company, enforceable against the Company in accordance with its terms, except as the enforcement thereof may be limited by bankruptcy, insolvency (including, without limitation, all laws relating to fraudulent transfers), reorganization, moratorium or other similar laws relating to or affecting
    7
    


enforcement of creditors’ rights generally and except as enforcement thereof is subject to general principles of equity (regardless of whether enforcement is considered in a proceeding in equity or at law) (collectively, the “Enforceability Exceptions”).
(xv) Authorization and Description of Securities. The Securities have been duly authorized and, when authenticated, issued and delivered in the manner provided for in the Indenture and paid for as provided for in this Agreement, will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, subject to the Enforceability Exceptions; and the issuance of the Securities is not subject to the preemptive or other similar rights of any securityholder of the Company. The Securities and the Common Stock conform in all material respects to all statements relating thereto contained in the Registration Statement, the General Disclosure Package and the Prospectus and such descriptions conform in all material respects to the rights set forth in the instruments defining the same. No holder of Securities will be subject to personal liability by reason of being such a holder.
(xvi) Authorization of Underlying Shares. Upon authentication, issuance and delivery of the Securities in accordance with this the Indenture and this Agreement, the Securities will be convertible into cash, Underlying Shares or a combination thereof in accordance with the terms of the Securities; the maximum number of Underlying Shares issuable upon conversion of the Securities (assuming the Underwriters exercise in full their option to purchase Option Securities, and including the maximum number of shares of Common Stock that may be issued upon conversions of Securities in connection with any “Make-Whole Fundamental Change” (as such terms are defined in the Indenture) and assuming physical settlement of all such conversions) (such maximum number of shares of Common Stock, the “Maximum Number of Underlying Shares”) has been duly authorized and reserved for issuance and, when issued upon conversion of the Securities in accordance with the terms of the Securities, such Maximum Number of Underlying Shares will be validly issued, fully paid and non-assessable, and the issuance of such Maximum Number of Underlying Shares will not be subject to any pre-emptive or similar rights.
(xvii) Authorization of Capped Call Confirmations. The Base Capped Call Confirmations have been, and any Additional Capped Call Confirmations on the date or dates that the Underwriters exercise their right to purchase the relevant Option Securities will have been, duly authorized, executed and delivered by the Company and, assuming due execution and delivery thereof by the Option Counterparties, constitute, or will constitute, as the case may be, valid and legally binding agreements of the Company enforceable against the Company in accordance with their terms, subject to the Enforceability Exceptions.
(xviii) Descriptions of the Transaction Agreements. Each of the Transaction Agreements conforms in all material respects to the description thereof contained in the Registration Statement, the General Disclosure Package and the Prospectus.
(xix) Registration Rights. There are no persons with registration rights or other similar rights to have any securities registered for sale pursuant to the Registration Statement or otherwise registered for sale or sold by the Company under the 1933 Act pursuant to this Agreement, other than those rights that have been disclosed in the Registration Statement, the General Disclosure Package and the Prospectus and have been waived.
(xx) Absence of Violations, Defaults and Conflicts. Neither the Company nor any Subsidiary is (A) in violation of its charter, by-laws or similar organizational document, (B) in
    8
    


default in the performance or observance of any obligation, agreement, covenant or condition contained in any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument to which the Company or any Subsidiary is a party or by which either of them may be bound or to which any of the properties or assets of the Company or any Subsidiary is subject (collectively, “Agreements and Instruments”), except for such defaults that would not, singly or in the aggregate, result in a Material Adverse Effect, or (C) in violation of any law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental body, regulatory body, administrative agency or other authority, body or agency having jurisdiction over the Company or its Subsidiaries or any of their respective properties, assets or operations (each, a “Governmental Entity”), except for such violations that would not, singly or in the aggregate, result in a Material Adverse Effect. The execution, delivery and performance of the Transaction Agreements and the consummation of the transactions contemplated thereby and in the Registration Statement, the General Disclosure Package and the Prospectus (including the issuance and sale of the Securities and the use of the proceeds from the sale of the Securities as described therein under the caption “Use of Proceeds”) and compliance by the Company with its obligations hereunder have been duly authorized by all necessary corporate action and do not and will not, whether with or without the giving of notice or passage of time or both, conflict with or constitute a breach of, or default or Repayment Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any properties or assets of the Company or its Subsidiaries pursuant to, the Agreements and Instruments (except for such conflicts, breaches, defaults or Repayment Events or liens, charges or encumbrances that would not, singly or in the aggregate, result in a Material Adverse Effect), nor will such action result in any violation of the provisions of the charter, by-laws or similar organizational document of the Company or its Subsidiaries or any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Entity. As used herein, a “Repayment Event” means any event or condition which gives the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or its Subsidiaries.
(xxi) Listing. The Company has submitted an application to list the number of shares of Common Stock equal to the Maximum Number of Underlying Shares on The Nasdaq Capital Market. To the Company’s knowledge, it is in compliance with all applicable listing requirements of The Nasdaq Capital Market.
(xxii) Absence of Labor Dispute. No labor dispute with the employees of the Company or its Subsidiaries exists or, to the knowledge of the Company, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or its Subsidiaries’ principal suppliers, manufacturers, customers or contractors, which, in either case, would result in a Material Adverse Effect.
(xxiii) Absence of Proceedings. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, there is no action, suit, proceeding, inquiry or investigation before or brought by any Governmental Entity (including, without limitation, any action, suit proceeding, inquiry or investigation before or brought by the U.S. Food and Drug Administration (the “FDA”)) now pending or, to the knowledge of the Company, threatened, against or affecting the Company or its Subsidiaries, which would reasonably be expected to result in a Material Adverse Effect, or which would reasonably be expected to materially and adversely affect (A) the possession by any of them of any Governmental Licenses (as defined
    9
    


herein) currently held by any of them, (B) the accreditation of any of their respective laboratories with the College of American Pathologists (“CAP”), (C) any of their qualification to perform services for and receive reimbursement from, Medicaid or Medicare, (D) any of their ability to conduct their clinical testing business in any state or (E) their respective properties or assets or the consummation of the transactions contemplated in the Transaction Agreements or the performance by the Company of its obligations thereunder; and the aggregate of all pending legal or governmental proceedings to which the Company or any such Subsidiary is a party or of which any of their respective properties or assets is the subject which are not described in the Registration Statement, the General Disclosure Package and the Prospectus, including ordinary routine litigation incidental to the business, would not reasonably be expected to result in a Material Adverse Effect.
(xxiv) Accuracy of Exhibits. There are no contracts or documents which are required to be described in the Registration Statement, the General Disclosure Package or the Prospectus or to be filed as exhibits to the Registration Statement which have not been so described and filed as required.
(xxv) Absence of Further Requirements. No filing with, or authorization, approval, consent, license, order, registration, qualification or decree of, any Governmental Entity is necessary or required for the performance by the Company of its obligations under the Transaction Agreements, in connection with the offering, issuance or sale of the Securities (including the issuance of any shares of Common Stock upon conversion thereof) or the consummation of the transactions contemplated by the Transaction Agreements, except such as have been already obtained or as may be required under the 1933 Act, the 1933 Act Regulations, the rules of the NASDAQ Stock Market LLC, state securities laws, the rules of FINRA, or in connection with the qualification of the Indenture under the 1939 Act.
(xxvi) Possession of Licenses and Permits. The Company and its Subsidiaries possess such permits, licenses, approvals, consents and other authorizations required (i) under the Medicare and Medicaid programs, (ii) under the Clinical Laboratories Improvement Act of 1967, as amended (“CLIA”) and (iii) as otherwise necessary to conduct the business now operated by them respectively, issued by United States Centers for Medicare and Medicaid Services (“CMS”), the FDA and each other appropriate federal, state, local or foreign regulatory agencies or bodies including, but not limited to, any foreign regulatory authorities performing functions similar to their respective functions (collectively, “Governmental Licenses”) issued by the appropriate Governmental Entities necessary to conduct the business now operated by them, except where the failure so to possess would not, singly or in the aggregate, result in a Material Adverse Effect. The Company and its Subsidiaries are in compliance with the terms and conditions of all Governmental Licenses, except where the failure so to comply would not, singly or in the aggregate, result in a Material Adverse Effect. All of the Governmental Licenses are valid and in full force and effect, except when the invalidity of such Governmental Licenses or the failure of such Governmental Licenses to be in full force and effect would not, singly or in the aggregate, result in a Material Adverse Effect. Neither the Company nor its Subsidiaries has received any notice of proceedings relating to the revocation or modification of any Governmental Licenses which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Effect, and nor are there, to the knowledge of the Company, any pending or threatened actions, suits, claims or proceedings against the Company or any subsidiary before any court, governmental agency or body including, but not limited to, CMS and the FDA or otherwise that would reasonably be expected to limit, revoke, cancel, suspend or
    10
    


cause not to be renewed any Governmental Licenses, in each case, which would result in a Material Adverse Effect.
(xxvii) Title to Property. The Company and its Subsidiaries have good and marketable title to all real property owned by them and good title to all other properties owned by them, in each case, free and clear of all mortgages, pledges, liens, security interests, claims, restrictions or encumbrances of any kind except such as (A) are described in the Registration Statement, the General Disclosure Package and the Prospectus or (B) do not, singly or in the aggregate, materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company or its Subsidiaries; and all of the leases and subleases material to the business of the Company and its Subsidiaries, considered as one enterprise, and under which the Company or its Subsidiaries holds properties described in the Registration Statement, the General Disclosure Package or the Prospectus, are in full force and effect, and neither the Company nor any such Subsidiary has any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or any Subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or such Subsidiary to the continued possession of the leased or subleased premises under any such lease or sublease.
(xxviii) Title to Intellectual Property.  Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, the Company and its Subsidiaries own or have valid, binding and enforceable licenses or other rights under any and all patents, licenses, inventions, copyrights, know how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade names and all other similar intellectual property or proprietary rights throughout the world (including all registrations and applications for registration of, and all goodwill associated with, the foregoing), necessary for, or used in, the conduct, or the proposed conduct, of the business of the Company in the manner described in the Registration Statement, the General Disclosure Package and the Prospectus (collectively, the “Intellectual Property”); the Intellectual Property is valid, enforceable, and subsisting and is owned free and clear of all liens, encumbrances, defects and other restrictions; other than as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, (A) neither the Company nor any of its Subsidiaries is obligated to pay a material royalty, grant a license to, or provide other material consideration to any third party in connection with the Intellectual Property, (B) neither the Company nor any of its Subsidiaries have not received any notice of any claim of infringement, misappropriation or other violation with any rights of others with respect to any of the Company’s products, services, processes or Intellectual Property, (C) neither the sale nor use of any of the discoveries, inventions, products, services or processes of the Company or its Subsidiaries referred to in the Registration Statement, the General Disclosure Package or the Prospectus do or will infringe, misappropriate or otherwise violate any rights of any third party, (D) none of the technology employed by the Company or any of its Subsidiaries has been obtained or is being used by the Company or any of its Subsidiaries in material violation of any contractual obligation binding on the Company or any of its subsidiaries or any of their respective officers, directors or employees or otherwise in violation of the rights of any persons, (E) no third party has any ownership right in or to any Intellectual Property that is owned by the Company or any of its Subsidiaries, other than any co-owner of any patent constituting Intellectual Property who is listed on the records of the U.S. Patent and Trademark Office (the “USPTO”) and any co-owner of any patent application constituting Intellectual Property who is named in such patent application, and, to the knowledge of the Company, no third party has any ownership right in or
    11
    


to any Intellectual Property in any field of use that is exclusively licensed to the Company or any of its Subsidiaries, other than any licensor to the Company or any of its Subsidiaries of such Intellectual Property, (F) to the knowledge of the Company, there is no infringement by third parties of any Intellectual Property, (G) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others (x) challenging the Company’s or any Subsidiary’s rights in or to any Intellectual Property, (y) challenging the ownership, validity, enforceability or scope of any Intellectual Property, or (z) alleging that the Company or any Subsidiary has infringed, misappropriated or otherwise violated any rights of any third party, and in the case of each of (x), (y) and (z), the Company is not aware of any facts that would form a reasonable basis for any such action, suit, proceeding or claim, (H) the Company and its Subsidiaries have at all times taken all reasonable steps in accordance with normal industry practice to maintain the confidentiality of all Intellectual Property, the value of which to the Company is contingent upon maintaining the confidentiality thereof, and (I) all founders, current and former employees, contractors, consultants and other parties involved in the development of the Intellectual Property have signed valid and enforceable confidentiality and invention assignment agreements with the Company or a Subsidiary pursuant to which the Company or a Subsidiary has obtained ownership and is the exclusive owner of such Intellectual Property.  The Company and its Subsidiaries are in compliance with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company, and all such agreements are in full force and effect.
(xxix) Patents and Patent Applications.  All patents and patent applications owned by or, to the knowledge of the Company, licensed to the Company and its Subsidiaries, or under which the Company or any Subsidiary otherwise has rights, have been duly and properly filed and maintained; the parties prosecuting the patent applications owned by or, to the knowledge of the Company, licensed to the Company or any of its Subsidiaries have complied with their duty of candor and disclosure to the USPTO in connection with such applications; and the Company is not aware of any facts required to be disclosed to the USPTO that were not disclosed to the USPTO and which would preclude the grant of a patent in connection with any such application or would reasonably be expected to form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications.  All patents and patent applications owned by the Company and its Subsidiaries and filed with the USPTO or any foreign or international patent authority (the “Company Patent Rights”) and, to the Company’s knowledge, all patents and patent applications in-licensed by the Company and its Subsidiaries and filed with the USPTO or any foreign or international patent authority (the “In-licensed Patent Rights”) have been duly and properly filed; the Company and its Subsidiaries have complied with their duty of candor and disclosure to the USPTO for the Company Patent Rights and, to the Company’s knowledge, the licensors of the In-licensed Patent Rights have complied with their duty of candor and disclosure to the USPTO for the In-licensed Patent Rights.
(xxx) FDA Compliance. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, the Company: (A) is and at all times has been in material compliance with all statutes, rules or regulations of the FDA and other comparable Governmental Entities applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed by the Company (“Applicable Laws”); (B) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA or any Governmental Authority alleging or asserting material noncompliance with any Applicable Laws
    12
    


or any licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”); (C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and the Company is not in material violation of any term of any such Authorizations; (D) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any Governmental Authority or third party alleging that any product operation or activity is in material violation of any Applicable Laws or Authorizations and has no knowledge that the FDA or any Governmental Authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (E) has not received notice that the FDA or any Governmental Authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has no knowledge that the FDA or any Governmental Authority is considering such action; and (F) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission).
(xxxi) Licensing and Accreditation of Laboratories. All of the regional laboratories of the Company and its subsidiaries are eligible for accreditation by CAP and are so accredited, and all of the laboratories of the Company and the Subsidiaries are in compliance, in all material respects, with the standards required by CLIA. Except as disclosed in the General Disclosure Package or as would not reasonably be expected to have a Material Adverse Effect, since January 1, 2015, the Company and its subsidiaries have not had any clinical laboratory test that it performs (“Test”) or laboratory site (whether Company-owned, or Company subsidiary-owned subject to a governmental authority (including the FDA) shutdown, and to the Company’s knowledge, neither the FDA nor any other governmental authority is considering such action.
(xxxii) Safety Notices. Except as would not reasonably be expected to have a Material Adverse Effect, (i) there have been no recalls, field notifications, field corrections, market withdrawals or replacements, warnings, “dear doctor” letters, investigator notices, safety alerts or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Company’s Tests (collectively, “Safety Notices”) since January 1, 2015, (ii) such Safety Notices, if any, were resolved or closed, and (iii) to the Company’s knowledge, there are no material complaints with respect to the Company’s Tests that are currently unresolved; to the Company’s knowledge, there are no facts that would be reasonably likely to result in (x) a material Safety Notice with respect to the Company’s Test candidates, (y) a material change in labeling of any the Company’s Tests, or (z) a termination or suspension of marketing or performing of any of the Company Tests;
(xxxiii) Compliance with Health Care Laws. The Company has operated and currently is in compliance with all applicable health care laws, rules and regulations (except where such failure to operate or non-compliance would not, singly or in the aggregate, result in a Material Adverse Effect), including, without limitation, (i) the Federal, Food, Drug and Cosmetic Act (21 U.S.C. §§ 301 et seq.); (ii) all applicable federal, state, local and all applicable foreign healthcare related fraud and abuse laws, including, without limitation, the federal Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)), the U.S. Physician Payments Sunshine Act (42 U.S.C. § 1320a-7h), the civil False Claims Act (31 U.S.C. §§ 3729 et seq.), the criminal False Claims Law (42 U.S.C. § 1320a-7b(a)), all criminal laws relating to healthcare fraud and abuse, including but not limited to
    13
    


18 U.S.C. Sections 286 and 287, the healthcare fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) (42 U.S.C. Section 1320d et seq.), the exclusion laws (42 U.S.C. § 1320a-7), Section 1877 of the Social Security Act (42 U.S.C. 1395nn), and the civil monetary penalties law (42 U.S.C. § 1320a-7a); (iii) HIPAA, as amended by the Health Information Technology for Economic Clinical Health Act (42 U.S.C. Section 17921 et seq.); (iv) the regulations promulgated pursuant to such laws; and (v) any other similar local, state, federal, or foreign laws (collectively, the “Health Care Laws”). Neither the Company, nor to the Company’s knowledge, any of its officers, directors, employees or agents have engaged in activities which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other state or federal healthcare program. The Company has not received written notice or other correspondence of any claim, action, suit, audit, survey, proceeding, hearing, enforcement, investigation, arbitration or other action (“Action”) from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care Laws, and, to the Company’s knowledge, no such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is threatened. The Company is not a party to and does not have any ongoing reporting obligations pursuant to any corporate integrity agreement, deferred prosecution agreement, monitoring agreement, consent decree, settlement order, plan of correction or similar agreement imposed by any governmental or regulatory authority. Additionally, neither the Company, nor to the Company’s knowledge, any of its employees, officers or directors, has been excluded, suspended or debarred from participation in any U.S. state or federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.
(xxxiv) Environmental Laws. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus or would not, singly or in the aggregate, result in a Material Adverse Effect, (A) neither the Company nor any Subsidiary is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products, asbestos-containing materials or toxic mold (collectively, “Hazardous Materials”) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, “Environmental Laws”), (B) the Company and its Subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws for the ownership or operation of their businesses or the occupancy or use of their real property facilities and are each in compliance with their requirements, (C) there are no pending or, to the knowledge of the Company threatened, administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any Subsidiary and (D) to the knowledge of the Company, there are no events or circumstances that would reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or Governmental Entity, against or affecting the Company or any Subsidiary relating to Hazardous Materials or any Environmental Laws.
    14
    


(xxxv) Accounting Controls and Disclosure Controls. The Company and each of its Subsidiaries maintain effective internal control over financial reporting (as defined under Rule 13-a15 and 15d-15 under the rules and regulations of the Commission under the 1934 Act Regulations and a system of internal accounting controls sufficient to provide reasonable assurances that (A) transactions are executed in accordance with management’s general or specific authorization; (B) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (C) access to assets is permitted only in accordance with management’s general or specific authorization; (D) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (E) the interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission’s rules and guidelines applicable thereto. Since the end of the Company’s most recent audited fiscal year, there has been (1) no material weakness in the Company’s internal control over financial reporting (whether or not remediated) and (2) no change in the Company’s internal control over financial reporting that has materially adversely affected, or is reasonably likely to materially adversely affect, the Company’s internal control over financial reporting. The Company and each of its Subsidiaries maintain an effective system of disclosure controls and procedures (as defined in Rule 13a-15 and Rule 15d-15 under the 1934 Act Regulations) that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and is accumulated and communicated to the Company’s management, including its principal executive officer or officers and principal financial officer or officers, as appropriate, to allow timely decisions regarding disclosure.
(xxxvi) Payment of Taxes. The Company and each of its Subsidiaries have filed all federal, state, local and foreign tax returns required to be filed through the date of this Agreement or have requested extensions thereof (except where the failure to file would not, individually or in the aggregate, have a Material Adverse Effect) and have paid all taxes required to be paid thereon (except for cases in which the failure to file or pay would not have a Material Adverse Effect, or, except as currently being contested in good faith and for which reserves required by U.S. GAAP have been recorded in the financial statements of the Company), and no tax deficiency has been determined adversely to the Company or any of its Subsidiaries which has had (and none of the Company and its Subsidiaries has any notice or knowledge of any tax deficiency which could reasonably be expected to be determined adversely to the Company or its Subsidiaries and which could reasonably be expected to have) a Material Adverse Effect.
(xxxvii) Insurance. The Company and its Subsidiaries carry or are entitled to the benefits of insurance, with financially sound and reputable insurers, in such amounts and covering such risks as is generally maintained by companies of established repute engaged in the same or similar business, and all such insurance is in full force and effect. The Company has no reason to believe that it or its Subsidiaries will not be able (A) to renew its existing insurance coverage as and when such policies expire or (B) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse Effect. Neither of the Company nor its Subsidiaries has been denied any insurance coverage which it has sought or for which it has applied.
    15
    


(xxxviii) Investment Company Act. The Company is not required, and after giving effect to the transactions contemplated by the Capped Call Confirmations, the issuance and sale of the Securities as herein contemplated and the application of the net proceeds therefrom as described in the Registration Statement, the General Disclosure Package and the Prospectus, will not be required, to register as an “investment company” under the Investment Company Act of 1940, as amended (the “1940 Act”).
(xxxix) Absence of Manipulation. Neither the Company nor any affiliate of the Company has taken, nor will the Company or any affiliate take, directly or indirectly, any action which is designed, or would be expected, to cause or result in, or which constitutes, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities or to result in a violation of Regulation M under the 1934 Act.
(xl) Underlying Shares. The Company will reserve and keep available at all times, free of pre-emptive rights, the number of shares of Common Stock equal to the Maximum Number of Underlying Shares for the purpose of enabling the Company to satisfy all obligations to issue Underlying Shares upon conversion of the Securities. The Company shall maintain the listing of such number of shares of Common Stock on The Nasdaq Capital Market.
(xli) Foreign Corrupt Practices Act. None of the Company, its Subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other person acting on behalf of the Company or its Subsidiaries is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the “FCPA”), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA and the Company and its Subsidiaries have and, to the knowledge of the Company, its affiliates have conducted their businesses in compliance with the FCPA and applicable anti-corruption laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed to ensure, and which are reasonably expected to continue to ensure, continued compliance with such laws and with the representations and warranties contained herein.
(xlii) Money Laundering Laws. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the “Money Laundering Laws”); and no action, suit or proceeding by or before any Governmental Entity involving the Company or its Subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.
(xliii) OFAC. None of the Company, its Subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or representative of the Company or its
    16
    


Subsidiaries is an individual or entity (“Person”) is, or is owned or controlled by one or more Persons that are the subject or target of any sanctions administered or enforced by the United States Government, including, without limitation, the U.S. Department of the Treasury’s Office of Foreign Assets Control, the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority (collectively, “Sanctions”), nor is the Company located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, Crimea, Cuba, Iran, North Korea and Syria); and the Company and its Subsidiaries have not knowingly engaged in, are not now knowingly engaged in, and will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions; and the Company will not, directly or indirectly, use the proceeds of the sale of the Securities, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partners or other Person: (i) to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions or (ii) in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise).
(xliv) Lending Relationship. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company (i) does not have any material lending or other relationship with any banking or lending affiliate of any Underwriter and (ii) does not intend to use any of the proceeds from the sale of the Securities to repay any outstanding debt owed to any affiliate of any Underwriter.
(xlv) Statistical and Market-Related Data. Any statistical and market-related data included in the Registration Statement, the General Disclosure Package or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate in all material respects and, to the extent required, the Company has obtained the written consent to the use of such data from such sources.
(xlvi) Maintenance of Rating. The Company has no debt securities or preferred stock that is rated by any “nationally recognized statistical rating organization” (as that term is defined by the Commission for purposes of Rule 436(g)(2) under the 1933 Act).
(xlvii) No Broker Fees. Except as disclosed in the General Disclosure Package, there are no contracts, agreements or understandings between the Company and any person that would give rise to a valid claim against the Company or any Underwriter for a brokerage commission, finder’s fee or other like payment in connection with the offering of the Securities contemplated hereby.
(xlviii) Cybersecurity. (i)(x) Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, there has been no security breach or other compromise of or relating to any of the information technology and computer systems, networks, hardware, software, data, equipment or technology owned, held or used by or for the Company (including the data of its customers, employees, suppliers, vendors and any third party data maintained by or on behalf of the Company) (collectively, the “IT Systems and Data”) and (y) the Company has not been notified of, and has no knowledge of any event or condition that would reasonably be expected to result in, any security breach or other compromise to the IT Systems and Data; (ii) the Company has complied, and is presently in compliance, with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or
    17
    


regulatory authority, internal policies and contractual obligations relating to (x) the collection, use, transfer, storage, protection, disposal and/or disclosure of personally identifiable information collected from or provided by third parties, (y) the privacy and security of the IT Systems and Data and (z) the protection of the IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, in the case of this clause (ii), individually or in the aggregate, have a Material Adverse Effect; and (iii) the Company has taken commercially reasonable steps to protect the IT Systems and Data, including by implementing backup, security and disaster recovery plans, procedures and technology consistent with industry standards and practices.
(xlix) Testing-the-Waters Materials. The Company (i) has not alone engaged in any Testing-the-Waters Communication with any person other than Testing-the-Waters Communications with the consent of the Representatives with entities that are qualified institutional buyers within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act and (ii) has not distributed any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the Securities Act (a “Written Testing-the-Waters Communication”) other than those listed on Schedule D hereto.
(b)Officer’s Certificates. Any certificate signed by any officer of the Company delivered to the Representatives or to counsel for the Underwriters shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered thereby.
SECTION 2.Sale and Delivery to Underwriters; Closing.
(a)Initial Securities. On the basis of the representations and warranties herein contained and subject to the terms and conditions herein set forth, the Company agrees to sell to each Underwriter, severally and not jointly, and each Underwriter, severally and not jointly, agrees to purchase from the Company, at a price equal to 97.00% of the principal amount thereof (the “Purchase Price”), plus accrued interest, if any, from January 11, 2021, the aggregate principal amount of Initial Securities set forth in Schedule A opposite the name of such Underwriter, plus any additional amount of Initial Securities which such Underwriter may become obligated to purchase pursuant to the provisions of Section 10 hereof, subject, in each case, to such adjustments among the Underwriters as the Representatives in their sole discretion shall make to ensure that any sales or purchases are in authorized denominations of $1,000.
(b)Option Securities. In addition, on the basis of the representations and warranties herein contained and subject to the terms and conditions herein set forth, the Company hereby grants an option to the Underwriters, severally and not jointly, to purchase up to all or any part of the Option Securities solely to cover over-allotments, at the Purchase Price, plus accrued interest, if any, from January 11, 2021. The option hereby granted may be exercised for 30 days after the date hereof and may be exercised in whole or in part at any time from time to time upon notice by the Representatives to the Company setting forth the principal amount of Option Securities as to which the several Underwriters are then exercising the option and the time and date of payment and delivery for such Option Securities. Any such time and date of delivery (a “Date of Delivery”) shall be determined by the Representatives, but any Date of Delivery after the Closing Time shall not be later than seven full business days nor earlier than two full business days after the exercise of said option, nor in any event prior to the Closing Time. If the option is exercised as to all or any portion of the Option Securities, each of the Underwriters, acting severally and not jointly, will purchase that proportion of the total amount of Option Securities then being purchased which the amount of Initial Securities set forth in Schedule A opposite the name of such Underwriter
    18
    


bears to the total principal amount of Initial Securities, subject, in each case, to such adjustments among the Underwriters as the Representatives in their sole discretion shall make to ensure that any sales or purchases are in authorized denominations of $1,000.
(c)Payment. Payment of the purchase price for the Initial Securities shall be made at the offices of Davis Polk & Wardwell LLP, or at such other place as shall be agreed upon by the Representatives and the Company, at 10:00 A.M. (New York City time) on the second (third, if the pricing occurs after 4:30 P.M. (New York City time) on any given day) business day after the date hereof (unless postponed in accordance with the provisions of Section 10), or such other time not later than ten business days after such date as shall be agreed upon by the Representatives and the Company (such time and date of payment and delivery being herein called the “Closing Time”). Delivery of the Initial Securities at the Closing Time shall be made through the facilities of The Depository Trust Company unless the Representatives shall otherwise instruct.
In addition, in the event that any or all of the Option Securities are purchased by the Underwriters, payment of the purchase price for such Option Securities shall be made at the above-mentioned offices, or at such other place as shall be agreed upon by the Representatives and the Company, on each Date of Delivery as specified in the notice from the Representatives to the Company. Delivery of the Option Securities on each such Date of Delivery shall be made through the facilities of The Depository Trust Company unless the Representatives shall otherwise instruct.
Payment shall be made to the Company by wire transfer of immediately available funds to a bank account designated by the Company, against delivery to the Representatives for the respective accounts of the Underwriters of the Securities to be purchased by them. It is understood that each Underwriter has authorized the Representatives, for their accounts, to accept delivery of, receipt for, and make payment of the purchase price for, the Initial Securities and the Option Securities, if any, which it has agreed to purchase. Each of the Representatives, individually and not as representatives of the Underwriters, may (but shall not be obligated to) make payment of the purchase price for the Initial Securities or the Option Securities, if any, to be purchased by any Underwriter whose funds have not been received by the Closing Time or the relevant Date of Delivery, as the case may be, but such payment shall not relieve such Underwriter from its obligations hereunder.
SECTION 3.Covenants of the Company. The Company covenants with each Underwriter as follows:
(a)Compliance with Securities Regulations and Commission Requests. The Company, subject to Section 3(b), will comply with the requirements of Rule 430B, and will notify the Representatives as soon as practicable, and confirm the notice in writing, (i) when any post-effective amendment to the Registration Statement shall become effective or any amendment or supplement to the Prospectus shall have been filed, (ii) of the receipt of any comments from the Commission, (iii) of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus (including any document incorporated by reference therein) or for additional information, (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment or of any order preventing or suspending the use of any preliminary prospectus or the Prospectus, or of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes or of any examination pursuant to Section 8(d) or 8(e) of the 1933 Act concerning the Registration Statement and (v) if the Company becomes the subject of a proceeding under Section 8A of the 1933 Act in connection with the offering of the Securities. The
    19
    


Company will effect all filings required under Rule 424(b), in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and will take such steps as it deems necessary to ascertain promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company will make every reasonable effort to prevent the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment. The Company shall pay the required Commission filing fees relating to the Securities within the time required by Rule 456(b)(1)(i) under the 1933 Act Regulations without regard to the proviso therein and otherwise in accordance with Rules 456(b) and 457(r) under the 1933 Act Regulations (including, if applicable, by updating the “Calculation of Registration Fee” table in accordance with Rule 456(b)(1)(ii) either in a post-effective amendment to the Registration Statement or on the cover page of a prospectus filed pursuant to Rule 424(b)).
(b)Continued Compliance with Securities Laws. The Company will comply with the 1933 Act, the 1933 Act Regulations, the 1934 Act and the 1934 Act Regulations so as to permit the completion of the distribution of the Securities as contemplated in this Agreement and in the Registration Statement, the General Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172 of the 1933 Act Regulations (“Rule 172”), would be) required by the 1933 Act to be delivered in connection with sales of the Securities, any event shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i) amend the Registration Statement in order that the Registration Statement will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii) amend or supplement the General Disclosure Package or the Prospectus in order that the General Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in the light of the circumstances existing at the time it is delivered to a purchaser or (iii) amend the Registration Statement or amend or supplement the General Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements of the 1933 Act or the 1933 Act Regulations, the Company will promptly (A) give the Representatives notice of such event, (B) prepare any amendment or supplement as may be necessary to correct such statement or omission or to make the Registration Statement, the General Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representatives with copies of any such amendment or supplement and (C) file with the Commission any such amendment or supplement; provided that the Company shall not file or use any such amendment or supplement to which the Representatives or counsel for the Underwriters shall object. The Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters may reasonably request. The Company has given the Representatives notice of any filings made pursuant to the 1934 Act or the 1934 Act Regulations within 48 hours prior to the Applicable Time; the Company will give the Representatives notice of its intention to make any such filing from the Applicable Time to the Closing Time and will furnish the Representatives with copies of any such documents a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any such document to which the Representatives or counsel for the Underwriters shall reasonably object.
(c)Delivery of Registration Statements. The Company has furnished or will deliver to the Representatives and counsel for the Underwriters, without charge, signed copies of the Registration Statement as originally filed and each amendment thereto (including exhibits filed therewith or incorporated by reference therein and documents incorporated or deemed incorporated by reference therein) and signed copies of all consents and certificates of experts, and will also deliver to the
    20
    


Representatives, without charge, a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) for each of the Underwriters. The copies of the Registration Statement and each amendment thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.
(d)Delivery of Prospectuses. The Company has delivered to each Underwriter, without charge, as many copies of each preliminary prospectus as such Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted by the 1933 Act. The Company will furnish to each Underwriter, without charge, during the period when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, such number of copies of the Prospectus (as amended or supplemented) as such Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.
(e)Blue Sky Qualifications. The Company will use its best efforts, in cooperation with the Underwriters, to qualify the Securities for offering and sale by the Company under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Representatives may designate and to maintain such qualifications in effect so long as required to complete the distribution of the Securities; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.
(f)Rule 158. The Company will timely file such reports pursuant to the 1934 Act as are necessary in order to make generally available to its securityholders as soon as practicable an earning statement for the purposes of, and to provide to the Underwriters the benefits contemplated by, the last paragraph of Section 11(a) of the 1933 Act.
(g)Use of Proceeds. The Company will use the net proceeds received by it from the sale of the Securities in all material respects in the manner specified in the Registration Statement, the General Disclosure Package and the Prospectus under the heading “Use of Proceeds.”
(h)Listing. The Company will use its best efforts to effect and maintain the listing of the number of shares of Common Stock equal to the Maximum Number of Underlying Shares on The Nasdaq Capital Market.
(i)Restriction on Sale of Securities. During a period of 90 days from the date of the Prospectus, the Company will not, without the prior written consent of the Representatives, (i) directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or file any registration statement under the 1933 Act with respect to any of the foregoing, (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Common Stock, whether any such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise or (iii) publicly announce an intention to effect any such swap, agreement or other transaction described in clauses (i) and (ii). The foregoing sentence shall not apply to (A) the
    21
    


Securities to be sold hereunder or the issuance of Common Stock upon conversion of the Securities to be sold hereunder; (B) entry into, or the consummation of the transactions contemplated by, the Capped Call Confirmations; (C) shares of Common Stock to be issued by the Company pursuant to that certain Underwriting Agreement, dated on or about the date hereof by and among the Company and the Representatives relating to the sale of shares of Common Stock (which sale is disclosed in the General Disclosure Package and the Prospectus); (D) any shares of Common Stock issued by the Company upon the exercise of an option or warrant or the conversion of a convertible security outstanding on the date hereof and referred to in the Registration Statement, the General Disclosure Package and the Prospectus; (E) any shares of Common Stock issued or options to purchase Common Stock granted pursuant to existing employee benefit plans of the Company referred to in the Registration Statement, the General Disclosure Package and the Prospectus; (F) any shares of Common Stock issued pursuant to any existing non-employee director stock plan or dividend reinvestment plan referred to in the Registration Statement, the General Disclosure Package and the Prospectus; (G) the filing by the Company of any registration statement on Form S-8 or a successor form thereto; or (H) the issuance of shares of Common Stock or securities convertible into, exercisable for or exchangeable for Common Stock as full or partial consideration in connection with a merger, acquisition, consolidation or purchase of the securities or assets of a corporation or other entity (or any division or business unit thereof); provided that the number of securities issued (on an as-converted to Common Stock basis) pursuant to this Section 3(i) shall not exceed 10% of the total number of shares of Common Stock outstanding immediately following the public offering of the Securities contemplated hereby, and each recipient of such securities shall execute and deliver to the Representatives, on or prior to the issuance of such securities, a lock-up agreement substantially to the effect set forth in this Section 3(i).
(j)Reporting Requirements. The Company, during the period when a Prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, will file all documents required to be filed with the Commission pursuant to the 1934 Act within the time periods required by the 1934 Act and 1934 Act Regulations.
(k)Final Term Sheet; Issuer Free Writing Prospectuses. The Company will prepare a final term sheet (the “Final Term Sheet”), in the form set forth in Schedule C hereto, reflecting the final terms of the Securities, in form and substance satisfactory to the Representatives, and shall file such final Term Sheet as an “issuer free writing prospectus” pursuant to Rule 433 prior to the close of business two business days after the date hereof; provided that the Company shall furnish the Representatives with copies of any such Final Term Sheet a reasonable amount of time prior to such proposed filing and will not use or file any such document to which the Representatives or counsel to the Underwriters shall object. The Company agrees that, unless it obtains the prior written consent of the Representatives, it will not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a “free writing prospectus,” or a portion thereof, required to be filed by the Company with the Commission or retained by the Company under Rule 433; provided that the Representatives will be deemed to have consented to the Issuer Free Writing Prospectuses listed on Schedule B hereto and any “road show that is a written communication” within the meaning of Rule 433(d)(8)(i) that has been reviewed by the Representatives. The Company represents that it has treated or agrees that it will treat each such free writing prospectus consented to, or deemed consented to, by the Representatives as an “issuer free writing prospectus,” as defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including timely filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement, any preliminary prospectus or the Prospectus or included or would include an
    22
    


untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.
(l)Testing-the-Waters Materials. If at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs an event or development as a result of which such Written Testing-the-Waters Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such untrue statement or omission.
SECTION 4.Payment of Expenses.
(a)Expenses. The Company will pay or cause to be paid all expenses incident to the performance of its obligations under this Agreement, including (i) the preparation, printing and filing of the Registration Statement (including financial statements and exhibits) as originally filed and each amendment thereto, (ii) the preparation, printing and delivery to the Underwriters of copies of each preliminary prospectus, each Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements thereto and any costs associated with electronic delivery of any of the foregoing by the Underwriters to investors, (iii) the preparation, issuance and delivery of the certificates or security entitlements for the Securities to the Underwriters, including any stock or other transfer taxes and any stamp or other duties payable upon the sale, issuance or delivery of the Securities to the Underwriters, (iv) the fees and disbursements of the Company’s counsel, accountants and other advisors, (v) the qualification of the Securities under securities laws in accordance with the provisions of Section 3(e) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Underwriters in connection therewith and in connection with the preparation of a “Blue Sky Survey” and any supplement thereto, (vi) any fees charged by rating agencies for rating the Securities, (vii) the fees and expenses of the Trustee and any agent (including the related fees and expenses of any counsel for such parties), (viii) the fees and expenses of any transfer agent or registrar for the Securities, (ix) the costs and expenses of the Company relating to investor presentations on any “road show” undertaken in connection with the marketing of the Securities, including without limitation, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations, travel and lodging expenses of the representatives and officers of the Company and any such consultants, and the cost of aircraft and other transportation chartered in connection with the road show, (x) the filing fees incident to, and the reasonable fees and disbursements of counsel to the Underwriters in connection with, the review by FINRA of the terms of the sale of the Securities, (xi) the fees and expenses incurred in connection with the listing of the Underlying Shares on The Nasdaq Capital Market, and (xii) the costs and expenses (including, without limitation, any damages or other amounts payable in connection with legal or contractual liability) associated with the reforming of any contracts for sale of the Securities made by the Underwriters caused by a breach of the representation contained in the third sentence of Section 1(a)(ii).
(b)Termination of Agreement. If this Agreement is terminated by the Representatives in accordance with the provisions of Section 5, Section 9(a)(i), Section 9(a)(iii) or Section 10 hereof, the Company shall reimburse the Underwriters for all of their reasonably documented out-of-pocket
    23
    


expenses, including the reasonable fees and disbursements of counsel for the Underwriters; provided, however, that if this Agreement is terminated by the Representatives pursuant to Section 10 hereof, the Company shall have no obligation to reimburse any out of pocket expenses of any Underwriter that has failed to purchase the Securities that such Underwriter has agreed to purchase hereunder.
SECTION 5.Conditions of Underwriters’ Obligations. The obligations of the several Underwriters hereunder are subject to the accuracy of the representations and warranties of the Company contained herein or in certificates of any officer of the Company or any of its Subsidiaries delivered pursuant to the provisions hereof, to the performance by the Company of its covenants and other obligations hereunder, and to the following further conditions:
(a)Effectiveness of Registration Statement. The Registration Statement has become effective and, at the Closing Time, no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company’s knowledge, contemplated; and the Company has complied with each request (if any) from the Commission for additional information to the reasonable satisfaction of counsel to the Underwriters.
(b)Opinion of Counsel for Company. At the Closing Time, the Representatives shall have received the opinion and the negative assurance letter, each dated the Closing Time, of (i) K&L Gates LLP, counsel for the Company and (ii) Snell & Wilmer LLP, Nevada counsel for the Company, each in form and substance satisfactory to counsel for the Underwriters, together with signed or reproduced copies of each such letter for each of the other Underwriters to the effect set forth in Exhibits A-1 and A-2 hereto and to such further effect as counsel to the Underwriters may reasonably request.
(c)Opinion of Counsel for Underwriters. At the Closing Time, the Representatives shall have received the opinion, and negative assurance letter, each dated the Closing Time, of Davis Polk & Wardwell LLP, counsel for the Underwriters, together with signed or reproduced copies of such letters for each of the other Underwriters in form and substance satisfactory to the Representatives. In giving such opinion such counsel may rely, as to all matters governed by the laws of jurisdictions other than the law of the State of New York, the General Corporation Law of the State of Delaware and the federal securities laws of the United States, upon the opinions of counsel satisfactory to the Representatives. Such counsel may also state that, insofar as such opinion involves factual matters, they have relied, to the extent they deem proper, upon certificates of officers and other representatives of the Company and its Subsidiaries and certificates of public officials.
(d)Officers’ Certificate. At the Closing Time, there shall not have been, since the date hereof or since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any Material Adverse Effect, and the Representatives shall have received a certificate of the principal executive officer of the Company and of the principal financial officer of the Company, dated the Closing Time, to the effect that (i) there has been no such Material Adverse Effect, (ii) the representations and warranties of the Company in this Agreement are true and correct with the same force and effect as though expressly made at and as of the Closing Time, (iii) the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied at or prior to the Closing Time, and (iv) no stop order suspending the effectiveness of the Registration Statement under the 1933 Act has been issued, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to their knowledge, contemplated.
    24
    


(e)Accountants’ Comfort Letters. At the time of the execution of this Agreement, the Representatives shall have received from each of (i) Crowe LLP and (ii) Deloitte & Touche LLP, a letter, dated such date, in form and substance satisfactory to the Representatives, together with signed or reproduced copies of such letter for each of the other Underwriters containing statements and information of the type ordinarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial information contained in the Registration Statement, the General Disclosure Package and the Prospectus.
(f)Bring-down Comfort Letters. At the Closing Time, the Representatives shall have received from each of (i) Crowe LLP and (ii) Deloitte & Touche LLP, a letter, dated as of the Closing Time, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection (e) of this Section, except that the specified date referred to shall be a date not more than three business days prior to the Closing Time.
(g)Approval of Listing. At the Closing Time, the number of shares of Common Stock equal to the Maximum Number of Underlying Shares shall have been approved for listing on The Nasdaq Capital Market, subject only to official notice of issuance.
(h)No Objection. FINRA has confirmed that it has not raised any objection with respect to the fairness and reasonableness of the underwriting terms and arrangements relating to the offering of the Securities.
(i)Lock-up Agreements. At the date of this Agreement, the Representatives shall have received an agreement substantially in the form of Exhibit B hereto signed by all of the Company’s directors and officers.
(j)Maintenance of Ratings. Neither the Company nor its subsidiaries have any debt securities or preferred stock that are rated by any “nationally recognized statistical rating agency” (as defined in Section 3(a)(62) of the 1934 Act).
(k)[Reserved].
(l)Conditions to Purchase of Option Securities. In the event that the Underwriters exercise their option provided in Section 2(b) hereof to purchase all or any portion of the Option Securities, the representations and warranties of the Company contained herein and the statements in any certificates furnished by the Company hereunder shall be true and correct as of each Date of Delivery and, at the relevant Date of Delivery, the Representatives shall have received:
(i)    Officers’ Certificate. A certificate, dated such Date of Delivery, of the principal executive officer of the Company and of the principal financial officer of the Company confirming that the certificate delivered at the Closing Time pursuant to Section 5(d) hereof remains true and correct as of such Date of Delivery.
(ii)    Opinion of Counsel for Company. If requested by the Representatives, the opinion, and negative assurance letter, of (i) K&L Gates LLP, counsel for the Company and (ii) Snell & Wilmer LLP, Nevada counsel for the Company, each in form and substance satisfactory to counsel for the Underwriters, dated such Date of Delivery, relating to the Option Securities to be purchased on such Date of Delivery and otherwise to the same effect as the opinions and negative assurance letter required by Section 5(b) hereof.
    25
    


(iii)    Opinion of Counsel for Underwriters. If requested by the Representatives, the opinion, and negative assurance letter, of Davis Polk & Wardwell LLP, counsel for the Underwriters, dated such Date of Delivery, relating to the Option Securities to be purchased on such Date of Delivery and otherwise to the same effect as the opinion and negative assurance letter required by Section 5(c) hereof.
(iv)    Bring-down Comfort Letters. If requested by the Representatives, a letter from each of (i) Crowe LLP and (ii) Deloitte & Touche LLP, in form and substance satisfactory to the Representatives and dated such Date of Delivery, substantially in the same form and substance as the letter furnished to the Representatives pursuant to subsection (f) of this Section, except that the “specified date” in the letter furnished pursuant to this paragraph shall be a date not more than three business days prior to such Date of Delivery.
(m)Additional Documents. At the Closing Time and at each Date of Delivery (if any), counsel for the Underwriters shall have been furnished with such documents and opinions as they may reasonably require for the purpose of enabling them to pass upon the issuance and sale of the Securities as herein contemplated, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Securities as herein contemplated shall be reasonably satisfactory in form and substance to the Representatives and counsel for the Underwriters.
(n)Termination of Agreement. If any condition specified in this Section shall not have been fulfilled when and as required to be fulfilled, this Agreement, or, in the case of any condition to the purchase of Option Securities on a Date of Delivery which is after the Closing Time, the obligations of the several Underwriters to purchase the relevant Option Securities, may be terminated by the Representatives by notice to the Company at any time at or prior to Closing Time or such Date of Delivery, as the case may be, and such termination shall be without liability of any party to any other party except as provided in Section 4 and except that Sections 1, 4, 6, 7, 8, 14, 15 and 16 shall survive any such termination and remain in full force and effect.
SECTION 6.Indemnification.
(a)Indemnification of Underwriters. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates (as such term is defined in Rule 501(b) under the 1933 Act (each, an “Affiliate”)), its selling agents and each person, if any, who controls any Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act (collectively, the “Underwriters Indemnitees”) as follows:
(i)    against any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading or arising out of any untrue statement or alleged untrue statement of a material fact included (A) in any preliminary prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package, the Prospectus (or any amendment or supplement thereto), or (B) in any Written Testing-the-Waters Communication or any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Securities (“Marketing Materials”), including any roadshow or investor presentations made to
    26
    


investors by the Company (whether in person or electronically), or the omission or alleged omission in any preliminary prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package, the Prospectus (or any amendment or supplement thereto), any Written Testing-the-Waters Communication or in any Marketing Materials of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
(ii)    against any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided that (subject to Section 6(d) below) any such settlement is effected with the written consent of the Company;
(iii)    against any and all expense whatsoever, as incurred (including the reasonable fees and disbursements of counsel chosen by the Representatives), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission, to the extent that any such expense is not paid under (i) or (ii) above;
provided, however, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue statement or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Underwriter Information.
(b)Indemnification of Company, Directors and Officers. Each Underwriter severally agrees to indemnify and hold harmless the Company, its directors, each of its officers who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act (collectively, the “Company Indemnitees”), against any and all loss, liability, claim, damage and expense described in the indemnity contained in subsection (a) of this Section, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Underwriter Information.
(c)Actions against Parties; Notification. Each indemnified party shall give notice as promptly as reasonably practicable to each indemnifying party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying party shall not relieve such indemnifying party from any liability hereunder to the extent it is not materially prejudiced as a result thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement. Upon request of the indemnified party, the indemnifying party shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the indemnifying party may designate in such proceeding and shall pay the fees and disbursements of such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of such counsel
    27
    


shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel, (ii) the named parties to any such proceeding (including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them, (iii) the indemnifying party has failed within a reasonable time to retain counsel reasonably satisfactory to the indemnified party or (iv) the indemnified party shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the indemnifying party. It is understood that the indemnifying party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for (i) the fees and expenses of more than one separate firm (in addition to any local counsel) for the Underwriters Indemnitees and (ii) the fees and expenses of more than one separate firm (in addition to any local counsel) for the Company Indemnitees, and that all such fees and expenses shall be reimbursed as they are incurred. In the case of any such separate firm for the Underwriters Indemnitees, such firm shall be designated in writing by the Underwriters. In the case of any such separate firm for the Company Indemnitees, such firm shall be designated in writing by the Company.
No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever in respect of which indemnification or contribution could be sought under this Section 6 or Section 7 hereof (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified party from all liability arising out of such litigation, investigation, proceeding or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.
(d)Settlement without Consent if Failure to Reimburse. If at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by Section 6(a)(ii) effected without its written consent if (i) such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall have received notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (iii) such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.
SECTION 7.Contribution. If the indemnification provided for in Section 6 hereof is for any reason unavailable to or insufficient to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such indemnified party, as incurred, (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Securities pursuant to this Agreement or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and of the Underwriters, on the other hand, in connection with the statements or omissions which resulted in such losses, liabilities, claims, damages or expenses, as well as any other relevant equitable considerations.
The relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Securities pursuant to this Agreement shall be deemed
    28
    


to be in the same respective proportions as the total net proceeds from the offering of the Securities pursuant to this Agreement (before deducting expenses) received by the Company, on the one hand, and the total underwriting discount received by the Underwriters, on the other hand, in each case as set forth on the cover of the Prospectus, bear to the aggregate initial public offering price of the Securities as set forth on the cover of the Prospectus.
The relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.
The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 7 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to above in this Section 7. The aggregate amount of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section 7 shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement or omission or alleged omission.
Notwithstanding the provisions of this Section 7, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions received by such Underwriter in connection with the Securities underwritten by it and distributed to the public.
No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
For purposes of this Section 7, each person, if any, who controls an Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act and each Underwriter’s Affiliates and selling agents shall have the same rights to contribution as such Underwriter, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act shall have the same rights to contribution as the Company. The Underwriters’ respective obligations to contribute pursuant to this Section 7 are several in proportion to the amount of Initial Securities set forth opposite their respective names in Schedule A hereto and not joint.
SECTION 8.Representations, Warranties and Agreements to Survive. All representations, warranties and agreements contained in this Agreement or in certificates of officers of the Company or any of its Subsidiaries submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i) any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter, its officers or directors or any person controlling the Company and (ii) delivery of and payment for the Securities.
SECTION 9.Termination of Agreement.
(a)Termination. The Representatives may terminate this Agreement, by notice to the Company, at any time at or prior to the Closing Time (i) if there has been, in the judgment of the
    29
    


Representatives, since the time of execution of this Agreement or since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any Material Adverse Effect, or (ii) if there has occurred any material adverse change in the financial markets in the United States or the international financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or development involving a prospective change in U.S. or international political, financial or economic conditions, in each case the effect of which is such as to make it, in the judgment of the Representatives, impracticable or inadvisable to proceed with the completion of the offering or to enforce contracts for the sale of the Securities, or (iii) if trading in any securities of the Company has been suspended or materially limited by the Commission or The Nasdaq Capital Market, or (iv) if trading generally on the NYSE American or the New York Stock Exchange or in The Nasdaq Capital Market has been suspended or materially limited, or minimum or maximum prices for trading have been fixed, or maximum ranges for prices have been required, by any of said exchanges or by order of the Commission, FINRA or any other governmental authority, or (v) a material disruption has occurred in commercial banking or securities settlement or clearance services in the United States or with respect to Clearstream or Euroclear systems in Europe, or (vi) if a banking moratorium has been declared by either Federal or New York authorities.
(b)Liabilities. If this Agreement is terminated pursuant to this Section, such termination shall be without liability of any party to any other party except as provided in Section 4 hereof, and provided further that Sections 1, 4, 6, 7, 8, 14, 15 and 16 shall survive such termination and remain in full force and effect.
SECTION 10.Default by One or More of the Underwriters. If one or more of the Underwriters shall fail at the Closing Time or a Date of Delivery to purchase the Securities which it or they are obligated to purchase under this Agreement (the “Defaulted Securities”), the Representatives shall have the right, within 24 hours thereafter, to make arrangements for one or more of the non-defaulting Underwriters, or any other underwriters, to purchase all, but not less than all, of the Defaulted Securities in such amounts as may be agreed upon and upon the terms herein set forth; if, however, the Representatives shall not have completed such arrangements within such 24-hour period, then:
(i) if the amount of Defaulted Securities does not exceed 10% of the aggregate principal amount of Securities to be purchased on such date, each of the non-defaulting Underwriters shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions that their respective underwriting obligations hereunder bear to the underwriting obligations of all non-defaulting Underwriters, or
(ii) if the amount of Defaulted Securities exceeds 10% of the aggregate amount of Securities to be purchased on such date, this Agreement or, with respect to any Date of Delivery which occurs after the Closing Time, the obligation of the Underwriters to purchase, and the Company to sell, the Option Securities to be purchased and sold on such Date of Delivery shall terminate without liability on the part of any non-defaulting Underwriter.
No action taken pursuant to this Section shall relieve any defaulting Underwriter from liability in respect of its default.
In the event of any such default which does not result in a termination of this Agreement or, in the case of a Date of Delivery which is after the Closing Time, which does not result in a termination of the obligation of the Underwriters to purchase and the Company to sell the relevant Option Securities, as the case may be, either the (i) Representatives or (ii) the Company shall have the right to postpone Closing
    30
    


Time or the relevant Date of Delivery, as the case may be, for a period not exceeding seven days in order to effect any required changes in the Registration Statement, the General Disclosure Package or the Prospectus or in any other documents or arrangements. As used herein, the term “Underwriter” includes any person substituted for an Underwriter under this Section 10.
SECTION 11.Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted by any standard form of telecommunication. Notices to the Underwriters shall be directed to BofA Securities, Inc., One Bryant Park, New York, New York 10036, attention of Syndicate Department (facsimile: (646) 855-3073), with a copy to ECM Legal (facsimile: (212) 230-8730); Morgan Stanley & Co. LLC at 1585 Broadway, New York, New York 10036, Attention: Equity Syndicate Desk, with a copy to the Legal Department; and Goldman Sachs at 200 West Street, New York, New York 10282, Attention: Registration Department and the Legal Department. Notices to the Company shall be directed to it at 12701 Commonwealth Dr., Suite 9, Fort Myers, FL 33913, Facsimile (239) 432-5601, Attention: Kathryn B. McKenzie, CFO, with a copy to K&L Gates LLP at 200 S. Biscayne Blvd., Suite 3900, Miami, FL 33131, Facsimile (305) 538-7095, Attention: Clayton Parker.
SECTION 12.No Advisory or Fiduciary Relationship. The Company acknowledges and agrees that (a) the purchase and sale of the Securities pursuant to this Agreement, including the determination of the initial public offering price of the Securities and any related discounts and commissions, is an arm’s-length commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b) in connection with the offering of the Securities and the process leading thereto, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, any of its Subsidiaries or their respective stockholders, creditors, employees or any other party, (c) no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering of the Securities or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company or any of its Subsidiaries on other matters) and no Underwriter has any obligation to the Company with respect to the offering of the Securities except the obligations expressly set forth in this Agreement, (d) the Underwriters and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company and (e) the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering of the Securities and the Company has consulted its own respective legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.
SECTION 13.Parties. This Agreement shall each inure to the benefit of and be binding upon the Underwriters and the Company and their respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or corporation, other than the Underwriters and the Company and their respective successors and the controlling persons and officers and directors referred to in Sections 6 and 7 and their heirs and legal representatives, any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision herein contained. This Agreement and all conditions and provisions hereof are intended to be for the sole and exclusive benefit of the Underwriters and the Company and their respective successors, and said controlling persons and officers and directors and their heirs and legal representatives, and for the benefit of no other person, firm or corporation. No purchaser of Securities from any Underwriter shall be deemed to be a successor by reason merely of such purchase.
SECTION 14.Waiver of Trial by Jury. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and each of the Underwriters hereby
    31
    


irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.
SECTION 15.GOVERNING LAW. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.
SECTION 16.Consent to Jurisdiction; Waiver of Immunity. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby shall be instituted in (i) the federal courts of the United States of America located in the City and County of New York, Borough of Manhattan or (ii) the courts of the State of New York located in the City and County of New York, Borough of Manhattan (collectively, the “Specified Courts”), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party’s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.
SECTION 17.TIME. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME.
SECTION 18.Partial Unenforceability. The invalidity or unenforceability of any Section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other Section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.
SECTION 19.Recognition of the U.S. Special Resolution Regimes.
(a)In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.
(b)In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.
As used in this Section 19:
    32
    


BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k).
Covered Entity” means any of the following:
(i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b);
(ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or
(iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b).
Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable.
U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.
SECTION 20.Counterparts. This Agreement may be executed in any number of counterparts (which may include counterparts delivered by any standard form of telecommunication), each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same agreement. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
SECTION 21.Effect of Headings. The Section headings herein are for convenience only and shall not affect the construction hereof.
SECTION 22.Entire Agreement. This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and the Underwriters with respect to the subject matter hereof.
[SIGNATURE PAGES FOLLOW]


    33
    


    If the foregoing is in accordance with your understanding of our agreement, please sign and return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts, will become a binding agreement among the Underwriters and the Company in accordance with its terms.

Very truly yours,

NEOGENOMICS, INC.



By:    /s/ Kathryn B. McKenzie
    Name: Kathryn B. McKenzie
    Title: Chief Financial Officer

CONFIRMED AND ACCEPTED
    As of the date first above written:


BOFA SECURITIES, INC.



By:    /s/ Omid Ahdieh
    Name: Omid Ahdieh
    Title: Managing Director


MORGAN STANLEY & CO. LLC



By:    /s/ Chris Rigoli
    Name: Chris Rigoli
    Title: Vice President


GOLDMAN SACHS & CO. LLC



By:    /s/ Bartosz Ostenda
    Name: Bartosz Ostenda
    Title: Managing Director



For themselves and as Representatives of the
other Underwriters named in Schedule A hereto.

    [SIGNATURE PAGE TO THE UNDERWRITING AGREEMENT]
    


SCHEDULE A
Name of Underwriter
Principal Amount of
Initial Securities
BofA Securities, Inc.$111,000,000 
Morgan Stanley & Co. LLC$81,000,000 
Goldman Sachs & Co. LLC$72,000,000 
SVB Leerink LLC$24,000,000 
Craig-Hallum Capital Group LLC$3,000,000 
Needham & Company, LLC$3,000,000 
Raymond James & Associates, Inc.$3,000,000 
Stephens Inc.$3,000,000 
Total$300,000,000 




    


SCHEDULE B
Free Writing Prospectuses



    


SCHEDULE C
Final Term Sheet

    


SCHEDULE D
Testing-the-Waters Communications
None.

    



Exhibit A-1
K&L Gates LLP Form Opinion
Based on the foregoing, and subject to the foregoing and the additional qualifications and other matters set forth below, it is our opinion that:
1. The Company is qualified, and is in good standing, as a foreign corporation in the State of New York. The Company is qualified as a foreign corporation and is authorized to transact business in the State of Florida.
2. The Registration Statement is an “automatic shelf registration statement” as defined in Rule 405 under the Securities Act that has been filed with the Commission not earlier than three years prior to the date of the Underwriting Agreement. Based solely on a review of the stop orders issued by the Commission as reflected on the Commission’s website as of [__:__] a.m. Eastern Standard time on the date hereof, no stop order suspending the effectiveness of the Registration Statement has been issued under the Securities Act and no proceedings for that purpose have been instituted by the Commission. Any required filing of the Time of Sale Disclosure Package and the Prospectus pursuant to Rule 424(b) under the Securities Act has been made in accordance with such Rule.
3. The Indenture has been duly qualified under the Trust Indenture Act.
4. Assuming the due authorization, execution and delivery of the Indenture by the Company and the Trustee, the Indenture constitutes a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms.
5. When duly authenticated in accordance with the Indenture and delivered to the Underwriters in accordance with the Underwriting Agreement against payment by the Underwriters of the consideration set forth in the Underwriting Agreement (which fact we did not determine by an inspection of the Securities), the Securities will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms and entitled to the benefits set forth in the Indenture.
6. The execution and delivery by the Company of the Underwriting Agreement, the Indenture and the Securities do not, and the performance by the Company of its obligations under the Underwriting Agreement, the Indenture and the Securities will not breach, constitute a default, or result in the creation or imposition of a security interest or other contractual lien on any of the assets of the Company under the express terms of any Specified Agreement; or (b) result in a violation by the Company of any statutory or regulatory provision of the Covered Laws under which a fine or other governmental sanction could be imposed against the Company.
7. No authorization, consent, approval, exemption, license or other action from, filing of any registration with, or notice to, any governmental authority is required under the Covered Laws to be obtained or made by the Company as a condition to its execution and delivery of the Underwriting Agreement, the Indenture and the Securities other than those which have been obtained or made and any that may be required under (a) state securities or blue sky laws or foreign securities laws of the various jurisdictions in which the Securities are being offered by the Underwriters or your selected dealers, if any, (b) any approval of FINRA of the terms and conditions of the Underwriting Agreement or (c)
    


authorizations, approvals, consents or orders of, or qualification with, any court or governmental authority of any jurisdiction outside of the United States, as to which we express no opinion.
8. The Registration Statement, as of its most recent effective date and insofar as it pertains to the offering of the Securities, the Time of Sale Disclosure Package and the Prospectus, as of its date, each appears on its face to be appropriately responsive in all material respects to the applicable form requirements for registration statements on Form S-3 of the Securities Act or, in the case of the Incorporated Documents, of the Exchange Act and the rules and regulations of the Commission thereunder; it being understood, however, that we express no view with respect to Regulation S-T or the financial statements, schedules or other financial data, included or incorporated in or omitted from the Registration Statement, the Time of Sale Disclosure Package, or the Prospectus or the Incorporated Documents.
9. Based solely on the Company’s Fact Certificate, and except as described in the Time of Sale Disclosure Package and the Prospectus, there are no contracts, agreements or understandings between the Company and any person granting such person registration rights with respect to the Securities or the Underlying Shares.
10. The Company is not required, and upon the sale of the Securities as contemplated in the Underwriting Agreement and the application of the net proceeds as described in the Prospectus, will not be required to register as an “investment company” as such term is defined under the Investment Company Act of 1940, as amended.
11. The statements in the Health Care Regulatory Sections of the Time of Sale Package and the Prospectus, insofar as such statements purport to describe or summarize applicable provisions of the Health Care Regulatory Laws including the qualifications set forth therein, are accurate in all material respects and fairly present such provisions of the Health Care Regulatory Laws.
12. The statements set forth in the Time of Sale Package and Prospectus under the caption “Material U.S. Federal Income Tax Considerations for Non-U.S. Holders”, insofar as they purport to constitute summaries of U.S. federal income and tax laws and regulations or conclusions with respect thereto (and subject to the limitations, qualifications, and assumptions set forth therein), are accurate and fairly summarized in all material respects.
13. The statements set forth in the Time of Sale Package and Prospectus under the captions “Description of Notes” and “[Capped Call Transactions]”, insofar as they purport to constitute matters of law or summaries of legal matters, such matters are accurate and fairly summarized in all material respects.

    2
    


Exhibit A-2
Snell & Wilmer LLP Form Opinion
Based on the foregoing, and subject to the assumptions, qualifications, and limitations stated in this letter, we are of the opinion that:
i.The Company is a corporation validly existing and in good standing under the laws of the State of Nevada.
ii.The Company has the corporate power to own its properties and conduct its business as currently being carried on as described in the Registration Statement, the General Disclosure Package and the Prospectus and to enter into and perform its obligations under the Underwriting Agreement, the Securities and the Indenture.
iii.The capital stock of the Company conforms as to legal matters to the description of the Company’s capital stock contained in the Registration Statement, the General Disclosure Package and the Prospectus. The maximum number of shares of Common Stock initially issuable upon conversion of the Securities (including the maximum number of shares of Common Stock that may be issued upon conversions of Securities in connection with any “Make-Whole Fundamental Change” (as such term is defined in the Indenture) have been duly authorized and reserved for issuance upon such conversion by all necessary corporate action and such shares, when issued upon such conversion, will be validly issued and will be fully paid and non-assessable; no holder of such shares will be subject to personal liability by reason of being such a holder; and the issuance of such shares upon such conversion will not be subject to the preemptive or other similar rights of any securityholder of the Company.
iv.The Securities and the Indenture conform as to legal matters in all material respects to the descriptions thereof contained in the Registration Statement, the General Disclosure Package and the Prospectus.
v.The Securities are in the form contemplated by the Indenture, and have been duly authorized, executed, issued and delivered by the Company. There are no preemptive rights or other similar rights to subscribe for or to purchase any of the Securities pursuant to the Company’s articles of incorporation or bylaws, or any agreement or other instrument known to us to which the Company is a party or by which the Company is bound.
vi.The Company has full corporate power and authority to enter into the Underwriting Agreement and the Underwriting Agreement has been duly authorized, executed, and delivered by the Company.
vii.The Company has full corporate power and authority to enter into the Indenture and the Indenture has been duly authorized, executed and delivered by the Company.
viii.The execution, delivery, and performance of the Underwriting Agreement, the Securities and the Indenture and the consummation of the transactions contemplated in such documents will not result in a breach or violation of any of the terms or provisions of, or constitute a default under, (i) any Nevada statute, rule, or regulation, (ii) any agreement known to us to which the Company is a party or by which the Company is bound or to which the Company’s property is subject, (iii) the Company’s articles of incorporation or bylaws, or (iv) any order or decree known to us of any Nevada court or Nevada governmental authority having jurisdiction over the Company or any of it properties.

    


Exhibit B
FORM OF D&O LOCK-UP AGREEMENT


[●], 20[20]

BofA Securities, Inc.
One Bryant Park
New York, New York 10036

Morgan Stanley & Co. LLC
1585 Broadway
New York, New York 10036

Goldman Sachs & Co. LLC
200 West Street New York, New York 10282
as Representatives of the several Underwriters

Re: Proposed Public Offering by NeoGenomics, Inc.

Ladies and Gentlemen:

The undersigned, an officer and/or director of NeoGenomics, Inc., a Nevada corporation (the “Company”), understands that BofA Securities, Inc., Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC (the “Representatives”) propose to enter into an Underwriting Agreement (the “Equity Underwriting Agreement”) with the Company providing for the public offering (the “Equity Offering”) of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The undersigned also understands that the Representatives propose to enter into an Underwriting Agreement (the “Convertible Notes Underwriting Agreement” and, together with the Equity Underwriting Agreement, the “Underwriting Agreements”) with the Company providing for the public offering (the “Convertible Notes Offering” and, together with the Public Equity Offering, the “Public Offering”) of convertible notes.

In recognition of the benefit that such an offering will confer upon the undersigned as a stockholder, an officer and/or a director of the Company, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each underwriter to be named in the Underwriting Agreements (collectively, the “Underwriters”) that, during the period beginning on the date hereof and ending on the date that is 90 days from the date of the Underwriting Agreements (the “Lock-Up Period”), the undersigned will not, without the prior written consent of the Representatives, on behalf of the Underwriters, directly or indirectly, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of, or otherwise dispose of or transfer any shares of Common Stock or any securities convertible into or exchangeable or exercisable for Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (collectively, the “Lock-Up Securities”), or exercise any right with respect to the registration of any of the Lock-Up Securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act of 1933, as amended; (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock-Up Securities, whether any such swap or transaction is to be

    


settled by delivery of Common Stock or other securities, in cash or otherwise; or (iii) publicly disclose the intention to take any of the actions described in the foregoing clauses (i) or (ii) of this paragraph.

Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer Lock-Up Securities without the prior written consent of the Representatives, provided, in each case, that (1) the Representatives receive a signed lock-up agreement for the balance of the Lock-Up Period from each donee, trustee, distributee, or transferee, as the case may be, (2) any such transfer shall not involve a disposition for value, (3) such transfers are not required to be reported with the Securities and Exchange Commission on Form 4 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and (4) the undersigned does not otherwise voluntarily effect any public filing or report regarding such transfers (other than a filing on a Form 5 made after the expiration of the Lock-Up Period):

i.as a bona fide gift or gifts;

ii.to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned (for purposes of this lock-up agreement, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin);
iii.as a distribution or other transfer by a partnership to its partners or former partners or by a limited liability company to its members or retired members or by a corporation to its stockholders or former stockholders or to any wholly-owned subsidiary of such corporation;

iv.to the undersigned’s affiliates or to any investment fund or other entity controlled or managed by the undersigned;

v.pursuant to a qualified domestic relations order or in connection with a divorce settlement;

vi.by will or intestate succession upon the death of the undersigned; or

vii.to the Company in satisfaction of any tax withholding obligation.

Furthermore, no provision in this letter shall be deemed to restrict or prohibit (1) the transfer of the undersigned’s Lock-Up Securities to the Company in connection with the termination of the undersigned’s services to the Company, provided that any filing under Section 16 of the Exchange Act made in connection with such transfer shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this clause (1); (2) the exercise or exchange by the undersigned of any option or warrant to acquire any shares of Common Stock or options to purchase shares of Common Stock, in each case for cash or on a “cashless” or “net exercise” basis, pursuant to any stock option, stock bonus or other stock plan or arrangement; provided, however, that any such plan or arrangement is in effect on the date hereof and is described in the prospectus filed with the Securities and Exchange Commission relating to the Public Offering; and provided further, however, that the underlying shares of Common Stock may only be transferred to the Company and shall continue to be subject to the restrictions on transfer set forth in this letter and that any filing under Section 16 of the Exchange Act made in connection with such exercise or exchange shall clearly indicate in the footnotes thereto that (a) the filing relates to the circumstances described in this clause (2) and (b) no shares were sold by the reporting person; (3) the transfer of Lock-Up Securities upon the completion of a bona fide third-party tender offer, merger, consolidation or other similar transaction made to all holders of the Company’s securities involving a “change of control” (as defined below) of the Company; provided, however, that in the event that such tender offer, merger, consolidation or other such transaction is not completed, such securities held by the undersigned shall remain subject to the restrictions on transfer set forth in this letter; and (4) the conversion of outstanding preferred stock of the Company into shares of Common Stock,

    


provided that any such shares received upon such conversion shall be subject to the restrictions on transfer set forth in this letter. “Change of control” means the consummation of any bona fide third-party tender offer, merger, consolidation or other similar transaction the result of which is that any “person” (as defined in Section 13(d)(3) of the Exchange Act), or group of persons, other than the Company, becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the Exchange Act) of more than 50% of total voting power of the voting stock of the Company.

Notwithstanding anything herein to the contrary, nothing herein shall prevent the undersigned from establishing a 10b5-1 trading plan that complies with Rule 10b5-1 under the Exchange Act (“10b5-1 Trading Plan”) or from amending an existing 10b5-1 Trading Plan so long as there are no sales of Lock-Up Securities under any such 10b5-1 Trading Plan during the Lock-Up Period; and provided that, the establishment of a 10b5-1 Trading Plan or the amendment of a 10b5-1 Trading Plan shall only be permitted if (i) the establishment or amendment of such plan is not required to be reported in any public report or filing with the Securities Exchange Commission, or otherwise and (ii) the undersigned or the Company does not otherwise voluntarily effect any public filing or report regarding the establishment or amendment of such plan.

The undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the Lock-Up Securities except in compliance with the foregoing restrictions. This lock-up agreement shall automatically terminate, and the undersigned shall be released from the undersigned’s obligations hereunder, upon the earliest to occur, if any, of (i) prior to the execution of the Underwriting Agreements, the Company advises the Representatives in writing that it has determined not to proceed with the Public Offering; (ii) the Underwriting Agreements are executed but are terminated prior to the closing of the Public Offering (other than the provisions thereof which survive termination), or (iii) February 28, 2021, in the event that the Underwriting Agreements have not been executed by such date.

The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the Underwriters solicited any action from the undersigned with respect to the offering of the securities and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate.

This agreement shall be governed by, and construed in accordance with, the laws of the State of New York.

[SIGNATURE PAGE FOLLOWS]
















    





Very truly yours,

________________________________________
Name of Security Holder (Print exact name)


By:________________________________________
Signature



If not signing in an individual capacity:

________________________________________
Name of Authorized Signatory (Print)

________________________________________
Title of Authorized Signatory (Print)

(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)


























[SIGNATURE PAGE TO LOCK-UP AGREEMENT]

    
EX-4.1 4 exhibit41formofindenture.htm EX-4.1 Document
Exhibit 4.1



NEOGENOMICS, INC.
AND
U.S. BANK NATIONAL ASSOCIATION,
as Trustee
INDENTURE
Dated as of January 11, 2021
0.25% Convertible Senior Notes due 2028


    


TABLE OF CONTENTS

PAGE
i
    


ii
    


iii
    


iv
    




v
    





EXHIBIT
Exhibit A    Form of Note    A-1


vi
    


INDENTURE, dated as of January 11, 2021, between NEOGENOMICS, INC., a Nevada corporation, as issuer (the “Company”, as more fully set forth in Section 1.01) and U.S. BANK NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee”, as more fully set forth in Section 1.01).
W I T N E S S E T H:
WHEREAS, for its lawful corporate purposes, the Company has duly authorized the issuance of its 0.25% Convertible Senior Notes due 2028 (the “Notes”), initially in an aggregate principal amount not to exceed $300,000,000 (or $345,000,000 if the Underwriters exercise their over-allotment option in accordance with the Underwriting Agreement in full), and in order to provide the terms and conditions upon which the Notes are to be authenticated, issued and delivered, the Company has duly authorized the execution and delivery of this Indenture; and
WHEREAS, the Form of Note, the certificate of authentication to be borne by each Note, the Form of Notice of Conversion, the Form of Fundamental Change Repurchase Notice and the Form of Assignment and Transfer to be borne by the Notes are to be substantially in the forms hereinafter provided; and
WHEREAS, all acts and things necessary to make the Notes, when executed by the Company and authenticated and delivered by the Trustee or a duly authorized authenticating agent, as in this Indenture provided, the valid, binding and legal obligations of the Company, and this Indenture a valid agreement according to its terms, have been done and performed, and the execution of this Indenture and the issuance hereunder of the Notes have in all respects been duly authorized.
NOW, THEREFORE, THIS INDENTURE WITNESSETH:
That in order to declare the terms and conditions upon which the Notes are, and are to be, authenticated, issued and delivered, and in consideration of the premises and of the purchase and acceptance of the Notes by the Holders thereof, the Company covenants and agrees with the Trustee for the equal and proportionate benefit of the respective Holders from time to time of the Notes (except as otherwise provided below), as follows:
Article 1DEFINITIONS
Section 1.01. Definitions. The terms defined in this Section 1.01 (except as herein otherwise expressly provided or unless the context otherwise requires) for all purposes of this Indenture and of any indenture supplemental hereto shall have the respective meanings specified in this Section 1.01. The words “herein,” “hereof,” “hereunder,” and words of similar import refer to this Indenture as a whole and not to any particular Article, Section or other subdivision. The terms defined in this Article include the plural as well as the singular.
Additional Interest” means all amounts, if any, payable pursuant to Section 6.03.
Additional Shares” shall have the meaning specified in Section 14.03(a).

    


Affiliate” of any specified Person means any other Person directly or indirectly controlling or controlled by or under direct or indirect common control with such specified Person. For the purposes of this definition, “control,” when used with respect to any specified Person means the power to direct or cause the direction of the management and policies of such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise; and the terms “controlling” and “controlled” have meanings correlative to the foregoing. Notwithstanding anything to the contrary herein, the determination of whether one Person is an “Affiliate” of another Person for purposes of this Indenture shall be made based on the facts at the time such determination is made or required to be made, as the case may be, hereunder.
Bid Solicitation Agent” means the Company or the Person appointed by the Company to solicit bids for the Trading Price of the Notes in accordance with Section 14.01(b)(i). The Company shall initially act as the Bid Solicitation Agent.
Board of Directors” means the board of directors of the Company or a committee of such board duly authorized to act for it hereunder.
Board Resolution” means a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company to have been duly adopted by the Board of Directors, and to be in full force and effect on the date of such certification, and delivered to the Trustee.
Business Day” means, with respect to any Note, any day other than a Saturday, a Sunday or a day on which the Federal Reserve Bank of New York is authorized or required by law or executive order to close or be closed.
Capital Stock” means, for any entity, any and all shares, interests, rights to purchase, warrants, options, participations or other equivalents of or interests in (however designated) stock issued by that entity.
Cash Settlement” shall have the meaning specified in Section 14.02(a).
Clause A Distribution” shall have the meaning specified in Section 14.04(c).
Clause B Distribution” shall have the meaning specified in Section 14.04(c).
Clause C Distribution” shall have the meaning specified in Section 14.04(c).
close of business” means 5:00 p.m. (New York City time).
Combination Settlement” shall have the meaning specified in Section 14.02(a).
Commission” means the U.S. Securities and Exchange Commission.
Common Equity” of any Person means Capital Stock of such Person that is generally entitled (a) to vote in the election of directors of such Person or (b) if such Person is not a
2
    


corporation, to vote or otherwise participate in the selection of the governing body, partners, managers or others that will control the management or policies of such Person.
Common Stock” means the common stock of the Company, par value $0.001 per share, at the date of this Indenture, subject to Section 14.07.
Company” shall have the meaning specified in the first paragraph of this Indenture, and subject to the provisions of Article 11, shall include its successors and assigns.
Company Order” means a written order of the Company, signed by the Company’s Chief Executive Officer, Chief Financial Officer, any President or Vice President (whether or not designated by a number or numbers or word or words added before or after the title “President” or “Vice President”) or the Company’s Treasurer, and delivered to the Trustee.
Conversion Agent” shall have the meaning specified in Section 4.02.
Conversion Consideration” shall have the meaning specified in Section 14.12(a).
Conversion Date” shall have the meaning specified in Section 14.02(c).
Conversion Obligation” shall have the meaning specified in Section 14.01(a).
Conversion Price” means as of any time, $1,000, divided by the Conversion Rate as of such time.
Conversion Rate” shall have the meaning specified in Section 14.01(a).
Corporate Trust Office” means the designated office of the Trustee at which at any time this Indenture shall be administered, which office at the date hereof is located at 1420 Fifth Ave, Seattle, WA 98101, Attention: R. Krupske (NeoGenomics, Inc.) or such other address as the Trustee may designate from time to time by notice to the Holders and the Company, or the designated corporate trust office of any successor trustee (or such other address as such successor trustee may designate from time to time by notice to the Holders and the Company).
Custodian” means the Trustee, as custodian for The Depository Trust Company, with respect to the Global Notes, or any successor entity thereto.
Daily Conversion Value” means, for each of the 30 consecutive Trading Days during the relevant Observation Period, one-thirtieth (1/30) of the product of (a) the Conversion Rate on such Trading Day and (b) the Daily VWAP on such Trading Day.
Daily Measurement Value” means the Specified Dollar Amount (if any), divided by 30.
Daily Settlement Amount,” for each of the 30 consecutive Trading Days during the relevant Observation Period, shall consist of:
3
    


(a)    cash in an amount equal to the lesser of (i) the Daily Measurement Value and (ii) the Daily Conversion Value on such Trading Day; and
(b)    if the Daily Conversion Value on such Trading Day exceeds the Daily Measurement Value, a number of shares of Common Stock equal to (i) the difference between the Daily Conversion Value and the Daily Measurement Value, divided by (ii) the Daily VWAP for such Trading Day.
Daily VWAP” means the per share volume-weighted average price as displayed under the heading “Bloomberg VWAP” on Bloomberg page “NEO <equity> AQR” (or its equivalent successor if such page is not available) in respect of the period from the scheduled open of trading until the scheduled close of trading of the primary trading session on such Trading Day (or if such volume-weighted average price is unavailable, the market value of one share of the Common Stock on such Trading Day determined, using a volume-weighted average method, by a nationally recognized independent investment banking firm retained for this purpose by the Company). The “Daily VWAP” shall be determined without regard to after-hours trading or any other trading outside of the regular trading session trading hours.
Default” means any event that is, or after notice or passage of time, or both, would be, an Event of Default.
Defaulted Amounts” means any amounts on any Note (including, without limitation, the Redemption Price, the Fundamental Change Repurchase Price, principal and interest) that are payable but are not punctually paid or duly provided for.
Default Settlement Method” means, initially, Combination Settlement with a Specified Dollar Amount of $1,000 per $1,000 principal amount of Notes; provided that the Company may, from time to time prior to September 15, 2027, change the Default Settlement Method by sending notice of the new Default Settlement Method to the Holders, the Trustee and the Conversion Agent (if other than the Trustee), all in accordance with, and subject to, the last paragraph of Section 14.02(a)(iii).

delivered” with respect to any notice to be delivered, given or mailed to a Holder pursuant to this Indenture, shall mean notice (x) given to the Depositary (or its designee) pursuant to the standing instructions from the Depositary or its designee, including by electronic mail in accordance with accepted practices or procedures at the Depositary (in the case of a Global Note) or (y) mailed to such Holder by first class mail, postage prepaid, at its address as it appears on the Note Register, in each case in accordance with Section 17.03. Notice so “delivered” shall be deemed to include any notice to be “mailed” or “given,” as applicable, under this Indenture.
Depositary” means, with respect to each Global Note, the Person specified in Section 2.05(c) as the Depositary with respect to such Notes, until a successor shall have been appointed and become such pursuant to the applicable provisions of this Indenture, and thereafter, “Depositary” shall mean or include such successor.
4
    


Designated Institution” shall have the meaning specified in Section 14.12(a).
Distributed Property” shall have the meaning specified in Section 14.04(c).
Effective Date” shall have the meaning specified in Section 14.03(c), except that, as used in Section 14.04 and Section 14.05, “Effective Date” means the first date on which shares of the Common Stock trade on the applicable exchange or in the applicable market, regular way, reflecting the relevant share split or share combination, as applicable.
Event of Default” shall have the meaning specified in Section 6.01.
Ex-Dividend Date” means the first date on which shares of the Common Stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive the issuance, dividend or distribution in question, from the Company or, if applicable, from the seller of the Common Stock on such exchange or market (in the form of due bills or otherwise) as determined by such exchange or market.
Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
Exchange Election” shall have the meaning specified in Section 14.12(a).
Form of Assignment and Transfer” shall mean the “Form of Assignment and Transfer” attached as Attachment 3 to the Form of Note attached hereto as Exhibit A.
Form of Fundamental Change Repurchase Notice” shall mean the “Form of Fundamental Change Repurchase Notice” attached as Attachment 2 to the Form of Note attached hereto as Exhibit A.
Form of Note” shall mean the “Form of Note” attached hereto as Exhibit A.
Form of Notice of Conversion” shall mean the “Form of Notice of Conversion” attached as Attachment 1 to the Form of Note attached hereto as Exhibit A.
Fundamental Change” shall be deemed to have occurred at the time after the Notes are originally issued if any of the following occurs prior to the Maturity Date:
(a)    a “person” or “group” within the meaning of Section 13(d) of the Exchange Act, other than the Company, its Wholly Owned Subsidiaries and the employee benefit plans of the Company and its Wholly Owned Subsidiaries, files a Schedule TO or any schedule, form or report under the Exchange Act disclosing that such person or group has become the direct or indirect “beneficial owner,” as defined in Rule 13d-3 under the Exchange Act, of the Common Stock representing more than 50% of the voting power of the Common Stock;
(b)    the consummation of (A) any recapitalization, reclassification or change of the Common Stock (other than changes resulting from a subdivision or combination) as a
5
    


result of which the Common Stock would be converted into, or exchanged for, stock, other securities, other property or assets; (B) any share exchange, consolidation or merger of the Company pursuant to which the Common Stock will be converted into cash, securities or other property or assets; or (C) any sale, lease or other transfer in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its Subsidiaries, taken as a whole, to any Person other than one of the Company’s Wholly Owned Subsidiaries; provided, however, that a transaction described in clause (B) in which the holders of all classes of the Company’s Common Equity immediately prior to such transaction own, directly or indirectly, more than 50% of all classes of Common Equity of the continuing or surviving corporation or transferee or the parent thereof immediately after such transaction in substantially the same proportions (relative to each other) as such ownership immediately prior to such transaction shall not be a Fundamental Change pursuant to this clause (b);
(c)    the stockholders of the Company approve any plan or proposal for the liquidation or dissolution of the Company; or
(d)    the Common Stock ceases to be listed or quoted on any of The Nasdaq Capital Market, The Nasdaq Global Select Market, The Nasdaq Global Market or The New York Stock Exchange (or any of their respective successors);
provided, however, that a transaction or transactions described in clause (a) or (b) above shall not constitute a Fundamental Change if at least 90% of the consideration received or to be received by the common stockholders of the Company, excluding cash payments for fractional shares and cash payments made in respect of dissenters’ statutory appraisal rights, in connection with such transaction or transactions consists of shares of common stock that are listed or quoted on any of The Nasdaq Capital Market, The Nasdaq Global Select Market, The Nasdaq Global Market or The New York Stock Exchange (or any of their respective successors) or will be so listed or quoted when issued or exchanged in connection with such transaction or transactions and as a result of such transaction or transactions the Notes become convertible into such consideration, excluding cash payments for fractional shares and cash payments made in respect of dissenters’ statutory appraisal rights (subject to the provisions of Section 14.07). If any transaction in which the Common Stock is replaced by the securities of another entity occurs, following completion of any related Make-Whole Fundamental Change Period (or, in the case of a transaction that would have been a Fundamental Change or a Make-Whole Fundamental Change but for the proviso in the immediately preceding paragraph, following the effective date of such transaction) references to the Company in this definition shall instead be references to such other entity.
For purposes of this definition of “Fundamental Change,” any transaction that constitutes a Fundamental Change pursuant to both clause (a) and clause (b) (excluding the proviso to such clause (b)) of such definition shall be deemed a Fundamental Change solely under clause (b) of such definition (subject to such proviso).
Fundamental Change Company Notice” shall have the meaning specified in Section 15.02(c).
6
    


Fundamental Change Repurchase Date” shall have the meaning specified in Section 15.02(a).
Fundamental Change Repurchase Notice” shall have the meaning specified in Section 15.02(b)(i).
Fundamental Change Repurchase Price” shall have the meaning specified in Section 15.02(a).
Global Note” shall have the meaning specified in Section 2.05(b).
Holder,” as applied to any Note, or other similar terms, shall mean any Person in whose name at the time a particular Note is registered on the Note Register.
Indenture” means this instrument as originally executed or, if amended or supplemented as herein provided, as so amended or supplemented.
Interest Payment Date” means each January 15 and July 15 of each year, beginning on July 15, 2021.
Last Reported Sale Price” of the Common Stock on any date means the closing sale price per share (or if no closing sale price is reported, the average of the bid and ask prices or, if more than one in either case, the average of the average bid and the average ask prices) on that date as reported in composite transactions for the principal U.S. national or regional securities exchange on which the Common Stock is traded. If the Common Stock is not listed for trading on a U.S. national or regional securities exchange on the relevant date, the “Last Reported Sale Price” shall be the last quoted bid price for the Common Stock in the over-the-counter market on the relevant date as reported by OTC Markets Group Inc. or a similar organization. If the Common Stock is not so quoted, the “Last Reported Sale Price” shall be the average of the mid-point of the last bid and ask prices for the Common Stock on the relevant date from each of at least three nationally recognized independent investment banking firms selected by the Company for this purpose. The “Last Reported Sale Price” shall be determined without regard to after-hours trading or any other trading outside of regular trading session hours.
Make-Whole Fundamental Change” means any transaction or event that constitutes a Fundamental Change (as defined above and determined after giving effect to any exceptions to or exclusions from such definition, but without regard to the proviso in clause (b) of the definition thereof).
Make-Whole Fundamental Change Period” shall have the meaning specified in Section 14.03(a).
Market Disruption Event” means, for the purposes of determining amounts due upon conversion (a) a failure by the primary U.S. national or regional securities exchange or market on which the Common Stock is listed or admitted for trading to open for trading during its regular trading session or (b) the occurrence or existence prior to 1:00 p.m., New York City time, on any
7
    


Scheduled Trading Day for the Common Stock for more than one half-hour period in the aggregate during regular trading hours of any suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the relevant stock exchange or otherwise) in the Common Stock or in any options contracts or futures contracts traded on any U.S. exchange relating to the Common Stock.
Maturity Date” means January 15, 2028.
Measurement Period” shall have the meaning specified in Section 14.01(b)(i).
Merger Event” shall have the meaning specified in Section 14.07(a).
Note” or “Notes” shall have the meaning specified in the first paragraph of the recitals of this Indenture.
Note Register” shall have the meaning specified in Section 2.05(a).
Note Registrar” shall have the meaning specified in Section 2.05(a).
Notice of Conversion” shall have the meaning specified in Section 14.02(b).
Observation Period” with respect to any Note surrendered for conversion means: (i) subject to clause (ii), if the relevant Conversion Date occurs prior to September 15, 2027, the 30 consecutive Trading Day period beginning on, and including, the second Trading Day immediately succeeding such Conversion Date; (ii) subject to clause (iii), if the relevant Conversion Date occurs during a Redemption Period pursuant to Section 16.02, the 30 consecutive Trading Days beginning on, and including, the 31st Scheduled Trading Day immediately preceding the relevant Redemption Date; and (iii) if the relevant Conversion Date occurs on or after September 15, 2027, the 30 consecutive Trading Days beginning on, and including, the 31st Scheduled Trading Day immediately preceding the Maturity Date.
Officer” means, with respect to the Company, the Chief Executive Officer, the Chief Financial Officer, the Chief Accounting Officer, the Treasurer, the Secretary, or any President or Vice President (whether or not designated by a number or numbers or word or words added before or after the title “President” or “Vice President”).
Officer’s Certificate,” when used with respect to the Company, means a certificate that is delivered to the Trustee and that is signed by an Officer of the Company. Each such certificate shall include the statements provided for in Section 17.05 if and to the extent required by the provisions of such Section. The Officer giving an Officer’s Certificate pursuant to Section 4.08 shall be the principal executive, financial or accounting officer of the Company.
open of business” means 9:00 a.m. (New York City time).
Opinion of Counsel” means an opinion in writing signed by legal counsel, who may be an employee of or counsel to the Company, or other counsel who is reasonably acceptable to the Trustee, that is delivered to the Trustee, which opinion may contain customary exceptions and
8
    


qualifications as to the matters set forth therein. Each such opinion shall include the statements provided for in Section 17.05 if and to the extent required by the provisions of such Section 17.05.
Optional Redemption” shall have the meaning specified in Section 16.01.
outstanding,” when used with reference to Notes, shall, subject to the provisions of Section 8.04, mean, as of any particular time, all Notes authenticated and delivered by the Trustee under this Indenture, except:
(a)    Notes theretofore canceled by the Trustee or accepted by the Trustee for cancellation;
(b)    Notes, or portions thereof, that have become due and payable and in respect of which monies in the necessary amount shall have been deposited in trust with the Trustee or with any Paying Agent (other than the Company) or shall have been set aside and segregated in trust by the Company (if the Company shall act as its own Paying Agent);
(c)    Notes that have been paid pursuant to Section 2.06 or Notes in lieu of which, or in substitution for which, other Notes shall have been authenticated and delivered pursuant to the terms of Section 2.06 unless proof satisfactory to the Trustee is presented that any such Notes are held by protected purchasers in due course;
(d)    Notes converted pursuant to Article 14 and required to be canceled pursuant to Section 2.08;
(e)    Notes redeemed pursuant to Article 16; and
(f)    Notes repurchased by the Company pursuant to the penultimate sentence of Section 2.10 and delivered to the Trustee for cancellation in accordance with the ultimate sentence of such Section 2.10.
Paying Agent” shall have the meaning specified in Section 4.02.
Person” means an individual, a corporation, a limited liability company, an association, a partnership, a joint venture, a joint stock company, a trust, an unincorporated organization or a government or an agency or a political subdivision thereof.
Physical Notes” means permanent certificated Notes in registered form issued in minimum denominations of $1,000 principal amount and multiples in excess thereof.
Physical Settlement” shall have the meaning specified in Section 14.02(a).
Predecessor Note” of any particular Note means every previous Note evidencing all or a portion of the same debt as that evidenced by such particular Note; and, for the purposes of this definition, any Note authenticated and delivered under Section 2.06 in lieu of or in exchange for
9
    


a mutilated, lost, destroyed or stolen Note shall be deemed to evidence the same debt as the mutilated, lost, destroyed or stolen Note that it replaces.
Prospectus” means the preliminary prospectus dated January 5, 2021, as supplemented by the related pricing term sheet dated January 6, 2021, relating to the offering and sale of the Notes.
Record Date” means, with respect to any dividend, distribution or other transaction or event in which the holders of Common Stock (or other applicable security) have the right to receive any cash, securities or other property or in which the Common Stock (or such other security) is exchanged for or converted into any combination of cash, securities or other property, the date fixed for determination of holders of the Common Stock (or such other security) entitled to receive such cash, securities or other property (whether such date is fixed by the Company, by statute, by contract or otherwise).
Redemption Date” shall have the meaning specified in Section 16.02(a).
Redemption Notice” shall have the meaning specified in Section 16.02(a).
Redemption Notice Date” means the date on which a Redemption Notice is delivered pursuant to Section 16.02.
Redemption Period” means the period from, and including, the relevant Redemption Notice Date until the close of business on the Scheduled Trading Day immediately preceding the related Redemption Date (or, if the Company defaults in the payment of the Redemption Price, such later date on which the Redemption Price has been paid or duly provided for).
Redemption Price” means, for any Notes to be redeemed pursuant to Section 16.01, 100% of the principal amount of such Notes, plus accrued and unpaid interest, if any, to, but excluding, the Redemption Date (unless the Redemption Date falls after a Regular Record Date but on or prior to the immediately succeeding Interest Payment Date, in which case interest accrued to the Interest Payment Date will be paid to Holders of record of such Notes on such Regular Record Date, and the Redemption Price will be equal to 100% of the principal amount of such Notes).
Reference Property” shall have the meaning specified in Section 14.07(a).
Regular Record Date,” with respect to any Interest Payment Date, shall mean the January 1 or July 1 (whether or not such day is a Business Day) immediately preceding the applicable January 15 or July 15 Interest Payment Date, respectively.
Reporting Obligations” shall have the meaning specified in Section 6.03.
Responsible Officer” means, when used with respect to the Trustee, any officer within the corporate trust department of the Trustee, including any vice president, assistant vice president, assistant secretary, assistant treasurer, trust officer or any other officer of the Trustee who customarily performs functions similar to those performed by the Persons who at the time
10
    


shall be such officers, respectively, or to whom any corporate trust matter relating to this Indenture is referred because of such person’s knowledge of and familiarity with the particular subject and who, in each case, shall have direct responsibility for the administration of this Indenture.
Scheduled Trading Day” means a day that is scheduled to be a Trading Day on the principal U.S. national or regional securities exchange or market on which the Common Stock is listed or admitted for trading. If the Common Stock is not so listed or admitted for trading, “Scheduled Trading Day” means a Business Day.
Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
Settlement Amount” has the meaning specified in Section 14.02(a)(iv).
Settlement Method Election Deadline” has the meaning specified in Section 14.02(a)(iii).

Settlement Method” means, with respect to any conversion of Notes, Physical Settlement, Cash Settlement or Combination Settlement, as elected (or deemed to have been elected) by the Company.
Settlement Notice” has the meaning specified in Section 14.02(a)(iii).
Significant Subsidiary” for purposes of Section 6.01(g)-(i), means a Subsidiary of the Company that meets the definition of “significant subsidiary” in Article 1, Rule 1-02 of Regulation S-X promulgated by the Commission (or any successor rule).
Specified Dollar Amount” means the maximum cash amount per $1,000 principal amount of Notes to be received upon conversion as specified in the Settlement Notice related to any converted Notes (or deemed specified pursuant to Section 14.02(a)).
Spin-Off” shall have the meaning specified in Section 14.04(c).
Stock Price” shall have the meaning specified in Section 14.03(c).
Subsidiary” means, with respect to any Person, any corporation, association, partnership or other business entity of which more than 50% of the total voting power of shares of Capital Stock or other interests (including partnership interests) entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers, general partners or trustees thereof is at the time owned or controlled, directly or indirectly, by (i) such Person; (ii) such Person and one or more Subsidiaries of such Person; or (iii) one or more Subsidiaries of such Person.
Successor Company” shall have the meaning specified in Section 11.01(a).
11
    


Trading Day” means, except for determining amounts due upon conversion as set forth below, a day on which (i) trading in the Common Stock (or other security for which a closing sale price must be determined) generally occurs on The Nasdaq Capital Market or, if the Common Stock (or such other security) is not then listed on The Nasdaq Capital Market, on the principal other U.S. national or regional securities exchange on which the Common Stock (or such other security) is then listed or, if the Common Stock (or such other security) is not then listed on a U.S. national or regional securities exchange, on the principal other market on which the Common Stock (or such other security) is then traded and (ii) a Last Reported Sale Price for the Common Stock (or closing sale price for such other security) is available on such securities exchange or market; provided that if the Common Stock (or such other security) is not so listed or traded, “Trading Day” means a Business Day; and provided, further, that for purposes of determining amounts due upon conversion only, “Trading Day” means a day on which (x) there is no Market Disruption Event and (y) trading in the Common Stock generally occurs on The Nasdaq Capital Market or, if the Common Stock is not then listed on The Nasdaq Capital Market, on the principal other U.S. national or regional securities exchange on which the Common Stock is then listed or, if the Common Stock is not then listed on a U.S. national or regional securities exchange, on the principal other market on which the Common Stock is then listed or admitted for trading, except that if the Common Stock is not so listed or admitted for trading, “Trading Day” means a Business Day.
Trading Price” of the Notes on any date of determination means the average of the secondary market bid quotations obtained by the Bid Solicitation Agent for $2,000,000 principal amount of Notes at approximately 3:30 p.m., New York City time, on such determination date from three independent nationally recognized securities dealers the Company selects for this purpose; provided that if three such bids cannot reasonably be obtained by the Bid Solicitation Agent but two such bids are obtained, then the average of the two bids shall be used, and if only one such bid can reasonably be obtained by the Bid Solicitation Agent, that one bid shall be used. If the Bid Solicitation Agent cannot reasonably obtain at least one bid for $2,000,000 principal amount of Notes from a nationally recognized securities dealer on any determination date, then the Trading Price per $1,000 principal amount of Notes on such determination date shall be deemed to be less than 98% of the product of the Last Reported Sale Price of the Common Stock and the Conversion Rate.
transfer” shall have the meaning specified in Section 2.05(c).
Trigger Event” shall have the meaning specified in Section 14.04(c).
Trust Indenture Act” means the Trust Indenture Act of 1939, as amended, as it was in force at the date of execution of this Indenture; provided, however, that in the event the Trust Indenture Act of 1939 is amended after the date hereof, the term “Trust Indenture Act” shall mean, to the extent required by such amendment, the Trust Indenture Act of 1939, as so amended.
Trustee” means the Person named as the “Trustee” in the first paragraph of this Indenture until a successor trustee shall have become such pursuant to the applicable provisions
12
    


of this Indenture, and thereafter “Trustee” shall mean or include each Person who is then a Trustee hereunder.
Underwriters” means the several underwriters named in Schedule A to the Underwriting Agreement.
Underwriting Agreement” means the underwriting agreement dated as of January 6, 2021 between the Company and BofA Securities, Inc., Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC, as representatives of the several Underwriters.
unit of Reference Property” shall have the meaning specified in Section 14.07(a).
Valuation Period” shall have the meaning specified in Section 14.04(c).
Wholly Owned Subsidiary” means, with respect to any Person, any Subsidiary of such Person, except that, solely for purposes of this definition, the reference to “more than 50%” in the definition of “Subsidiary” shall be deemed replaced by a reference to “100%”.
Section 1.02. References to Interest. Unless the context otherwise requires, any reference to interest on, or in respect of, any Note in this Indenture shall be deemed to include Additional Interest if, in such context, Additional Interest is, was or would be payable pursuant to Section 6.03. Unless the context otherwise requires, any express mention of Additional Interest in any provision hereof shall not be construed as excluding Additional Interest in those provisions hereof where such express mention is not made.
Section 1.03. Incorporation by Reference of Trust Indenture Act. Each provision of the Trust Indenture Act that is required to be part of this Indenture by virtue of its qualification under the Trust Indenture Act is incorporated by reference in and made a part of this Indenture. All terms used in this Indenture that are defined by the Trust Indenture Act, defined by Trust Indenture Act reference to another statute or defined by Commission rule under the Trust Indenture Act and not otherwise defined herein are used herein as so defined. None of the provisions of this Indenture to be qualified were inserted pursuant to Sections 310 through 318(a) of the Trust Indenture Act since those provisions have not required such insertion since the effective date of the Trust Indenture Reform Act of 1990.
Section 1.04. Conflicts with the Trust Indenture Act. If any provision hereof limits, qualifies or conflicts with another provision hereof that is required to be included in this Indenture by any of the provisions of the Trust Indenture Act, such required provision shall control. If any provision hereof limits, qualifies or conflicts with the duties imposed by section 318(c) of the Trust Indenture Act, such imposed duties shall control. If any provision hereof limits, qualifies or conflicts with a provision of the Trust Indenture Act that is required under the Trust Indenture Act to be a part of and govern this Indenture, such provision of the Trust Indenture Act shall control. If any provision hereof modifies or excludes any provision of the Trust Indenture Act that may be so modified or excluded, the latter provision shall be deemed to apply to this Indenture as such provision of the Trust Indenture Act is so modified or excluded, as the case may be.
13
    


ARTICLE 2     ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES
Section 2.01. Designation and Amount. The Notes shall be designated as the “0.25% Convertible Senior Notes due 2028.” The aggregate principal amount of Notes that may be authenticated and delivered under this Indenture is initially limited to $300,000,000 (or $345,000,000 if the Underwriters exercise their over-allotment option in accordance with the Underwriting Agreement in full), subject to Section 2.10 and except for Notes authenticated and delivered upon registration or transfer of, or in exchange for, or in lieu of other Notes to the extent permitted hereunder.
Section 2.02. Form of Notes. The Notes and the Trustee’s certificate of authentication to be borne by such Notes shall be substantially in the respective forms set forth in Exhibit A, the terms and provisions of which shall constitute, and are hereby expressly incorporated in and made a part of this Indenture. To the extent applicable, the Company and the Trustee, by their execution and delivery of this Indenture, expressly agree to such terms and provisions and to be bound thereby. In the case of any conflict between this Indenture and a Note, the provisions of this Indenture shall control and govern to the extent of such conflict.
Any Global Note may be endorsed with or have incorporated in the text thereof such legends or recitals or changes not inconsistent with the provisions of this Indenture as may be required by the Custodian or the Depositary, or as may be required to comply with any applicable law or any regulation thereunder or with the rules and regulations of any securities exchange or automated quotation system upon which the Notes may be listed or traded or designated for issuance or to conform with any usage with respect thereto, or to indicate any special limitations or restrictions to which any particular Notes are subject.
Any of the Notes may have such letters, numbers or other marks of identification and such notations, legends or endorsements as the Officer executing the same may approve (execution thereof to be conclusive evidence of such approval) and as are not inconsistent with the provisions of this Indenture, or as may be required to comply with any law or with any rule or regulation made pursuant thereto or with any rule or regulation of any securities exchange or automated quotation system on which the Notes may be listed or designated for issuance, or to conform to usage or to indicate any special limitations or restrictions to which any particular Notes are subject.
Each Global Note shall represent such principal amount of the outstanding Notes as shall be specified therein and shall provide that it shall represent the aggregate principal amount of outstanding Notes from time to time endorsed thereon and that the aggregate principal amount of outstanding Notes represented thereby may from time to time be increased or reduced to reflect redemptions, repurchases, cancellations, conversions, transfers or exchanges permitted hereby. Any endorsement of a Global Note to reflect the amount of any increase or decrease in the amount of outstanding Notes represented thereby shall be made by the Trustee or the Custodian, at the direction of the Trustee, in such manner and upon instructions given by the Holder of such Notes in accordance with this Indenture. Payment of principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, and accrued and unpaid interest
14
    


on, a Global Note shall be made to the Holder of such Note on the date of payment, unless a record date or other means of determining Holders eligible to receive payment is provided for herein.
Section 2.03. Date and Denomination of Notes; Payments of Interest and Defaulted Amounts. (a) The Notes shall be issuable in registered form without coupons in minimum denominations of $1,000 principal amount and multiples in excess thereof. Each Note shall be dated the date of its authentication and shall bear interest from the date specified on the face of such Note. Accrued interest on the Notes shall be computed on the basis of a 360-day year composed of twelve 30-day months and, for partial months, on the basis of the number of days actually elapsed in a 30-day month.
(b)    The Person in whose name any Note (or its Predecessor Note) is registered on the Note Register at the close of business on any Regular Record Date with respect to any Interest Payment Date shall be entitled to receive the interest payable on such Interest Payment Date. The principal amount of any Note (x) in the case of any Physical Note, shall be payable at the office or agency of the Company designated by the Company for such purposes in the contiguous United States of America, which shall initially be the Corporate Trust Office and (y) in the case of any Global Note, shall be payable by wire transfer of immediately available funds to the account of the Depositary or its nominee. The Company shall pay (or cause the Paying Agent to pay to the extent funded by the Company) interest (i) on any Physical Notes (A) to Holders holding Physical Notes having an aggregate principal amount of $5,000,000 or less, by check mailed to the Holders of these Notes at their address as it appears in the Note Register and (A) to Holders holding Physical Notes having an aggregate principal amount of more than $5,000,000, either by check mailed to each such Holder or, upon written application by such a Holder to the Note Registrar (containing the requisite information for the Trustee or Paying Agent to make such wire transfer) not later than the relevant Regular Record Date, by wire transfer in immediately available funds to that Holder’s account within the United States of America, which application shall remain in effect until the Holder notifies, in writing, the Note Registrar to the contrary or (A) on any Global Note by wire transfer of immediately available funds to the account of the Depositary or its nominee.
(c)    Any Defaulted Amounts shall forthwith cease to be payable to the Holder on the relevant payment date but shall accrue interest per annum at the rate borne by the Notes from, and including, such relevant payment date, and such Defaulted Amounts together with such interest thereon shall be paid by the Company, at its election in each case, as provided in clause (i) or (ii) below:
(i)    The Company may elect to make payment of any Defaulted Amounts to the Persons in whose names the Notes (or their respective Predecessor Notes) are registered at the close of business on a special record date for the payment of such Defaulted Amounts, which shall be fixed in the following manner. The Company shall notify the Trustee in writing of the amount of the Defaulted Amounts proposed to be paid on each Note and the date of the proposed payment (which shall be not less than 25 days after the receipt by the Trustee of such notice, unless the Trustee shall consent to an
15
    


earlier date), and at the same time the Company shall deposit with the Trustee an amount of money equal to the aggregate amount to be paid in respect of such Defaulted Amounts or shall make arrangements satisfactory to the Trustee for such deposit on or prior to the date of the proposed payment, such money when deposited to be held in trust for the benefit of the Persons entitled to such Defaulted Amounts as in this clause provided. Thereupon the Company shall fix a special record date for the payment of such Defaulted Amounts which shall be not more than 15 days and not less than 10 days prior to the date of the proposed payment, and not less than 10 days after the receipt by the Trustee of the notice of the proposed payment (provided, that the Trustee has received such notice at least two Business Days prior to the date such notice is to be sent (or such shorter period as shall be acceptable to the Trustee)). The Company shall promptly notify the Trustee in writing of such special record date and the Trustee, in the name and at the expense of the Company, shall cause notice of the proposed payment of such Defaulted Amounts and the special record date therefor to be delivered to each Holder at its address as it appears in the Note Register, or by electronic means to the Depositary in the case of Global Notes, not less than 10 days prior to such special record date. Notice of the proposed payment of such Defaulted Amounts and the special record date therefor having been so delivered, such Defaulted Amounts shall be paid to the Persons in whose names the Notes (or their respective Predecessor Notes) are registered at the close of business on such special record date and shall no longer be payable pursuant to the following clause (ii) of this Section 2.03(c). The Trustee shall have no responsibility whatsoever for the calculation of the Defaulted Amounts.
(ii)    The Company may make payment of any Defaulted Amounts in any other lawful manner not inconsistent with the requirements of any securities exchange or automated quotation system on which the Notes may be listed or designated for issuance, and upon such notice as may be required by such exchange or automated quotation system, if, after written notice given by the Company to the Trustee of the proposed payment pursuant to this clause, such manner of payment shall be deemed practicable by the Trustee.
Section 2.04. Execution, Authentication and Delivery of Notes. The Notes shall be signed in the name and on behalf of the Company by the manual or facsimile or other electronic signature of any of its Chief Executive Officer, President, Chief Financial Officer, Treasurer, Secretary or any of its Executive or Senior Vice Presidents.
At any time and from time to time after the execution and delivery of this Indenture, the Company may deliver Notes executed by the Company to the Trustee for authentication, together with a Company Order for the authentication and delivery of such Notes, and the Trustee in accordance with such Company Order shall authenticate and deliver such Notes, without any further action by the Company hereunder; provided that the Trustee shall be entitled to receive an Officer’s Certificate and an Opinion of Counsel of the Company with respect to the issuance, authentication and delivery of such Notes.
16
    


Only such Notes as shall bear thereon a certificate of authentication substantially in the form set forth on the Form of Note attached as Exhibit A hereto, executed manually by an authorized signatory of the Trustee (or an authenticating agent appointed by the Trustee as provided by Section 17.10), shall be entitled to the benefits of this Indenture or be valid or obligatory for any purpose. Such certificate by the Trustee (or such an authenticating agent) upon any Note executed by the Company shall be conclusive evidence that the Note so authenticated has been duly authenticated and delivered hereunder and that the Holder is entitled to the benefits of this Indenture.
In case any Officer of the Company who shall have signed any of the Notes shall cease to be such Officer before the Notes so signed shall have been authenticated and delivered by the Trustee, or disposed of by the Company, such Notes nevertheless may be authenticated and delivered or disposed of as though the Person who signed such Notes had not ceased to be such Officer of the Company; and any Note may be signed on behalf of the Company by such persons as, at the actual date of the execution of such Note, shall be the Officers of the Company, although at the date of the execution of this Indenture any such Person was not such an Officer.
Section 2.05. Exchange and Registration of Transfer of Notes; Depositary. (a) The Company shall cause to be kept at the Corporate Trust Office a register (the register maintained in such office or in any other office or agency of the Company designated pursuant to Section 4.02, the “Note Register”) in which, subject to such reasonable regulations as it may prescribe, the Company shall provide for the registration of Notes and of transfers of Notes. Such register shall be in written form or in any form capable of being converted into written form within a reasonable period of time. The Trustee is hereby initially appointed the “Note Registrar” for the purpose of registering Notes and transfers of Notes as herein provided. The Company may appoint one or more co-Note Registrars in accordance with Section 4.02.
Upon surrender for registration of transfer of any Note to the Note Registrar or any co-Note Registrar, and satisfaction of the requirements for such transfer set forth in this Section 2.05, the Company shall execute, and the Trustee shall authenticate and deliver, in the name of the designated transferee or transferees, one or more new Notes of any authorized denominations and of a like aggregate principal amount and bearing such legends as may be required by this Indenture.
Notes may be exchanged for other Notes of any authorized denominations and of a like aggregate principal amount, upon surrender of the Notes to be exchanged at any such office or agency maintained by the Company pursuant to Section 4.02. Whenever any Notes are so surrendered for exchange, the Company shall execute, and the Trustee shall authenticate and deliver, the Notes that the Holder making the exchange is entitled to receive, bearing registration numbers not contemporaneously outstanding.
All Notes presented or surrendered for registration of transfer or for exchange, repurchase or conversion shall (if so required by the Company, the Trustee, the Note Registrar or any co-Note Registrar) be duly endorsed, or be accompanied by a written instrument or instruments of transfer in form satisfactory to the Company and duly executed, by the Holder thereof or its attorney-in-fact duly authorized in writing.
17
    


No service charge shall be imposed by the Company, the Trustee, the Note Registrar, any co-Note Registrar or the Paying Agent for any exchange or registration of transfer of Notes, but the Company may require a Holder to pay a sum sufficient to cover any documentary, stamp or similar issue or transfer tax or other similar governmental charge required in connection therewith as a result of the name of the Holder of new Notes issued upon such exchange or registration of transfer being different from the name of the Holder of the old Notes surrendered for exchange or registration of transfer or otherwise required by law.
None of the Company, the Trustee, the Note Registrar or any co-Note Registrar shall be required to exchange or register a transfer of (i) any Notes surrendered for conversion or, if a portion of any Note is surrendered for conversion, such portion thereof surrendered for conversion, (ii) any Notes, or a portion of any Note, surrendered for repurchase (and not withdrawn) in accordance with Article 15 or (iii) any Notes selected for redemption in accordance with Article 16, except the unredeemed portion of any Note being redeemed in part or (iv) any Notes between a Regular Record Date and corresponding Interest Payment Date.
All Notes issued upon any registration of transfer or exchange of Notes in accordance with this Indenture shall be the valid obligations of the Company, evidencing the same debt, and entitled to the same benefits under this Indenture as the Notes surrendered upon such registration of transfer or exchange.
(b)    So long as the Notes are eligible for book-entry settlement with the Depositary, unless otherwise required by law, subject to the fourth paragraph from the end of Section 2.05(c) all Notes shall be represented by one or more Notes in global form (each, a “Global Note”) registered in the name of the Depositary or the nominee of the Depositary. The transfer and exchange of beneficial interests in a Global Note that does not involve the issuance of a Physical Note shall be effected through the Depositary (but not the Trustee or the Custodian) in accordance with this Indenture and the procedures of the Depositary therefor.
(c)    Notwithstanding any other provisions of this Indenture (other than the provisions set forth in this Section 2.05(c)), a Global Note may not be transferred as a whole or in part except (i) by the Depositary to a nominee of the Depositary or by a nominee of the Depositary to the Depositary or another nominee of the Depositary or by the Depositary or any such nominee to a successor Depositary or a nominee of such successor Depositary and (ii) for exchange of a Global Note or a portion thereof for one or more Physical Notes in accordance with the second immediately succeeding paragraph.
The Depositary shall be a clearing agency registered under the Exchange Act. The Company initially appoints The Depository Trust Company to act as Depositary with respect to each Global Note. Initially, each Global Note shall be issued to the Depositary, registered in the name of Cede & Co., as the nominee of the Depositary, and deposited with the Trustee as custodian for Cede & Co.
If (i) the Depositary notifies the Company at any time that the Depositary is unwilling or unable to continue as depositary for the Global Notes and a successor depositary is not appointed within 90 days, (ii) the Depositary ceases to be registered as a clearing agency under the
18
    


Exchange Act and a successor depositary is not appointed within 90 days or (iii) an Event of Default with respect to the Notes has occurred and is continuing and, subject to the Depositary’s applicable procedures, a beneficial owner of any Note requests that its beneficial interest therein be issued as a Physical Note, the Company shall execute, and the Trustee, upon receipt of an Officer’s Certificate and a Company Order for the authentication and delivery of Notes, shall authenticate and deliver (x) in the case of clause (iii), a Physical Note to such beneficial owner in a principal amount equal to the principal amount of such Note corresponding to such beneficial owner’s beneficial interest and (y) in the case of clause (i) or (ii), Physical Notes to each beneficial owner of the related Global Notes (or a portion thereof) in an aggregate principal amount equal to the aggregate principal amount of such Global Notes in exchange for such Global Notes, and upon delivery of the Global Notes to the Trustee such Global Notes shall be canceled.
Physical Notes issued in exchange for all or a part of the Global Note pursuant to this Section 2.05(c) shall be registered in such names and in such authorized denominations as the Depositary, pursuant to instructions from its direct or indirect participants or otherwise, or, in the case of clause (iii) of the immediately preceding paragraph, the relevant beneficial owner, shall instruct the Trustee. Upon execution and authentication, the Trustee shall deliver such Physical Notes to the Persons in whose names such Physical Notes are so registered.
At such time as all interests in a Global Note have been converted, canceled, redeemed, repurchased or transferred, such Global Note shall be, upon receipt thereof, canceled by the Trustee in accordance with standing procedures and existing instructions between the Depositary and the Custodian. At any time prior to such cancellation, if any interest in a Global Note is exchanged for Physical Notes, converted, canceled, redeemed, repurchased or transferred to a transferee who receives Physical Notes therefor or any Physical Note is exchanged or transferred for part of such Global Note, the principal amount of such Global Note shall, in accordance with the standing procedures and instructions existing between the Depositary and the Custodian, be appropriately reduced or increased, as the case may be, and an endorsement shall be made on such Global Note, by the Trustee or the Custodian, at the direction of the Trustee, to reflect such reduction or increase.
None of the Company, the Trustee, the Paying Agent, the Conversion Agent or any other agent of the Company or the Trustee shall have any responsibility or liability for the payment of amounts to owners of beneficial interest in a Global Note, for any aspect of the records relating to or payments made on account of those interests by the Depositary, or for maintaining, supervising or reviewing any records of the Depositary relating to such beneficial ownership those interests.
(d)    Neither the Trustee nor any agent shall have any responsibility or liability for any actions taken or not taken by the Depositary.
Section 2.06. Mutilated, Destroyed, Lost or Stolen Notes. In case any Note shall become mutilated or be destroyed, lost or stolen, the Company in its discretion may execute, and upon its written request the Trustee or an authenticating agent appointed by the Trustee shall authenticate and deliver, a new Note, bearing a registration number not contemporaneously outstanding, in
19
    


exchange and substitution for the mutilated Note, or in lieu of and in substitution for the Note so destroyed, lost or stolen. In every case the applicant for a substituted Note shall furnish to the Company, to the Trustee and, if applicable, to such authenticating agent such security or indemnity as may be required by them to save each of them harmless from any loss, liability, cost or expense caused by or connected with such substitution, and, in every case of destruction, loss or theft, the applicant shall also furnish to the Company, to the Trustee and, if applicable, to such authenticating agent evidence to their satisfaction of the destruction, loss or theft of such Note and of the ownership thereof.
The Trustee or such authenticating agent may authenticate any such substituted Note and deliver the same upon the receipt of such security or indemnity as the Trustee, the Company and, if applicable, such authenticating agent may require. No service charge shall be imposed by the Company, the Trustee, the Note Registrar, any co-Note Registrar or the Paying Agent upon the issuance of any substitute Note, but the Company may require a Holder to pay a sum sufficient to cover any documentary, stamp or similar issue or transfer tax or other similar governmental charge required in connection therewith as a result of the name of the Holder of the new substitute Note being different from the name of the Holder of the old Note that became mutilated or was destroyed, lost or stolen. In case any Note that has matured or is about to mature or has been surrendered for required repurchase or is about to be converted in accordance with Article 14 shall become mutilated or be destroyed, lost or stolen, the Company may, in its sole discretion, instead of issuing a substitute Note, pay or authorize the payment of or convert or authorize the conversion of the same (without surrender thereof except in the case of a mutilated Note), as the case may be, if the applicant for such payment or conversion shall furnish to the Company, to the Trustee and, if applicable, to such authenticating agent such security or indemnity as may be required by them to save each of them harmless for any loss, liability, cost or expense caused by or connected with such substitution, and, in every case of destruction, loss or theft, evidence satisfactory to the Company, the Trustee and, if applicable, any Paying Agent or Conversion Agent of the destruction, loss or theft of such Note and of the ownership thereof.
Every substitute Note issued pursuant to the provisions of this Section 2.06 by virtue of the fact that any Note is destroyed, lost or stolen shall constitute an additional contractual obligation of the Company, whether or not the destroyed, lost or stolen Note shall be found at any time, and shall be entitled to all the benefits of (but shall be subject to all the limitations set forth in) this Indenture equally and proportionately with any and all other Notes duly issued hereunder. To the extent permitted by law, all Notes shall be held and owned upon the express condition that the foregoing provisions are exclusive with respect to the replacement, payment, conversion, redemption or repurchase of mutilated, destroyed, lost or stolen Notes and shall preclude any and all other rights or remedies notwithstanding any law or statute existing or hereafter enacted to the contrary with respect to the replacement, payment, conversion, redemption or repurchase of negotiable instruments or other securities without their surrender.
Section 2.07. Temporary Notes. Pending the preparation of Physical Notes, the Company may execute and the Trustee or an authenticating agent appointed by the Trustee shall, upon written request of the Company, authenticate and deliver temporary Notes (printed or lithographed). Temporary Notes shall be issuable in any authorized denomination, and
20
    


substantially in the form of the Physical Notes but with such omissions, insertions and variations as may be appropriate for temporary Notes, all as may be determined by the Company. Every such temporary Note shall be executed by the Company and authenticated by the Trustee or such authenticating agent upon the same conditions and in substantially the same manner, and with the same effect, as the Physical Notes. Without unreasonable delay, the Company shall execute and deliver to the Trustee or such authenticating agent Physical Notes (other than any Global Note) and thereupon any or all temporary Notes (other than any Global Note) may be surrendered in exchange therefor, at each office or agency maintained by the Company pursuant to Section 4.02 and the Trustee or such authenticating agent shall authenticate and deliver in exchange for such temporary Notes an equal aggregate principal amount of Physical Notes upon the written request of the Company. Such exchange shall be made by the Company at its own expense and without any charge therefor. Until so exchanged, the temporary Notes shall in all respects be entitled to the same benefits and subject to the same limitations under this Indenture as Physical Notes authenticated and delivered hereunder.
Section 2.08. Cancellation of Notes Paid, Converted, Etc. The Company shall cause all Notes surrendered for payment, redemption, repurchase, registration of transfer or exchange or conversion, if surrendered to any Person other than the Trustee (including any of the Company’s agents, Subsidiaries or Affiliates), to be delivered to the Trustee for cancellation. All Notes delivered to the Trustee shall be canceled promptly by it, and no Notes shall be authenticated in exchange therefor except as expressly permitted by any of the provisions of this Indenture. The Trustee shall dispose of canceled Notes in accordance with its customary procedures and, after such disposition, shall deliver a certificate of such disposition to the Company upon the Company’s written request in a Company Order.
Section 2.09. CUSIP Numbers. The Company in issuing the Notes may use “CUSIP” numbers (if then generally in use), and, if so, the Trustee shall use “CUSIP” numbers in all notices issued to Holders as a convenience to such Holders; provided that any such notice may state that no representation is made as to the correctness of such numbers either as printed on the Notes or on such notice and that reliance may be placed only on the other identification numbers printed on the Notes. The Company shall promptly notify the Trustee in writing of any change in the “CUSIP” numbers.
Section 2.10. Additional Notes; Repurchases. The Company may, without the consent of or notice to the Holders and notwithstanding Section 2.01, reopen this Indenture and issue additional Notes hereunder with the same terms as the Notes initially issued hereunder (other than differences in the issue date, the issue price, interest accrued prior to the issue date of such additional Notes and, if applicable, restrictions on transfer in respect of such additional Notes) in an unlimited aggregate principal amount; provided that if any such additional Notes are not fungible with the Notes initially issued hereunder for U.S. federal income tax purposes, such additional Notes shall have one or more separate CUSIP numbers. Any additional Notes will be treated as a single series for all purposes under this Indenture except as set forth in the first sentence of this Section 2.10. Prior to the issuance of any such additional Notes, the Company shall deliver to the Trustee a Company Order, an Officer’s Certificate and an Opinion of Counsel, such Officer’s Certificate and Opinion of Counsel to cover such matters required by
21
    


Section 17.05. In addition, the Company may, to the extent permitted by law, and directly or indirectly (regardless of whether such Notes are surrendered to the Company), repurchase Notes in the open market or otherwise, whether by the Company or its Subsidiaries or through a private or public tender or exchange offer or through counterparties to private agreements, including by cash-settled swaps or other derivatives, in each case, without prior written notice to Holders. The Company shall cause any Notes so repurchased (other than Notes repurchased pursuant to cash-settled swaps or other derivatives) to be surrendered to the Trustee for cancellation in accordance with Section 2.08 and such Notes shall no longer be considered outstanding under this Indenture upon their repurchase and cancellation and, upon receipt of a Company Order and an Officer’s Certificate, the Trustee shall cancel all Notes so surrendered.
ARTICLE 3     SATISFACTION AND DISCHARGE
Section 3.01. Satisfaction and Discharge. This Indenture shall upon request of the Company contained in an Officer’s Certificate cease to be of further effect, and the Trustee, at the expense of the Company, shall execute such instruments reasonably requested by the Company acknowledging satisfaction and discharge of this Indenture, when (A) (i) all Notes theretofore authenticated and delivered (other than (x) Notes which have been destroyed, lost or stolen and which have been replaced, paid or converted as provided in Section 2.06 and (y) Notes for whose payment money has theretofore been deposited in trust or segregated and held in trust by the Company and thereafter repaid to the Company or discharged from such trust, as provided in Section 4.04(d)) have been delivered to the Trustee for cancellation; or (ii) the Company has deposited with the Trustee or delivered to Holders, as applicable, after the Notes have become due and payable, whether on the Maturity Date, any Redemption Date, any Fundamental Change Repurchase Date, upon conversion or otherwise, cash or cash, shares of Common Stock or a combination thereof, as applicable, solely to satisfy the Conversion Obligation, sufficient, without consideration of reinvestment, to pay all of the outstanding Notes and all other sums due and payable under this Indenture by the Company; and (A) the Company has delivered to the Trustee an Officer’s Certificate and an Opinion of Counsel, each stating that all conditions precedent herein provided for relating to the satisfaction and discharge of this Indenture have been complied with. Notwithstanding the satisfaction and discharge of this Indenture, the obligations of the Company to the Trustee under Section 7.06 shall survive.
ARTICLE 4     PARTICULAR COVENANTS OF THE COMPANY
Section 4.01. Payment of Principal and Interest. The Company covenants and agrees that it will cause to be paid the principal (including the Redemption Price, the Fundamental Change Repurchase Price, if applicable) of, and accrued and unpaid interest on, each of the Notes at the places, at the respective times and in the manner provided herein and in the Notes.
Notwithstanding anything to the contrary contained in this Indenture, the Company may, to the extent it is required to do so by law, deduct or withhold income or other similar taxes imposed by the United States of America from principal, premium or interest (including any Additional Interest) payments hereunder
22
    


Section 4.02. Maintenance of Office or Agency. The Company will maintain in the contiguous United States of America an office or agency where the Notes may be presented for registration of transfer or exchange or for payment or repurchase (“Paying Agent”) or for conversion (“Conversion Agent”) and where notices and demands to or upon the Company in respect of the Notes and this Indenture may be served. The Company will give prompt written notice to the Trustee of the location, and any change in the location, of such office or agency. If at any time the Company shall fail to maintain any such required office or agency or shall fail to furnish the Trustee with the address thereof, such presentations, surrenders, notices and demands may be made or served at the Corporate Trust Office in the United States of America as a place where Notes may be presented for payment or for registration of transfer.
The Company may also from time to time designate as co-Note Registrars one or more other offices or agencies where the Notes may be presented or surrendered for any or all such purposes and may from time to time rescind such designations; provided that no such designation or rescission shall in any manner relieve the Company of its obligation to maintain an office or agency in the contiguous United States of America so designated by the Trustee as a place for such purposes. The Company will give prompt written notice to the Trustee of any such designation or rescission and of any change in the location of any such other office or agency. The terms “Paying Agent” and “Conversion Agent” include any such additional or other offices or agencies, as applicable.
The Company hereby initially designates the Trustee as the Paying Agent, Note Registrar, Custodian and Conversion Agent and the Corporate Trust Office as the office or agency in the contiguous United States of America where Notes may be presented for registration of transfer or exchange or for payment or repurchase or for conversion and where notices and demands to or upon the Company in respect of the Notes and this Indenture may be served; provided that no office of the Trustee shall be a place for service of legal process on the Company.
Section 4.03. Appointments to Fill Vacancies in Trustee’s Office. The Company, whenever necessary to avoid or fill a vacancy in the office of Trustee, will appoint, in the manner provided in Section 7.09, a Trustee, so that there shall at all times be a Trustee hereunder.
Section 4.04. Provisions as to Paying Agent. (A) If the Company shall appoint a Paying Agent other than the Trustee, the Company will cause such Paying Agent to execute and deliver to the Trustee an instrument in which such agent shall agree with the Trustee, subject to the provisions of this Section 4.04:
(i)     that it will hold all sums held by it as such agent for the payment of the principal (including the Redemption Price, the Fundamental Change Repurchase Price, if applicable) of, and accrued and unpaid interest on, the Notes in trust for the benefit of the Holders of the Notes;
(ii)     that it will give the Trustee prompt written notice of any failure by the Company to make any payment of the principal (including the Redemption Price, the
23
    


Fundamental Change Repurchase Price, if applicable) of, and accrued and unpaid interest on, the Notes when the same shall be due and payable; and
(iii)     that at any time during the continuance of an Event of Default, upon request of the Trustee, it will forthwith pay to the Trustee all sums so held in trust.
The Company shall, on or before each due date of the principal (including the Redemption Price, the Fundamental Change Repurchase Price, if applicable) of, or accrued and unpaid interest on, the Notes, deposit with the Paying Agent a sum in immediately available U.S. Dollars sufficient to pay such principal (including the Redemption Price, the Fundamental Change Repurchase Price, if applicable) or accrued and unpaid interest, and (unless such Paying Agent is the Trustee) the Company will promptly notify the Trustee in writing of any failure to take such action; provided that if such deposit is made on the due date, such deposit must be received by the Paying Agent by 11:00 a.m., New York City time, on such date.
(b)    If the Company shall act as its own Paying Agent, it will, on or before each due date of the principal (including the Redemption Price, the Fundamental Change Repurchase Price, if applicable) of, and accrued and unpaid interest on, the Notes, set aside, segregate and hold in trust for the benefit of the Holders of the Notes a sum sufficient to pay such principal (including the Redemption Price, the Fundamental Change Repurchase Price, if applicable) and accrued and unpaid interest so becoming due and will promptly notify the Trustee in writing of any failure to take such action and of any failure by the Company to make any payment of the principal (including the Redemption Price, the Fundamental Change Repurchase Price, if applicable) of, or accrued and unpaid interest on, the Notes when the same shall become due and payable.
(c)    Anything in this Section 4.04 to the contrary notwithstanding, the Company may, at any time, for the purpose of obtaining a satisfaction and discharge of this Indenture, or for any other reason, pay, cause to be paid or deliver to the Trustee all sums or amounts held in trust by the Company or any Paying Agent hereunder as required by this Section 4.04, such sums or amounts to be held by the Trustee upon the trusts herein contained and upon such payment or delivery by the Company or any Paying Agent to the Trustee, the Company or such Paying Agent shall be released from all further liability but only with respect to such sums or amounts. Upon the occurrence of any event specified in Section 6.01(h) or Section 6.01(i), the Trustee shall automatically become the Paying Agent.
(d)    Subject to applicable escheatment laws, any money or property deposited with the Trustee or any Paying Agent, or then held by the Company, in trust for the payment of the principal (including the Redemption Price, the Fundamental Change Repurchase Price, if applicable) of, accrued and unpaid interest on and the consideration due upon conversion of any Note and remaining unclaimed for two years after such principal (including the Redemption Price, the Fundamental Change Repurchase Price, if applicable), interest or consideration due upon conversion has become due and payable shall be paid to the Company on request of the Company contained in an Officer’s Certificate, or (if then held by the Company) shall be discharged from such trust and the Trustee shall have no further liability with respect to such funds; and the Holder of such Note shall thereafter, as an unsecured general creditor, look only to
24
    


the Company for payment thereof, and all liability of the Trustee or such Paying Agent with respect to such trust money and shares of Common Stock, and all liability of the Company as trustee thereof, shall thereupon cease.
Section 4.05. Existence. Subject to Article 11, the Company shall do or cause to be done all things necessary to preserve and keep in full force and effect its corporate existence.
Section 4.06. Annual Reports. (a) The Company shall file with the Trustee, within 15 days after the same are required to be filed with the Commission (giving effect to any grace period provided by Rule 12b-25 (or any successor rule) under the Exchange Act), copies of any documents or reports that the Company is required to file with the Commission pursuant to Section 13 or 15(d) of the Exchange Act (excluding any such information, documents or reports, or portions thereof, subject to confidential treatment and any correspondence with the Commission). Any such document or report that the Company files with the Commission via the Commission’s EDGAR system (or any successor thereto) shall be deemed to be filed with the Trustee for purposes of this Section 4.06 at the time such documents are filed via the EDGAR system (or any successor thereto), it being understood that the Trustee shall not be responsible for determining whether such filings have been made.
(b)    Delivery of the reports and documents described in subsection (a) above to the Trustee is for informational purposes only, and the Trustee’s receipt of such shall not constitute actual or constructive notice of any information contained therein or determinable from information contained therein, including the Company’s compliance with any of its covenants hereunder (as to which the Trustee is entitled to conclusively rely on an Officer’s Certificate).
Section 4.07. Stay, Extension and Usury Laws. The Company covenants (to the extent that it may lawfully do so) that it shall not at any time insist upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law or other law that would prohibit or forgive the Company from paying all or any portion of the principal of or interest on the Notes as contemplated herein, wherever enacted, now or at any time hereafter in force, or that may affect the covenants or the performance of this Indenture; and the Company (to the extent it may lawfully do so) hereby expressly waives all benefit or advantage of any such law, and covenants that it will not, by resort to any such law, hinder, delay or impede the execution of any power herein granted to the Trustee, but will suffer and permit the execution of every such power as though no such law had been enacted.
Section 4.08. Compliance Certificate; Statements as to Defaults. The Company shall deliver to the Trustee within 120 days after the end of each fiscal year of the Company (beginning with the fiscal year ending on December 31, 2020) an Officer’s Certificate stating whether the signers thereof know of any Default or Event of Default that occurred during the previous year.
In addition, the Company shall deliver to the Trustee, within 30 days after the occurrence thereof, written notice of any Event of Default or Default, its status and what action the Company is taking or proposing to take in respect thereof; provided that the Company will not be
25
    


required to deliver such notice if such Event of Default or Default is no longer continuing or has been cured.
Section 4.09. Further Instruments and Acts. Upon request of the Trustee, the Company will execute and deliver such further instruments and do such further acts as may be reasonably necessary or proper to carry out more effectively the purposes of this Indenture.
ARTICLE 5     LISTS OF HOLDERS AND REPORTS BY THE COMPANY AND THE TRUSTEE
Section 5.01. Lists of Holders. The Company covenants and agrees that it will furnish or cause to be furnished to the Trustee, semi-annually, not more than 5 days after each January 1 and July 1 in each year beginning with July 1, 2021, and at such other times as the Trustee may request in writing, within 5 days after receipt by the Company of any such request (or such lesser time as the Trustee may reasonably request in order to enable it to timely provide any notice to be provided by it hereunder), a list in such form as the Trustee may reasonably require of the names and addresses of the Holders as of a date not more than 15 days (or such other date as the Trustee may reasonably request in order to so provide any such notices) prior to the time such information is furnished, except that no such list need be furnished so long as the Trustee is acting as Note Registrar.
Section 5.02. Preservation and Disclosure of Lists. The Trustee shall preserve, in as current a form as is reasonably practicable, all information as to the names and addresses of the Holders contained in the most recent list furnished to it as provided in Section 5.01 or maintained by the Trustee in its capacity as Note Registrar, if so acting. The Trustee may destroy any list furnished to it as provided in Section 5.01 upon receipt of a new list so furnished.
Section 5.03. Communications to Holders. Holders may communicate pursuant to Trust Indenture Act Section 312(b) with other Holders with respect to their rights under this Indenture or the Notes. The Company, the Trustee, the Note Registrar and anyone else shall have the protection of Trust Indenture Act Section 312(c).
Section 5.04. Reports by Trustee. As promptly as practicable after each May 15 beginning with May 15, 2021 after the issuance of Notes pursuant to this Indenture, for so long as Notes remain outstanding, the Trustee shall mail to each Holder a brief report dated as of such reporting date that complies with Section 313(a) of the Trust Indenture Act. The Trustee shall also comply with Sections 313(b) and 313(c) of the Trust Indenture Act.
ARTICLE 6     DEFAULTS AND REMEDIES
Section 6.01. Events of Default. Each of the following events shall be an “Event of Default” with respect to the Notes:
(a)    default in any payment of interest on any Note when due and payable, and the default continues for a period of 30 days;
26
    


(b)    default in the payment of principal of any Note when due and payable on the Maturity Date, upon Optional Redemption, upon any required repurchase, upon declaration of acceleration or otherwise;
(c)    failure by the Company to comply with its obligation to convert the Notes in accordance with this Indenture upon exercise of a Holder’s conversion right, and such failure continues for a period of five (5) Business Days;
(d)    failure by the Company to issue (i) a Fundamental Change Company Notice in accordance with Section 15.02(c) or (ii) notice of a specified corporate transaction or event in accordance with Section 14.01(b)(ii) or (iii), in each case when due;
(e)    failure by the Company to comply with its obligations under Article 11;
(f)    failure by the Company for 60 days after written notice from the Trustee or the Holders of at least 25% in aggregate principal amount of the Notes then outstanding has been received by the Company to comply with any of its other agreements contained in the Notes or this Indenture;
(g)    default by the Company or any Significant Subsidiary of the Company with respect to any mortgage, agreement or other instrument under which there may be outstanding, or by which there may be secured or evidenced, any indebtedness for money borrowed in excess of $30,000,000 (or its foreign currency equivalent) in the aggregate of the Company and/or any such Significant Subsidiary, whether such indebtedness now exists or shall hereafter be created (i) resulting in such indebtedness becoming or being declared due and payable prior to its stated maturity or (ii) constituting a failure to pay the principal of any such indebtedness when due and payable (after the expiration of all applicable grace periods) at its stated maturity, upon required repurchase, upon declaration of acceleration or otherwise;
(h)    the Company or any Significant Subsidiary shall commence a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to the Company or any such Significant Subsidiary or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of the Company or any such Significant Subsidiary or any substantial part of its property, or shall consent to any such relief or to the appointment of or taking possession by any such official in an involuntary case or other proceeding commenced against it, or shall make a general assignment for the benefit of creditors, or shall fail generally to pay its debts as they become due; or
(i)    an involuntary case or other proceeding shall be commenced against the Company or any Significant Subsidiary seeking liquidation, reorganization or other relief with respect to the Company or such Significant Subsidiary or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of the Company or such Significant Subsidiary or any substantial part of its property, and such involuntary case or other proceeding shall remain undismissed and unstayed for a period of 30 consecutive days.
27
    


Section 6.02. Acceleration; Rescission and Annulment. If one or more Events of Default shall have occurred and be continuing (whatever the reason for such Event of Default and whether it shall be voluntary or involuntary or be effected by operation of law or pursuant to any judgment, decree or order of any court or any order, rule or regulation of any administrative or governmental body), then, and in each and every such case (other than an Event of Default specified in Section 6.01(h) or Section 6.01(i) with respect to the Company), unless the principal of all of the Notes shall have already become due and payable, either the Trustee or the Holders of at least 25% in aggregate principal amount of the Notes then outstanding determined in accordance with Section 8.04, by notice in writing to the Company (and to the Trustee if given by Holders), may declare 100% of the principal of, and accrued and unpaid interest on, all the Notes to be due and payable immediately, and upon any such declaration the same shall become and shall automatically be immediately due and payable, anything in this Indenture or in the Notes contained to the contrary notwithstanding. If an Event of Default specified in Section 6.01(h) or Section 6.01(i) with respect to the Company occurs and is continuing, 100% of the principal of, and accrued and unpaid interest, if any, on, all Notes shall become and shall automatically be immediately due and payable without any declaration or other act on the part of the Trustee or any Holder.
The immediately preceding paragraph, however, is subject to the conditions that if, at any time after the principal of the Notes shall have been so declared due and payable, and before any judgment or decree for the payment of the monies due shall have been obtained or entered as hereinafter provided, the Company shall pay or shall deposit with the Trustee a sum sufficient to pay installments of accrued and unpaid interest upon all Notes and the principal of any and all Notes that shall have become due otherwise than by acceleration (with interest on overdue installments of accrued and unpaid interest, and on such principal at the rate borne by the Notes at such time) and amounts due to the Trustee pursuant to Section 7.06, and if (1) rescission would not conflict with any judgment or decree of a court of competent jurisdiction and (2) any and all existing Events of Default under this Indenture, other than the nonpayment of the principal of and accrued and unpaid interest, if any, on Notes that shall have become due solely by such acceleration, shall have been cured or waived pursuant to Section 6.09, then and in every such case (except as provided in the immediately succeeding sentence) the Holders of a majority in aggregate principal amount of the Notes then outstanding, by written notice to the Company and to the Trustee, may waive all Defaults or Events of Default with respect to the Notes and rescind and annul such declaration and its consequences and such Default shall cease to exist, and any Event of Default arising therefrom shall be deemed to have been cured for every purpose of this Indenture; but no such waiver or rescission and annulment shall extend to or shall affect any subsequent Default or Event of Default, or shall impair any right consequent thereon. Notwithstanding anything to the contrary herein, no such waiver or rescission and annulment shall extend to or shall affect any Default or Event of Default resulting from (i) the nonpayment of the principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, or accrued and unpaid interest on, any Notes, (ii) a failure to repurchase any Notes when required or (iii) a failure to pay or deliver, as the case may be, the consideration due upon conversion of the Notes.
28
    


Section 6.03. Additional Interest. Notwithstanding anything in this Indenture or in the Notes to the contrary, to the extent the Company elects, the sole remedy for an Event of Default relating to the Company’s failure to comply with its obligations as set forth in Section 4.06(a) or its failure to file with the Trustee pursuant to Section 314(a)(1) of the Trust Indenture Act (together, the “Reporting Obligations”) shall, for the first 360 days after the occurrence of such an Event of Default, consist exclusively of the right to receive Additional Interest on the Notes at a rate equal to (i) 0.25% per annum of the principal amount of the Notes outstanding for each day during the first 180 calendar days after the occurrence of such an Event of Default during which such an Event of Default is continuing (or, if earlier, the date on which such Event of Default is cured or waived as provided for in this Indenture) and (ii) 0.50% per annum of the principal amount of the Notes outstanding for each day from, and including, the 181st calendar day to, but excluding, the 360th calendar day following the occurrence of such an Event of Default during which such Event of Default is continuing (or, if earlier, the date on which such Event of Default is cured or waived as provided for in this Indenture). If the Company so elects, such Additional Interest shall be payable in the same manner and on the same dates as the stated interest payable on the Notes. On the 361st day after such an Event of Default (if the Event of Default relating to the Company’s failure to comply with its Reporting Obligations is not cured or waived prior to such 361st day), the Notes shall be subject to acceleration as provided in Section 6.02. The provisions of this paragraph will not affect the rights of Holders in the event of the occurrence of any Event of Default other than the Company’s failure to comply with its Reporting Obligations. In the event the Company does not elect to pay Additional Interest following an Event of Default in accordance with this Section 6.03 or the Company elected to make such payment but does not pay the Additional Interest when due, the Notes shall be immediately subject to acceleration as provided in Section 6.02.
In order to elect to pay Additional Interest as the sole remedy during the first 360 days after the occurrence of an Event of Default relating to the Company’s failure to comply with its Reporting Obligations in accordance with the immediately preceding paragraph, the Company must notify all Holders, the Trustee and the Paying Agent in writing of such election prior to the beginning of such 360-day period. Upon the failure to timely give such notice, the Notes shall be immediately subject to acceleration as provided in Section 6.02.
Section 6.04. Payments of Notes on Default; Suit Therefor. If an Event of Default described in clause (a) or (b) of Section 6.01 shall have occurred and be continuing, the Company shall, upon demand of the Trustee, pay to the Trustee, for the benefit of the Holders of the Notes, the whole amount then due and payable on the Notes for principal and interest, if any, with interest on any overdue principal and interest, if any, at the rate borne by the Notes at such time, and, in addition thereto, such further amount as shall be sufficient to cover any amounts due to the Trustee under Section 7.06. If the Company shall fail to pay such amounts forthwith upon such demand, the Trustee, in its own name and as trustee of an express trust, may institute a judicial proceeding for the collection of the sums so due and unpaid, may prosecute such proceeding to judgment or final decree and may enforce the same against the Company or any other obligor upon the Notes and collect the moneys adjudged or decreed to be payable in the manner provided by law out of the property of the Company or any other obligor upon the Notes, wherever situated.
29
    


In the event there shall be pending proceedings for the bankruptcy or for the reorganization of the Company or any other obligor on the Notes under Title 11 of the United States Code, or any other applicable law, or in case a receiver, assignee or trustee in bankruptcy or reorganization, liquidator, sequestrator or similar official shall have been appointed for or taken possession of the Company or such other obligor, the property of the Company or such other obligor, or in the event of any other judicial proceedings relative to the Company or such other obligor upon the Notes, or to the creditors or property of the Company or such other obligor, the Trustee, irrespective of whether the principal of the Notes shall then be due and payable as therein expressed or by declaration or otherwise and irrespective of whether the Trustee shall have made any demand pursuant to the provisions of this Section 6.04, shall be entitled and empowered, by intervention in such proceedings or otherwise, to file and prove a claim or claims for the whole amount of principal and accrued and unpaid interest, if any, in respect of the Notes, and, in case of any judicial proceedings, to file such proofs of claim and other papers or documents and to take such other actions as it may deem necessary or advisable in order to have the claims of the Trustee (including any claim for the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel) and of the Holders allowed in such judicial proceedings relative to the Company or any other obligor on the Notes, its or their creditors, or its or their property, and to collect and receive any monies or other property payable or deliverable on any such claims, and to distribute the same after the deduction of any amounts due to the Trustee under Section 7.06; and any receiver, assignee or trustee in bankruptcy or reorganization, liquidator, custodian or similar official is hereby authorized by each of the Holders to make such payments to the Trustee, as administrative expenses, and, in the event that the Trustee shall consent to the making of such payments directly to the Holders, to pay to the Trustee any amount due it for reasonable compensation, expenses, advances and disbursements, including agents and counsel fees, and including any other amounts due to the Trustee under Section 7.06, incurred by it up to the date of such distribution. To the extent that such payment of reasonable compensation, expenses, advances and disbursements out of the estate in any such proceedings shall be denied for any reason, payment of the same shall be secured by a lien on, and shall be paid out of, any and all distributions, dividends, monies, securities and other property that the Holders of the Notes may be entitled to receive in such proceedings, whether in liquidation or under any plan of reorganization or arrangement or otherwise.
Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Holder any plan of reorganization, arrangement, adjustment or composition affecting such Holder or the rights of any Holder thereof, or to authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding.
All rights of action and of asserting claims under this Indenture, or under any of the Notes, may be enforced by the Trustee without the possession of any of the Notes, or the production thereof at any trial or other proceeding relative thereto, and any such suit or proceeding instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment shall, after provision for the payment of the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, be for the ratable benefit of the Holders of the Notes.
30
    


In any proceedings brought by the Trustee (and in any proceedings involving the interpretation of any provision of this Indenture to which the Trustee shall be a party) the Trustee shall be held to represent all the Holders of the Notes, and it shall not be necessary to make any Holders of the Notes parties to any such proceedings.
In case the Trustee shall have proceeded to enforce any right under this Indenture and such proceedings shall have been discontinued or abandoned because of any waiver pursuant to Section 6.09 or any rescission and annulment pursuant to Section 6.02 or for any other reason or shall have been determined adversely to the Trustee, then and in every such case the Company, the Holders and the Trustee shall, subject to any determination in such proceeding, be restored respectively to their several positions and rights hereunder, and all rights, remedies and powers of the Company, the Holders and the Trustee shall continue as though no such proceeding had been instituted.
Section 6.05. Application of Monies Collected by Trustee. Any monies or property collected by the Trustee pursuant to this Article 6 with respect to the Notes shall be applied in the following order, at the date or dates fixed by the Trustee for the distribution of such monies, upon presentation of the several Notes, and stamping thereon the payment, if only partially paid, and upon surrender thereof, if fully paid:
First, to the payment of all amounts due the Trustee in any of its capacities hereunder under Section 7.06;
Second, in case the principal of the outstanding Notes shall not have become due and be unpaid, to the payment of interest on, and any cash due upon conversion of, the Notes in default in the order of the date due of the payments of such interest and cash due upon conversion, as the case may be, with interest (to the extent that such interest has been collected by the Trustee) upon such overdue payments at the rate borne by the Notes at such time, such payments to be made ratably to the Persons entitled thereto;
Third, in case the principal of the outstanding Notes shall have become due, by declaration or otherwise, and be unpaid to the payment of the whole amount (including, if applicable, the payment of the Redemption Price, the Fundamental Change Repurchase Price and any cash due upon conversion) then owing and unpaid upon the Notes for principal and interest, if any, with interest on the overdue principal and, to the extent that such interest has been collected by the Trustee, upon overdue installments of interest at the rate borne by the Notes at such time, and in case such monies shall be insufficient to pay in full the whole amounts so due and unpaid upon the Notes, then to the payment of such principal (including, if applicable, the Redemption Price, the Fundamental Change Repurchase Price and any cash due upon conversion) and interest without preference or priority of principal over interest, or of interest over principal or of any installment of interest over any other installment of interest, or of any Note over any other Note, ratably to the aggregate of such principal (including, if applicable, the Redemption Price, the Fundamental Change Repurchase Price and any cash due upon conversion) and accrued and unpaid interest; and
Fourth, to the payment of the remainder, if any, to the Company.
31
    


Section 6.06. Proceedings by Holders. Except to enforce the right to receive payment of principal (including, if applicable, the Redemption Price and the Fundamental Change Repurchase Price) or interest when due, or the right to receive payment or delivery of the consideration due upon conversion, no Holder of any Note shall have any right by virtue of or by availing of any provision of this Indenture or the Notes to institute any suit, action or proceeding in equity or at law upon or under or with respect to this Indenture, or for the appointment of a receiver, trustee, liquidator, custodian or other similar official, or for any other remedy hereunder, unless:
(a)    such Holder previously shall have given to the Trustee written notice of an Event of Default and of the continuance thereof, as herein provided;
(b)    Holders of at least 25% in aggregate principal amount of the Notes then outstanding shall have made written request upon the Trustee to institute such action, suit or proceeding in its own name as Trustee hereunder;
(c)    such Holders shall have offered to the Trustee such security or indemnity satisfactory to it against any loss, liability or expense to be incurred therein or thereby;
(d)    the Trustee for 60 days after its receipt of such notice, request and offer of such security or indemnity, shall have neglected or refused to institute any such action, suit or proceeding; and
(e)    no direction that, in the opinion of the Trustee, is inconsistent with such written request shall have been given to the Trustee by the Holders of a majority of the aggregate principal amount of the Notes then outstanding within such 60-day period pursuant to Section 6.09,
it being understood and intended, and being expressly covenanted by the taker and Holder of every Note with every other taker and Holder and the Trustee that no one or more Holders shall have any right in any manner whatever by virtue of or by availing of any provision of this Indenture to affect, disturb or prejudice the rights of any other Holder (it being understood that the Trustee shall not have an affirmative duty to ascertain whether or not any such direction is unduly prejudicial to any other Holder), or to obtain or seek to obtain priority over or preference to any other such Holder, or to enforce any right under this Indenture, except in the manner herein provided and for the equal, ratable and common benefit of all Holders (except as otherwise provided herein). For the protection and enforcement of this Section 6.06, each and every Holder and the Trustee shall be entitled to such relief as can be given either at law or in equity.
Notwithstanding any other provision of this Indenture and any provision of any Note, the right of any Holder to receive payment or delivery, as the case may be, of (x) the principal (including the Redemption Price, the Fundamental Change Repurchase Price, if applicable) of, (y) accrued and unpaid interest, if any, on, and (z) the consideration due upon conversion of, such Note, on or after the respective due dates expressed or provided for in such Note or in this Indenture, or to institute suit for the enforcement of any such payment or delivery, as the case
32
    


may be, on or after such respective dates against the Company shall not be impaired or affected without the consent of such Holder.
Section 6.07. Proceedings by Trustee. In case of an Event of Default, the Trustee may in its discretion proceed to protect and enforce the rights vested in it by this Indenture by such appropriate judicial proceedings as are necessary to protect and enforce any of such rights, either by suit in equity or by action at law or by proceeding in bankruptcy or otherwise, whether for the specific enforcement of any covenant or agreement contained in this Indenture or in aid of the exercise of any power granted in this Indenture, or to enforce any other legal or equitable right vested in the Trustee by this Indenture or by law.
Section 6.08. Remedies Cumulative and Continuing. Except as provided in the last paragraph of Section 2.06, all powers and remedies given by this Article 6 to the Trustee or to the Holders shall, to the extent permitted by law, be deemed cumulative and not exclusive of any thereof or of any other powers and remedies available to the Trustee or the Holders of the Notes, by judicial proceedings or otherwise, to enforce the performance or observance of the covenants and agreements contained in this Indenture, and no delay or omission of the Trustee or of any Holder of any of the Notes to exercise any right or power accruing upon any Default or Event of Default shall impair any such right or power, or shall be construed to be a waiver of any such Default or Event of Default or any acquiescence therein; and, subject to the provisions of Section 6.06, every power and remedy given by this Article 6 or by law to the Trustee or to the Holders may be exercised from time to time, and as often as shall be deemed expedient, by the Trustee or by the Holders.
Section 6.09. Direction of Proceedings and Waiver of Defaults by Majority of Holders. The Holders of a majority of the aggregate principal amount of the Notes at the time outstanding determined in accordance with Section 8.04 shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee or exercising any trust or power conferred on the Trustee with respect to the Notes; provided, however, that (A) such direction shall not be in conflict with any rule of law or with this Indenture, and (A) the Trustee may take any other action deemed proper by the Trustee that is not inconsistent with such direction. The Trustee may refuse to follow any direction that it determines is unduly prejudicial to the rights of any other Holder (it being understood that the Trustee shall not have an affirmative duty to ascertain whether or not any such direction is unduly prejudicial to any other Holder) or that would involve the Trustee in personal liability or for which it has not received indemnity or security satisfactory to it against any loss, liability or expense. The Holders of a majority in aggregate principal amount of the Notes at the time outstanding determined in accordance with Section 8.04 may on behalf of the Holders of all of the Notes waive any past Default or Event of Default hereunder and its consequences except (i) a default in the payment of accrued and unpaid interest, if any, on, or the principal (including any Redemption Price, any Fundamental Change Repurchase Price) of, the Notes when due that has not been cured pursuant to the provisions of Section 6.01, (i) a failure by the Company to pay or deliver, as the case may be, the consideration due upon conversion of the Notes or (i) a default in respect of a covenant or provision hereof which under Article 10 cannot be modified or amended without the consent of each Holder of an outstanding Note affected. Upon any such waiver the
33
    


Company, the Trustee and the Holders of the Notes shall be restored to their former positions and rights hereunder; but no such waiver shall extend to any subsequent or other Default or Event of Default or impair any right consequent thereon. Whenever any Default or Event of Default hereunder shall have been waived as permitted by this Section 6.09, said Default or Event of Default shall for all purposes of the Notes and this Indenture be deemed to have been cured and to be not continuing; but no such waiver shall extend to any subsequent or other Default or Event of Default or impair any right consequent thereon.
Section 6.10. Notice of Defaults. The Trustee shall, within 90 days after the occurrence and continuance of a Default of which a Responsible Officer of the Trustee has been notified in writing or has actual knowledge, deliver to all Holders notice of all such Defaults known to a Responsible Officer, unless such Defaults shall have been cured or waived before the giving of such notice; provided that, except in the case of a Default in the payment of the principal of (including the Redemption Price, the Fundamental Change Repurchase Price, if applicable), or accrued and unpaid interest on, any of the Notes or a Default in the payment or delivery of the consideration due upon conversion, the Trustee shall be protected in withholding such notice if and so long as it in good faith determines that the withholding of such notice is in the interests of the Holders.
Section 6.11. Undertaking to Pay Costs. All parties to this Indenture agree, and each Holder of any Note by its acceptance thereof shall be deemed to have agreed, that any court may, in its discretion, require, in any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken or omitted by it as Trustee, the filing by any party litigant in such suit of an undertaking to pay the costs of such suit and that such court may in its discretion assess reasonable costs, including reasonable attorneys’ fees and expenses, against any party litigant in such suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant; provided that the provisions of this Section 6.11 (to the extent permitted by law) shall not apply to any suit instituted by the Trustee, to any suit instituted by any Holder, or group of Holders, holding in the aggregate more than 10% in principal amount of the Notes at the time outstanding determined in accordance with Section 8.04, or to any suit instituted by any Holder for the enforcement of the payment of the principal of or accrued and unpaid interest, if any, on any Note (including, but not limited to, the Redemption Price, the Fundamental Change Repurchase Price with respect to the Notes being repurchased as provided in this Indenture) on or after the due date expressed or provided for in such Note or to any suit for the enforcement of the right to convert any Note in accordance with the provisions of Article 14.
ARTICLE 7     CONCERNING THE TRUSTEE
Section 7.01. Duties and Responsibilities of Trustee. The Trustee, prior to the occurrence of an Event of Default of which a Responsible Officer of the Trustee has written notice or actual knowledge and after the curing or waiver of all Events of Default that may have occurred, undertakes to perform such duties and only such duties as are specifically set forth in this Indenture. In the event an Event of Default has occurred and is continuing of which a Responsible Officer of the Trustee has written notice or actual knowledge, the Trustee shall
34
    


exercise such of the rights and powers vested in it by this Indenture, and use the same degree of care and skill in its exercise, as a prudent person would exercise or use under the circumstances in the conduct of such person’s own affairs; provided that if an Event of Default occurs and is continuing, the Trustee will be under no obligation to exercise any of the rights or powers under this Indenture at the request or direction of any of the Holders unless such Holders have offered (and, if requested, provided) to the Trustee indemnity or security satisfactory to it against any loss, liability or expense that might be incurred by it in compliance with such request or direction.
No provision of this Indenture shall be construed to relieve the Trustee from liability for its own grossly negligent action, its own grossly negligent failure to act or its own willful misconduct, except that:
(a)    prior to the occurrence of an Event of Default of which a Responsible Officer of the Trustee has written notice or actual knowledge and after the curing or waiving of all Events of Default that may have occurred:
(i)    the duties and obligations of the Trustee shall be determined solely by the express provisions of this Indenture, and the Trustee shall not be liable except for the performance of such duties and obligations as are specifically set forth in this Indenture and no implied covenants or obligations shall be read into this Indenture against the Trustee; and
(ii)    in the absence of gross negligence or willful misconduct on the part of the Trustee, the Trustee may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon any certificates or opinions furnished to the Trustee and conforming to the requirements of this Indenture; but, in the case of any such certificates or opinions that by any provisions hereof are specifically required to be furnished to the Trustee, the Trustee shall be under a duty to examine the same to determine whether or not they conform to the requirements of this Indenture (but need not confirm or investigate the accuracy of any mathematical calculations or other facts stated therein);
(b)    the Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer or Officers of the Trustee, unless it shall be proved that the Trustee was grossly negligent in ascertaining the pertinent facts;
(c)    the Trustee shall not be liable with respect to any action taken or omitted to be taken by it in good faith in accordance with the direction of the Holders of not less than a majority of the aggregate principal amount of the Notes at the time outstanding determined as provided in Section 8.04 relating to the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee, under this Indenture;
35
    


(d)    whether or not therein provided, every provision of this Indenture relating to the conduct or affecting the liability of, or affording protection to, the Trustee shall be subject to the provisions of this Section;
(e)    the Trustee shall not be liable in respect of any payment (as to the correctness of amount, entitlement to receive or any other matters relating to payment) or notice effected by the Company or any Paying Agent or any records maintained by any co-Note Registrar with respect to the Notes;
(f)    if any party fails to deliver a notice relating to an event the fact of which, pursuant to this Indenture, requires notice to be sent to the Trustee, the Trustee may conclusively rely on its failure to receive such notice as reason to act as if no such event occurred;
(g)    in the absence of written investment direction from the Company, all cash received by the Trustee shall be placed in a non-interest bearing trust account, and in no event shall the Trustee be liable for the selection of investments or for investment losses incurred thereon or for losses incurred as a result of the liquidation of any such investment prior to its maturity date or the failure of the party directing such investments prior to its maturity date or the failure of the party directing such investment to provide timely written investment direction, and the Trustee shall have no obligation to invest or reinvest any amounts held hereunder in the absence of such written investment direction from the Company;
(h)    in the event that the Trustee is also acting as Custodian, Note Registrar, Paying Agent, Conversion Agent, Bid Solicitation Agent or transfer agent hereunder, the rights and protections afforded to the Trustee pursuant to this Article 7 shall also be afforded to such Custodian, Note Registrar, Paying Agent, Conversion Agent, Bid Solicitation Agent or transfer agent; and
(i)    under no circumstances shall the Trustee be liable in its individual capacity for the obligations evidenced by the Notes.
None of the provisions contained in this Indenture shall require the Trustee to expend or risk its own funds or otherwise incur personal financial liability in the performance of any of its duties or in the exercise of any of its rights or powers. The Trustee will be under no obligation to exercise any of its rights and powers under this Indenture at the request or direction of any of the Holders unless such Holder has offered (and, if requested, provided) to the Trustee indemnity or security satisfactory to it against any loss, liability or expense.
Section 7.02. Reliance on Documents, Opinions, Etc. Except as otherwise provided in Section 7.01:
(a)    the Trustee may conclusively rely and shall be fully protected in acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, judgment, order, bond, note, coupon or other paper or document (whether in its original or facsimile form) believed by it in good faith to be genuine and to have been signed or presented by the proper party or parties;
36
    


(b)    any request, direction, order or demand of the Company mentioned herein shall be sufficiently evidenced by an Officer’s Certificate (unless other evidence in respect thereof be herein specifically prescribed); and any Board Resolution may be evidenced to the Trustee by a copy thereof certified by the Secretary or an Assistant Secretary of the Company;
(c)    the Trustee may consult with counsel of its selection and require an Opinion of Counsel and any written or verbal advice of such counsel or Opinion of Counsel shall be full and complete authorization and protection in respect of any action taken or omitted by it hereunder in good faith and in accordance with such advice or Opinion of Counsel;
(d)    the Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, judgment, order, bond, debenture or other paper or document, but the Trustee, in its discretion, may make such further inquiry or investigation into such facts or matters as it may see fit, and, if the Trustee shall determine to make such further inquiry or investigation, it shall be entitled to examine the books, records and premises of the Company, personally or by agent or attorney at the expense of the Company and shall incur no liability of any kind by reason of such inquiry or investigation;
(e)    the Trustee may execute any of the trusts or powers hereunder or perform any duties hereunder either directly or by or through agents, custodians, nominees or attorneys and the Trustee shall not be responsible for any misconduct or negligence on the part of any agent, custodian, nominee or attorney appointed by it with due care hereunder;
(f)    the permissive rights of the Trustee enumerated herein shall not be construed as duties;
(g)    the Trustee shall not be required to give any bond or surety in respect of the performance of its powers and duties hereunder;
(h)    the Trustee may request that the Company deliver an Officer’s Certificate setting forth the names of individuals and/or titles of officers authorized at such time to take specified actions pursuant to this Indenture;
(i)    the Trustee shall not be liable for any action taken, suffered, or omitted to be taken by it in good faith and reasonably believed by it to be authorized or within the discretion or rights or powers conferred upon it by this Indenture; and
(j)    the Trustee shall not be obligated to take possession of any Common Stock, whether upon conversion or in connection with any discharge of this Indenture pursuant to Article 3 hereof, but shall satisfy its obligation as Conversion Agent by working through the stock transfer agent of the Company from time to time as directed by the Company.
In no event shall the Trustee be liable for any consequential, punitive, incidental, special or indirect loss or damage of any kind whatsoever (including but not limited to lost profits), even if the Trustee has been advised of the likelihood of such loss or damage and regardless of the
37
    


form of action. The Trustee shall not be charged with knowledge of any Default or Event of Default with respect to the Notes, unless either (1) a Responsible Officer shall have actual knowledge of such Default or Event of Default or (2) written notice of such Default or Event of Default shall have been actually received by a Responsible Officer of the Trustee by the Company or by any Holder of the Notes at the Corporate Trust Office and such notice references the Notes and/or this Indenture.
Section 7.03. No Responsibility for Recitals, Etc. The recitals contained herein and in the Notes (except in the Trustee’s certificate of authentication) shall be taken as the statements of the Company, and the Trustee assumes no responsibility for the correctness of the same. The Trustee makes no representations as to the validity or sufficiency of this Indenture or of the Notes or of the Common Stock (or other Reference Property) underlying the Notes. The Trustee shall not be accountable for the use or application by the Company of any Notes or the proceeds of any Notes authenticated and delivered by the Trustee in conformity with the provisions of this Indenture or any money paid to the Company or upon the Company’s direction under any provision of the Indenture.
Section 7.04. Trustee, Paying Agents, Conversion Agents, Bid Solicitation Agent or Note Registrar May Own Notes. The Trustee, any Paying Agent, any Conversion Agent, Bid Solicitation Agent (if other than the Company or any Affiliate thereof) or Note Registrar, in its individual or any other capacity, may become the owner or pledgee of Notes with the same rights it would have if it were not the Trustee, Paying Agent, Conversion Agent, Bid Solicitation Agent or Note Registrar.
Section 7.05. Monies to Be Held in Trust. All monies received by the Trustee shall, until used or applied as herein provided, be held in trust for the purposes for which they were received. Money held by the Trustee in trust hereunder need not be segregated from other funds or property except to the extent required by law. The Trustee shall be under no liability for interest or investment income on any money received by it hereunder except as may be agreed from time to time by the Company and the Trustee.
Section 7.06. Compensation and Expenses of Trustee. The Company covenants and agrees to pay to the Trustee, in any capacity under this Indenture, from time to time, and the Trustee shall be entitled to, compensation for all services rendered by it hereunder in any capacity (which shall not be limited by any provision of law in regard to the compensation of a trustee of an express trust) as mutually agreed to in writing between the Trustee and the Company, and the Company will pay or reimburse the Trustee upon its request for all reasonable expenses, disbursements and advances reasonably incurred or made by the Trustee in accordance with any of the provisions of this Indenture in any capacity thereunder (including the reasonable compensation and the expenses and disbursements of its agents and counsel and of all Persons not regularly in its employ) except any such expense, disbursement or advance as shall have been caused by its gross negligence or willful misconduct as determined by a final, non-appealable decision of a court of competent jurisdiction. The Company also covenants to indemnify the Trustee in any capacity under this Indenture and any other document or transaction entered into in connection herewith and its officers, directors, attorneys, employees and agents and any
38
    


authenticating agent for, and to hold them harmless against, any loss, claim (whether asserted by the Company, a Holder or any Person), damage, liability or expense incurred without gross negligence or willful misconduct on the part of the Trustee, its officers, directors, attorneys, agents or employees, or such agent or authenticating agent, as the case may be, as determined by a final, non-appealable decision of a court of competent jurisdiction, and arising out of or in connection with the acceptance or administration of this Indenture or in any other capacity hereunder, including the costs and expenses of defending themselves against any claim of liability in the premises. The obligations of the Company under this Section 7.06 to compensate or indemnify the Trustee and to pay or reimburse the Trustee for expenses, disbursements and advances shall be secured by a senior lien to which the Notes are hereby made subordinate on all money or property held or collected by the Trustee, except, subject to the effect of Section 6.05, funds held in trust herewith for the benefit of the Holders of particular Notes. The Trustee’s right to receive payment of any amounts due under this Section 7.06 shall not be subordinate to any other liability or indebtedness of the Company. The obligation of the Company under this Section 7.06 shall survive the satisfaction and discharge of this Indenture, the payment or conversion of the Notes and the earlier resignation or removal of the Trustee. The Company need not pay for any settlement made without its consent, which consent shall not be unreasonably withheld. The indemnification provided in this Section 7.06 shall extend to the officers, directors, attorneys, agents and employees of the Trustee.
Without prejudice to any other rights available to the Trustee under applicable law, when the Trustee and its agents and any authenticating agent incur expenses or render services after an Event of Default specified in Section 6.01(h) or Section 6.01(i) occurs, the expenses and the compensation for the services are intended to constitute expenses of administration under any bankruptcy, insolvency or similar laws.
Section 7.07. Officer’s Certificate as Evidence. Except as otherwise provided in Section 7.01, whenever in the administration of the provisions of this Indenture the Trustee shall deem it necessary or desirable that a matter be proved or established prior to taking or omitting any action hereunder, such matter (unless other evidence in respect thereof be herein specifically prescribed) may, in the absence of gross negligence and willful misconduct on the part of the Trustee, be deemed to be conclusively proved and established by an Officer’s Certificate delivered to the Trustee, and such Officer’s Certificate, in the absence of gross negligence or willful misconduct on the part of the Trustee, shall be full warrant to the Trustee for any action taken or omitted by it under the provisions of this Indenture upon the faith thereof.
Section 7.08. Eligibility of Trustee. There shall at all times be a Trustee hereunder which shall be a Person that is eligible pursuant to the Trust Indenture Act to act as such and has a combined capital and surplus of at least $50,000,000. If such Person publishes reports of condition at least annually, pursuant to law or to the requirements of any supervising or examining authority, then for the purposes of this Section, the combined capital and surplus of such Person shall be deemed to be its combined capital and surplus as set forth in its most recent report of condition so published. If at any time the Trustee shall cease to be eligible in accordance with the provisions of this Section, it shall resign immediately in the manner and with the effect hereinafter specified in this Article.
39
    


Section 7.09. Resignation or Removal of Trustee. (a) The Trustee may at any time resign by giving written notice of such resignation to the Company. Upon receiving such notice of resignation, the Company shall promptly appoint a successor trustee by written instrument, in duplicate, executed by order of the Board of Directors, one copy of which instrument shall be delivered to the resigning Trustee and one copy to the successor trustee. If no successor trustee shall have been so appointed and have accepted appointment within 60 days after the giving of such notice of resignation to the Company, the resigning Trustee may, upon ten Business Days’ notice to the Company and the Holders and at the expense of the Company, petition any court of competent jurisdiction for the appointment of a successor trustee, or any Holder who has been a bona fide holder of a Note or Notes for at least six months (or since the date of this Indenture) may, subject to the provisions of Section 6.11, on behalf of himself or herself and all others similarly situated, petition any such court for the appointment of a successor trustee. Such court may thereupon, after such notice, if any, as it may deem proper and prescribe, appoint a successor trustee.
(b)    In case at any time any of the following shall occur:
(i)    the Trustee shall cease to be eligible in accordance with the provisions of Section 7.08 and shall fail to resign after written request therefor by the Company or by any such Holder, or
(ii)    the Trustee shall become incapable of acting, or shall be adjudged a bankrupt or insolvent, or a receiver of the Trustee or of its property shall be appointed, or any public officer shall take charge or control of the Trustee or of its property or affairs for the purpose of rehabilitation, conservation or liquidation,
then, in either case, the Company may by a Board Resolution remove the Trustee and appoint a successor trustee by written instrument, in duplicate, executed by order of the Board of Directors, one copy of which instrument shall be delivered to the Trustee so removed and one copy to the successor trustee, or, subject to the provisions of Section 6.11, any Holder who has been a bona fide holder of a Note or Notes for at least six months (or since the date of this Indenture) may, on behalf of himself or herself and all others similarly situated, petition any court of competent jurisdiction for the removal of the Trustee and the appointment of a successor trustee. Such court may thereupon, after such notice, if any, as it may deem proper and prescribe, remove the Trustee and appoint a successor trustee.
(b)    The Holders of a majority in aggregate principal amount of the Notes at the time outstanding, as determined in accordance with Section 8.04, may at any time remove the Trustee and nominate a successor trustee that shall be deemed appointed as successor trustee unless within ten days after notice to the Company of such nomination the Company objects thereto, in which case the Trustee so removed or any Holder, upon the terms and conditions and otherwise as in Section 7.09(a) provided, may petition any court of competent jurisdiction for an appointment of a successor trustee.
40
    


(c)    Any resignation or removal of the Trustee and appointment of a successor trustee pursuant to any of the provisions of this Section 7.09 shall become effective upon acceptance of appointment by the successor trustee as provided in Section 7.10.
Section 7.10. Acceptance by Successor Trustee. Any successor trustee appointed as provided in Section 7.09 shall execute, acknowledge and deliver to the Company and to its predecessor trustee an instrument accepting such appointment hereunder, and thereupon the resignation or removal of the predecessor trustee shall become effective and such successor trustee, without any further act, deed or conveyance, shall become vested with all the rights, powers, duties and obligations of its predecessor hereunder, with like effect as if originally named as Trustee herein; but, nevertheless, on the written request of the Company or of the successor trustee, the trustee ceasing to act shall, upon payment of any amounts then due it pursuant to the provisions of Section 7.06, execute and deliver an instrument transferring to such successor trustee all the rights and powers of the trustee so ceasing to act. Upon request of any such successor trustee, the Company shall execute any and all instruments in writing for more fully and certainly vesting in and confirming to such successor trustee all such rights and powers. Any trustee ceasing to act shall, nevertheless, retain a senior lien to which the Notes are hereby made subordinate on all money or property held or collected by such trustee as such, except for funds held in trust for the benefit of Holders of particular Notes, to secure any amounts then due it pursuant to the provisions of Section 7.06.
No successor trustee shall accept appointment as provided in this Section 7.10 unless at the time of such acceptance such successor trustee shall be eligible under the provisions of Section 7.08.
Upon acceptance of appointment by a successor trustee as provided in this Section 7.10, each of the Company and the successor trustee, at the written direction and at the expense of the Company shall deliver or cause to be delivered notice of the succession of such trustee hereunder to the Holders. If the Company fails to deliver such notice within ten days after acceptance of appointment by the successor trustee, the successor trustee shall cause such notice to be delivered at the expense of the Company.
Section 7.11. Succession by Merger, Etc. Any corporation or other entity into which the Trustee may be merged or converted or with which it may be consolidated, or any corporation or other entity resulting from any merger, conversion or consolidation to which the Trustee shall be a party, or any corporation or other entity succeeding to all or substantially all of the corporate trust business of the Trustee (including the administration of this Indenture), shall be the successor to the Trustee hereunder without the execution or filing of any paper or any further act on the part of any of the parties hereto; provided that in the case of any corporation or other entity succeeding to all or substantially all of the corporate trust business of the Trustee such corporation or other entity shall be eligible under the provisions of Section 7.08.
In case at the time such successor to the Trustee shall succeed to the trusts created by this Indenture, any of the Notes shall have been authenticated but not delivered, any such successor to the Trustee may adopt the certificate of authentication of any predecessor trustee or authenticating agent appointed by such predecessor trustee, and deliver such Notes so
41
    


authenticated; and in case at that time any of the Notes shall not have been authenticated, any successor to the Trustee or an authenticating agent appointed by such successor trustee may authenticate such Notes either in the name of any predecessor trustee hereunder or in the name of the successor trustee; and in all such cases such certificates shall have the full force which it is anywhere in the Notes or in this Indenture provided that the certificate of the Trustee shall have; provided, however, that the right to adopt the certificate of authentication of any predecessor trustee or to authenticate Notes in the name of any predecessor trustee shall apply only to its successor or successors by merger, conversion or consolidation.
Section 7.12. Trustee’s Application for Instructions from the Company. Any application by the Trustee for written instructions from the Company (other than with regard to any action proposed to be taken or omitted to be taken by the Trustee that affects the rights of the Holders of the Notes under this Indenture) may, at the option of the Trustee, set forth in writing any action proposed to be taken or omitted by the Trustee under this Indenture and the date on and/or after which such action shall be taken or such omission shall be effective. The Trustee shall not be liable for any action taken by, or omission of, the Trustee in accordance with a proposal included in such application on or after the date specified in such application (which date shall not be less than three Business Days after notice to the Company has been deemed to have been given pursuant to Section 17.03, unless any such officer shall have consented in writing to any earlier date), unless, prior to taking any such action (or the effective date in the case of any omission), the Trustee shall have received written instructions in accordance with this Indenture in response to such application specifying the action to be taken or omitted.
Section 7.13. Preferential Collection of Claims. If and when the Trustee shall be or become a creditor of the Company (or any other obligor upon the Notes), the Trustee shall be subject to the provisions of the Trust Indenture Act regarding the collection of claims against the Company (or any such other obligor).
ARTICLE 8     CONCERNING THE HOLDERS
Section 8.01. Action by Holders. Whenever in this Indenture it is provided that the Holders of a specified percentage of the aggregate principal amount of the Notes may take any action (including the making of any demand or request, the giving of any notice, consent or waiver or the taking of any other action), the fact that at the time of taking any such action, the Holders of such specified percentage have joined therein may be evidenced (i) by any instrument or any number of instruments of similar tenor executed by Holders in person or by agent or proxy appointed in writing, or (i) by the record of the Holders voting in favor thereof at any meeting of Holders duly called and held in accordance with the provisions of Article 9, or (i) by a combination of such instrument or instruments and any such record of such a meeting of Holders. Whenever the Company or the Trustee solicits the taking of any action by the Holders of the Notes, the Company or the Trustee may fix, but shall not be required to, in advance of such solicitation, a date as the record date for determining Holders entitled to take such action. The record date if one is selected shall be not more than fifteen days prior to the date of commencement of solicitation of such action.
42
    


Section 8.02. Proof of Execution by Holders. Subject to the provisions of Section 7.01, Section 7.02 and Section 9.05, proof of the execution of any instrument by a Holder or its agent or proxy shall be sufficient if made in accordance with such reasonable rules and regulations as may be prescribed by the Trustee or in such manner as shall be satisfactory to the Trustee. The holding of Notes shall be proved by the Note Register or by a certificate of the Note Registrar. The record of any Holders’ meeting shall be proved in the manner provided in Section 9.06.
Section 8.03. Who Are Deemed Absolute Owners. The Company, the Trustee, any authenticating agent, any Paying Agent, any Conversion Agent and any Note Registrar may deem the Person in whose name a Note shall be registered upon the Note Register to be, and may treat it as, the absolute owner of such Note (whether or not such Note shall be overdue and notwithstanding any notation of ownership or other writing thereon made by any Person other than the Company or any Note Registrar) for the purpose of receiving payment of or on account of the principal (including any Redemption Price and any Fundamental Change Repurchase Price) of and (subject to Section 2.03) accrued and unpaid interest on such Note, for conversion of such Note and for all other purposes under this Indenture; and neither the Company nor the Trustee nor any Paying Agent nor any Conversion Agent nor any Note Registrar shall be affected by any notice to the contrary. The sole registered holder of a Global Note shall be the Depositary or its nominee. All such payments or deliveries so made to any Holder for the time being, or upon its order, shall be valid, and, to the extent of the sums or shares of Common Stock so paid or delivered, effectual to satisfy and discharge the liability for monies payable or shares deliverable upon any such Note. Notwithstanding anything to the contrary in this Indenture or the Notes following an Event of Default, any owner of a beneficial interest in a Global Note may directly enforce against the Company, without the consent, solicitation, proxy, authorization or any other action of the Depositary or any other Person, such holder’s right to exchange such beneficial interest for a Note in certificated form in accordance with the provisions of this Indenture.
Section 8.04. Company-Owned Notes Disregarded. In determining whether the Holders of the requisite aggregate principal amount of Notes have concurred in any direction, consent, waiver or other action under this Indenture, Notes that are owned by the Company, by any Subsidiary thereof or by any Person directly or indirectly controlling or controlled by or under direct or indirect common control with the Company or any Subsidiary thereof shall be disregarded and deemed not to be outstanding for the purpose of any such determination; provided that for the purposes of determining whether the Trustee shall be protected in relying on any such direction, consent, waiver or other action, only Notes with respect to which a Responsible Officer has received written notice that such Notes are so owned shall be so disregarded. Notes so owned that have been pledged in good faith may be regarded as outstanding for the purposes of this Section 8.04 if the pledgee shall establish to the satisfaction of the Trustee the pledgee’s right to so act with respect to such Notes and that the pledgee is not the Company, a Subsidiary thereof or a Person directly or indirectly controlling or controlled by or under direct or indirect common control with the Company or a Subsidiary thereof. In the case of a dispute as to such right, any decision or indecision by the Trustee taken upon the advice of counsel shall be full protection to the Trustee. Upon request of the Trustee, the Company shall furnish to the Trustee promptly an Officer’s Certificate listing and identifying all Notes, if
43
    


any, known by the Company to be owned or held by or for the account of any of the above described Persons; and, subject to Section 7.01, the Trustee shall be entitled to accept such Officer’s Certificate as conclusive evidence of the facts therein set forth and of the fact that all Notes not listed therein are outstanding for the purpose of any such determination.
Section 8.05. Revocation of Consents; Future Holders Bound. At any time prior to (but not after) the evidencing to the Trustee, as provided in Section 8.01, of the taking of any action by the Holders of the percentage of the aggregate principal amount of the Notes specified in this Indenture in connection with such action, any Holder of a Note that is shown by the evidence to be included in the Notes the Holders of which have consented to such action may, by filing written notice with the Trustee at its Corporate Trust Office and upon proof of holding as provided in Section 8.02, revoke such action so far as concerns such Note. Except as aforesaid, any such action taken by the Holder of any Note shall be conclusive and binding upon such Holder and upon all future Holders and owners of such Note and of any Notes issued in exchange or substitution therefor or upon registration of transfer thereof, irrespective of whether any notation in regard thereto is made upon such Note or any Note issued in exchange or substitution therefor or upon registration of transfer thereof.
ARTICLE 9     HOLDERS’ MEETINGS
Section 9.01. Purpose of Meetings. A meeting of Holders may be called at any time and from time to time pursuant to the provisions of this Article 9 for any of the following purposes:
(a)    to give any notice to the Company or to the Trustee or to give any directions to the Trustee permitted under this Indenture, or to consent to the waiving of any Default or Event of Default hereunder (in each case, as permitted under this Indenture) and its consequences, or to take any other action authorized to be taken by Holders pursuant to any of the provisions of Article 6;
(b)    to remove the Trustee and nominate a successor trustee pursuant to the provisions of Article 7;
(c)    to consent to the execution of an indenture or indentures supplemental hereto pursuant to the provisions of Article 10; or
(d)    to take any other action authorized to be taken by or on behalf of the Holders of any specified aggregate principal amount of the Notes under any other provision of this Indenture or under applicable law.
Section 9.02. Call of Meetings by Trustee. The Trustee may at any time call a meeting of Holders to take any action specified in Section 9.01, to be held at such time and at such place as the Trustee shall determine. Notice of every meeting of the Holders, setting forth the time and the place of such meeting and in general terms the action proposed to be taken at such meeting and the establishment of any record date pursuant to Section 8.01, shall be delivered to Holders of such Notes. Such notice shall also be delivered to the Company. Such notices shall be delivered not less than 20 nor more than 90 days prior to the date fixed for the meeting.
44
    


Any meeting of Holders shall be valid without notice if the Holders of all Notes then outstanding are present in person or by proxy or if notice is waived before or after the meeting by the Holders of all Notes then outstanding, and if the Company and the Trustee are either present by duly authorized representatives or have, before or after the meeting, waived notice.
Section 9.03. Call of Meetings by Company or Holders. In case at any time the Company, pursuant to a Board Resolution, or the Holders of at least 10% of the aggregate principal amount of the Notes then outstanding, shall have requested the Trustee to call a meeting of Holders, by written request setting forth in reasonable detail the action proposed to be taken at the meeting, and the Trustee shall not have delivered the notice of such meeting within 20 days after receipt of such request, then the Company or such Holders may determine the time and the place for such meeting and may call such meeting to take any action authorized in Section 9.01, by delivering notice thereof as provided in Section 9.02.
Section 9.04. Qualifications for Voting. To be entitled to vote at any meeting of Holders a Person shall (a) be a Holder of one or more Notes on the record date pertaining to such meeting or (b) be a Person appointed by an instrument in writing as proxy by a Holder of one or more Notes on the record date pertaining to such meeting. The only Persons who shall be entitled to be present or to speak at any meeting of Holders shall be the Persons entitled to vote at such meeting and their counsel and any representatives of the Trustee and its counsel and any representatives of the Company and its counsel.
Section 9.05. Regulations. Notwithstanding any other provisions of this Indenture, the Trustee may make such reasonable regulations as it may deem advisable for any meeting of Holders, in regard to proof of the holding of Notes and of the appointment of proxies, and in regard to the appointment and duties of inspectors of votes, the submission and examination of proxies, certificates and other evidence of the right to vote, and such other matters concerning the conduct of the meeting as it shall think fit.
The Trustee shall, by an instrument in writing, appoint a temporary chairman of the meeting, unless the meeting shall have been called by the Company or by Holders as provided in Section 9.03, in which case the Company or the Holders calling the meeting, as the case may be, shall in like manner appoint a temporary chairman. A permanent chairman and a permanent secretary of the meeting shall be elected by vote of the Holders of a majority in aggregate principal amount of the Notes represented at the meeting and entitled to vote at the meeting.
Subject to the provisions of Section 8.04, at any meeting of Holders each Holder or proxyholder shall be entitled to one vote for each $1,000 principal amount of Notes held or represented by him or her; provided, however, that no vote shall be cast or counted at any meeting in respect of any Note challenged as not outstanding and ruled by the chairman of the meeting to be not outstanding. The chairman of the meeting shall have no right to vote other than by virtue of Notes held by it or instruments in writing as aforesaid duly designating it as the proxy to vote on behalf of other Holders. Any meeting of Holders duly called pursuant to the provisions of Section 9.02 or Section 9.03 may be adjourned from time to time by the Holders of a majority of the aggregate principal amount of Notes represented at the meeting, whether or not constituting a quorum, and the meeting may be held as so adjourned without further notice.
45
    


Section 9.06. Voting. The vote upon any resolution submitted to any meeting of Holders shall be by written ballot on which shall be subscribed the signatures of the Holders or of their representatives by proxy and the outstanding aggregate principal amount of the Notes held or represented by them. The permanent chairman of the meeting shall appoint two inspectors of votes who shall count all votes cast at the meeting for or against any resolution and who shall make and file with the secretary of the meeting their verified written reports in duplicate of all votes cast at the meeting. A record in duplicate of the proceedings of each meeting of Holders shall be prepared by the secretary of the meeting and there shall be attached to said record the original reports of the inspectors of votes on any vote by ballot taken thereat and affidavits by one or more Persons having knowledge of the facts setting forth a copy of the notice of the meeting and showing that said notice was delivered as provided in Section 9.02. The record shall show the aggregate principal amount of the Notes voting in favor of or against any resolution. The record shall be signed and verified by the affidavits of the permanent chairman and secretary of the meeting and one of the duplicates shall be delivered to the Company and the other to the Trustee to be preserved by the Trustee, the latter to have attached thereto the ballots voted at the meeting.
Any record so signed and verified shall be conclusive evidence of the matters therein stated.
Section 9.07. No Delay of Rights by Meeting. Nothing contained in this Article 9 shall be deemed or construed to authorize or permit, by reason of any call of a meeting of Holders or any rights expressly or impliedly conferred hereunder to make such call, any hindrance or delay in the exercise of any right or rights conferred upon or reserved to the Trustee or to the Holders under any of the provisions of this Indenture or of the Notes. Nothing contained in this Article 9 shall be deemed or construed to limit any Holder’s actions pursuant to the applicable procedures of the Depositary so long as the Notes are Global Notes.
ARTICLE 10     SUPPLEMENTAL INDENTURES
Section 10.01. Supplemental Indentures Without Consent of Holders. Without the consent of any Holder, the Company and the Trustee, at the Company’s expense, may from time to time and at any time enter into an indenture or indentures supplemental hereto for one or more of the following purposes:
(a)    to cure any ambiguity, omission, defect or inconsistency;
(b)    to provide for the assumption by a Successor Company of the obligations of the Company under this Indenture pursuant to Article 11;
(c)    to add guarantees with respect to the Notes;
(d)    to secure the Notes;
46
    


(e)    to add to the covenants or Events of Default of the Company for the benefit of the Holders or surrender any right or power conferred upon the Company under this Indenture or the Notes;
(f)    to make any change that does not adversely affect the rights of any Holder under this Indenture or the Notes, as determined by the Company in good faith;
(g)    in connection with any Merger Event, to provide that the Notes are convertible into Reference Property, subject to the provisions of Section 14.02 and in accordance with Section 14.07;
(h)    to increase the Conversion Rate as provided in this Indenture;
(i)    to provide for the issuance of Additional Notes as provided for in Section 2.10 of this Indenture;
(j)    to provide for the appointment of and acceptance of appointment by a successor trustee pursuant to Section 7.09 or to facilitate the administration of the trusts under this Indenture by more than one trustee;
(k)    to irrevocably elect a Settlement Method or a Specified Dollar Amount, or eliminate the Company’s right to elect a Settlement Method (provided that no such election or elimination will affect any Settlement Method previously elected (or deemed to be elected) with respect to any Note);
(l)    to conform the provisions of this Indenture or the Notes to any provision of the “Description of Notes” section of the Prospectus, as certified by the Company in an Officer’s Certificate; or
(m)    comply with any requirement of the Commission in connection with the qualification of this Indenture under the Trust Indenture Act.
Upon the written request of the Company, the Trustee is hereby authorized to, and shall join with the Company in the execution of any such supplemental indenture, to make any further appropriate agreements and stipulations that may be therein contained, except that the Trustee shall not be obligated to, but may in its discretion, enter into any supplemental indenture that affects the Trustee’s own rights, duties, liabilities or immunities under this Indenture or otherwise.
Any supplemental indenture authorized by the provisions of this Section 10.01 may be executed by the Company and the Trustee without the consent of the Holders of any of the Notes at the time outstanding, notwithstanding any of the provisions of Section 10.02.
Section 10.02. Supplemental Indentures with Consent of Holders. With the consent (evidenced as provided in Article 8) of the Holders of at least a majority of the aggregate principal amount of the Notes then outstanding (determined in accordance with Article 8 and including, without limitation, consents obtained in connection with a repurchase of, or tender or
47
    


exchange offer for, the Notes), the Company and the Trustee, at the Company’s expense, may from time to time and at any time enter into an indenture or indentures supplemental hereto for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Indenture, the Notes or any supplemental indenture or of modifying in any manner the rights of the Holders; provided, however, that, without the consent of each Holder of an outstanding Note affected, no such supplemental indenture shall:
(a)    reduce the principal amount of Notes whose Holders must consent to an amendment;
(b)    reduce the rate of or extend the stated time for payment of interest on any Note;
(c)    reduce the principal of or extend the Maturity Date of any Note;
(d)    make any change that adversely affects the conversion rights of any Notes;
(e)    reduce the Redemption Price or the Fundamental Change Repurchase Price of any Note or amend or modify in any manner adverse to the Holders the Company’s obligation to make such payments, whether through an amendment or waiver of provisions in the covenants, definitions or otherwise;
(f)    make any Note payable in money, or at a place of payment, other than that stated in the Note;
(g)    change the ranking of the Notes;
(h)    impair the right of any Holder to receive payment of principal and interest on such Holder’s Notes on or after the due dates therefor or to institute suit for the enforcement of any payment on or with respect to such Holder’s Note; or
(i)    make any change in this Article 10 that requires each Holder’s consent or in the waiver provisions in Section 6.02 or Section 6.09.
Upon the written request of the Company, and upon the filing with the Trustee of evidence of the consent of the requisite Holders as aforesaid and subject to Section 10.05, the Trustee shall join with the Company in the execution of such supplemental indenture unless such supplemental indenture affects the Trustee’s own rights, duties, privileges, indemnities or immunities under this Indenture or otherwise, in which case the Trustee may in its discretion, but shall not be obligated to, enter into such supplemental indenture.
Holders do not need under this Section 10.02 to approve the particular form of any proposed supplemental indenture. It shall be sufficient if such Holders approve the substance thereof. After any such supplemental indenture becomes effective, the Company shall deliver to the Holders (with a copy to the Trustee) a notice briefly describing such supplemental indenture. However, the failure to give such notice to all the Holders (with a copy to the Trustee), or any defect in the notice, will not impair or affect the validity of the supplemental indenture.
48
    


Section 10.03. Effect of Supplemental Indentures. Upon the execution of any supplemental indenture pursuant to the provisions of this Article 10, this Indenture shall be and be deemed to be modified and amended in accordance therewith and the respective rights, limitation of rights, obligations, duties and immunities under this Indenture of the Trustee, the Company and the Holders shall thereafter be determined, exercised and enforced hereunder subject in all respects to such modifications and amendments and all the terms and conditions of any such supplemental indenture shall be and be deemed to be part of the terms and conditions of this Indenture for any and all purposes.
Section 10.04. Notation on Notes. Notes authenticated and delivered after the execution of any supplemental indenture pursuant to the provisions of this Article 10 may, at the Company’s request and expense, bear a notation in form approved by the Trustee as to any matter provided for in such supplemental indenture. If the Company or the Trustee shall so determine, new Notes so modified as to conform, in the opinion of the Trustee and the Company, to any modification of this Indenture contained in any such supplemental indenture may, at the Company’s expense, be prepared and executed by the Company, authenticated upon receipt of a Company Order by the Trustee (or an authenticating agent duly appointed by the Trustee pursuant to Section 17.10) and delivered in exchange for the Notes then outstanding, upon surrender of such Notes then outstanding.
Section 10.05. Evidence of Compliance of Supplemental Indenture to Be Furnished Trustee. In addition to the documents required by Section 17.05, the Trustee shall receive an Officer’s Certificate and an Opinion of Counsel as conclusive evidence that any supplemental indenture executed pursuant hereto complies with the requirements of this Article 10 and is permitted or authorized by this Indenture and that the supplemental indenture constitutes the legal, valid and binding obligation of the Company enforceable in accordance with its terms.
ARTICLE 11     CONSOLIDATION, MERGER, SALE, CONVEYANCE AND LEASE
Section 11.01. Company May Consolidate, Etc. on Certain Terms. Subject to the provisions of Section 11.02, the Company shall not consolidate with, merge with or into, or sell, convey, transfer or lease in one transaction or a series of transactions all or substantially all the consolidated properties and assets of the Company and its Subsidiaries, taken as a whole, to another Person, unless:
(a)    the resulting, surviving or transferee Person (the “Successor Company”), if not the Company, shall be a corporation organized and existing under the laws of the United States of America, any State thereof or the District of Columbia, and the Successor Company (if not the Company) shall expressly assume, by supplemental indenture all of the obligations of the Company under the Notes and this Indenture; and
(b)    immediately after giving effect to such transaction, no Default or Event of Default shall have occurred and be continuing under this Indenture.
49
    


For purposes of this Section 11.01, the sale, conveyance, transfer or lease of all or substantially all of the properties and assets of one or more Subsidiaries of the Company to another Person, which properties and assets constitute all or substantially all of the properties and assets of the Company on a consolidated basis, shall be deemed to be the sale, conveyance, transfer or lease of all or substantially all of the properties and assets of the Company to another Person.
Section 11.02. Successor Corporation to Be Substituted. In case of any such consolidation, merger, sale, conveyance, transfer or lease and upon the assumption by the Successor Company, by supplemental indenture, executed and delivered to the Trustee, of all of the obligations of the Company under the Notes and this Indenture, such Successor Company (if not the Company) shall succeed to and, except in the case of a lease of all or substantially all of the Company’s properties and assets, shall be substituted for the Company, with the same effect as if it had been named herein as the party of the first part, and may thereafter exercise every right and power of, the Company under this Indenture. Such Successor Company thereupon may cause to be signed, and may issue either in its own name or in the name of the Company any or all of the Notes issuable hereunder which theretofore shall not have been signed by the Company and delivered to the Trustee; and, upon the order of such Successor Company instead of the Company and subject to all the terms, conditions and limitations in this Indenture prescribed, the Trustee shall authenticate and shall deliver, or cause to be authenticated and delivered, any Notes that previously shall have been signed and delivered by the Officers of the Company to the Trustee for authentication, and any Notes that such Successor Company thereafter shall cause to be signed and delivered to the Trustee for that purpose. All the Notes so issued shall in all respects have the same legal rank and benefit under this Indenture as the Notes theretofore or thereafter issued in accordance with the terms of this Indenture as though all of such Notes had been issued at the date of the execution hereof. In the event of any such consolidation, merger, sale, conveyance or transfer (but not in the case of a lease), upon compliance with this Article 11 the Person named as the “Company” in the first paragraph of this Indenture (or any successor that shall thereafter have become such in the manner prescribed in this Article 11) may be dissolved, wound up and liquidated at any time thereafter and, except in the case of a lease, such Person shall be released from its liabilities as obligor and maker of the Notes and from its obligations under this Indenture and the Notes.
In case of any such consolidation, merger, sale, conveyance, transfer or lease, such changes in phraseology and form (but not in substance) may be made in the Notes thereafter to be issued as may be appropriate.
Section 11.03. Officer’s Certificate and Opinion of Counsel to Be Given to Trustee. No such consolidation, merger, sale, conveyance, transfer or lease shall be effective unless the Trustee shall receive an Officer’s Certificate and an Opinion of Counsel each stating and as conclusive evidence that any such consolidation, merger, sale, conveyance, transfer or lease and any such assumption and, if a supplemental indenture is required in connection with such transaction, such supplemental indenture, complies with the provisions of this Article 11.
50
    


ARTICLE 12     IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS
Section 12.01. Indenture and Notes Solely Corporate Obligations. No recourse for the payment of the principal of or accrued and unpaid interest on any Note, nor for any claim based thereon or otherwise in respect thereof, and no recourse under or upon any obligation, covenant or agreement of the Company in this Indenture or in any supplemental indenture or in any Note, nor because of the creation of any indebtedness represented thereby, shall be had against any incorporator, stockholder, employee, agent, Officer or director or Subsidiary, as such, past, present or future, of the Company or of any successor corporation, either directly or through the Company or any successor corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise; it being expressly understood that all such liability is hereby expressly waived and released as a condition of, and as a consideration for, the execution of this Indenture and the issue of the Notes.
ARTICLE 13     INTENTIONALLY OMITTED
ARTICLE 14     CONVERSION OF NOTES
Section 14.01. Conversion Privilege. (a) Subject to and upon compliance with the provisions of this Article 14, each Holder of a Note shall have the right, at such Holder’s option, to convert all or any portion (if the portion to be converted is $1,000 principal amount or a multiple thereof) of such Note (i) subject to satisfaction of the conditions described in Section 14.01(b), at any time prior to the close of business on the Business Day immediately preceding September 15, 2027 under the circumstances and during the periods set forth in Section 14.01(b), and (ii) regardless of the conditions described in Section 14.01(b), on or after September 15, 2027 and prior to the close of business on the second Business Day immediately preceding the Maturity Date, in each case, at an initial conversion rate of 15.1172 shares of Common Stock (subject to adjustment as provided in this Article 14, the “Conversion Rate”) per $1,000 principal amount of Notes (subject to, and in accordance with, the settlement provisions of Section 14.02, the “Conversion Obligation”).
(b)    (i) Prior to the close of business on the Business Day immediately preceding September 15, 2027, a Holder may surrender all or any portion of its Notes for conversion at any time during the five Business Day period immediately after any five consecutive Trading Day period (the “Measurement Period”) in which the Trading Price per $1,000 principal amount of Notes, as determined following a written request by a Holder of Notes in accordance with this Section 14.01(b)(i), for each Trading Day of the Measurement Period was less than 98% of the product of the Last Reported Sale Price of the Common Stock and the Conversion Rate on each such Trading Day. The Trading Prices shall be determined by the Bid Solicitation Agent pursuant to this Section 14.01(b)(i) and the definition of Trading Price set forth in this Indenture. The Bid Solicitation Agent (if other than the Company) shall have no obligation to determine the Trading Price per $1,000 principal amount of Notes unless the Company has requested such determination in writing, and the Company shall have no obligation to make such request (or, if the Company is acting as Bid Solicitation Agent, the Company shall have no obligation to
51
    


determine the Trading Price per $1,000 principal amount of Notes) unless a Holder of at least $2,000,000 aggregate principal amount of Notes provides the Company with reasonable evidence that the Trading Price per $1,000 principal amount of Notes would be less than 98% of the product of the Last Reported Sale Price of the Common Stock and the Conversion Rate, at which time the Company shall instruct the Bid Solicitation Agent in writing (if other than the Company) to determine, or if the Company is acting as Bid Solicitation Agent, the Company shall determine the Trading Price per $1,000 principal amount of Notes beginning on the next Trading Day and on each successive Trading Day until the Trading Price per $1,000 principal amount of Notes is greater than or equal to 98% of the product of the Last Reported Sale Price of the Common Stock and the Conversion Rate. At such time as the Company directs the Bid Solicitation Agent in writing to solicit bid quotations, the Company shall provide the Bid Solicitation Agent with the names and contact details of the three independent nationally recognized securities dealers selected by the Company, and the Company shall direct those security dealers to provide bids to the Bid Solicitation Agent. Any such determination will be conclusive absent manifest error. If (x) the Company is not acting as Bid Solicitation Agent, and the Company does not, when the Company is required to, instruct the Bid Solicitation Agent to obtain bids, or if the Company so instructs the Bid Solicitation Agent to obtain bids and the Bid Solicitation Agent fails to make such determination, or (y) the Company is acting as Bid Solicitation Agent and the Company fails to make such determination. then, in either case, the Trading Price per $1,000 principal amount of Notes shall be deemed to be less than 98% of the product of the Last Reported Sale Price of the Common Stock and the Conversion Rate on each Trading Day of such failure. If the Trading Price condition set forth above has been met, the Company shall so notify the Holders, the Trustee and the Conversion Agent (if other than the Trustee) in writing. If, at any time after the Trading Price condition set forth above has been met, the Trading Price per $1,000 principal amount of Notes is greater than or equal to 98% of the product of the Last Reported Sale Price of the Common Stock and the Conversion Rate for such date, the Company shall so notify the Holders, the Trustee and the Conversion Agent (if other than the Trustee) in writing, and thereafter neither the Company nor the Bid Solicitation Agent (if other than the Company) shall be required to solicit bids (or determine the Trading Price of the Notes as set forth in this Indenture) again until a new Holder request is made pursuant to this Section 14.01(b)(i).
(ii)     If, prior to the close of business on the Business Day immediately preceding September 15, 2027, the Company elects to:
(A)    issue to all or substantially all holders of the Common Stock any rights, options or warrants (other than in connection with a stockholder rights plan) entitling them, for a period of not more than 45 calendar days after the announcement date of such issuance, to subscribe for or purchase shares of the Common Stock at a price per share that is less than the average of the Last Reported Sale Prices of the Common Stock for the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of such issuance; or
52
    


(B)     distribute to all or substantially all holders of the Common Stock the Company’s assets, securities or rights to purchase securities of the Company (other than in connection with a stockholder rights plan prior to the separation of such rights from the Common Stock), which distribution has a per share value, as reasonably determined by the Company, exceeding 10% of the Last Reported Sale Price of the Common Stock on the Trading Day preceding the date of announcement for such distribution,
then, in either case, the Company shall notify the Holders of the Notes, the Trustee and the Conversion Agent (if other than the Trustee) in writing at least 40 Scheduled Trading Days prior to the Ex-Dividend Date for such issuance or distribution. Once the Company has given such notice, a Holder may surrender all or any portion of its Notes for conversion at any time until the earlier of (1) the close of business on the Business Day immediately preceding the Ex-Dividend Date for such issuance or distribution and (2) the Company’s announcement that such issuance or distribution will not take place, even if the Notes are not otherwise convertible at such time.
(iii)     If (i) a transaction or event that constitutes (x) a Fundamental Change or (y) a Make-Whole Fundamental Change occurs prior to the close of business on the Business Day immediately preceding September 15, 2027, regardless of whether a Holder has the right to require the Company to repurchase the Notes pursuant to Section 15.02, or (ii) if the Company is a party to a consolidation, merger, binding share exchange, or transfer or lease of all or substantially all of its assets that occurs prior to the close of business on the Business Day immediately preceding September 15, 2027, in each case pursuant to which the Common Stock would be converted into cash, securities or other assets (other than a merger effected solely to change the Company’s jurisdiction of incorporation that does not otherwise constitute a Make-Whole Fundamental Change or a Fundamental Change), then, in each case, all or any portion of a Holder’s Notes may be surrendered for conversion at any time from or after the effective date of the transaction or event until 35 Trading Days after the actual effective date of such transaction or event or, if such transaction also constitutes a Fundamental Change, until the related Fundamental Change Repurchase Date. The Company shall notify Holders, the Trustee and the Conversion Agent (if other than the Trustee) in writing as promptly as practicable following the date the Company publicly announces such transaction or event, but in no event later than the actual effective date of such transaction or event.
(iv)     Prior to the close of business on the Business Day immediately preceding September 15, 2027, a Holder may surrender all or any portion of its Notes for conversion at any time during any calendar quarter commencing after the calendar quarter ending on June 30, 2021 (and only during such calendar quarter), if the Last Reported Sale Price of the Common Stock for at least 20 Trading Days (whether or not consecutive) during the period of 30 consecutive Trading Days ending on, and including, the last Trading Day of the immediately preceding calendar quarter is greater than or equal to 130% of the Conversion Price on each applicable Trading Day.
53
    


(v)      If the Company calls any or all of the Notes for redemption pursuant to Article 16 prior to the Maturity Date, then a Holder may surrender all or any portion of its Notes for conversion at any time prior to the close of business on the second Scheduled Trading Day prior to the Redemption Date, even if such Notes are not otherwise convertible at such time. After that time, the right to convert such Notes on account of the Company’s delivery of a Redemption Notice shall expire, unless the Company defaults in the payment of the Redemption Price, in which case a Holder of Notes may convert all or a portion of its Notes until the Redemption Price has been paid or duly provided for.
Section 14.02. Conversion Procedure; Settlement Upon Conversion.
(a)    Subject to this Section 14.02, Section 14.03(b) and Section 14.07(a), upon conversion of any Note, the Company shall satisfy its Conversion Obligation by paying or delivering, as the case may be, to the converting Holder, in respect of each $1,000 principal amount of Notes being converted, cash (“Cash Settlement”), shares of Common Stock, together with cash, if applicable, in lieu of delivering any fractional share of Common Stock in accordance with subsection (j) of this Section 14.02 (“Physical Settlement”) or a combination of cash and shares of Common Stock, together with cash, if applicable, in lieu of delivering any fractional share of Common Stock in accordance with subsection (j) of this Section 14.02 (“Combination Settlement”), at its election, as set forth in this Section 14.02.
(i)    All conversions occurring (x) on or after September 15, 2027 or (y) during a Redemption Period shall be settled using the same Settlement Method.
(ii)    Except for any conversions for which the relevant Conversion Date occurs during a Redemption Period and any conversions for which the relevant Conversion Date occurs on or after September 15, 2027, the Company shall use the same Settlement Method for all conversions occurring on the same Conversion Date, but the Company shall not have any obligation to use the same Settlement Method with respect to conversions that occur on different Conversion Dates.
(iii) If, in respect of any Conversion Date (or one of the periods described in the fourth immediately succeeding set of parentheses, as the case may be), the Company elects a Settlement Method, the Company shall deliver a written notice (the “Settlement Notice”) of the Settlement Method so elected in respect of such Conversion Date (or such period, as the case may be) to converting Holders, the Trustee and the Conversion Agent (if other than the Trustee) no later than the close of business on the Trading Day immediately following the relevant Conversion Date (or, in the case of any conversions (x) occurring (i) during a Redemption Period, in such Redemption Notice, or (ii) on or after September 15, 2027, no later than the close of business on the Business Day immediately preceding September 15, 2027, or (y) for which the Company has irrevocably elected Combination Settlement, with a Specified Dollar Amount per $1,000 principal amount of Notes of $1,000, to apply pursuant to the provisions described in the immediately succeeding paragraph, in the related notice described in such paragraph) (in each case, the “Settlement Method Election Deadline”). If the Company does not
54
    


timely elect a Settlement Method prior to the Settlement Method Election Deadline, the Company shall no longer have the right to elect Cash Settlement or Physical Settlement for such conversion or during such period and the Company shall be deemed to have elected the Default Settlement Method in respect of its Conversion Obligation. Such Settlement Notice shall specify the relevant Settlement Method and in the case of an election of Combination Settlement, the relevant Settlement Notice shall indicate the Specified Dollar Amount per $1,000 principal amount of Notes. If the Company delivers a Settlement Notice electing Combination Settlement in respect of its Conversion Obligation but does not indicate a Specified Dollar Amount per $1,000 principal amount of Notes in such Settlement Notice, the Specified Dollar Amount per $1,000 principal amount of Notes shall be deemed to be $1,000.
By written notice to the Holders, the Trustee and the Conversion Agent, the Company may, prior to September 15, 2027, irrevocably elect Combination Settlement, with a Specified Dollar Amount per $1,000 principal amount of Notes of $1,000, to apply to all conversions for which the relevant Conversion Date occurs subsequent to the date of delivery of such notice; provided that any such election that is made during a Redemption Period (but after the Redemption Notice Date) will not apply to any conversions of Notes with Conversion Dates that occur during such Redemption Period. If the Company irrevocably elects Combination Settlement with an ability to continue to set the Specified Dollar Amount per $1,000 principal amount of Notes at or above a specific amount, the Company shall, after the date of such election, inform Holders, the Trustee, and the Conversion Agent (if other than the Trustee) of such Specified Dollar Amount no later than the Settlement Method Election Deadline, or, if the Company does not timely notify Holders, the Trustee, and the Conversion Agent of the Specified Dollar Amount, such Specified Dollar Amount shall be the specific amount set forth in the notice of such change or election or, if no specific amount was set forth in the notice of such change or election, such Specified Dollar Amount shall be $1,000 per $1,000 principal amount of Notes. If the Company changes the Default Settlement Method or irrevocably elects to fix the Settlement Method pursuant to the preceding sentence, the Company shall promptly either post the Default Settlement Method or the fixed Settlement Method, as applicable, on its website or disclose the same in a current report on Form 8-K (or any successor form) that is filed with the Commission. The irrevocable election shall apply to all conversions of Notes with a Conversion Date occurring subsequent to delivery of such notice; provided, however, that no such change in the Default Settlement Method or irrevocable election will affect any Settlement Method theretofore elected (or deemed to be elected) with respect to any Note. For the avoidance of doubt, such an irrevocable election, if made, will be effective without the need to amend this Indenture or the Notes, including pursuant to Section 10.01(k). However, the Company may nonetheless choose to execute such an amendment at its option.
(iv)     The cash, shares of Common Stock or combination of cash and shares of Common Stock in respect of any conversion of Notes (the “Settlement Amount”) shall be computed as follows:
55
    


(A)     if the Company elects to satisfy its Conversion Obligation in respect of such conversion by Physical Settlement, the Company shall deliver to the converting Holder in respect of each $1,000 principal amount of Notes being converted a number of shares of Common Stock equal to the Conversion Rate in effect on the Conversion Date;
(B)     if the Company elects to satisfy its Conversion Obligation in respect of such conversion by Cash Settlement, the Company shall pay to the converting Holder in respect of each $1,000 principal amount of Notes being converted cash in an amount equal to the sum of the Daily Conversion Values for each of the 30 consecutive Trading Days during the related Observation Period; and
(C)     if the Company elects (or is deemed to have elected) to satisfy its Conversion Obligation in respect of such conversion by Combination Settlement, the Company shall pay or deliver, as the case may be, in respect of each $1,000 principal amount of Notes being converted, a Settlement Amount equal to the sum of the Daily Settlement Amounts for each of the 30 consecutive Trading Days during the related Observation Period.
(v)     The Daily Settlement Amounts (if applicable) and the Daily Conversion Values (if applicable) shall be determined by the Company promptly following the last day of the Observation Period. Promptly after such determination of the Daily Settlement Amounts or the Daily Conversion Values, as the case may be, and the amount of cash payable in lieu of delivering any fractional share of Common Stock, the Company shall notify the Trustee and the Conversion Agent (if other than the Trustee) in writing of the Daily Settlement Amounts or the Daily Conversion Values, as the case may be, and the amount of cash payable in lieu of delivering fractional shares of Common Stock. The Trustee and the Conversion Agent (if other than the Trustee) shall have no responsibility for any such determination.
(b)     Subject to Section 14.02(e), before any Holder of a Note shall be entitled to convert a Note as set forth above, such Holder shall (i) in the case of a Global Note, comply with the procedures of the Depositary in effect at that time for converting a beneficial interest in a Global Note and, if required, pay funds equal to interest payable on the next Interest Payment Date to which such Holder is not entitled as set forth in Section 14.02(h) (and, if required, pay all transfer or similar taxes, if any, as set forth in Section 14.02(d) and Section 14.02(e)) and (i) in the case of a Physical Note (1) complete, manually sign and deliver an irrevocable notice to the Conversion Agent as set forth in the Form of Notice of Conversion (or a facsimile, PDF or other electronic transmission thereof) (a “Notice of Conversion”) at the office of the Conversion Agent and state in writing therein the principal amount of Notes to be converted and the name or names (with addresses) in which such Holder wishes the certificate or certificates for any shares of Common Stock to be delivered upon settlement of the Conversion Obligation to be registered, (2) surrender such Notes, duly endorsed to the Company or in blank (and accompanied by appropriate endorsement and transfer documents), at the office of the Conversion Agent, (3) if
56
    


required, furnish appropriate endorsements and transfer documents and (4) if required, pay funds equal to interest payable on the next Interest Payment Date to which such Holder is not entitled as set forth in Section 14.02(h). The Trustee (and, if different, the Conversion Agent) shall notify the Company of any conversion pursuant to this Article 14 on the Conversion Date for such conversion. No Notes may be surrendered for conversion by a Holder thereof if such Holder has also delivered a Fundamental Change Repurchase Notice to the Company in respect of such Notes and has not validly withdrawn such Fundamental Change Repurchase Notice in accordance with Section 15.03.
If more than one Note shall be surrendered for conversion at one time by the same Holder, the Conversion Obligation with respect to such Notes shall be computed on the basis of the aggregate principal amount of the Notes (or specified portions thereof to the extent permitted thereby) so surrendered.
(c)     A Note shall be deemed to have been converted immediately prior to the close of business on the date (the “Conversion Date”) that the Holder has complied with the requirements set forth in subsection (b) above. Except as set forth in Section 14.03(b) and Section 14.07(a), the Company shall pay or deliver, as the case may be, the consideration due in respect of the Conversion Obligation on the second Business Day immediately following the relevant Conversion Date, if the Company elects Physical Settlement, or on the second Business Day immediately following the last Trading Day of the relevant Observation Period, in the case of any other Settlement Method; provided that, with respect to any Conversion Date occurring during a Redemption Period, the Company will settle any such conversion for which Physical Settlement is applicable on the relevant Redemption Date; provided further that, notwithstanding the foregoing, with respect to any Conversion Date occurring on or after September 15, 2027, the Company will settle any such conversion for which Physical Settlement is applicable on the Maturity Date. If any shares of Common Stock are due to converting Holders, the Company shall issue or cause to be issued, and deliver to such Holder, or such Holder’s nominee or nominees, certificates or a book-entry transfer through the Depositary for the full number of shares of Common Stock to which such Holder shall be entitled in satisfaction of the Company’s Conversion Obligation.
(d)     In case any Physical Note shall be surrendered for partial conversion, the Company shall execute and the Trustee shall authenticate and deliver to or upon the written order of the Holder of the Physical Note so surrendered a new Physical Note or Physical Notes in authorized denominations in an aggregate principal amount equal to the unconverted portion of the surrendered Physical Note, without payment of any service charge by the converting Holder but, if required by the Company or Trustee, with payment of a sum sufficient to cover any documentary, stamp or similar issue or transfer tax or similar governmental charge required by law or that may be imposed in connection therewith as a result of the name of the Holder of the new Physical Notes issued upon such conversion being different from the name of the Holder of the old Physical Notes surrendered for such conversion.
(e)     If a Holder submits a Note for conversion, the Company shall pay any documentary, stamp or similar issue or transfer tax or other similar governmental charge due on
57
    


any issuance of any shares of Common Stock upon conversion, unless the tax is due because the Holder requests any such shares to be issued in a name other than the Holder’s name, in which case the Holder shall pay that tax. The Conversion Agent may refuse to deliver the certificates representing the shares of Common Stock being issued in a name other than the Holder’s name until the Trustee receives a sum sufficient to pay any tax that is due by such Holder in accordance with the immediately preceding sentence.
(f)     Except as provided in Section 14.04, no adjustment shall be made for dividends on any shares of Common Stock issued upon the conversion of any Note as provided in this Article 14.
(g)     Upon the conversion of an interest in a Global Note, the Trustee, or the Custodian at the direction of the Trustee, shall make a notation on such Global Note as to the reduction in the principal amount represented thereby. The Company shall notify the Trustee in writing of any conversion of Notes effected through any Conversion Agent other than the Trustee.
(h)     Upon conversion, a Holder shall not receive any separate cash payment for accrued and unpaid interest, if any, except as set forth below. The Company’s settlement of the full Conversion Obligation shall be deemed to satisfy in full its obligation to pay the principal amount of the Note and accrued and unpaid interest, if any, to, but excluding, the relevant Conversion Date. As a result, accrued and unpaid interest, if any, to, but excluding, the relevant Conversion Date shall be deemed to be paid in full rather than canceled, extinguished or forfeited. Upon a conversion of Notes into a combination of cash and shares of Common Stock, accrued and unpaid interest will be deemed to be paid first out of the cash paid upon such conversion. Notwithstanding the foregoing, if Notes are converted after the close of business on a Regular Record Date and prior to the open of business on the corresponding Interest Payment Date, Holders of such Notes as of the close of business on such Regular Record Date will receive the full amount of interest payable on such Notes on the corresponding Interest Payment Date notwithstanding the conversion. Notes surrendered for conversion during the period from the close of business on any Regular Record Date to the open of business on the immediately following Interest Payment Date must be accompanied by funds equal to the amount of interest payable on the Notes so converted; provided that no such payment shall be required (1) for conversions following the Regular Record Date immediately preceding the Maturity Date; (2) if the Company has specified a Fundamental Change Repurchase Date that is after a Regular Record Date and on or prior to the Business Day immediately succeeding the corresponding Interest Payment Date; (3) for conversions during any Redemption Period; or (4) to the extent of any overdue interest, if any overdue interest exists at the time of conversion with respect to such Note. Therefore, for the avoidance of doubt, all Holders of record on the Regular Record Date immediately preceding the Maturity Date shall receive the full interest payment due on the Maturity Date in cash regardless of whether their Notes have been converted following such Regular Record Date.
(i)     The Person in whose name the certificate for any shares of Common Stock delivered upon conversion is registered shall be deemed to be the holder of record of such shares of Common Stock as of the close of business on the relevant Conversion Date (if the Company
58
    


elects to satisfy the related Conversion Obligation by Physical Settlement) or the last Trading Day of the relevant Observation Period (if the Company elects to satisfy the related Conversion Obligation by Combination Settlement), as the case may be. Upon a conversion of Notes, such Person shall no longer be a Holder of such Notes surrendered for conversion.
(j)     The Company shall not issue any fractional share of Common Stock upon conversion of the Notes and shall instead pay cash in lieu of delivering any fractional share of Common Stock issuable upon conversion based on the Daily VWAP on the relevant Conversion Date (in the case of Physical Settlement) or based on the Daily VWAP on the last Trading Day of the relevant Observation Period (in the case of Combination Settlement). For each Note surrendered for conversion, if the Company has elected (or is deemed to have elected) Combination Settlement, the full number of shares that shall be issued upon conversion thereof shall be computed on the basis of the aggregate Daily Settlement Amounts for the relevant Observation Period and any fractional shares remaining after such computation shall be paid in cash.
Section 14.03. Increased Conversion Rate Applicable to Certain Notes Surrendered in Connection with Make-Whole Fundamental Changes or During a Redemption Period. (a) If (x) the Effective Date of a Make-Whole Fundamental Change occurs prior to the Maturity Date and a Holder elects to convert its Notes in connection with such Make-Whole Fundamental Change or (y) the Company issues a Redemption Notice pursuant to Section 16.02 and a Holder elects to convert its Notes during the related Redemption Period, the Company shall, under the circumstances described below, increase the Conversion Rate for the Notes so surrendered for conversion by a number of additional shares of Common Stock (the “Additional Shares”), as described below. A conversion of Notes shall be deemed for these purposes to be “in connection with” such Make-Whole Fundamental Change if the relevant Notice of Conversion is received by the Conversion Agent from, and including, the Effective Date of the Make-Whole Fundamental Change up to, and including, the Business Day immediately prior to the related Fundamental Change Repurchase Date (or, in the case of a Make-Whole Fundamental Change that would have been a Fundamental Change but for the proviso in clause (b) of the definition thereof, the 35th Trading Day immediately following the Effective Date of such Make-Whole Fundamental Change) (such period, the “Make-Whole Fundamental Change Period”).
(b)    Upon surrender of Notes for conversion in connection with a Make-Whole Fundamental Change pursuant to Section 14.01(b)(iii) or upon surrender of Notes during a Redemption Period, the Company shall, at its option, satisfy the related Conversion Obligation by Physical Settlement, Cash Settlement or Combination Settlement in accordance with Section 14.02 based on the Conversion Rate as increased to reflect the Additional Shares pursuant to the table below; provided, however, that if, the Reference Property in any Make-Whole Fundamental Change described in clause (b) of the definition of Fundamental Change is composed entirely of cash, for any conversion of Notes following the Effective Date of such Make-Whole Fundamental Change, the Conversion Obligation shall be calculated based solely on the Stock Price for the transaction and shall be deemed to be an amount of cash per $1,000 principal amount of converted Notes equal to the Conversion Rate (including any increase to reflect the Additional Shares), multiplied by such Stock Price. In such event, the Conversion Obligation
59
    


shall be determined and paid to Holders in cash on the second Business Day following the Conversion Date. The Company shall notify, in writing, the Holders, the Trustee and the Conversion Agent (if other than the Trustee) of the Effective Date of any Make-Whole Fundamental Change no later than five Business Days after such Effective Date.
(c)    The number of Additional Shares, if any, by which the Conversion Rate shall be increased for conversions during the Make-Whole Fundamental Change Period or, with respect to conversions of Notes, during the Redemption Period shall be determined by reference to the table below, based on the date on which the Make-Whole Fundamental Change occurs or becomes effective (the “Effective Date”) or the Redemption Notice Date, as applicable and the price (the “Stock Price”) paid (or deemed to be paid) per share of Common Stock in the Make-Whole Fundamental Change or on the Redemption Notice Date, as applicable, as set forth in this Section 14.03. If the holders of the Common Stock receive in exchange for their Common Stock only cash in a Make-Whole Fundamental Change described in clause (b) of the definition of Fundamental Change, the Stock Price shall be the cash amount paid per share. In the case of any other Make-Whole Fundamental Change or in the case of any Optional Redemption, the Stock Price shall be the average of the Last Reported Sale Prices of the Common Stock over the five consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the Effective Date of the Make-Whole Fundamental Change or the Redemption Notice Date, as the case may be. In the event that a Conversion Date occurs during both a Redemption Period and a Make-Whole Fundamental Change Period, a Holder of any such Notes to be converted will be entitled to a single increase to the Conversion Rate with respect to the first to occur of the applicable Redemption Notice Date or Effective Date, and the later event shall be deemed not to have occurred for purposes of this Section 14.03.
(d)    The Stock Prices set forth in the column headings of the table below shall be adjusted as of any date on which the Conversion Rate for the Notes is otherwise adjusted. The adjusted Stock Prices shall equal the Stock Prices applicable immediately prior to such adjustment, multiplied by a fraction, the numerator of which is the Conversion Rate immediately prior to such adjustment giving rise to the Stock Price adjustment and the denominator of which is the Conversion Rate as so adjusted. The number of Additional Shares set forth in the table below shall be adjusted in the same manner and at the same time as the Conversion Rate as set forth in Section 14.04.
(e)    The following table sets forth the number of Additional Shares by which the Conversion Rate shall be increased per $1,000 principal amount of Notes pursuant to this Section 14.03 for each Stock Price and Effective Date or Redemption Notice Date, as applicable, set forth below:




60
    



Effective Date / Redemption Notice DateStock Price
$49.00$55.00$60.00$66.15$75.00$85.99$100.00$115.00$130.00$150.00$175.00$225.00$275.00
January 11, 20215.29094.23553.55722.90202.20331.59981.09100.73910.50650.30730.16130.03400.0011
January 15, 20225.29094.23533.54782.87092.15411.54151.03160.68460.45920.26980.13480.02340.0000
January 15, 20235.29094.23513.50282.80392.07091.45260.94740.61080.39720.22270.10300.01240.0000
January 15, 20245.29094.18203.41772.69461.94611.32690.83360.51530.31990.16680.06800.00340.0000
January 15, 20255.29094.08643.28072.52831.76491.15180.68270.39480.22750.10470.03330.00000.0000
January 15, 20265.29093.90873.04502.25561.48270.89500.47830.24530.12280.04350.00650.00000.0000
January 15, 20275.29093.57272.60051.75360.99690.50160.21260.08290.02850.00320.00000.00000.0000
January 15, 20285.29093.06461.54940.00000.00000.00000.00000.00000.00000.00000.00000.00000.0000
The exact Stock Prices and Effective Dates or Redemption Notice Dates, may not be set forth in the table above, in which case:
(i)     if the Stock Price is between two Stock Prices in the table above or the Effective Date or the Redemption Notice Date, as the case may be, is between two Effective Dates or Redemption Notice Dates, as applicable, in the table above, the number of Additional Shares by which the Conversion Rate shall be increased shall be determined by a straight-line interpolation between the number of Additional Shares set forth for the higher and lower Stock Prices and the earlier and later Effective Dates or Redemption Notice Dates, as applicable, based on a 365-day year;
(ii)     if the Stock Price is greater than $275.00 per share (subject to adjustment in the same manner as the Stock Prices set forth in the column headings of the table above pursuant to subsection (d) above), no Additional Shares shall be added to the Conversion Rate; and
(iii)     if the Stock Price is less than $49.00 per share (subject to adjustment in the same manner as the Stock Prices set forth in the column headings of the table above pursuant to subsection (d) above), no Additional Shares shall be added to the Conversion Rate.
Notwithstanding the foregoing, in no event shall the Conversion Rate per $1,000 principal amount of Notes exceed 20.4018 shares of Common Stock, subject to adjustment in the same manner as the Conversion Rate pursuant to Section 14.04.
(f)    Nothing in this Section 14.03 shall prevent an adjustment to the Conversion Rate that would otherwise be required pursuant to Section 14.04.
Section 14.04. Adjustment of Conversion Rate. The Conversion Rate shall be adjusted from time to time by the Company if any of the following events occurs, except that the Company shall not make any adjustments to the Conversion Rate if Holders of the Notes participate (other than in the case of (x) a share split or share combination or (y) a tender or exchange offer), at the same time and upon the same terms as holders of the Common Stock and
61
    


solely as a result of holding the Notes, in any of the transactions described in this Section 14.04, without having to convert their Notes, as if they held a number of shares of Common Stock equal to the Conversion Rate, multiplied by the principal amount (expressed in thousands) of Notes held by such Holder.
(a)    If the Company exclusively issues shares of Common Stock as a dividend or distribution on shares of the Common Stock, or if the Company effects a share split or share combination, the Conversion Rate shall be adjusted based on the following formula:
image6a.jpg
where,
CR0    =    the Conversion Rate in effect immediately prior to the open of business on the Ex-Dividend Date of such dividend or distribution, or immediately prior to the open of business on the Effective Date of such share split or share combination, as applicable;
CR'    =    the Conversion Rate in effect immediately after the open of business on such Ex-Dividend Date or Effective Date;
OS0    =    the number of shares of Common Stock outstanding immediately prior to the open of business on such Ex-Dividend Date or Effective Date (before giving effect to any such dividend, distribution, share split or share combination); and
OS'    =    the number of shares of Common Stock outstanding immediately after giving effect to such dividend, distribution, share split or share combination.
Any adjustment made under this Section 14.04(a) shall become effective immediately after the open of business on the Ex-Dividend Date for such dividend or distribution, or immediately after the open of business on the Effective Date for such share split or share combination, as applicable. If any dividend or distribution of the type described in this Section 14.04(a) is declared but not so paid or made, the Conversion Rate shall be immediately readjusted, effective as of the date the Company determines not to pay such dividend or distribution, to the Conversion Rate that would then be in effect if such dividend or distribution had not been declared.
(b)    If the Company issues to all or substantially all holders of Common Stock any rights, options or warrants entitling them, for a period of not more than 45 calendar days after the announcement date of such issuance, to subscribe for or purchase shares of Common Stock at a price per share that is less than the average of the Last Reported Sale Prices of Common Stock for the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of such issuance, the Conversion Rate shall be increased based on the following formula:
62
    


image5a.jpg
where,
CR0    =    the Conversion Rate in effect immediately prior to the open of business on the Ex-Dividend Date for such issuance;
CR'    =    the Conversion Rate in effect immediately after the open of business on such Ex-Dividend Date;
OS0    =    the number of shares of Common Stock outstanding immediately prior to the open of business on such Ex-Dividend Date;
X    =    the total number of shares of Common Stock issuable pursuant to such rights, options or warrants; and
Y    =    the number of shares of Common Stock equal to the aggregate price payable to exercise such rights, options or warrants, divided by the average of the Last Reported Sale Prices of the Common Stock over the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of the issuance of such rights, options or warrants.
Any increase made under this Section 14.04(b) shall be made successively whenever any such rights, options or warrants are issued and shall become effective immediately after the open of business on the Ex-Dividend Date for such issuance. To the extent that shares of the Common Stock are not delivered after the expiration of such rights, options or warrants, the Conversion Rate shall be decreased to the Conversion Rate that would then be in effect had the increase with respect to the issuance of such rights, options or warrants been made on the basis of delivery of only the number of shares of Common Stock actually delivered. If such rights, options or warrants are not so issued, the Conversion Rate shall be decreased to the Conversion Rate that would then be in effect if such Ex-Dividend Date for such issuance had not occurred.
For purposes of this Section 14.04(b) and Section 14.01(b)(ii)(A), in determining whether any rights, options or warrants entitle the holders of Common Stock to subscribe for or purchase shares of the Common Stock at less than such average of the Last Reported Sale Prices of the Common Stock for the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of such issuance, and in determining the aggregate offering price of such shares of Common Stock, there shall be taken into account any consideration received by the Company for such rights, options or warrants and any amount payable on exercise or conversion thereof, the value of such consideration, if other than cash, to be determined by the Company.
(c)    If the Company distributes shares of its Capital Stock, evidences of its indebtedness, other assets or property of the Company or rights, options or warrants to acquire its
63
    


Capital Stock or other securities of the Company, to all or substantially all holders of the Common Stock, excluding (i) dividends, distributions or issuances as to which an adjustment was effected pursuant to Section 14.04(a) or Section 14.04(b), (i) dividends or distributions paid exclusively in cash as to which an adjustment was effected pursuant to Section 14.04(d), (i) distributions of Reference Property in a transaction described in Section 14.07 and (i) Spin-Offs as to which the provisions set forth below in this Section 14.04(c) shall apply (any of such shares of Capital Stock, evidences of indebtedness, other assets or property or rights, options or warrants to acquire Capital Stock or other securities, the “Distributed Property”), then the Conversion Rate shall be increased based on the following formula:
image4c.jpg
where,
CR0    =    the Conversion Rate in effect immediately prior to the open of business on the Ex-Dividend Date for such distribution;
CR'    =    the Conversion Rate in effect immediately after the open of business on such Ex-Dividend Date;
SP0    =    the average of the Last Reported Sale Prices of the Common Stock over the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the Ex-Dividend Date for such distribution; and
FMV    =    the fair market value (as determined by the Company) of the Distributed Property with respect to each outstanding share of the Common Stock on the Ex-Dividend Date for such distribution.
Any increase made under the portion of this Section 14.04(c) above shall become effective immediately after the open of business on the Ex-Dividend Date for such distribution. If such distribution is not paid or made, the Conversion Rate shall be decreased to the Conversion Rate that would then be in effect if such distribution had not been declared. In the case of any distribution of rights, options or warrants, to the extent such rights, options or warrants expire unexercised, the applicable Conversion Rate shall be immediately readjusted to the applicable Conversion Rate that would then be in effect had the increase made for the distribution of such rights, options or warrants been made on the basis of delivery of only the number of shares of Common Stock actually delivered upon the exercise of such rights, options or warrants. Notwithstanding the foregoing, if “FMV” (as defined above) is equal to or greater than “SP0” (as defined above), in lieu of the foregoing increase, each Holder of a Note shall receive, in respect of each $1,000 principal amount thereof, at the same time and upon the same terms as holders of the Common Stock receive the Distributed Property, the amount and kind of Distributed Property such Holder would have received if such Holder owned a number of shares of Common Stock equal to the Conversion Rate in effect on the Ex-Dividend Date for the distribution.
64
    


With respect to an adjustment pursuant to this Section 14.04(c) where there has been a payment of a dividend or other distribution on the Common Stock of shares of Capital Stock of any class or series, or similar equity interest, of or relating to any Subsidiary or other business unit of the Company, that are, or, when issued, will be, listed or admitted for trading on a U.S. national securities exchange (a “Spin-Off”), the Conversion Rate shall be increased based on the following formula:
image3c.jpg
where,
CR0    =    the Conversion Rate in effect immediately prior to the end of the Valuation Period;
CR'    =    the Conversion Rate in effect immediately after the end of the Valuation Period;
FMV0    =    the average of the Last Reported Sale Prices of the Capital Stock or similar equity interest distributed to holders of the Common Stock applicable to one share of the Common Stock (determined by reference to the definition of Last Reported Sale Price as set forth in Section 1.01 as if references therein to Common Stock were to such Capital Stock or similar equity interest) over the first 10 consecutive Trading Day period after, and including, the Ex-Dividend Date of the Spin-Off (the “Valuation Period”); and
MP0    =    the average of the Last Reported Sale Prices of the Common Stock over the Valuation Period.
The adjustment to the Conversion Rate under the preceding paragraph shall occur at the close of business on the last Trading Day of the Valuation Period; provided that (x) in respect of any conversion of Notes for which Physical Settlement is applicable, if the relevant Conversion Date occurs during the Valuation Period, references to “10” in the portion of this Section 14.04(c) related to Spin-Offs shall be deemed replaced with such lesser number of Trading Days as have elapsed from, and including, the Ex-Dividend Date of such Spin-Off to, and including, the Conversion Date in determining the Conversion Rate and (y) in respect of any conversion of Notes for which Cash Settlement or Combination Settlement is applicable, for any Trading Day that falls within the relevant Observation Period for such conversion and within the Valuation Period, references to “10” in the portion of this Section 14.04(c) related to Spin-Offs shall be deemed replaced with such lesser number of Trading Days as have elapsed from, and including, the Ex-Dividend Date of such Spin-Off to, and including, such Trading Day in determining the Conversion Rate as of such Trading Day of such Observation Period. If any dividend or distribution that constitutes a Spin-Off is declared but not so paid or made, the Conversion Rate shall be immediately decreased, effective as of the date the Company determines not to pay or make such dividend or distribution, to the Conversion Rate that would then be in effect if such dividend or distribution had not been declared or announced.
65
    


For purposes of this Section 14.04(c) (and subject in all respect to Section 14.11), rights, options or warrants distributed by the Company to all holders of the Common Stock entitling them to subscribe for or purchase shares of the Company’s Capital Stock, including Common Stock (either initially or under certain circumstances), which rights, options or warrants, until the occurrence of a specified event or events (“Trigger Event”): (i) are deemed to be transferred with such shares of the Common Stock; (ii) are not exercisable; and (iii) are also issued in respect of future issuances of the Common Stock, shall be deemed not to have been distributed for purposes of this Section 14.04(c) (and no adjustment to the Conversion Rate under this Section 14.04(c) will be required) until the occurrence of the earliest Trigger Event, whereupon such rights, options or warrants shall be deemed to have been distributed and an appropriate adjustment (if any is required) to the Conversion Rate shall be made under this Section 14.04(c). If any such right, option or warrant, including any such existing rights, options or warrants distributed prior to the date of this Indenture, are subject to events, upon the occurrence of which such rights, options or warrants become exercisable to purchase different securities, evidences of indebtedness or other assets, then the date of the occurrence of any and each such event shall be deemed to be the date of distribution and Ex-Dividend Date with respect to new rights, options or warrants with such rights (in which case the existing rights, options or warrants shall be deemed to terminate and expire on such date without exercise by any of the holders thereof). In addition, in the event of any distribution (or deemed distribution) of rights, options or warrants, or any Trigger Event or other event (of the type described in the immediately preceding sentence) with respect thereto that was counted for purposes of calculating a distribution amount for which an adjustment to the Conversion Rate under this Section 14.04(c) was made, (1) in the case of any such rights, options or warrants that shall all have been redeemed or purchased without exercise by any holders thereof, upon such final redemption or purchase (x) the Conversion Rate shall be readjusted as if such rights, options or warrants had not been issued and (y) the Conversion Rate shall then again be readjusted to give effect to such distribution, deemed distribution or Trigger Event, as the case may be, as though it were a cash distribution, equal to the per share redemption or purchase price received by a holder or holders of Common Stock with respect to such rights, options or warrants (assuming such holder had retained such rights, options or warrants), made to all holders of Common Stock as of the date of such redemption or purchase, and (2) in the case of such rights, options or warrants that shall have expired or been terminated without exercise by any holders thereof, the Conversion Rate shall be readjusted as if such rights, options and warrants had not been issued.
For purposes of Section 14.04(a), Section 14.04(b) and this Section 14.04(c), if any dividend or distribution to which this Section 14.04(c) is applicable also includes one or both of:
(A)    a dividend or distribution of shares of Common Stock to which Section 14.04(a) is applicable (the “Clause A Distribution”); or
(B)    a dividend or distribution of rights, options or warrants to which Section 14.04(b) is applicable (the “Clause B Distribution”),
then, in either case, (1) such dividend or distribution, other than the Clause A Distribution and the Clause B Distribution, shall be deemed to be a dividend or distribution to which this Section
66
    


14.04(c) is applicable (the “Clause C Distribution”) and any Conversion Rate adjustment required by this Section 14.04(c) with respect to such Clause C Distribution shall then be made, and (2) the Clause A Distribution and Clause B Distribution shall be deemed to immediately follow the Clause C Distribution and any Conversion Rate adjustment required by Section 14.04(a) and Section 14.04(b) with respect thereto shall then be made, except that, if determined by the Company (I) the “Ex-Dividend Date” of the Clause A Distribution and the Clause B Distribution shall be deemed to be the Ex-Dividend Date of the Clause C Distribution and (II) any shares of Common Stock included in the Clause A Distribution or Clause B Distribution shall be deemed not to be “outstanding immediately prior to the open of business on such Ex-Dividend Date or Effective Date” within the meaning of Section 14.04(a) or “outstanding immediately prior to the open of business on such Ex-Dividend Date” within the meaning of Section 14.04(b).
(d)    If any cash dividend or distribution is made to all or substantially all holders of the Common Stock, the Conversion Rate shall be adjusted based on the following formula:
image2c.jpg
where,
CR0    =    the Conversion Rate in effect immediately prior to the open of business on the Ex-Dividend Date for such dividend or distribution;
CR'    =    the Conversion Rate in effect immediately after the open of business on the Ex-Dividend Date for such dividend or distribution;
SP0    =    the Last Reported Sale Price of the Common Stock on the Trading Day immediately preceding the Ex-Dividend Date for such dividend or distribution; and
C    =    the amount in cash per share the Company distributes to all or substantially all holders of the Common Stock.
Any increase pursuant to this Section 14.04(d) shall become effective immediately after the open of business on the Ex-Dividend Date for such dividend or distribution. If such dividend or distribution is not so paid, the Conversion Rate shall be decreased, effective as of the date the Company determines not to make or pay such dividend or distribution, to be the Conversion Rate that would then be in effect if such dividend or distribution had not been declared. Notwithstanding the foregoing, if “C” (as defined above) is equal to or greater than “SP0” (as defined above), in lieu of the foregoing increase, each Holder of a Note shall receive, for each $1,000 principal amount of Notes it holds, at the same time and upon the same terms as holders of shares of the Common Stock, the amount of cash that such Holder would have received if such Holder owned a number of shares of Common Stock equal to the Conversion Rate in effect on the Ex-Dividend Date for such cash dividend or distribution.
67
    


(e)    If the Company or any of its Subsidiaries makes a payment in respect of a tender or exchange offer for the Common Stock (other than any odd-lot tender offer), to the extent that the cash and value of any other consideration included in the payment per share of the Common Stock exceeds the average of the Last Reported Sale Prices of the Common Stock over the 10 consecutive Trading Day period commencing on, and including, the Trading Day next succeeding the last date on which tenders or exchanges may be made pursuant to such tender or exchange offer, the Conversion Rate shall be increased based on the following formula:
image1d.jpg
where,
CR0    =    the Conversion Rate in effect immediately prior to the close of business on the 10th Trading Day immediately following, and including, the Trading Day next succeeding the date such tender or exchange offer expires;
CR'    =    the Conversion Rate in effect immediately after the close of business on the 10th Trading Day immediately following, and including, the Trading Day next succeeding the date such tender or exchange offer expires;
AC    =    the aggregate value of all cash and any other consideration (as determined by the Company) paid or payable for shares of Common Stock purchased in such tender or exchange offer;
OS0    =    the number of shares of Common Stock outstanding immediately prior to the date such tender or exchange offer expires (prior to giving effect to the purchase of all shares of Common Stock accepted for purchase or exchange in such tender or exchange offer);
OS'    =    the number of shares of Common Stock outstanding immediately after the date such tender or exchange offer expires (after giving effect to the purchase of all shares of Common Stock accepted for purchase or exchange in such tender or exchange offer); and
SP'    =    the average of the Last Reported Sale Prices of the Common Stock over the 10 consecutive Trading Day period commencing on, and including, the Trading Day next succeeding the date such tender or exchange offer expires.
The adjustment to the Conversion Rate under this Section 14.04(e) shall occur at the close of business on the 10th Trading Day immediately following, and including, the Trading Day next succeeding the date such tender or exchange offer expires; provided that (x) in respect of any conversion of Notes for which Physical Settlement is applicable, if the relevant Conversion Date occurs during the 10 Trading Days immediately following, and including, the Trading Day next succeeding the expiration date of any tender or exchange offer, references to “10” or “10th” in
68
    


this Section 14.04(e) shall be deemed replaced with such lesser number of Trading Days as have elapsed from, and including, the Trading Day next succeeding the date that such tender or exchange offer expires to, and including, the Conversion Date in determining the Conversion Rate and (y) in respect of any conversion of Notes for which Cash Settlement or Combination Settlement is applicable, for any Trading Day that falls within the relevant Observation Period for such conversion and within the 10 Trading Days immediately following, and including, the Trading Day next succeeding the expiration date of any tender or exchange offer, references to “10” or “10th” in this Section 14.04(e) shall be deemed replaced with such lesser number of Trading Days as have elapsed from, and including, the Trading Day next succeeding the expiration date of such tender or exchange offer to, and including, such Trading Day in determining the Conversion Rate as of such Trading Day.
If the Company or its Subsidiaries are obligated to purchase shares of Common Stock pursuant to any such tender or exchange offer described in this Section 14.04(e) but is permanently prevented by applicable law from effecting any such purchase or all such purchases are rescinded, the applicable Conversion Rate will be readjusted to be the Conversion Rate that would then be in effect if such tender or exchange offer had not been made or had been made only in respect of the purchases that have been made.
(f)    Notwithstanding this Section 14.04 or any other provision of this Indenture or the Notes, if a Conversion Rate adjustment becomes effective on any Ex-Dividend Date, and a Holder that has converted its Notes on or after such Ex-Dividend Date and on or prior to the related Record Date would be deemed to be the record holder of the shares of Common Stock as of the related Conversion Date as described under Section 14.02(i) based on an adjusted Conversion Rate for such Ex-Dividend Date, then, notwithstanding the Conversion Rate adjustment provisions in this Section 14.04, the Conversion Rate adjustment relating to such Ex-Dividend Date shall not be made for such converting Holder. Instead, such Holder shall be treated as if such Holder were the record owner of the shares of Common Stock on an unadjusted basis and participate in the related dividend, distribution or other event giving rise to such adjustment.
(g)    Except as stated herein, the Company shall not adjust the Conversion Rate for the issuance of shares of the Common Stock or any securities convertible into or exchangeable for shares of the Common Stock or the right to purchase shares of the Common Stock or such convertible or exchangeable securities.
(h)    In addition to those adjustments required by clauses (a), (b), (c), (d) and (e) of this Section 14.04, and subject to the applicable listing standards of The Nasdaq Capital Market, the Company from time to time may increase the Conversion Rate by any amount for a period of at least 20 Business Days if the Company determines that such increase would be in the Company’s best interest. In addition, subject to the applicable listing standards of The Nasdaq Capital Market, the Company may (but is not required to) increase the applicable Conversion Rate to avoid or diminish income tax to holders of Common Stock or rights to purchase shares of Common Stock in connection with a dividend or distribution of shares of Common Stock (or rights to acquire shares of Common Stock) or similar event.
69
    


(i)    Notwithstanding anything to the contrary in this Article 14, the Conversion Rate shall not be adjusted:
(i)    upon the issuance of any shares of Common Stock pursuant to any present or future plan providing for the reinvestment of dividends or interest payable on the Company’s securities and the investment of additional optional amounts in shares of Common Stock under any plan;
(ii)    upon the issuance of any shares of Common Stock or options or rights to purchase those shares pursuant to any present or future employee, director or consultant benefit or incentive plan or program of or assumed by the Company or any of the Company’s Subsidiaries;
(iii)    upon the issuance of any shares of Common Stock pursuant to any option, warrant, right or exercisable, exchangeable or convertible security not described in clause (ii) of this subsection and outstanding as of the date the Notes were first issued;
(iv)    upon the repurchase of shares of Common Stock pursuant to an open-market share repurchase program or other buy-back transaction that is not a tender offer or exchange offer of the nature described in Section 14.04(e);
(v)    solely for a change in the par value of the Common Stock; or
(vi)    for accrued and unpaid interest, if any.
(j)    The Company shall not be required to make an adjustment pursuant to clauses (a), (b), (c), (d) or (e) of this Section 14.04 unless such adjustment would result in a change of at least 1% of the then effective Conversion Rate. However, notwithstanding the foregoing, the Company shall defer and carry forward any adjustment that the Company would otherwise have to make and take that adjustment into account in any subsequent adjustment. Notwithstanding the foregoing, all such carried-forward adjustments shall be made with respect to the Notes (i) where the aggregate of all such carried-forward adjustments equals or exceeds 1% of the Conversion Rate and (ii) regardless of whether the aggregate adjustment is less than 1% of the Conversion Rate, (w) on the Conversion Date for any Notes (in the case of Physical Settlement), (x) on each Trading Day of any Observation Period with respect to any Notes (in the case of Cash Settlement or Combination Settlement), (y) the effective date of a Fundamental Change or the Effective Date of a Make-Whole Fundamental Change or (z) September 15, 2027. All calculations and other determinations under this Article 14 shall be made by the Company and shall be made to the nearest one-ten thousandth (1/10,000th) of a share.
(k)    Whenever the Conversion Rate is adjusted as herein provided, the Company shall promptly file with the Trustee (and the Conversion Agent if not the Trustee) an Officer’s Certificate setting forth (i) the adjusted Conversion Rate, (ii) the subsection of this Section 14.04 pursuant to which such adjustment has been made, showing in reasonable detail the facts upon which such adjustment is based and (iii) the date as of which such adjustment is effective (which certificates shall be conclusive evidence of the accuracy of such adjustment absent manifest
70
    


error). Unless and until a Responsible Officer of the Trustee shall have received such Officer’s Certificate, the Trustee shall not be deemed to have knowledge of any adjustment of the Conversion Rate and may assume without inquiry that the last Conversion Rate of which it has knowledge is still in effect. Promptly after delivery of such certificate, the Company shall prepare a notice of such adjustment of the Conversion Rate setting forth the adjusted Conversion Rate and the date on which each adjustment becomes effective and shall deliver such notice of such adjustment of the Conversion Rate to each Holder. Failure to deliver such notice shall not affect the legality or validity of any such adjustment.
(l)    For purposes of this Section 14.04, the number of shares of Common Stock at any time outstanding shall not include shares of Common Stock held in the treasury of the Company so long as the Company does not pay any dividend or make any distribution on shares of Common Stock held in the treasury of the Company, but shall include shares of Common Stock issuable in respect of scrip certificates issued in lieu of fractions of shares of Common Stock.
Section 14.05. Adjustments of Prices. Whenever any provision of this Indenture requires the Company to calculate the Last Reported Sale Prices, the Daily VWAPs, the Daily Conversion Values or the Daily Settlement Amounts over a span of multiple days (including, without limitation, an Observation Period and the period, if any, for determining the Stock Price for purposes of a Make-Whole Fundamental Change), the Company shall make appropriate adjustments in good faith and in a commercially reasonable manner to each to account for any adjustment to the Conversion Rate that becomes effective, or any event requiring an adjustment to the Conversion Rate where the Ex-Dividend Date, Effective Date or expiration date of the event occurs, at any time during the period when the Last Reported Sale Prices, the Daily VWAPs, the Daily Conversion Values or the Daily Settlement Amounts are to be calculated.
Section 14.06. Shares to Be Fully Paid. The Company shall provide, free from preemptive rights, out of its authorized but unissued shares or shares held in treasury, sufficient shares of Common Stock to provide for conversion of the Notes from time to time as such Notes are presented for conversion (assuming delivery of the maximum number of Additional Shares pursuant to Section 14.03 and that at the time of computation of such number of shares, all such Notes would be converted by a single Holder and that Physical Settlement is applicable).
Section 14.07. Effect of Recapitalizations, Reclassifications and Changes of the Common Stock.
(a)    In the case of:
(i)    any recapitalization, reclassification or change of the Common Stock (other than changes resulting from a subdivision or combination),
(ii)    any consolidation, merger or combination involving the Company,
(iii)    any sale, lease or other transfer to a third party of the consolidated assets of the Company and the Company’s Subsidiaries substantially as an entirety or
71
    


(iv)    any statutory share exchange,
in each case, as a result of which the Common Stock would be converted into, or exchanged for, stock, other securities, other property or assets (including cash or any combination thereof) (any such event, a “Merger Event”), then, at and after the effective time of such Merger Event, the right to convert each $1,000 principal amount of Notes shall be changed into a right to convert such principal amount of Notes into the kind and amount of shares of stock, other securities or other property or assets (including cash or any combination thereof) that a holder of a number of shares of Common Stock equal to the Conversion Rate immediately prior to such Merger Event would have owned or been entitled to receive (the “Reference Property”, with each “unit of Reference Property” meaning the kind and amount of Reference Property that a holder of one share of Common Stock is entitled to receive) upon such Merger Event and, prior to or at the effective time of such Merger Event, the Company or the successor or purchasing Person, as the case may be, shall execute with the Trustee a supplemental indenture permitted under Section 10.01(g) providing for such change in the right to convert each $1,000 principal amount of Notes; provided, however, that at and after the effective time of the Merger Event (A) the Company shall continue to have the right to determine the form of consideration to be paid or delivered, as the case may be, upon conversion of Notes in accordance with Section 14.02 and (B) (I) any amount payable in cash upon conversion of the Notes in accordance with Section 14.02 shall continue to be payable in cash, (II) any shares of Common Stock that the Company would have been required to deliver upon conversion of the Notes in accordance with Section 14.02 shall instead be deliverable in the amount and type of Reference Property that a holder of that number of shares of Common Stock would have received in such Merger Event and (III) the Daily VWAP shall be calculated based on the value of a unit of Reference Property.
    If the Merger Event causes the Common Stock to be converted into, or exchanged for, the right to receive more than a single type of consideration (determined based in part upon any form of stockholder election), then (i) the Reference Property into which the Notes will be convertible shall be deemed to be the weighted average of the types and amounts of consideration actually received by the holders of Common Stock, and (ii) the unit of Reference Property for purposes of the immediately preceding paragraph shall refer to the consideration referred to in clause (i) attributable to one share of Common Stock. If the holders of the Common Stock receive only cash in such Merger Event, then for all conversions for which the relevant Conversion Date occurs after the effective date of such Merger Event (A) the consideration due upon conversion of each $1,000 principal amount of Notes shall be solely cash in an amount equal to the Conversion Rate in effect on the Conversion Date (as may be increased by any Additional Shares pursuant to Section 14.03), multiplied by the price paid per share of Common Stock in such Merger Event and (B) the Company shall satisfy the Conversion Obligation by paying cash to converting Holders on the second Business Day immediately following the relevant Conversion Date. The Company shall notify Holders, the Trustee and the Conversion Agent (if other than the Trustee) in writing of such weighted average as soon as practicable after such determination is made.
    Such supplemental indenture described in the second immediately preceding paragraph shall provide for anti-dilution and other adjustments that are as nearly equivalent as possible to
72
    


the adjustments provided for in this Article 14. If, in the case of any Merger Event, the Reference Property includes shares of stock, securities or other property or assets of a Person other than the Company or the successor or purchasing corporation (excluding, for the avoidance of doubt, cash paid by such surviving company, successor or purchasing corporation), as the case may be, in such Merger Event, then such supplemental indenture shall also be executed by such other Person and shall contain such additional provisions to protect the interests of the Holders as the Company reasonably considers necessary by reason of the foregoing, including the provisions providing for the purchase rights set forth in Article 15.
(b)    When the Company executes a supplemental indenture pursuant to subsection (a) of this Section 14.07, the Company shall promptly file with the Trustee an Officer’s Certificate briefly stating the reasons therefor, the kind or amount of cash, securities or property or asset that will comprise a unit of Reference Property after any such Merger Event, any adjustment to be made with respect thereto and that all conditions precedent have been complied with, and shall promptly deliver or cause to be delivered notice thereof to all Holders. The Company shall cause notice of the execution of such supplemental indenture to be delivered to each Holder within 20 days after execution thereof. Failure to deliver such notice shall not affect the legality or validity of such supplemental indenture.
(c)    The Company shall not become a party to any Merger Event unless its terms are consistent with this Section 14.07. None of the foregoing provisions shall affect the right of a holder of Notes to convert its Notes into cash, shares of Common Stock or a combination of cash and shares of Common Stock, as applicable, as set forth in Section 14.01 and Section 14.02 prior to the effective date of such Merger Event.
(d)    The above provisions of this Section shall similarly apply to successive Merger Events.
(e)    Upon the consummation of any Merger Event, references to “Common Stock” shall be deemed to refer to any Reference Property that constitutes capital stock after giving effect to such Merger Event.
Section 14.08. Certain Covenants. (a) The Company covenants that all shares of Common Stock issued upon conversion of Notes will be fully paid and non-assessable by the Company and free from all taxes, liens and charges with respect to the issue thereof.
(b)    The Company covenants that, if any shares of Common Stock to be provided for the purpose of conversion of Notes hereunder require registration with or approval of any governmental authority under any federal or state law before such shares of Common Stock may be validly issued upon conversion, the Company will, to the extent then permitted by the rules and interpretations of the Commission, secure such registration or approval, as the case may be.
(c)    The Company further covenants that if at any time the Common Stock shall be listed on any national securities exchange or automated quotation system the Company will list and keep listed, so long as the Common Stock shall be so listed on such exchange or automated quotation system, any Common Stock issuable upon conversion of the Notes.
73
    


Section 14.09. Responsibility of Trustee. The Trustee and any other Conversion Agent shall not at any time be under any duty or responsibility to any Holder to determine the Conversion Rate (or any adjustment thereto) or whether any facts exist that may require any adjustment (including any increase) of the Conversion Rate, or with respect to the nature or extent or calculation of any such adjustment when made, or with respect to the method employed, or herein or in any supplemental indenture provided to be employed, in making the same. The Trustee and any other Conversion Agent shall not be accountable with respect to the validity or value (or the kind or amount) of any shares of Common Stock, or of any securities, property or cash that may at any time be issued or delivered upon the conversion of any Note; and the Trustee and any other Conversion Agent make no representations with respect thereto. Neither the Trustee nor any Conversion Agent shall be responsible for any failure of the Company to issue, transfer or deliver any shares of Common Stock or stock certificates or other securities or property or cash upon the surrender of any Note for the purpose of conversion or to comply with any of the duties, responsibilities or covenants of the Company contained in this Article. Without limiting the generality of the foregoing, neither the Trustee nor any Conversion Agent shall be under any responsibility to determine the correctness of any provisions contained in any supplemental indenture entered into pursuant to Section 14.07 relating either to the kind or amount of shares of stock or securities or property (including cash) receivable by Holders upon the conversion of their Notes after any event referred to in such Section 14.07 or to any adjustment to be made with respect thereto, but, subject to the provisions of Section 7.01, may accept (without any independent investigation) as conclusive evidence of the correctness of any such provisions, and shall be protected in conclusively relying upon, the Officer’s Certificate and Opinion of Counsel (which the Company shall be obligated to file with the Trustee prior to the execution of any such supplemental indenture) with respect thereto. Neither the Trustee nor the Conversion Agent shall be responsible for determining whether any event contemplated by Section 14.01(b) has occurred that makes the Notes eligible for conversion or no longer eligible therefor until the Company has delivered to the Trustee and the Conversion Agent the notices referred to in Section 14.01(b) with respect to the commencement or termination of such conversion rights, on which notices the Trustee and the Conversion Agent may conclusively rely, and the Company agrees to deliver such notices to the Trustee and the Conversion Agent immediately after the occurrence of any such event or at such other times as shall be provided for in Section 14.01(b). Except as otherwise expressly provided herein, neither the Trustee nor any other agent acting under this Indenture (other than the Company, if acting in such capacity) shall have any obligation to make any calculation or to determine whether the Notes may be surrendered for conversion pursuant to this Indenture, or to notify the Company or the Depositary or any of the Holders if the Notes have become convertible pursuant to the terms of this Indenture.
Section 14.10. Notice to Holders Prior to Certain Actions. In case of any:
(a)    action by the Company or one of its Subsidiaries that would require an adjustment in the Conversion Rate pursuant to Section 14.04 or Section 14.11;
(b)    Merger Event; or
74
    


(c)    voluntary or involuntary dissolution, liquidation or winding-up of the Company or any of its Subsidiaries;
then, in each case (unless notice of such event is otherwise required pursuant to another provision of this Indenture), the Company shall cause to be filed with the Trustee and the Conversion Agent (if other than the Trustee) and to be delivered to each Holder, as promptly as possible but in any event at least 20 days prior to the applicable date hereinafter specified, a notice stating (i) the date on which a record is to be taken for the purpose of such action by the Company or one of its Subsidiaries or, if a record is not to be taken, the date as of which the holders of Common Stock of record are to be determined for the purposes of such action by the Company or one of its Subsidiaries, or (ii) the date on which such Merger Event, dissolution, liquidation or winding-up is expected to become effective or occur, and the date as of which it is expected that holders of Common Stock of record shall be entitled to exchange their Common Stock for securities or other property deliverable upon such Merger Event, dissolution, liquidation or winding-up. Failure to give such notice, or any defect therein, shall not affect the legality or validity of such action by the Company or one of its Subsidiaries, Merger Event, dissolution, liquidation or winding-up.
Section 14.11. Stockholder Rights Plans. If the Company has a stockholder rights plan in effect upon conversion of the Notes, each share of Common Stock, if any, issued upon such conversion shall be entitled to receive the appropriate number of rights, if any, and the certificates representing the Common Stock issued upon such conversion shall bear such legends, if any, in each case as may be provided by the terms of any such stockholder rights plan, as the same may be amended from time to time. However, if, prior to any conversion of Notes, the rights have separated from the shares of Common Stock in accordance with the provisions of the applicable stockholder rights plan so that the Holders would not be entitled to receive any rights in respect of Common Stock, if any, issuable upon conversion of the Notes, the Conversion Rate shall be adjusted at the time of separation as if the Company distributed to all or substantially all holders of the Common Stock Distributed Property as provided in Section 14.04(c), subject to readjustment in the event of the expiration, termination or redemption of such rights.
Section 14.12. Exchange In Lieu Of Conversion. (a) When a Holder surrenders its Notes for conversion, the Company may, at its election, direct the Conversion Agent to surrender, on or prior to the Business Day immediately following the relevant Conversion Date, such Notes to one or more financial institutions designated by the Company (each, a “Designated Institution”) for exchange in lieu of conversion (an “Exchange Election”). In order to accept any Notes surrendered for conversion for exchange in lieu of conversion, the Designated Institution(s) must agree to timely pay or deliver, as the case may be, in exchange for such Notes, cash, shares of Common Stock or a combination of cash and shares of Common Stock, at the Company’s election, that would otherwise be due upon conversion as described in Section 14.02 above or such other amount agreed to by the converting Holder and the Designated Institution(s) (the “Conversion Consideration”). If the Company makes the election described above, the Company shall, by the close of business on the Business Day following the relevant Conversion Date, notify in writing the Holder surrendering Notes for conversion, the Trustee and the Conversion Agent (if other than the Trustee), that it has made such election, and the Company
75
    


shall notify the Designated Institution(s) of the relevant deadline for delivery of the Conversion Consideration and the type of Conversion Consideration to be paid and/or delivered (unless the form of Conversion Consideration has been otherwise agreed by the Holder and the Designated Institution(s) as set forth in this Section 14.12. Any Notes exchanged by any Designated Institution will remain outstanding, subject to applicable procedures of the Depositary.
(b)    If any Designated Institution agrees to accept any Notes for exchange but does not timely pay and/or deliver, as the case may be, the related Conversion Consideration to the Conversion Agent, or if such Designated Institution does not accept such Notes for exchange, the Company shall, within the time period specified in Section 14.02(c), pay or deliver, as the case may be, the Conversion Consideration in accordance with the provisions of Section 14.02 as if the Company had not made the Exchange Election.
(c)    For the avoidance of doubt, in no event will the Company’s designation of a Designated Institution pursuant to this Section 14.12 require such Designated Institution to accept any Notes for exchange.
ARTICLE 15     REPURCHASE OF NOTES AT OPTION OF HOLDERS
Section 15.01. Intentionally Omitted.
Section 15.02. Repurchase at Option of Holders Upon a Fundamental Change. (a) If a Fundamental Change occurs at any time prior to the Maturity Date, each Holder shall have the right, at such Holder’s option, to require the Company to repurchase for cash all of such Holder’s Notes, or any portion of the principal amount thereof properly surrendered and not validly withdrawn pursuant to Section 15.03 that is equal to $1,000 or a multiple of $1,000, on the date (the “Fundamental Change Repurchase Date”) specified by the Company that is not less than 20 or more than 35 Business Days following the date of the Fundamental Change Company Notice (provided that the Fundamental Change Repurchase Date shall be subject to postponement in order to allow the Company to comply with applicable law as a result of changes to such applicable law occurring after the date hereof) at a repurchase price equal to 100% of the principal amount thereof, plus accrued and unpaid interest thereon to, but excluding, the Fundamental Change Repurchase Date (the “Fundamental Change Repurchase Price”), unless the Fundamental Change Repurchase Date falls after a Regular Record Date but on or prior to the Interest Payment Date to which such Regular Record Date relates, in which case the Company shall instead pay the full amount of accrued and unpaid interest to the Holder of record as of such Regular Record Date, and the Fundamental Change Repurchase Price shall be equal to 100% of the principal amount of Notes to be repurchased pursuant to this Article 15. Any Notes so repurchased by the Company shall be paid for in cash.
(b)    Repurchases of Notes under this Section 15.02 shall be made, at the option of the Holder thereof, upon:
(i)    delivery to the paying agent by a Holder of a duly completed written notice (the “Fundamental Change Repurchase Notice”) in the form set forth in
76
    


Attachment 2 to the Form of Note attached hereto as Exhibit A, if the Notes are Physical Notes, or in compliance with the Depositary’s procedures for surrendering interests in Global Notes, if the Notes are Global Notes, in each case on or before the close of business on the Business Day immediately preceding the Fundamental Change Repurchase Date; and
(ii)    delivery of the Notes, if the Notes are Physical Notes, to the paying agent at any time after delivery of the Fundamental Change Repurchase Notice (together with all necessary endorsements for transfer) at the Corporate Trust Office of the paying agent, or book-entry transfer of the Notes, if the Notes are Global Notes, in compliance with the procedures of the Depositary, in each case such delivery being a condition to receipt by the Holder of the Fundamental Change Repurchase Price therefor.
The Fundamental Change Repurchase Notice in respect of any Notes to be repurchased shall state:
(i)     in the case of Physical Notes, the certificate numbers of the Notes to be delivered for repurchase;
(ii)     the portion of the principal amount of Notes to be repurchased, which must be $1,000 or a multiple thereof; and
(iii)     that the Notes are to be repurchased by the Company pursuant to the applicable provisions of the Notes and this Indenture;
provided, however, that if the Notes are Global Notes, the Fundamental Change Repurchase Notice must comply with appropriate Depositary procedures.
Notwithstanding anything herein to the contrary, any Holder delivering to the paying agent the Fundamental Change Repurchase Notice contemplated by this Section 15.02 shall have the right to withdraw, in whole or in part, such Fundamental Change Repurchase Notice at any time prior to the close of business on the Business Day immediately preceding the Fundamental Change Repurchase Date by delivery of a written notice of withdrawal to the paying agent in accordance with Section 15.03.
The paying agent shall promptly notify the Company of the receipt by it of any Fundamental Change Repurchase Notice or written notice of withdrawal thereof.
(c)    On or before the 20th calendar day after the occurrence of the effective date of a Fundamental Change, the Company shall provide to all Holders and the Trustee and the paying agent (in the case of a paying agent other than the Trustee) a written notice (the “Fundamental Change Company Notice”) of the occurrence of the effective date of the Fundamental Change and of the resulting repurchase right at the option of the Holders arising as a result thereof. In the case of Physical Notes, such notice shall be by first class mail or, in the case of Global Notes, such notice shall be delivered in accordance with the applicable procedures of the Depositary. Each Fundamental Change Company Notice shall specify:
77
    


(i)    the events causing the Fundamental Change;
(ii)    the effective date of the Fundamental Change;
(iii)     the last date on which a Holder may exercise the repurchase right pursuant to this Article 15;
(iv)     the Fundamental Change Repurchase Price;
(v)    the Fundamental Change Repurchase Date;
(vi)     the name and address of the paying agent and the Conversion Agent, if applicable;
(vii)    if applicable, the Conversion Rate and any adjustments to the Conversion Rate as a result of such Fundamental Change (or related Make-Whole Fundamental Change);
(viii)    that the Notes with respect to which a Fundamental Change Repurchase Notice has been delivered by a Holder may be converted only if the Holder validly withdraws the Fundamental Change Repurchase Notice in accordance with the terms of this Indenture; and
(ix)    the procedures that Holders must follow to require the Company to repurchase their Notes.
No failure of the Company to give the foregoing notices and no defect therein shall limit the Holders’ repurchase rights or affect the validity of the proceedings for the repurchase of the Notes pursuant to this Section 15.02.
At the Company’s request, given at least five days prior to the date the Fundamental Change Company Notice is to be sent (or such shorter period as may be agreed to by the Trustee), the Trustee shall give such notice in the Company’s name and at the Company’s expense; provided, however, that, in all cases, the text of such Fundamental Change Company Notice shall be prepared by the Company.
(d)    Notwithstanding the foregoing, no Notes may be repurchased by the Company on any date at the option of the Holders upon a Fundamental Change if the principal amount of the Notes has been accelerated, and such acceleration has not been rescinded, on or prior to such date (except in the case of an acceleration resulting from a Default by the Company in the payment of the Fundamental Change Repurchase Price with respect to such Notes). The paying agent will promptly return to the respective Holders thereof any Physical Notes held by it during the acceleration of the Notes (except in the case of an acceleration resulting from a Default by the Company in the payment of the Fundamental Change Repurchase Price with respect to such Notes), or any instructions for book-entry transfer of the Notes in compliance with the procedures of the Depositary shall be deemed to have been canceled, and, upon such return or
78
    


cancellation, as the case may be, the Fundamental Change Repurchase Notice with respect thereto shall be deemed to have been withdrawn.
(e)    The Company shall not be required to repurchase or make an offer to repurchase Notes upon the occurrence of a Fundamental Change otherwise required under this Section 15.02 if a third party makes such an offer to purchase Notes in the same manner, at the same time and otherwise in compliance with the requirements for an offer made by the Company as set forth in this Indenture and such third party purchases all Notes properly surrendered and not validly withdrawn under such offer to purchase.
Section 15.03. Withdrawal of Fundamental Change Repurchase Notice. (a) A Fundamental Change Repurchase Notice may be withdrawn (in whole or in part) by means of a written notice of withdrawal received by the paying agent in accordance with this Section 15.03 at any time prior to the close of business on the Business Day immediately preceding the relevant Fundamental Change Repurchase Date, specifying:
(i)    the principal amount of the Notes with respect to which such notice of withdrawal is being submitted, which must be $1,000 or a multiple thereof,
(ii)    if Physical Notes have been issued, the certificate numbers of the Notes in respect of which such notice of withdrawal is being submitted, and
(iii)    the principal amount, if any, of such Notes that remains subject to the original Fundamental Change Repurchase Notice, which portion must be in principal amounts of $1,000 or a multiple of $1,000;
provided, however, that if the Notes are Global Notes, the notice must comply with appropriate procedures of the Depositary.
Section 15.04. Deposit of Fundamental Change Repurchase Price. (a) The Company will deposit with the Trustee (or other paying agent appointed by the Company, or if the Company is acting as its own paying agent, set aside, segregate and hold in trust as provided in Section 4.04) on or prior to 11:00 a.m., New York City time, on the Fundamental Change Repurchase Date an amount of money sufficient to repurchase all of the Notes to be repurchased at the appropriate Fundamental Change Repurchase Price. Subject to receipt of funds and/or Notes by the Trustee (or other paying agent appointed by the Company), payment for Notes surrendered for repurchase (and not withdrawn prior to the close of business on the Business Day immediately preceding the Fundamental Change Repurchase Date) will be made on the later of (i) the Fundamental Change Repurchase Date (provided the Holder has satisfied the conditions in Section 15.02) and (ii) the time of book-entry transfer or the delivery of such Note to the Trustee (or other paying agent appointed by the Company) by the Holder thereof in the manner required by Section 15.02 by mailing checks for the amount payable to the Holders of such Notes entitled thereto as they shall appear in the Note Register; provided, however, that payments to the Depositary shall be made by wire transfer of immediately available funds to the account of the Depositary or its nominee. The Trustee shall, promptly after such payment and upon written
79
    


demand by the Company, return to the Company any funds in excess of the Fundamental Change Repurchase Price.
(b)    If by 11:00 a.m. New York City time, on the Fundamental Change Repurchase Date, the Trustee (or other paying agent appointed by the Company) holds money sufficient to pay the Fundamental Change Repurchase Price of the Notes to be repurchased on the Fundamental Change Repurchase Date, then, with respect to the Notes that have been properly surrendered for repurchase and have not been validly withdrawn in accordance with the provisions of this Indenture, (i) such Notes will cease to be outstanding, (ii) interest will cease to accrue on such Notes (whether or not book-entry transfer of the Notes has been made or the Notes have been delivered to the Trustee or paying agent) and (iii) all other rights of the Holders of such Notes will terminate (other than the right to receive the Fundamental Change Repurchase Price).
(c)    Upon surrender of a Physical Note that is to be repurchased in part pursuant to Section 15.02, the Company shall execute and the Trustee shall authenticate and deliver to the Holder a new Physical Note in an authorized denomination equal in principal amount to the unrepurchased portion of the Physical Note surrendered.
Section 15.05. Covenant to Comply with Applicable Laws Upon Repurchase of Notes. In connection with any repurchase offer pursuant to this Article 15, the Company will, if required:
(a)    comply with the provisions of any tender offer rules under the Exchange Act that may then be applicable;
(b)    file a Schedule TO or any other required schedule under the Exchange Act; and
(c)    otherwise comply with all federal and state securities laws in connection with any offer by the Company to repurchase the Notes;
in each case, so as to permit the rights and obligations under this Article 15 to be exercised in the time and in the manner specified in this Article 15.
ARTICLE 16     OPTIONAL REDEMPTION
Section 16.01. Optional Redemption. The Notes shall not be redeemable by the Company prior to January 20, 2025. On or after January 20, 2025, the Company may, at its option, redeem (an “Optional Redemption”) for cash all or any portion of the Notes, at the Redemption Price, if the Last Reported Sale Price of the Common Stock has been at least 130% of the Conversion Price then in effect for at least 20 Trading Days (whether or not consecutive) during any 30 consecutive Trading Day period (including the last trading day of such period) ending on, and including, the Trading Day immediately preceding the date on which the Company provides the Redemption Notice in accordance with Section 16.02.
Section 16.02. Notice of Optional Redemption; Selection of Notes. (a) In case the Company exercises its Optional Redemption right to redeem all or, as the case may be, any part
80
    


of the Notes pursuant to Section 16.01, it shall fix a date for redemption (each, a “Redemption Date”) and it or, at its written request received by the Trustee not less than 5 Business Days prior to the date such Redemption Notice is to be sent (or such shorter period of time as may be acceptable to the Trustee), the Trustee, in the name of and at the expense of the Company, shall deliver or cause to be delivered a written notice of such Optional Redemption (a “Redemption Notice”) not less than 40 nor more than 50 Scheduled Trading Days prior to the Redemption Date to the Trustee, the Conversion Agent (if other than the Trustee), the Paying Agent, and each Holder of Notes so to be redeemed as a whole or in part; provided, however, that, if the Company shall give such notice, it shall also give written notice of the Redemption Date to the Trustee. The Redemption Date must be a Business Day.
(b)    The Redemption Notice, if delivered in the manner herein provided, shall be conclusively presumed to have been duly given, whether or not the Holder receives such notice. In any case, failure to give such Redemption Notice or any defect in the Redemption Notice to the Holder of any Note designated for redemption as a whole or in part shall not affect the validity of the proceedings for the redemption of any other Note.
(c)    Each Redemption Notice shall specify:
(i)    the Redemption Date;
(ii)    the Redemption Price;
(iii)     that on the Redemption Date, the Redemption Price will become due and payable upon each Note to be redeemed, and that interest thereon, if any, shall cease to accrue on and after the Redemption Date;
(iv) the place or places where such Notes are to be surrendered for payment of the Redemption Price;
(v)    that Holders of Notes may surrender their Notes for conversion at any time prior to the close of business on the second Scheduled Trading Day immediately preceding the Redemption Date;
(vi)     the procedures a converting Holder must follow to convert its Notes and the Settlement Method;
(vii) the Conversion Rate and, if applicable, the number of Additional Shares added to the Conversion Rate in accordance with Section 14.03;
(viii) the CUSIP, ISIN or other similar numbers, if any, assigned to such Notes; and
(ix) in case any Note is to be redeemed in part only, the portion of the principal amount thereof to be redeemed and on and after the Redemption Date, upon surrender of such Note, a new Note in principal amount equal to the unredeemed portion thereof shall be issued, which principal amount must be $1,000 or a multiple thereof.
81
    


A Redemption Notice shall be irrevocable.
(d)    If fewer than all of the outstanding Notes are to be redeemed, the Notes to be redeemed will be selected according to the Depositary’s applicable procedures, in the case of Notes represented by a Global Note, or, in the case of Notes represented by Physical Notes, the Trustee shall select, pro rata or by lot or in such other manner as it shall deem appropriate and fair, Notes to be redeemed in whole or in part. If any Note selected for partial redemption is submitted for conversion in part after such selection, the portion of the Note submitted for conversion shall be deemed (so far as may be possible) to be the portion selected for redemption, subject, in the case of Notes represented by a Global Note, to the Depositary’s applicable procedures.
Section 16.03. Payment of Notes Called for Redemption. (a) If any Redemption Notice has been given in respect of the Notes in accordance with Section 16.02, the Notes called for redemption shall become due and payable on the Redemption Date at the place or places stated in the Redemption Notice and at the applicable Redemption Price. On presentation and surrender of such Notes at the place or places stated in the Redemption Notice, such Notes shall be paid and redeemed by the Company at the applicable Redemption Price.
(b)    Prior to 11:00 a.m. New York City time on the Redemption Date, the Company shall deposit with the Paying Agent or, if the Company or a Subsidiary of the Company is acting as the Paying Agent, shall segregate and hold in trust as provided in Section 7.05 an amount of cash (in immediately available funds if deposited on the Redemption Date), sufficient to pay the Redemption Price of all of the Notes to be redeemed on such Redemption Date. Subject to receipt of funds by the Paying Agent, payment for the Notes to be redeemed shall be made on the Redemption Date for such Notes. The Paying Agent shall, promptly after such payment and upon written demand by the Company, return to the Company any funds in excess of the Redemption Price.
Section 16.04. Restrictions on Redemption. The Company may not redeem any Notes on any date if the principal amount of the Notes has been accelerated in accordance with the terms of this Indenture, and such acceleration has not been rescinded, on or prior to the Redemption Date (except in the case of an acceleration resulting from a Default by the Company in the payment of the Redemption Price with respect to such Notes).
ARTICLE 17     MISCELLANEOUS PROVISIONS
Section 17.01. Provisions Binding on Company’s Successors. All the covenants, stipulations, promises and agreements of the Company contained in this Indenture shall bind its successors and assigns whether so expressed or not.
Section 17.02. Official Acts by Successor Corporation. Any act or proceeding by any provision of this Indenture authorized or required to be done or performed by any board, committee or Officer of the Company shall and may be done and performed with like force and
82
    


effect by the like board, committee or officer of any corporation or other entity that shall at the time be the lawful sole successor of the Company.
Section 17.03. Addresses for Notices, Etc. Any notice or demand that by any provision of this Indenture is required or permitted to be given or served by the Trustee or by the Holders on the Company shall be deemed to have been sufficiently given or made, for all purposes if given or served by being deposited postage prepaid by registered or certified mail in a post office letter box addressed (until another address is filed by the Company with the Trustee) to NeoGenomics, Inc., 12701 Commonwealth Dr., Suite 9, Fort Myers, Florida 33913, Attention: General Counsel. Any notice, direction, request or demand hereunder to or upon the Trustee (in any capacity hereunder) shall be deemed to have been sufficiently given or made, for all purposes, if given or served by being deposited postage prepaid by registered or certified mail in a post office letter box addressed to the Corporate Trust Office or sent electronically in PDF format (it being agreed that such notice to the Trustee shall be deemed to have been sufficiently given or made, for all purposes, if it is in writing and actually received by the Trustee).
The Trustee, by notice to the Company, may designate additional or different addresses for subsequent notices or communications.
Any notice or communication delivered or to be delivered to a Holder of Physical Notes shall be mailed to it by first class mail, postage prepaid, at its address as it appears on the Note Register and shall be sufficiently given to it if so mailed within the time prescribed. Any notice or communication delivered or to be delivered to a Holder of Global Notes shall be delivered in accordance with the applicable procedures of the Depositary and shall be sufficiently given to it if so delivered within the time prescribed.
Failure to mail or deliver a notice or communication to a Holder or any defect in it shall not affect its sufficiency with respect to other Holders. If a notice or communication is mailed or delivered, as the case may be, in the manner provided above, it is duly given, whether or not the addressee receives it.
In case by reason of the suspension of regular mail service or by reason of any other cause it shall be impracticable to give such notice to Holders by mail, then such notification as shall be made with the approval of the Trustee shall constitute a sufficient notification for every purpose hereunder.
Section 17.04. Governing Law; Jurisdiction. THIS INDENTURE AND EACH NOTE, AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS INDENTURE AND EACH NOTE, SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.
The Company irrevocably consents and agrees, for the benefit of the Holders from time to time of the Notes and the Trustee, that any legal action, suit or proceeding against it with respect to obligations, liabilities or any other matter arising out of or in connection with this Indenture or the Notes may be brought in the courts of the State of New York or the courts of the United States located in the Borough of Manhattan, New York City, New York and, until
83
    


amounts due and to become due in respect of the Notes have been paid, hereby irrevocably consents and submits to the non-exclusive jurisdiction of each such court in personam, generally and unconditionally with respect to any action, suit or proceeding for itself in respect of its properties, assets and revenues.
The Company irrevocably and unconditionally waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of venue of any of the aforesaid actions, suits or proceedings arising out of or in connection with this Indenture brought in the courts of the State of New York or the courts of the United States located in the Borough of Manhattan, New York City, New York and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.
Section 17.05. Evidence of Compliance with Conditions Precedent; Certificates and Opinions of Counsel to Trustee. Upon any application or demand by the Company to the Trustee to take any action under any of the provisions of this Indenture, the Company shall furnish to the Trustee an Officer’s Certificate and an Opinion of Counsel stating that such action is permitted by the terms of this Indenture and that in the opinion of the signers, all conditions precedent, if any, provided for in this Indenture relating to the proposed action have been complied with. With respect to matters of fact, an Opinion of Counsel may rely on an Officer’s Certificate or certificates of public officials.
Each Officer’s Certificate and Opinion of Counsel provided for, by or on behalf of the Company in this Indenture and delivered to the Trustee with respect to compliance with this Indenture (other than the Officer’s Certificates provided for in Section 4.08) shall include (a) a statement that the person signing such certificate is familiar with the requested action and this Indenture; (b) a brief statement as to the nature and scope of the examination or investigation upon which the statement contained in such certificate is based; (c) a statement that, in the judgment of such person, he or she has made such examination or investigation as is necessary to enable him or her to express an informed judgment as to whether or not such action is permitted by this Indenture; and (d) a statement as to whether or not, in the judgment of such person, such action is permitted by this Indenture and that all conditions precedent thereto have been complied with.
Notwithstanding anything to the contrary in this Section 17.05, if any provision in this Indenture specifically provides that the Trustee shall or may receive an Opinion of Counsel in connection with any action to be taken by the Trustee or the Company hereunder, the Trustee shall be entitled to such Opinion of Counsel.
Section 17.06. Legal Holidays. In any case where any Interest Payment Date, Fundamental Change Repurchase Date or Maturity Date is not a Business Day, then any action to be taken on such date need not be taken on such date, but may be taken on the next succeeding Business Day with the same force and effect as if taken on such date, and no interest shall accrue in respect of the delay.
84
    


Section 17.07. No Security Interest Created. Nothing in this Indenture or in the Notes, expressed or implied, shall be construed to constitute a security interest under the Uniform Commercial Code or similar legislation, as now or hereafter enacted and in effect, in any jurisdiction.
Section 17.08. Benefits of Indenture. Nothing in this Indenture or in the Notes, expressed or implied, shall give to any Person, other than the Holders, the parties hereto, any Paying Agent, any Conversion Agent, any authenticating agent, any Note Registrar and their successors hereunder, any benefit or any legal or equitable right, remedy or claim under this Indenture.
Section 17.09. Table of Contents, Headings, Etc. The table of contents and the titles and headings of the articles and sections of this Indenture have been inserted for convenience of reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof.
Section 17.10. Authenticating Agent. The Trustee may appoint an authenticating agent that shall be authorized to act on its behalf and subject to its direction in the authentication and delivery of Notes in connection with the original issuance thereof and transfers and exchanges of Notes hereunder, including under Section 2.04, Section 2.05, Section 2.06, Section 2.07, Section 10.04 and Section 15.04 as fully to all intents and purposes as though the authenticating agent had been expressly authorized by this Indenture and those Sections to authenticate and deliver Notes. For all purposes of this Indenture, the authentication and delivery of Notes by the authenticating agent shall be deemed to be authentication and delivery of such Notes “by the Trustee” and a certificate of authentication executed on behalf of the Trustee by an authenticating agent shall be deemed to satisfy any requirement hereunder or in the Notes for the Trustee’s certificate of authentication. Such authenticating agent shall at all times be a Person eligible to serve as trustee hereunder pursuant to Section 7.08.
Any corporation or other entity into which any authenticating agent may be merged or converted or with which it may be consolidated, or any corporation or other entity resulting from any merger, consolidation or conversion to which any authenticating agent shall be a party, or any corporation or other entity succeeding to the corporate trust business of any authenticating agent, shall be the successor of the authenticating agent hereunder, if such successor corporation or other entity is otherwise eligible under this Section 17.10, without the execution or filing of any paper or any further act on the part of the parties hereto or the authenticating agent or such successor corporation or other entity.
Any authenticating agent may at any time resign by giving written notice of resignation to the Trustee and to the Company. The Trustee may at any time terminate the agency of any authenticating agent by giving written notice of termination to such authenticating agent and to the Company. Upon receiving such a notice of resignation or upon such a termination, or in case at any time any authenticating agent shall cease to be eligible under this Section, the Trustee may appoint a successor authenticating agent (which may be the Trustee), shall give written notice of such appointment to the Company.
85
    


The Company agrees to pay to the authenticating agent from time to time reasonable compensation for its services although the Company may terminate the authenticating agent, if it determines such agent’s fees to be unreasonable.
The provisions of Section 7.02, Section 7.03, Section 7.04, Section 8.03 and this Section 17.10 shall be applicable to any authenticating agent.
If an authenticating agent is appointed pursuant to this Section 17.10, the Notes may have endorsed thereon, in addition to the Trustee’s certificate of authentication, an alternative certificate of authentication in the following form:
__________________________,
as Authenticating Agent, certifies that this is one of the Notes described in the within-named Indenture.
By: ____________________
Authorized Signatory

Section 17.11. Execution in Counterparts. This Indenture may be executed in any number of counterparts, each of which shall be an original, but such counterparts shall together constitute but one and the same instrument. The exchange of copies of this Indenture and of signature pages by facsimile, PDF transmission or other electronic signature or transmission shall constitute effective execution and delivery of this Indenture as to the parties hereto and may be used in lieu of the original Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes. Unless otherwise provided herein or in the Notes, the words “execute,” “execution,” “signed,” and “signature” and words of similar import used in or related to any document to be signed in connection with this Indenture, any Note or any of the transactions contemplated hereby (including amendments, waivers, consents and other modifications) shall be deemed to include electronic signatures and the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature in ink or the use of a paper-based recordkeeping system, as applicable, to the fullest extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, and any other similar state laws based on the Uniform Electronic Transactions Act; provided that, notwithstanding anything herein to the contrary, the Trustee is not under any obligation to agree to accept electronic signatures in any form or in any format unless expressly agreed to by the Trustee pursuant to procedures approved by the Trustee.
Section 17.12. Severability. In the event any provision of this Indenture or in the Notes shall be invalid, illegal or unenforceable, then (to the extent permitted by law) the validity, legality or enforceability of the remaining provisions shall not in any way be affected or impaired.
86
    


Section 17.13. Waiver of Jury Trial. EACH OF THE COMPANY AND THE TRUSTEE HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE NOTES OR THE TRANSACTIONS CONTEMPLATED HEREBY.
Section 17.14. Force Majeure. In no event shall the Trustee be responsible or liable for any failure or delay in the performance of its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, pandemics, epidemics, civil or military disturbances, nuclear or natural catastrophes or acts of God, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services or the unavailability of the Federal Reserve Bank wire or telex wire or communication facility; it being understood that the Trustee shall use reasonable efforts that are consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances.
Section 17.15. Calculations. Except as otherwise provided herein, the Company shall be responsible for making all calculations called for under the Notes. These calculations include, but are not limited to, determinations of the Stock Price, the Last Reported Sale Prices of the Common Stock, the Trading Prices, the Redemption Prices, the Daily VWAPs, the Daily Conversion Values, the Daily Settlement Amounts, accrued interest payable on the Notes (including, for the avoidance of doubt, any Additional Interest payable under this Indenture), the Conversion Rate and the Conversion Price of the Notes. The Company shall make all these calculations in good faith and, absent manifest error, the Company’s calculations shall be final and binding on Holders. The Company shall provide a schedule of its calculations to each of the Trustee and the Conversion Agent, and each of the Trustee and Conversion Agent is entitled to rely conclusively upon the accuracy of the Company’s calculations without independent verification. The Company will forward the Company’s calculations to any Holder upon the written request of that Holder at the sole cost and expense of the Company.
Section 17.16. U.S.A. PATRIOT Act. The parties hereto acknowledge that in accordance with Section 326 of the U.S.A. PATRIOT Act, the Trustee, like all financial institutions and in order to help fight the funding of terrorism and money laundering, is required to obtain, verify, and record information that identifies each person or legal entity that establishes a relationship or opens an account with the Trustee. The parties to this Indenture agree that they will provide the Trustee with such information as it may request in order for the Trustee to satisfy the requirements of the U.S.A. PATRIOT Act.
[Remainder of page intentionally left blank]

87
    


IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed as of the date first written above.
NEOGENOMICS, INC.
By:/s/ Kathryn B. McKenzie
Name: Kathryn B. McKenzie
Title: Chief Financial Officer
U.S. BANK NATIONAL ASSOCIATION, as Trustee
By:/s/ Richard Krupske
Name: Richard Krupske
Title: Vice President


    


EXHIBIT A
[FORM OF FACE OF NOTE]
[INCLUDE FOLLOWING LEGEND IF A GLOBAL NOTE]
[UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT HEREUNDER IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO.,HAS AN INTEREST HEREIN.]
A-1
    


NeoGenomics, Inc.
0.25% Convertible Senior Note due 2028
No. [__]    [Initially]1 $[_________]
CUSIP No. [●]
NeoGenomics, Inc., a corporation duly organized and validly existing under the laws of the State of Delaware (the “Company,” which term includes any successor corporation or other entity under the Indenture referred to on the reverse hereof), for value received hereby promises to pay to [CEDE & CO.]2 [_______]3, or registered assigns, the principal sum [as set forth in the “Schedule of Exchanges of Notes” attached hereto]4 [of $[_______]]5, which amount, taken together with the principal amounts of all other outstanding Notes, shall not, unless permitted by the Indenture, exceed $300,000,000 (or $345,000,000 if the Underwriters exercise their over-allotment option in accordance with the Underwriting Agreement in full) in aggregate at any time, in accordance with the rules and procedures of the Depositary, on January 15, 2028, and interest thereon as set forth below.
This Note shall bear interest at the rate of 0.25% per year from and including January 11, 2021, or from and including the most recent date to which interest has been paid or provided for to, but excluding, the next scheduled Interest Payment Date until January 15, 2028. Accrued interest on this Note shall be computed on the basis of a 360-day year composed of twelve 30-day months and, for partial months, on the basis of the number of days actually elapsed in a 30-day month. Interest is payable semi-annually in arrears on each January 15 and July 15, commencing on July 15, 2021, to Holders of record at the close of business on the preceding January 1 and July 1 (whether or not such day is a Business Day), respectively. Additional Interest will be payable as set forth in Section 6.03 of the within-mentioned Indenture, and any reference to interest on, or in respect of, any Note therein shall be deemed to include Additional Interest if, in such context, Additional Interest is, was or would be payable pursuant to such Section 6.03, and any express mention of the payment of Additional Interest in any provision therein shall not be construed as excluding Additional Interest in those provisions thereof where such express mention is not made.
Any Defaulted Amounts shall accrue interest per annum at the rate borne by the Notes, from, and including, the relevant payment date to, but excluding, the date on which such Defaulted Amounts shall have been paid by the Company, at its election, in accordance with Section 2.03(c) of the Indenture.
     1 Include if a global note
     2 Include if a global note
     3 Include if a physical note
     4 Include if a global note
     5 Include if a physical note
A-2
    


The Company shall pay the principal of and interest on this Note, if and so long as such Note is a Global Note, in immediately available funds in lawful money of the United States at the time to the Depositary or its nominee, as the case may be, as the registered Holder of such Note. As provided in and subject to the provisions of the Indenture, the Company shall pay the principal of any Notes (other than Notes that are Global Notes) at the office or agency designated by the Company for that purpose. The Company has initially designated the Trustee as its Paying Agent and Note Registrar in respect of the Notes and its Corporate Trust Office in the contiguous United States of America, as a place where Notes may be presented for payment or for registration of transfer and exchange.
Reference is made to the further provisions of this Note set forth on the reverse hereof, including, without limitation, provisions giving the Holder of this Note the right to convert this Note into cash, shares of Common Stock or a combination of cash and shares of Common Stock, as applicable, on the terms and subject to the limitations set forth in the Indenture. Such further provisions shall for all purposes have the same effect as though fully set forth at this place.
This Note, and any claim, controversy or dispute arising under or related to this Note, shall be construed in accordance with and governed by the laws of the State of New York.
In the case of any conflict between this Note and the Indenture, the provisions of the Indenture shall control and govern.
This Note shall not be valid or become obligatory for any purpose until the certificate of authentication hereon shall have been signed manually by the Trustee or a duly authorized authenticating agent under the Indenture.
[Remainder of page intentionally left blank]

A-3
    


IN WITNESS WHEREOF, the Company has caused this Note to be duly executed.
NEOGENOMICS, INC.
By:
Name:
Title:
Dated:
TRUSTEE’S CERTIFICATE OF AUTHENTICATION
U.S. BANK NATIONAL ASSOCIATION
as Trustee, certifies that this is one of the Notes described
in the within-named Indenture.

By:__________________
Authorized Signatory

    


[FORM OF REVERSE OF NOTE]
NeoGenomics, Inc.
0.25% Convertible Senior Note due 2028
This Note is one of a duly authorized issue of Notes of the Company, designated as its 0.25% Convertible Senior Notes due 2028 (the “Notes”), initially limited to the aggregate principal amount of $300,000,000 (or $345,000,000 if the Underwriters exercise their over-allotment option in accordance with the Underwriting Agreement in full) all issued or to be issued under and pursuant to an Indenture dated as of January 11, 2021 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee (the “Trustee”), to which Indenture and all indentures supplemental thereto reference is hereby made for a description of the rights, limitations of rights, obligations, duties and immunities thereunder of the Trustee, the Company and the Holders of the Notes. Additional Notes may be issued in an unlimited aggregate principal amount, subject to certain conditions specified in the Indenture. Capitalized terms used in this Note and not defined in this Note shall have the respective meanings set forth in the Indenture.
In case certain Events of Default, as defined in the Indenture, shall have occurred and be continuing, the principal of, and interest on, all Notes may be declared, by either the Trustee or Holders of at least 25% in aggregate principal amount of Notes then outstanding, and upon said declaration shall become, due and payable, in the manner, with the effect and subject to the conditions and certain exceptions set forth in the Indenture.
Subject to the terms and conditions of the Indenture, the Company will make all payments and deliveries in respect of the Fundamental Change Repurchase Price on the Fundamental Change Repurchase Date and the principal amount on the Maturity Date, as the case may be, to the Holder who surrenders a Note to a Paying Agent to collect such payments in respect of the Note. The Company will pay cash amounts in money of the United States that at the time of payment is legal tender for payment of public and private debts.
The Indenture contains provisions permitting the Company and the Trustee in certain circumstances, without the consent of the Holders of the Notes, and in certain other circumstances, with the consent of the Holders of not less than a majority in aggregate principal amount of the Notes at the time outstanding, evidenced as in the Indenture provided, to execute supplemental indentures modifying the terms of the Indenture and the Notes as described therein. It is also provided in the Indenture that, subject to certain exceptions, the Holders of a majority in aggregate principal amount of the Notes at the time outstanding may on behalf of the Holders of all of the Notes waive any past Default or Event of Default under the Indenture and its consequences.
No reference herein to the Indenture and no provision of this Note or of the Indenture shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay or deliver, as the case may be, the principal (including the Redemption Price, the Fundamental Change Repurchase Price, if applicable) of, accrued and unpaid interest on, and the consideration
R-1
    


due upon conversion of, this Note at the place, at the respective times, at the rate and in the lawful money herein prescribed.
The Notes are issuable in registered form without coupons in minimum denominations of $1,000 principal amount and multiples in excess thereof. At the office or agency of the Company referred to on the face hereof, and in the manner and subject to the limitations provided in the Indenture, Notes may be exchanged for a like aggregate principal amount of Notes of other authorized denominations, without payment of any service charge but, if required by the Company or Trustee, with payment of a sum sufficient to cover any transfer or similar tax that may be imposed in connection therewith as a result of the name of the Holder of the new Notes issued upon such exchange of Notes being different from the name of the Holder of the old Notes surrendered for such exchange.
The Notes shall be redeemable at the Company’s option on or after January 20, 2025, in accordance with the terms and subject to the conditions specified in the Indenture. No sinking fund is provided for the Notes.
Upon the occurrence of a Fundamental Change, the Holder has the right, at such Holder’s option, to require the Company to repurchase for cash all of such Holder’s Notes or any portion thereof (in principal amounts of $1,000 or multiples thereof) on the Fundamental Change Repurchase Date at a price equal to the Fundamental Change Repurchase Price.
Subject to the provisions of the Indenture, the Holder hereof has the right, at its option, during certain periods and upon the occurrence of certain conditions specified in the Indenture, prior to the close of business on the second Business Day immediately preceding the Maturity Date, to convert any Notes or portion thereof that is $1,000 or a multiple thereof, into cash, shares of Common Stock or a combination of cash and shares of Common Stock, as applicable, at the Conversion Rate specified in the Indenture, as adjusted from time to time as provided in the Indenture.
Terms used in this Note and defined in the Indenture are used herein as therein defined.
R-2
    


ABBREVIATIONS
The following abbreviations, when used in the inscription of the face of this Note, shall be construed as though they were written out in full according to applicable laws or regulations:
TEN COM = as tenants in common    

UNIF GIFT MIN ACT = Uniform Gifts to Minors Act

CUST = Custodian

TEN ENT = as tenants by the entireties        

JT TEN = joint tenants with right of survivorship and not as tenants in common     

Additional abbreviations may also be used though not in the above list.

R-3
    


SCHEDULE A6
SCHEDULE OF EXCHANGES OF NOTES
NeoGenomics, Inc.
0.25% Convertible Senior Notes due 2028
The initial principal amount of this Global Note is _______ DOLLARS ($[_________]). The following increases or decreases in this Global Note have been made:
Date of exchange
Amount of decrease in principal amount of this Global Note
Amount of increase in principal amount of this Global Note
Principal amount of this Global Note following such decrease or increase
Signature of authorized signatory of Trustee or Custodian




     6 Include if a global note.

R-4
    


ATTACHMENT 1
[FORM OF NOTICE OF CONVERSION]
To: NeoGenomics, Inc.
To: U.S. Bank National Association
1420 Fifth Ave
Seattle, WA 98101
Attention: R. Krupske (NeoGenomics, Inc.)

The undersigned registered owner of this Note hereby exercises the option to convert this Note, or the portion hereof (that is $1,000 principal amount or a multiple thereof) below designated, into cash, shares of Common Stock or a combination of cash and shares of Common Stock, as applicable, in accordance with the terms of the Indenture referred to in this Note, and directs that any cash payable and any shares of Common Stock issuable and deliverable upon such conversion, together with any cash for any fractional share, and any Notes representing any unconverted principal amount hereof, be issued and delivered to the registered Holder hereof unless a different name has been indicated below. If any shares of Common Stock or any portion of this Note not converted are to be issued in the name of a Person other than the undersigned, the undersigned will pay all documentary, stamp or similar issue or transfer taxes, if any in accordance with Section 14.02(d) and Section 14.02(e) of the Indenture. Any amount required to be paid to the undersigned on account of interest accompanies this Note. Capitalized terms used herein but not defined shall have the meanings ascribed to such terms in the Indenture.
Dated:    _____________________    ________________________________
    ________________________________
    Signature(s)
___________________________
Signature Guarantee
Signature(s) must be guaranteed by an eligible Guarantor Institution (banks, stock brokers, savings and loan associations and credit unions) with membership in an approved signature guarantee medallion program pursuant to Securities and Exchange Commission Rule 17Ad-15 if shares of Common Stock are to be issued, or Notes are to be delivered, other than to and in the name of the registered holder.
Fill in for registration of shares if to be issued, and Notes if to be delivered, other than to and in the name of the registered holder:


1
    




_________________________
(Name)
_________________________
(Street Address)
_________________________
(City, State and Zip Code)
Please print name and address
Principal amount to be converted (if less than all): $______,000
NOTICE: The above signature(s) of the Holder(s) hereof must correspond with the name as written upon the face of the Note in every particular without alteration or enlargement or any change whatever.
_________________________
Social Security or Other Taxpayer
Identification Number



2
    


ATTACHMENT 2
[FORM OF FUNDAMENTAL CHANGE REPURCHASE NOTICE]
To: NeoGenomics, Inc.
To: U.S. Bank National Association
1420 Fifth Ave    
Seattle, WA 98101
Attention: R. Krupske (NeoGenomics, Inc.)

The undersigned registered owner of this Note hereby acknowledges receipt of a notice from NeoGenomics, Inc. (the “Company”) as to the occurrence of a Fundamental Change with respect to the Company and specifying the Fundamental Change Repurchase Date and requests and instructs the Company to pay to the registered holder hereof in accordance with Section 15.02 of the Indenture referred to in this Note (1) the entire principal amount of this Note, or the portion thereof (that is $1,000 principal amount or a multiple thereof) below designated, and (2) if such Fundamental Change Repurchase Date does not fall during the period after a Regular Record Date and on or prior to the corresponding Interest Payment Date, accrued and unpaid interest, if any, thereon to, but excluding, such Fundamental Change Repurchase Date. Capitalized terms used herein but not defined shall have the meanings ascribed to such terms in the Indenture.
In the case of Physical Notes, the certificate numbers of the Notes to be repurchased are as set forth below:
Dated:    _____________________
    ________________________________
    Signature(s)

_________________________
Social Security or Other Taxpayer Identification Number
Principal amount to be repurchased (if less than all): $______,000
NOTICE: The above signature(s) of the Holder(s) hereof must correspond with the name as written upon the face of the Note in every particular without alteration or enlargement or any change whatever
1
    
EX-5.1 5 exhibit51snellwilmeropinio.htm EX-5.1 Document
Exhibit 5.1
image3b.jpg
image2b.jpg
January 11, 2021


NeoGenomics, Inc.
12701 Commonwealth Drive, Suite 9
Fort Myers, Florida 33913

Re: Common Stock Prospectus Supplement

Ladies and Gentlemen:
Ladies and Gentlemen:
We have acted as your special counsel in connection with the Prospectus Supplement filed on January 8, 2021 by NeoGenomics, Inc., a Nevada corporation (the “Company”), with the Securities and Exchange Commission (the “Prospectus Supplement”) pursuant to the Securities Act of 1933, as amended (the “Securities Act”), which is part of the Registration Statement on Form S-3 (File No. 333-231608) that was filed with the Securities and Exchange Commission and became effective on May 20, 2019 (the “Registration Statement”), relating to (i) the sale by the Company and purchase by the Underwriters of 4,081,632 shares of common stock, par value $0.001 per share, of the Company Stock, as set forth in Schedule A (the “Initial Securities”) to that certain underwriting agreement dated January 6, 2021 between the Company and BofA Securities, Inc., Morgan Stanley & Co. LLC, and Goldman Sachs & Co. LLC as representatives of the Underwriters (the “Underwriting Agreement”), acting severally and not jointly and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) of the Underwriting Agreement to purchase all or any part of 612,244 additional shares of Common Stock (the “Option Securities”, collectively with the Initial Securities, the “Securities”). Capitalized terms used in this letter which are not otherwise defined shall have the meanings given to such terms in the Prospectus Supplement or the Underwriting Agreement.
You have requested our opinion as to the matters set forth below in connection with the Prospectus Supplement. For purposes of rendering this opinion, we have examined the Registration Statement, the Prospectus Supplement, the Company’s articles of incorporation, as amended, and bylaws, as amended, and we have made such other investigation as we have deemed appropriate. We have examined and relied upon certificates of public officials and, as to
Snell & Wilmer is a member of LEX MUNDI, The Leading Association of Independent Law Firms.


image1c.jpg

certain matters of fact that are material to our opinion, we have also relied upon certificates made by officers of the Company. In rendering our opinion, in addition to the assumptions that are customary in opinion letters of this kind, we have assumed the genuineness of signatures on the documents we have examined, the legal capacity and authority of the persons signing the documents we have examined, the truth and accuracy of all representations and warranties, that the issuance and sale of the Securities from time to time will be duly authorized and established by proper action of the Company, that the Registration Statement and Prospectus Supplement have become effective and have been properly filed, the conformity to authentic documents of all documents submitted to us as copies, that all parties to the Underwriting Agreement have or will comply with their obligations under such agreement, including, without limitation, making the required payment for the Securities, and that the Company will have sufficient authorized and unissued shares of common stock available with respect to the Securities. We have not verified any of these assumptions.
This opinion is rendered as of the date of this letter and is limited to matters of Nevada corporate law, including applicable provisions of the Nevada Constitution and reported judicial decisions interpreting those laws. We express no opinion as to the laws of any other state, the federal law of the United States, or the effect of any federal or state securities laws.
Based upon and subject to the foregoing, it is our opinion that the Securities were duly authorized for issuance by the Company and, when issued and paid for as described in the Underwriting Agreement, the Registration Statement and the Prospectus Supplement, will be validly issued, fully paid, and nonassessable.
We consent to the filing of this opinion as an exhibit to the Prospectus Supplement and to the reference to this firm in the Prospectus Supplement under the caption “Legal Matters.” In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations under such act.

Very truly yours,

/s/ image4b.jpg
Snell & Wilmer L.L.P.



Snell & Wilmer is a member of LEX MUNDI, The Leading Association of Independent Law Firms.
EX-5.2 6 exhibit52snellwilmeropinio.htm EX-5.2 Document
Exhibit 5.2
image2a.jpg
image1b.jpg
January 11, 2021


NeoGenomics, Inc.
12701 Commonwealth Drive, Suite 9
Fort Myers, Florida 33913

Re: Convertible Notes Prospectus

Ladies and Gentlemen:
We have acted as your special counsel in connection with prospectus filed on January 8, 2021 by NeoGenomics, Inc., a Nevada corporation (the “Company”), with the Securities and Exchange Commission (the “Prospectus”) pursuant to the Securities Act of 1933, as amended (the “Securities Act”), which is part of the Registration Statement on Form S-3 (File No. 333-251901) filed on January 5, 2021 (the “Registration Statement”), relating to (i) the registration of an aggregate of $300,000,000 principal amount of the Company’s Convertible 0.25% Senior Notes due 2028 (the “Initial Securities”) which may be sold as set forth in the Prospectus and (ii) the grant by the Company of the option to purchase, solely to cover over-allotments, all or any part of up to an additional $45,000,000 aggregate principal amount of the Company’s 0.25% Convertible Senior Notes due 2028 (the “Option Securities”, collectively with the Initial Securities, the “Securities”). The Securities are to be issued pursuant to the form of an indenture attached to the Registration Statement (the “Indenture”). The Common Stock, par value $0.001 per share, of the Company is referred to as the “Common Stock”. The Securities may be convertible into cash, shares of Common Stock (the “Underlying Shares”), or a combination of cash and Underlying Shares at the option of Company, as set forth in the Indenture. Capitalized terms used in this letter which are not otherwise defined shall have the meanings given to such terms in the Registration Statement or the Prospectus.
You have requested our opinion as to the matters set forth below in connection with the Prospectus. For purposes of rendering this opinion, we have examined the Registration Statement, the Prospectus, the underwriting agreement dated January 6, 2021 between the Company and BofA Securities, Inc., Morgan Stanley & Co. LLC, and Goldman Sachs & Co. LLC as representatives of the Underwriters (the “Underwriting Agreement”), acting severally and not jointly, the Indenture, the issuer free writing prospectus filed by the Company on January 7, 2021, the form of the Securities, the Company’s articles of incorporation, as amended (the
Snell & Wilmer is a member of LEX MUNDI, The Leading Association of Independent Law Firms.


image4a.jpg


“Articles”), and bylaws, as amended (together with the Articles, the “Company’s Organizational Documents”), and we have made such other investigation as we have deemed appropriate. We have examined and relied upon certificates of public officials and, as to certain matters of fact that are material to our opinion, we have also relied upon certificates made by officers of the Company. In rendering our opinion, in addition to the assumptions that are customary in opinion letters of this kind, we have assumed the genuineness of signatures on the documents we have examined, the legal capacity and authority of the persons signing the documents we have examined, the truth and accuracy of all representations and warranties, that the issuance and sale of the Securities from time to time will be duly authorized and established by proper action of the Company, that the Registration Statement and Prospectus have become effective and have been properly filed, the conformity to authentic documents of all documents submitted to us as copies, that all parties to the Indenture have or will comply with their obligations under such agreement, including, without limitation, making the required payment for the Securities, and that the Company will have sufficient authorized and unissued shares of common stock available with respect to the Underlying Shares. We have not verified any of these assumptions.
This opinion is rendered as of the date of this letter and is limited to matters of Nevada corporate law, including applicable provisions of the Nevada Constitution and reported judicial decisions interpreting those laws. We express no opinion as to the laws of any other state, the federal law of the United States, or the effect of any federal or state securities laws.
Based upon and subject to the foregoing, it is our opinion that (i) the Securities were duly authorized for issuance by the Company and, when issued and paid for as described in the Underwriting Agreement, Prospectus and the Indenture, will be validly issued, fully paid, and nonassessable and (ii) the Underlying Shares, when issued upon conversion of the Securities in accordance with the terms of the Underwriting Agreement and Indenture, will be validly issued, fully paid and nonassessable.
We consent to the filing of this opinion as an exhibit to the Prospectus and to the reference to this firm in the Prospectus under the caption “Legal Matters.” In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations under such act.

Very truly yours,

/s/ image3a.jpg
Snell & Wilmer L.L.P.
Snell & Wilmer is a member of LEX MUNDI, The Leading Association of Independent Law Firms.
EX-10.1 7 exhibit101cappedcallconfir.htm EX-10.1 Document

Exhibit 10.1

image_11a.jpg




[GOLDMAN SACHS & CO. LLC | 200 WEST STREET | NEW YORK, NEW YORK 10282-2198 | TEL: 212-902-1000
Opening Transaction]1
[Bank of America, N.A.
One Bryant Park
New York, NY 10036]2

[Morgan Stanley & Co. LLC
1585 Broadway, 4th Floor
New York, NY 10036]3

[__________], 2021
To: NeoGenomics, Inc.
12701 Commonwealth Drive, Suite 9
Fort Myers, FL 33913

Attention: Kathryn McKenzie, Chief Financial Officer
Telephone No.: 239.768.0600
Email: kathryn.mckenzie@neogenomics.com

Re: [Base][Additional] Call Option Transaction
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [Bank of America, N.A.]4[Morgan Stanley & Co. LLC]5[Goldman Sachs & Co. LLC]6 (“Dealer”) and NeoGenomics, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. Each party further agrees that this Confirmation together with the Agreement evidence a complete binding agreement between Counterparty and Dealer as to the subject matter and terms of the Transaction to which this Confirmation relates, and shall supersede all prior or contemporaneous written or oral communications with respect thereto.
The definitions and provisions contained in the 2002 ISDA Equity Derivatives Definitions (the “Equity Definitions”), as published by the International Swaps and Derivatives Association, Inc. (“ISDA”) are incorporated into this Confirmation. In the event of any inconsistency between the Equity Definitions and this Confirmation, this Confirmation shall govern. Certain defined terms used herein are based on terms that are defined in the Prospectus dated January 5, 2021, as supplemented by the Prospectus Supplement dated January 6, 2021 (as so supplemented, the “Prospectus”) relating to the 0.25% Convertible Senior Notes due 2028 (as originally issued by Counterparty, the “Convertible Notes” and each USD 1,000 principal amount of Convertible Notes, a “Convertible Note”) issued by Counterparty in an aggregate initial principal amount of USD 300,000,000 (as increased by [up to]7 an aggregate principal amount of USD 45,000,000 [if and to the extent that]8[pursuant to the exercise by]9 the Underwriters (as defined herein) [exercises]10[of]11 their option to purchase additional Convertible Notes pursuant to the Underwriting Agreement (as defined herein)) pursuant to an Indenture to be dated January 11, 2021 between Counterparty and
1 Insert for GS.
2 Insert for BofA.
3 Insert for MS.
4 Insert for BofA.
5 Insert for MS.
6 Insert for GS.
7 Include in the Base Call Option Confirmation.
8 Include in the Base Call Option Confirmation.
9 Include in the Additional Call Option Confirmation.
10 Include in the Base Call Option Confirmation.
11 Include in the Additional Call Option Confirmation.








U.S. Bank National Association, as trustee (the “Indenture”). In the event of any inconsistency between the terms defined in the Prospectus, the Indenture and this Confirmation, this Confirmation shall govern. The parties acknowledge that this Confirmation is entered into on the date hereof with the understanding that (i) definitions set forth in the Indenture which are also defined herein by reference to the Indenture and (ii) sections of the Indenture that are referred to herein will conform in all material respects to the descriptions thereof in the Prospectus. If any such definitions in the Indenture or any such sections of the Indenture differ from the descriptions thereof in the Prospectus, the descriptions thereof in the Prospectus will govern for purposes of this Confirmation. The parties further acknowledge that the Indenture section numbers used herein are based on the draft of the Indenture last reviewed by Dealer as of the date of this Confirmation, and if any such section numbers are changed in the Indenture as executed, the parties will amend this Confirmation in good faith and in a commercially reasonable manner to preserve the intent of the parties. Subject to the foregoing, references to the Indenture herein are references to the Indenture as in effect on the date of its execution, and if the Indenture is amended or supplemented following such date (other than any amendment or supplement (x) pursuant to Section 10.01 of the Indenture that, as determined by the Calculation Agent, conforms the Indenture to the description of Convertible Notes in the Prospectus or (y) pursuant to Section 14.07 of the Indenture, subject, in the case of this clause (y), to the second paragraph under “Method of Adjustment” in Section 3), any such amendment or supplement will be disregarded for purposes of this Confirmation (other than as provided in Section 9(i)(iii) below) unless the parties agree otherwise in writing.
Each party is hereby advised, and each such party acknowledges, that the other party has engaged in, or refrained from engaging in, substantial financial transactions and has taken other material actions in reliance upon the parties’ entry into the Transaction to which this Confirmation relates on the terms and conditions set forth below.
1.This Confirmation evidences a complete and binding agreement between Dealer and Counterparty as to the terms of the Transaction to which this Confirmation relates. This Confirmation shall supplement, form a part of, and be subject to an agreement in the form of the 2002 ISDA Master Agreement (the “Agreement”) as if Dealer and Counterparty had executed an agreement in such form (but without any Schedule except for the election of the laws of the State of New York as the governing law (without reference to choice of law doctrine)) on the Trade Date. In the event of any inconsistency between provisions of the Agreement and this Confirmation, this Confirmation will prevail for the purpose of the Transaction to which this Confirmation relates. The parties hereby agree that no transaction other than the Transaction to which this Confirmation relates shall be governed by the Agreement.
2.The terms of the particular Transaction to which this Confirmation relates are as follows:
General Terms.
Trade Date: [__________], 2021

Effective Date: The second Exchange Business Day immediately prior to the Premium Payment Date

Option Style: “Modified American”, as described under “Procedures for Exercise” below

Option Type: Call

Buyer: Counterparty

Seller: Dealer

Shares: The common stock of Counterparty, par value USD 0.001 per share (Exchange symbol “NEO”).

Number of Options: [_______]12. For the avoidance of doubt, the Number of Options shall be reduced by any Options exercised by Counterparty. In no event will the Number of Options be less than zero.
12 For the Base Call Option Confirmation, this is equal to the number of Convertible Notes in principal amount of $1,000 initially issued on the closing date for the Convertible Notes. For the Additional Call Option Confirmation, this is equal to the number of additional Convertible Notes in principal amount of $1,000.

    

2






Applicable Percentage: [__]%
Option Entitlement: A number equal to the product of the Applicable Percentage and [______]13.

Strike Price: USD [______]

Cap Price: USD [______]

Premium: USD [______]

Premium Payment Date: [__________], 2021

Exchange: The Nasdaq Capital Market

Related Exchange(s): All Exchanges

Excluded Provisions: Section 14.04(h) and Section 14.03 of the Indenture.

Procedures for Exercise.

Conversion Date:    With respect to any conversion of a Convertible Note (other than any conversion of Convertible Notes with a Conversion Date occurring prior to the Free Convertibility Date (any such conversion, an “Early Conversion”), to which the provisions of Section 9(i)(i) of this Confirmation shall apply), the date on which the Holder (as such term is defined in the Indenture) of such Convertible Note satisfies all of the requirements for conversion thereof as set forth in Section 14.02(b) of the Indenture; provided that if Counterparty has not delivered to Dealer a related Notice of Exercise, then in no event shall a Conversion Date be deemed to occur hereunder (and no Option shall be exercised or deemed to be exercised hereunder) with respect to any surrender of a Convertible Note for conversion in respect of which Counterparty has elected to designate a financial institution for exchange in lieu of conversion of such Convertible Note pursuant to Section 14.12 of the Indenture.

Free Convertibility Date: September 15, 2027
Expiration Time: The Valuation Time

Expiration Date: January 15, 2028, subject to earlier exercise.

Multiple Exercise: Applicable, as described under “Automatic Exercise” below.

Automatic Exercise: Notwithstanding Section 3.4 of the Equity Definitions, on each Conversion Date occurring on or after the Free Convertibility Date, in respect of which a Notice of Conversion that is effective as to Counterparty has been delivered by the relevant converting Holder, a number of Options equal to [(i)] the number of Convertible Notes in denominations of USD 1,000 as to which such Conversion Date has occurred [minus (ii) the number of Options that are or are deemed to be automatically exercised on such Conversion Date under the Base Call Option Transaction Confirmation letter agreement dated [__________], 2021 between Dealer and Counterparty (the “Base Call
13 Insert the initial Conversion Rate for the Convertible Notes.

    

3





Option Confirmation”),]14 shall be deemed to be automatically exercised; provided that such Options shall be exercised or deemed exercised only if Counterparty has provided a Notice of Exercise to Dealer in accordance with “Notice of Exercise” below.
                
Notwithstanding the foregoing, in no event shall the number of Options that are exercised or deemed exercised hereunder exceed the Number of Options.

Notice of Exercise: Notwithstanding anything to the contrary in the Equity Definitions or under “Automatic Exercise” above, in order to exercise any Options relating to Convertible Notes with a Conversion Date occurring on or after the Free Convertibility Date, Counterparty must notify Dealer in writing before 5:00 p.m. (New York City time) on the Scheduled Valid Day immediately preceding the Expiration Date specifying the number of such Options; provided that if the Relevant Settlement Method for such Options is (x) Net Share Settlement and the Specified Dollar Amount (as defined below) is not USD 1,000, (y) Cash Settlement or (z) Combination Settlement, Dealer shall have received a separate notice (the “Notice of Final Settlement Method”) in respect of all such Convertible Notes before 5:00 p.m. (New York City time) on the Free Convertibility Date specifying (1) the Relevant Settlement Method for such Options, and (2) if the settlement method for the related Convertible Notes is not Settlement in Shares or Settlement in Cash (each as defined below), the fixed amount of cash per Convertible Note that Counterparty has elected to deliver to Holders (as such term is defined in the Indenture) of the related Convertible Notes (the “Specified Dollar Amount”). Counterparty acknowledges its responsibilities under applicable securities laws, and in particular Section 9 and Section 10(b) of the Exchange Act (as defined below) and the rules and regulations thereunder, in respect of any election of a settlement method with respect to the Convertible Notes.

Valuation Time:     At the close of trading of the regular trading session on the Exchange; provided that if the principal trading session is extended, the Calculation Agent shall determine the Valuation Time in its reasonable discretion.

Market Disruption Event:    Section 6.3(a) of the Equity Definitions is hereby replaced in its entirety by the following:

“‘Market Disruption Event’ means, in respect of a Share, (i) a failure by the primary United States national or regional securities exchange or market on which the Shares are listed or admitted for trading to open for trading during its regular trading session or (ii) the occurrence or existence prior to 1:00 p.m. (New York City time) on any Scheduled Valid Day for the Shares for more than one half-hour period in the aggregate during regular trading hours of any suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the relevant stock exchange or otherwise) in the Shares or in any options contracts traded on any United States exchange or futures contracts relating to the Shares.”

Settlement Terms.
Settlement Method: For any Option, Net Share Settlement; provided that if the Relevant Settlement Method set forth below for such Option is not Net Share
14 Include for Additional Call Option Confirmation only.

    

4





Settlement, then the Settlement Method for such Option shall be such Relevant Settlement Method, but only if Counterparty shall have notified Dealer of the Relevant Settlement Method in the Notice of Final Settlement Method for such Option.
Relevant Settlement Method: In respect of any Option:
(i) if Counterparty has elected to settle its conversion obligations in respect of the related Convertible Note (A) entirely in Shares pursuant to Section 14.02(a)(iv)(A) of the Indenture (together with cash in lieu of fractional Shares) (such settlement method, “Settlement in Shares”), (B) in a combination of cash and Shares pursuant to Section 14.02(a)(iv)(C) of the Indenture with a Specified Dollar Amount less than USD 1,000 (such settlement method, “Low Cash Combination Settlement”) or (C) in a combination of cash and Shares pursuant to Section 14.02(a)(iv)(C) of the Indenture with a Specified Dollar Amount equal to USD 1,000, then, in each case, the Relevant Settlement Method for such Option shall be Net Share Settlement;
(ii)    if Counterparty has elected to settle its conversion obligations in respect of the related Convertible Note in a combination of cash and Shares pursuant to Section 14.02(a)(iv)(C) of the Indenture with a Specified Dollar Amount greater than USD 1,000, then the Relevant Settlement Method for such Option shall be Combination Settlement; and
(iii)    if Counterparty has elected to settle its conversion obligations in respect of the related Convertible Note entirely in cash pursuant to Section 14.02(a)(iv)(B) of the Indenture (such settlement method, “Settlement in Cash”), then the Relevant Settlement Method for such Option shall be Cash Settlement.
Net Share Settlement: If Net Share Settlement is applicable to any Option exercised or deemed exercised hereunder, Dealer will deliver to Counterparty, on the relevant Settlement Date for each such Option, a number of Shares (the “Net Share Settlement Amount”) equal to the sum, for each Valid Day during the Settlement Averaging Period for each such Option, of (i) (a) the Daily Option Value for such Valid Day, divided by (b) the Relevant Price on such Valid Day, divided by (ii) the number of Valid Days in the Settlement Averaging Period; provided that in no event shall the Net Share Settlement Amount for any Option exceed a number of Shares equal to the Applicable Limit for such Option divided by the Applicable Limit Price on the Settlement Date for such Option.
Dealer will pay cash in lieu of delivering any fractional Shares to be delivered with respect to any Net Share Settlement Amount valued at the Relevant Price for the last Valid Day of the Settlement Averaging Period.
Combination Settlement: If Combination Settlement is applicable to any Option exercised or deemed exercised hereunder, Dealer will pay or deliver, as the case may be, to Counterparty, on the relevant Settlement Date for each such Option:

    

5





(i)    cash (the “Combination Settlement Cash Amount”) equal to the sum, for each Valid Day during the Settlement Averaging Period for such Option, of (A) an amount (the “Daily Combination Settlement Cash Amount”) equal to the lesser of (1) the product of (x) the Applicable Percentage and (y) the Specified Dollar Amount minus USD 1,000 and (2) the Daily Option Value, divided by (B) the number of Valid Days in the Settlement Averaging Period; provided that if the calculation in clause (A) above results in zero or a negative number for any Valid Day, the Daily Combination Settlement Cash Amount for such Valid Day shall be deemed to be zero; and
(ii)    Shares (the “Combination Settlement Share Amount”) equal to the sum, for each Valid Day during the Settlement Averaging Period for such Option, of a number of Shares for such Valid Day (the “Daily Combination Settlement Share Amount”) equal to (A) (1) the Daily Option Value on such Valid Day minus the Daily Combination Settlement Cash Amount for such Valid Day, divided by (2) the Relevant Price on such Valid Day, divided by (B) the number of Valid Days in the Settlement Averaging Period; provided that if the calculation in sub-clause (A)(1) above results in zero or a negative number for any Valid Day, the Daily Combination Settlement Share Amount for such Valid Day shall be deemed to be zero;
provided that in no event shall the sum of (x) the Combination Settlement Cash Amount for any Option and (y) the Combination Settlement Share Amount for such Option multiplied by the Applicable Limit Price on the Settlement Date for such Option, exceed the Applicable Limit for such Option.
Dealer will pay cash in lieu of delivering any fractional Shares to be delivered with respect to any Combination Settlement Share Amount valued at the Relevant Price for the last Valid Day of the Settlement Averaging Period.
Cash Settlement: If Cash Settlement is applicable to any Option exercised or deemed exercised hereunder, in lieu of Section 8.1 of the Equity Definitions, Dealer will pay to Counterparty, on the relevant Settlement Date for each such Option, an amount of cash (the “Cash Settlement Amount”) equal to the sum, for each Valid Day during the Settlement Averaging Period for such Option, of (i) the Daily Option Value for such Valid Day, divided by (ii) the number of Valid Days in the Settlement Averaging Period.
Daily Option Value: For any Valid Day, an amount equal to (i) the Option Entitlement on such Valid Day, multiplied by (ii) (A) the lesser of the Relevant Price on such Valid Day and the Cap Price, less (B) the Strike Price on such Valid Day; provided that if the calculation contained in clause (ii) above results in a

    

6





negative number, the Daily Option Value for such Valid Day shall be deemed to be zero. In no event will the Daily Option Value be less than zero.
Applicable Limit:     For any Option, an amount of cash equal to the Applicable Percentage multiplied by the excess of (i) the aggregate of (A) the amount of cash, if any, paid to the Holder of the related Convertible Note upon conversion of such Convertible Note and (B) the number of Shares, if any, delivered to the Holder of the related Convertible Note upon conversion of such Convertible Note multiplied by the Applicable Limit Price on the Settlement Date for such Option, over (ii) USD 1,000.
Applicable Limit Price: On any day, the opening price as displayed under the heading “Op” on Bloomberg page NEO <equity> (or any successor thereto).
Valid Day: A day on which (i) there is no Market Disruption Event and (ii) trading in the Shares generally occurs on the Exchange or, if the Shares are not then listed on the Exchange, on the principal other United States national or regional securities exchange on which the Shares are then listed or, if the Shares are not then listed on a United States national or regional securities exchange, on the principal other market on which the Shares are then listed or admitted for trading. If the Shares are not so listed or admitted for trading, “Valid Day” means a Business Day.
Scheduled Valid Day: A day that is scheduled to be a Valid Day on the principal United States national or regional securities exchange or market on which the Shares are listed or admitted for trading. If the Shares are not so listed or admitted for trading, “Scheduled Valid Day” means a Business Day.
Business Day: Any day other than a Saturday, a Sunday or a day on which the Federal Reserve Bank of New York is authorized or required by law or executive order to close or be closed.
Relevant Price: On any Valid Day, the per Share volume-weighted average price as displayed under the heading “Bloomberg VWAP” on Bloomberg page NEO <equity> AQR (or its equivalent successor if such page is not available) in respect of the period from the scheduled opening time of the Exchange to the Scheduled Closing Time of the Exchange on such Valid Day (or if such volume-weighted average price is unavailable at such time, the market value of one Share on such Valid Day, as determined by the Calculation Agent using, if practicable, a volume-weighted average method). The Relevant Price will be determined without regard to after-hours trading or any other trading outside of the regular trading session trading hours.
Settlement Averaging Period: For any Option, the 30 consecutive Valid Days commencing on, and including, the 31st Scheduled Valid Day immediately prior to the Expiration Date; provided that if the Notice of Final Settlement Method for such Option specifies that Settlement in Shares or Low Cash Combination Settlement applies to the related Convertible Note, the Settlement Averaging Period shall be the consecutive Valid Days commencing on, and including, the 61st Scheduled Valid Day immediately prior to the Expiration Date.
Settlement Date: For any Option, the second Business Day immediately following the final Valid Day of the Settlement Averaging Period for such Option.
Settlement Currency: USD

    

7





Other Applicable Provisions: The provisions of Sections 9.1(c), 9.8, 9.9 and 9.11 of the Equity Definitions will be applicable, except that all references in such provisions to “Physically-settled” shall be read as references to “Share Settled”. “Share Settled” in relation to any Option means that Net Share Settlement or Combination Settlement is applicable to that Option.
Representation and Agreement: Notwithstanding anything to the contrary in the Equity Definitions (including, but not limited to, Section 9.11 thereof), the parties acknowledge that (i) any Shares delivered to Counterparty shall be, upon delivery, subject to restrictions and limitations arising from Counterparty’s status as issuer of the Shares under applicable securities laws, (ii) Dealer may deliver any Shares required to be delivered hereunder in certificated form in lieu of delivery through the Clearance System and (iii) any Shares delivered to Counterparty may be “restricted securities” (as defined in Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”)).
3.Additional Terms applicable to the Transaction.
Adjustments applicable to the Transaction:
Potential Adjustment Events: Notwithstanding Section 11.2(e) of the Equity Definitions, a “Potential Adjustment Event” means an occurrence of any event or condition, as set forth in any Dilution Adjustment Provision, that would result in an adjustment under the Indenture to the “Conversion Rate” or the composition of a “unit of Reference Property” or to any “Last Reported Sale Price” , “Daily VWAP,” “Daily Conversion Value” or “Daily Settlement Amount” (each as defined in the Indenture). For the avoidance of doubt, Dealer shall not have any delivery or payment obligation hereunder, and no adjustment shall be made to the terms of the Transaction, on account of (x) any distribution of cash, property or securities by Counterparty to holders of the Convertible Notes (upon conversion or otherwise) or (y) any other transaction in which holders of the Convertible Notes are entitled to participate, in each case, in lieu of an adjustment under the Indenture of the type referred to in the immediately preceding sentence (including, without limitation, pursuant to [the fifth sentence of the first paragraph of Section 14.04(c) of the Indenture or the last sentence of Section 14.04(d) of the Indenture.
Method of Adjustment: Calculation Agent Adjustment, which means that, notwithstanding Section 11.2(c) of the Equity Definitions, upon any Potential Adjustment Event, the Calculation Agent shall make a corresponding adjustment to any one or more of the Strike Price, Number of Options, Option Entitlement and any other variable relevant to the exercise, settlement or payment for the Transaction.
Notwithstanding the foregoing and “Consequences of Merger Events / Tender Offers” below:
(i)    if the Calculation Agent in good faith disagrees with any adjustment to the Convertible Notes that involves an exercise of discretion by Counterparty or its board of directors (including, without

    

8





limitation, pursuant to Section 14.05 of the Indenture, Section 14.07 of the Indenture or any supplemental indenture entered into thereunder or in connection with any proportional adjustment or the determination of the fair value of any securities, property, rights or other assets), then in each such case, the Calculation Agent will determine the adjustment to be made to any one or more of the Strike Price, Number of Options, Option Entitlement and any other variable relevant to the exercise, settlement or payment for the Transaction in a commercially reasonable manner; provided that, notwithstanding the foregoing, if any Potential Adjustment Event occurs during the Settlement Averaging Period but no adjustment was made to any Convertible Note under the Indenture because the relevant Holder (as such term is defined in the Indenture) was deemed to be a record owner of the underlying Shares on the related Conversion Date, then the Calculation Agent shall make an adjustment, as determined by it, to the terms hereof in order to account for such Potential Adjustment Event;
(ii)    in connection with any Potential Adjustment Event as a result of an event or condition set forth in Section 14.04(b) of the Indenture or Section 14.04(c) of the Indenture where, in either case, the period for determining “Y” (as such term is used in Section 14.04(b) of the Indenture) or “SP0” (as such term is used in Section 14.04(c) of the Indenture), as the case may be, begins before Counterparty has publicly announced the event or condition giving rise to such Potential Adjustment Event, then the Calculation Agent shall have the right to adjust any variable relevant to the exercise, settlement or payment for the Transaction as appropriate to reflect the costs (including, but not limited to, hedging mismatches and market losses) and expenses incurred by Dealer in connection with its hedging activities as a result of such event or condition not having been publicly announced prior to the beginning of such period; and
(iii)    if any Potential Adjustment Event is declared and (a) the event or condition giving rise to such Potential Adjustment Event is subsequently amended, modified, cancelled or abandoned, (b) the “Conversion Rate” (as defined in the Indenture) is otherwise not adjusted at the time or in the manner contemplated by the relevant Dilution Adjustment Provision based on such declaration or (c) the “Conversion Rate” (as defined in the Indenture) is adjusted as a result of

    

9





such Potential Adjustment Event and subsequently re-adjusted (each of clauses (a), (b) and (c), a “Potential Adjustment Event Change”) then, in each case, the Calculation Agent shall have the right to adjust any variable relevant to the exercise, settlement or payment for the Transaction as appropriate to reflect the costs (including, but not limited to, hedging mismatches and market losses) and expenses incurred by Dealer in connection with its hedging activities as a result of such Potential Adjustment Event Change.
Dilution Adjustment Provisions: Sections 14.04(a), (b), (c), (d) and (e) and Section 14.05of the Indenture.

Extraordinary Events applicable to the Transaction:

Merger Events: Applicable; provided that notwithstanding Section 12.1(b) of the Equity Definitions, a “Merger Event” means the occurrence of any event or condition set forth in the definition of “Merger Event” in Section 14.07 of the Indenture.

Tender Offers: Applicable; provided that notwithstanding Section 12.1(d) of the Equity Definitions, a “Tender Offer” means the occurrence of any event or condition set forth in Section 14.04(e) of the Indenture.

Consequences of Merger Events/Tender Offers: Notwithstanding Section 12.2 and Section 12.3 of the Equity Definitions, upon the occurrence of a Merger Event or a Tender Offer, the Calculation Agent shall make a corresponding adjustment in respect of any adjustment under the Indenture to any one or more of the nature of the Shares (in the case of a Merger Event), Strike Price, Number of Options, Option Entitlement and any other variable relevant to the exercise, settlement or payment for the Transaction, subject to the second paragraph under “Method of Adjustment”; provided, however, that such adjustment shall be made without regard to any adjustment to the Conversion Rate pursuant to any Excluded Provision; provided further that if, with respect to a Merger Event or a Tender Offer, (i) the consideration for the Shares includes (or, at the option of a holder of Shares, may include) shares of an entity or person that is not a corporation or is not organized under the laws of the United States, any State thereof or the District of Columbia, then, in either case, Cancellation and Payment (Calculation Agent Determination) may apply at Dealer’s sole election; provided further that, for the avoidance of doubt, adjustments shall be made pursuant to the provisions set forth above regardless of whether any Merger Event or Tender Offer gives rise to an Early Conversion.

Consequences of Announcement Events: Modified Calculation Agent Adjustment as set forth in Section 12.3(d) of the Equity Definitions; provided that, in respect of an Announcement Event, (x) references to “Tender Offer” shall be replaced by references to “Announcement Event” and references to “Tender Offer Date” shall be replaced by references to “date of such Announcement Event”, (y) the word “shall” in the second line shall be replaced with “may” and the phrase “exercise, settlement, payment or

    

10





any other terms of the Transaction (including, without limitation, the spread)” shall be replaced with the phrase “Cap Price (provided that in no event shall the Cap Price be less than the Strike Price)”, and (z) for the avoidance of doubt, the Calculation Agent may determine in a commercially reasonable manner whether the relevant Announcement Event has had an economic effect on the Transaction (and, if so, may adjust the Cap Price accordingly) on one or more occasions on or after the date of the Announcement Event up to, and including, the Expiration Date, any Early Termination Date and/or any other date of cancellation, it being understood that any adjustment in respect of an Announcement Event shall take into account any earlier adjustment relating to the same Announcement Event. An Announcement Event shall be an “Extraordinary Event” for purposes of the Equity Definitions, to which Article 12 of the Equity Definitions is applicable.
Announcement Event: (i) The public announcement by any entity of (x) any transaction or event that, if completed, would constitute a Merger Event or Tender Offer, (y) any potential acquisition or disposition by Issuer and/or its subsidiaries where the aggregate consideration exceeds 25% of the market capitalization of Issuer as of the date of such announcement (an “Acquisition Transaction”) or (z) the intention to enter into a Merger Event or Tender Offer or an Acquisition Transaction, (ii) the public announcement by Issuer of an intention to solicit or enter into, or to explore strategic alternatives or other similar undertaking that may include, a Merger Event or Tender Offer or an Acquisition Transaction or (iii) any subsequent public announcement by any entity of a change to a transaction or intention that is the subject of an announcement of the type described in clause (i) or (ii) of this sentence (including, without limitation, a new announcement, whether or not by the same party, relating to such a transaction or intention or the announcement of a withdrawal from, or the abandonment or discontinuation of, such a transaction or intention), as determined by the Calculation Agent. For the avoidance of doubt, the occurrence of an Announcement Event with respect to any transaction or intention shall not preclude the occurrence of a later Announcement Event with respect to such transaction or intention. For purposes of this definition of “Announcement Event,” (A) “Merger Event” shall mean such term as defined under Section 12.1(b) of the Equity Definitions (but, for the avoidance of doubt, the remainder of the definition of “Merger Event” in Section 12.1(b) of the Equity Definitions following the definition of “Reverse Merger” therein shall be disregarded) and (B) “Tender Offer” shall mean such term as defined under Section 12.1(d) of the Equity Definitions.
Nationalization, Insolvency or Delisting: Cancellation and Payment (Calculation Agent Determination); provided that, in addition to the provisions of Section 12.6(a)(iii) of the Equity Definitions, it will also constitute a Delisting if the Exchange is located in the United States and the Shares are not immediately re-listed, re-traded or re-quoted on any of the New York Stock Exchange, The Nasdaq Global Select Market, The Nasdaq Global Market or The Nasdaq Capital Market (or their respective successors); if the Shares are immediately re-listed, re-traded or re-quoted on any of the New York Stock Exchange, The Nasdaq Global Select Market, The Nasdaq Global Market or The Nasdaq Capital Market (or their respective successors), such exchange or quotation system shall thereafter be deemed to be the Exchange.

    

11





Additional Disruption Events:

Change in Law: Applicable; provided that Section 12.9(a)(ii) of the Equity Definitions is hereby amended by (i) replacing the phrase “the interpretation” in the third line thereof with the phrase “, or public announcement of, the formal or informal interpretation”, (ii) replacing the word “Shares” where it appears in clause (X) thereof with the words “Hedge Position” and (iii) replacing the parenthetical beginning after the word “regulation” in the second line thereof the words “(including, for the avoidance of doubt and without limitation, (x) any tax law or (y) adoption, effectiveness or promulgation of new regulations authorized or mandated by existing statute)”.

Failure to Deliver: Applicable

Hedging Disruption: Applicable; provided that:

(i)    Section 12.9(a)(v) of the Equity Definitions is hereby amended by (a) inserting the following words at the end of clause (A) thereof: “in the manner contemplated by the Hedging Party on the Trade Date” and (b) inserting the following two phrases at the end of such Section:
“For the avoidance of doubt, the term “equity price risk” shall be deemed to include, but shall not be limited to, stock price and volatility risk. And, for the further avoidance of doubt, any such transactions or assets referred to in phrases (A) or (B) above must be available on commercially reasonable pricing terms.”; and
(ii)    Section 12.9(b)(iii) of the Equity Definitions is hereby amended by inserting in the third line thereof, after the words “to terminate the Transaction”, the words “or a portion of the Transaction affected by such Hedging Disruption”.
Increased Cost of Hedging: Applicable
Hedging Party: For all applicable Additional Disruption Events, Dealer.
Determining Party: For all applicable Extraordinary Events, Dealer.
Non-Reliance: Applicable
Agreements and Acknowledgments
Regarding Hedging Activities: Applicable
Additional Acknowledgments: Applicable

4. Calculation Agent.
Dealer. For the avoidance of doubt, whenever the Calculation Agent or Determining Party is called upon to make an adjustment pursuant to the terms of this Confirmation or the

    

12





Equity Definitions to take into account the effect of an event, the Calculation Agent or Determining Party, as applicable, shall make such adjustment in good faith and in a commercially reasonable manner by reference to the effect of such event on such party, assuming that such party maintains, establishes or unwinds a commercially reasonable hedge position at the time of the event. Following the occurrence and during the continuance of an Event of Default of the type described in Section 5(a)(vii) of the Agreement with respect to which Dealer is the sole Defaulting Party, if the Calculation Agent fails to timely make any calculation, adjustment or determination required to be made by the Calculation Agent hereunder or to perform any obligation of the Calculation Agent hereunder and such failure continues for five (5) Exchange Business Days following notice to the Calculation Agent by Counterparty of such failure, Counterparty shall have the right to designate a nationally recognized third-party dealer in over-the-counter corporate equity derivatives to act, during the period commencing on the date such Event of Default occurred and ending on the Early Termination Date with respect to such Event of Default (or, if earlier, the date on which such Event of Default is no longer continuing), as the Calculation Agent, and the parties shall work in good faith to execute any appropriate documentation required by such person. Following any adjustment, determination or calculation by the Calculation Agent hereunder, upon written request by Counterparty, the Calculation Agent shall promptly (but in any event within three (3) Exchange Business Days) provide to Counterparty by e-mail to the e-mail address provided by Counterparty in such request a report (in a commonly used file format for the storage and manipulation of financial data) displaying in reasonable detail the basis for such adjustment, determination or calculation (including any assumptions used in making such adjustment, determination or calculation), it being understood that the Calculation Agent shall not be obligated to disclose any proprietary or confidential models used by it for such adjustment, determination or calculation or any information that is proprietary or confidential or subject to an obligation not to disclose such information. All calculations and determinations by the Calculation Agent shall be made in good faith and in a commercially reasonable manner.

5. Account Details.
(a)Account for payments to Counterparty15:
Bank: [____________]
ABA#: [____________]
Acct No.: [____________]
Beneficiary: [____________]
Ref: [____________]
Account for delivery of Shares to Counterparty:
To be provided.
(b)Account for payments to Dealer:
Beneficiary Bank: [____________]
ABA: [____________]
SWIFT: [____________]
Acct #: [____________]
Acct Name: [____________]16

Bank: [____________]
SWIFT: [____________]
Bank Routing: [____________]
15 Issuer/Issuer’s counsel to provide.
16 Insert for BofA.

    

13





Acct Name: [____________]
Acct No.: [____________]17

Beneficiary Bank:
A/C: [____________]
ABA: [____________]18

Account for delivery of Shares from Dealer:
To be provided.
6. Offices.
(a) The Office of Counterparty for the Transaction is: Inapplicable, Counterparty is not a Multibranch Party.
(b) The Office of Dealer for the Transaction is: [New York]19[200 West Street, New York, New York 10282-2198]20
[Bank of America, N.A.
One Bryant Park
New York, NY 10036]21
[Morgan Stanley& Co. LLC
1585 Broadway, 4th Floor
NewYork,NY10036]22
7. Notices.
(a) Address for notices or communications to Counterparty:
NeoGenomics, Inc.
12701 Commonwealth Drive, Suite 9
Fort Myers, FL 33913

Kathryn McKenzie, Chief Financial Officer
Telephone No.: 239.768.0600
Facsimile No.:
Email: kathryn.mckenzie@neogenomics.com

(b) Address for notices or communications to Dealer:
[To: Bank of America, N.A.
One Bryant Park
New York, NY 10036
Attn: Eric Coghlin, Managing Director
Telephone: 646-855-7598
Email: eric.coghlin@bofa.com

With a copy to:
Bank of America, N.A.
One Bryant Park, 5th Fl.
New York, NY 10036
Attn: Aurélien Bonnet
Email: aurelien.bonnet@bofa.com
17 Insert for MS.
18 Insert for GS.
19 Insert for BofA and MS.
20 Insert for GS.
21 Insert for BofA.
22 Insert for MS.

    

14





With a copy to: dg.esf_ny@bofa.com]23
[1585 Broadway, 4th Floor
New York, NY 10036
Attn: Usman Khan
Telephone: (212) 761-0955
Email: Usman.S.Khan@morganstanley.com

With a copy to:

Morgan Stanley & Co. LLC
1221 Avenue of the Americas, 34th Floor
New York, NY 10020
Attention: Steven Seltzer
Telephone: (212) 761-1719
Facsimile: (212) 404-9480
Email: Steven.Seltzer1@morganstanley.com]24
[To: Goldman Sachs & Co. LLC
200 West Street
New York, NY 10282-2198
Attn: Michael Voris,
Equity Capital Markets
Telephone: 212-902-4895
Facsimile: 212-291-5027
Email: michael.voris@gs.com
And email notification to the following address:
Eq-derivs-notifications@am.ibd.gs.com]25

8.      Representations and Warranties of Counterparty.
Each of the representations and warranties of Counterparty set forth in Section 1(a) of the Underwriting Agreement (the “Underwriting Agreement”) dated as of January 6, 2021, among Counterparty and BofA Securities, Inc., Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC, as representatives of the Underwriters party thereto (the “Underwriters”), are true and correct and are hereby deemed to be repeated to Dealer as if set forth herein. Counterparty hereby further represents and warrants to Dealer on the date hereof and on and as of the Premium Payment Date that:
(a)Counterparty has all necessary corporate power and authority to execute, deliver and perform its obligations in respect of the Transaction; such execution, delivery and performance have been duly authorized by all necessary corporate action on Counterparty’s part; and this Confirmation has been duly and validly executed and delivered by Counterparty and constitutes its valid and binding obligation, enforceable against Counterparty in accordance with its terms, subject to applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and similar laws affecting creditors’ rights and remedies generally, and subject, as to enforceability, to general principles of equity, including principles of commercial reasonableness, good faith and fair dealing (regardless of whether enforcement is sought in a proceeding at law or in equity) and except that rights to indemnification and contribution hereunder may be limited by federal or state securities laws or public policy relating thereto.
(b)Neither the execution and delivery of this Confirmation nor the incurrence or performance of obligations of Counterparty hereunder will conflict with or result in a breach of the certificate of incorporation or bylaws (or any equivalent documents) of Counterparty, or any applicable law or
23 Insert for BofA.
24 Insert for MS.
25 Insert for GS.

    

15





regulation, or any order, writ, injunction or decree of any court or governmental authority or agency, or any agreement or instrument to which Counterparty or any of its subsidiaries is a party or by which Counterparty or any of its subsidiaries is bound or to which Counterparty or any of its subsidiaries is subject, or constitute a default under, or result in the creation of any lien under, any such agreement or instrument.
(c)No consent, approval, authorization, or order of, or filing with, any governmental agency or body or any court is required in connection with the execution, delivery or performance by Counterparty of this Confirmation, except such as have been obtained or made and such as may be required under the Securities Act of 1933, as amended (the “Securities Act”), or state securities laws.
(d)Counterparty is not and, after consummation of the transactions contemplated hereby, will not be required to register as an “investment company” as such term is defined in the Investment Company Act of 1940, as amended.
(e)Counterparty is an “eligible contract participant” (as such term is defined in Section 1a(18) of the Commodity Exchange Act, as amended, other than a person that is an eligible contract participant under Section 1a(18)(C) of the Commodity Exchange Act).
(f)Each of it and its affiliates is not, on the date hereof, in possession of any material non-public information with respect to Counterparty or the Shares.
(g)No state or local (including any non-U.S. jurisdiction’s) law, rule, regulation or regulatory order applicable to the Shares would give rise to any reporting, consent, registration or other requirement (including without limitation a requirement to obtain prior approval from any person or entity) as a result of Dealer or its affiliates owning or holding (however defined) Shares.
(h)Counterparty (A) is capable of evaluating investment risks independently, both in general and with regard to all transactions and investment strategies involving a security or securities; (B) will exercise independent judgment in evaluating the recommendations of any broker-dealer or its associated persons, unless it has otherwise notified the broker-dealer in writing; and (C) has total assets of at least USD 50 million.
(i)Counterparty represents and warrants that neither it nor any of its subsidiaries has applied, and neither it nor any of its subsidiaries shall until after the first date on which no portion of the Transaction remains outstanding following any final exercise and settlement, cancellation or early termination of the Transaction, apply, for a loan, loan guarantee, direct loan (as that term is defined in the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”)) or other investment, or to receive any financial assistance or relief under any program or facility (collectively “Financial Assistance”) that (i) is established under applicable law (whether in existence as of the Trade Date or subsequently enacted, adopted or amended), including without limitation the CARES Act and the Federal Reserve Act, as amended, and (ii) (A) requires under applicable law (or any regulation, guidance, interpretation or other pronouncement of a governmental authority with jurisdiction for such program or facility) as a condition of such Financial Assistance, that Counterparty or any of its subsidiaries comply with any requirement not to, or otherwise agree, attest, certify or warrant that it or any of its subsidiaries has not, as of the date specified in such condition, repurchased, or will not repurchase, any equity security of Counterparty, and that neither it nor any of its subsidiaries has, as of the date specified in the condition, made a capital distribution or will make a capital distribution, or (B) where the terms of the Transaction would cause Counterparty or any of its subsidiaries under any circumstances to fail to satisfy any condition for application for or receipt or retention of the Financial Assistance (collectively “Restricted Financial Assistance”); provided that Counterparty or any of its subsidiaries may apply for Restricted Financial Assistance if Counterparty either (x) determines based on the advice of outside counsel of national standing that the terms of the Transaction would not cause Counterparty or any of its subsidiaries to fail to satisfy any condition for application for or receipt or retention of such Financial Assistance based on the terms of the program or facility as of the date of such advice or (y) delivers to Dealer evidence or other guidance from a

    

16





governmental authority with jurisdiction for such program or facility that the Transaction is permitted under such program or facility (either by specific reference to the Transaction or by general reference to transactions with the attributes of the Transaction in all relevant respects).  Counterparty further represents and warrants that the Premium is not being paid, in whole or in part, directly or indirectly, with funds received under or pursuant to any program or facility, including the U.S. Small Business Administration’s “Paycheck Protection Program”, that (a) is established under applicable law (whether in existence as of the Trade Date or subsequently enacted, adopted or amended), including without limitation the CARES Act and the Federal Reserve Act, as amended, and (b) requires under such applicable law (or any regulation, guidance, interpretation or other pronouncement of a governmental authority with jurisdiction for such program or facility) that such funds be used for specified or enumerated purposes that do not include the purchase of the Transaction (either by specific reference to the Transaction or by general reference to transactions with the attributes of the Transaction in all relevant respects).
(j)On and immediately after the Trade Date and the Premium Payment Date, (A) the value of the total assets of Counterparty is greater than the sum of the total liabilities (including contingent liabilities) and the capital (as such terms are defined under applicable Nevada law) of Counterparty, (B) the capital of Counterparty is adequate to conduct the business of Counterparty, and Counterparty’s entry into the Transaction will not impair its capital, (C) Counterparty has the ability to pay its debts and obligations as such debts mature and does not intend to, or does not believe that it will, incur debt beyond its ability to pay as such debts mature, (D) Counterparty will be able to continue as a going concern; (E) Counterparty is not “insolvent” (as such term is defined under Section 101(32) of the U.S. Bankruptcy Code (Title 11 of the United States Code) (the “Bankruptcy Code”)) and (F) Counterparty would be able to purchase the number of Shares with respect to the Transaction in compliance with the laws of the jurisdiction of Counterparty’s incorporation (including the provisions of Section 78.288 of the Nevada Revised Statutes).

9. Other Provisions.
(a)Opinions. Counterparty shall deliver to Dealer an opinion of counsel, dated as of the Trade Date, with respect to the matters set forth in Sections 8(a) through (c) of this Confirmation. Delivery of such opinion to Dealer shall be a condition precedent for the purpose of Section 2(a)(iii) of the Agreement with respect to each obligation of Dealer under Section 2(a)(i) of the Agreement.
(b)Repurchase Notices. Counterparty shall, on any day on which Counterparty effects any repurchase of Shares, promptly give Dealer a written notice of such repurchase (a “Repurchase Notice”) on such day if following such repurchase, the number of outstanding Shares as determined on such day is (i) less than [__]26 million (in the case of the first such notice) or (ii) thereafter more than [__]27 million less than the number of Shares included in the immediately preceding Repurchase Notice. Counterparty agrees to indemnify and hold harmless Dealer and its affiliates and their respective officers, directors, employees, affiliates, advisors, agents and controlling persons (each, an “Indemnified Person”) from and against any and all losses (including losses relating to Dealer’s hedging activities as a consequence of becoming, or of the risk of becoming, a Section 16 “insider”, including without limitation, any forbearance from hedging activities or cessation of hedging activities and any losses in connection therewith with respect to the Transaction), claims, damages, judgments, liabilities and expenses (including reasonable attorney’s fees), joint or several, which an Indemnified Person may become subject to, as a result of Counterparty’s failure to provide Dealer with a Repurchase Notice on the day and in the manner specified in this paragraph, and to reimburse, within 30 days, upon written request, each of such Indemnified Persons for any reasonable legal or other expenses incurred in
26 Insert the number of Shares outstanding that would cause Dealer’s current position in the Shares underlying the Transaction (including the number of Shares underlying any additional transaction if the greenshoe is exercised in full, and any Shares under pre-existing call option transactions with Counterparty) to increase by 0.5%.
27 Insert the number of Shares that, if repurchased, would cause Dealer’s current position in the Shares underlying the Transaction (including the number of Shares underlying any additional transaction if the greenshoe is exercised in full, and any Shares under pre-existing call option transactions with Counterparty) to increase by a further 0.5% from the threshold for the first Repurchase Notice.

    

17





connection with investigating, preparing for, providing testimony or other evidence in connection with or defending any of the foregoing. If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand shall be brought or asserted against the Indemnified Person as a result of Counterparty’s failure to provide Dealer with a Repurchase Notice in accordance with this paragraph, such Indemnified Person shall promptly notify Counterparty in writing, and Counterparty, upon request of the Indemnified Person, shall retain counsel reasonably satisfactory to the Indemnified Person to represent the Indemnified Person and any others Counterparty may designate in such proceeding and shall pay the fees and expenses of such counsel related to such proceeding. Counterparty shall not be liable for any settlement of any proceeding contemplated by this paragraph that is effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, Counterparty agrees to indemnify any Indemnified Person from and against any loss or liability by reason of such settlement or judgment. Counterparty shall not, without the prior written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding contemplated by this paragraph that is in respect of which any Indemnified Person is or could have been a party and indemnity could have been sought hereunder by such Indemnified Person, unless such settlement includes an unconditional release of such Indemnified Person from all liability on claims that are the subject matter of such proceeding on terms reasonably satisfactory to such Indemnified Person. If the indemnification provided for in this paragraph is unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then Counterparty hereunder, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities. The remedies provided for in this paragraph (b) are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity. The indemnity and contribution agreements contained in this paragraph shall remain operative and in full force and effect regardless of the termination of the Transaction.
(c)Regulation M. Counterparty is not on the Trade Date engaged in a distribution, as such term is used in Regulation M under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), of any securities of Counterparty, other than (i) a distribution meeting the requirements of the exception set forth in Rules 101(b)(10) and 102(b)(7) of Regulation M, (ii) the distribution of the Convertible Notes and (iii) the distribution by Counterparty of Shares concurrently with the distribution of the Convertible Notes. Counterparty shall not, until the second Scheduled Trading Day immediately following the Effective Date, engage in any such distribution.
(d)No Manipulation. Counterparty is not entering into the Transaction to create actual or apparent trading activity in the Shares (or any security convertible into or exchangeable for the Shares) or to raise or depress or otherwise manipulate the price of the Shares (or any security convertible into or exchangeable for the Shares) or otherwise in violation of the Exchange Act.
(e)Transfer or Assignment.
(i) Counterparty shall have the right to transfer or assign its rights and obligations hereunder with respect to all, but not less than all, of the Options hereunder (such Options, the “Transfer Options”); provided that such transfer or assignment shall be subject to reasonable conditions that Dealer may impose, including but not limited, to the following conditions:

(A)    With respect to any Transfer Options, Counterparty shall not be released from its notice and indemnification obligations pursuant to Section 9(b) or any obligations under Section 9(n) or 9(s) of this Confirmation;
(B) Any Transfer Options shall only be transferred or assigned to a third party that is a United States person (as defined in the Internal Revenue Code of 1986, as amended);

    

18





(C)     Such transfer or assignment shall be effected on terms, including any reasonable undertakings by such third party (including, but not limited to, an undertaking with respect to compliance with applicable securities laws in a manner that, in the reasonable judgment of Dealer, will not expose Dealer to material risks under applicable securities laws) and execution of any documentation and delivery of legal opinions with respect to securities laws and other matters by such third party and Counterparty, as are requested and reasonably satisfactory to Dealer;
(D)     Dealer will not, as a result of such transfer and assignment, be required to pay the transferee on any payment date an amount under Section 2(d)(i)(4) of the Agreement greater than an amount that Dealer would have been required to pay to Counterparty in the absence of such transfer and assignment;
(E)     An Event of Default, Potential Event of Default or Termination Event will not occur as a result of such transfer and assignment;
(F)     Without limiting the generality of clause (B), Counterparty shall cause the transferee to make such Payee Tax Representations and to provide such tax documentation as may be reasonably requested by Dealer to permit Dealer to determine that results described in clauses (D) and (E) will not occur upon or after such transfer and assignment; and
(G)     Counterparty shall be responsible for all reasonable costs and expenses, including reasonable counsel fees, incurred by Dealer in connection with such transfer or assignment.
(ii) Dealer may, without Counterparty’s consent, transfer or assign all or any part of its rights or obligations under the Transaction (A) to any affiliate of Dealer (1) that has a long-term issuer rating that is equal to or better than Dealer’s credit rating at the time of such transfer or assignment, or (2) whose obligations hereunder will be guaranteed, pursuant to the terms of a customary guarantee in a form used by Dealer generally for similar transactions, by Dealer or Dealer’s ultimate parent, or (B) to any other third party with a long-term issuer rating equal to or better than the lesser of (1) the credit rating of Dealer at the time of the transfer and (2) A- by Standard and Poor’s Rating Group, Inc. or its successor (“S&P”), or A3 by Moody’s Investor Service, Inc. (“Moody’s”) or, if either S&P or Moody’s ceases to rate such debt, at least an equivalent rating or better by a substitute rating agency mutually agreed by Counterparty and Dealer. If at any time at which (A) the Section 16 Percentage exceeds 7.5%, (B) the Option Equity Percentage exceeds 14.5%, or (C) the Share Amount exceeds the Applicable Share Limit (if any applies) (any such condition described in clauses (A), (B) or (C), an “Excess Ownership Position”), Dealer is unable after using its commercially reasonable efforts to effect a transfer or assignment of Options to a third party on pricing terms reasonably acceptable to Dealer and within a time period reasonably acceptable to Dealer such that no Excess Ownership Position exists, then Dealer may designate any Exchange Business Day as an Early Termination Date with respect to a portion of the Transaction (the “Terminated Portion”), such that following such partial termination no Excess Ownership Position exists. In the event that Dealer so designates an Early Termination Date with respect to a portion of the Transaction, a payment shall be made pursuant to Section 6 of the Agreement as if (1) an Early Termination Date had been designated in respect of a Transaction having terms identical to the Transaction and a Number of Options equal to the number of Options underlying the Terminated Portion, (2) Counterparty were the sole Affected Party with respect to such partial termination and (3) the Terminated Portion were the sole Affected Transaction (and, for the avoidance of doubt, the provisions of Section 9(l) shall apply to any amount that is payable by Dealer to Counterparty pursuant to this sentence as if Counterparty was not the Affected Party). The “Section 16 Percentage” as of any day is the fraction, expressed as a percentage, (A) the numerator

    

19





of which is the number of Shares that Dealer and any of its affiliates or any other person subject to aggregation with Dealer for purposes of the “beneficial ownership” test under Section 13 of the Exchange Act, or any “group” (within the meaning of Section 13 of the Exchange Act) of which Dealer is or may be deemed to be a part beneficially owns (within the meaning of Section 13 of the Exchange Act), without duplication, on such day (or, to the extent that for any reason the equivalent calculation under Section 16 of the Exchange Act and the rules and regulations thereunder results in a higher number, such higher number) and (B) the denominator of which is the number of Shares outstanding on such day. The “Option Equity Percentage” as of any day is the fraction, expressed as a percentage, (A) the numerator of which is the sum of (1) the product of the Number of Options and the Option Entitlement and (2) the aggregate number of Shares underlying any other call option transaction sold by Dealer to Counterparty, and (B) the denominator of which is the number of Shares outstanding. The “Share Amount” as of any day is the number of Shares that Dealer and any person whose ownership position would be aggregated with that of Dealer (Dealer or any such person, a “Dealer Person”) under any law, rule, regulation, regulatory order or organizational documents or contracts of Counterparty that are, in each case, applicable to ownership of Shares (“Applicable Restrictions”), owns, beneficially owns, constructively owns, controls, holds the power to vote or otherwise meets a relevant definition of ownership under any Applicable Restriction, as determined by Dealer in its reasonable discretion. The “Applicable Share Limit” means a number of Shares equal to (A) the minimum number of Shares that could give rise to reporting or registration obligations or other requirements (including obtaining prior approval from any person or entity) of a Dealer Person, or could result in an adverse effect on a Dealer Person, under any Applicable Restriction, as determined by Dealer in its reasonable discretion, minus (B) 1% of the number of Shares outstanding.
(iii)     Notwithstanding any other provision in this Confirmation to the contrary requiring or allowing Dealer to purchase, sell, receive or deliver any Shares or other securities, or make or receive any payment in cash, to or from Counterparty, Dealer may designate any of its affiliates to purchase, sell, receive or deliver such Shares or other securities, or to make or receive such payment in cash, and otherwise to perform Dealer’s obligations in respect of the Transaction and any such designee may assume such obligations. Dealer shall be discharged of its obligations to Counterparty to the extent of any such performance.
(f)     Staggered Settlement. If upon advice of counsel with respect to applicable legal and regulatory requirements, including any requirements relating to Dealer’s hedging activities hereunder, Dealer reasonably determines that it would not be practicable or advisable to deliver, or to acquire Shares to deliver, any or all of the Shares to be delivered by Dealer on any Settlement Date for the Transaction, Dealer may, by notice to Counterparty on or prior to any Settlement Date (a “Nominal Settlement Date”), elect to deliver the Shares on two or more dates (each, a “Staggered Settlement Date”) as follows:
(i) in such notice, Dealer will specify to Counterparty the related Staggered Settlement Dates (the first of which will be such Nominal Settlement Date and the last of which will be no later than the twentieth (20th) Exchange Business Day following such Nominal Settlement Date) and the number of Shares that it will deliver on each Staggered Settlement Date;
(ii) the aggregate number of Shares that Dealer will deliver to Counterparty hereunder on all such Staggered Settlement Dates will equal the number of Shares that Dealer would otherwise be required to deliver on such Nominal Settlement Date; and
(iii) if the Net Share Settlement terms or the Combination Settlement terms set forth above were to apply on the Nominal Settlement Date, then the Net Share Settlement terms or the Combination Settlement terms, as the case may be, will apply on each Staggered Settlement Date, except that the Shares otherwise deliverable on such

    

20





Nominal Settlement Date will be allocated among such Staggered Settlement Dates as specified by Dealer in the notice referred to in clause (i) above.
(g) Risk Disclosure Statement. Counterparty represents and warrants that it has received, read and understands the OTC Options Risk Disclosure Statement provided by Dealer and a copy of the most recent disclosure pamphlet prepared by The Options Clearing Corporation entitled “Characteristics and Risks of Standardized Options”.
(h) Conduct Rules. Each party acknowledges and agrees to be bound by the Conduct Rules of the Financial Industry Regulatory Authority, Inc. applicable to transactions in options, and further agrees not to violate the position and exercise limits set forth therein.
(i) Additional Termination Events.
(i)     Notwithstanding anything to the contrary in this Confirmation, upon any Early Conversion in respect of which a Notice of Conversion that is effective as to Counterparty has been delivered by the relevant converting Holder:
(A)    Counterparty shall, within one Scheduled Trading Day of the Conversion Date for such Early Conversion, provide written notice (an “Early Conversion Notice”) to Dealer specifying the number of Convertible Notes surrendered for conversion on such Conversion Date (such Convertible Notes, the “Affected Convertible Notes”)[(provided that any “Early Conversion Notice” delivered to Dealer pursuant to the Base Call Option Confirmation shall be deemed to be an Early Conversion Notice pursuant to this Confirmation and the terms of such Early Conversion Notice shall apply, mutatis mutandis, to this Confirmation)]28, and the giving of such Early Conversion Notice shall constitute an Additional Termination Event as provided in this clause (i);
(B)    upon receipt of any such Early Conversion Notice, Dealer shall designate an Exchange Business Day as an Early Termination Date (which Exchange Business Day shall be no earlier than one Scheduled Trading Day following the Conversion Date for such Early Conversion) with respect to the portion of the Transaction corresponding to a number of Options (the “Affected Number of Options”) equal to the lesser of (x) the number of Affected Convertible Notes [minus the “Affected Number of Options” (as defined in the Base Call Option Confirmation), if any, that relate to such Affected Convertible Notes (and for purposes of determining whether any Options under this Confirmation or under the Base Call Option Confirmation will be among the Affected Number of Options hereunder or under, and as defined in, the Base Call Option Confirmation, the Convertible Notes specified in such Early Conversion Notice shall be allocated first to the Base Call Option Confirmation until all Options thereunder are exercised or terminated)]29 and (y) the Number of Options as of the Conversion Date for such Early Conversion;
(C)    any payment hereunder with respect to such termination shall be calculated pursuant to Section 6 of the Agreement as if (x) an Early Termination Date had been designated in respect of a Transaction having terms identical to the Transaction and a Number of Options equal to the Affected Number of Options, (y) Counterparty were the
28 Include in Additional Call Option Confirmation only.
29 Include in Additional Call Option Confirmation only.

    

21





sole Affected Party with respect to such Additional Termination Event and (z) the terminated portion of the Transaction were the sole Affected Transaction; provided that the amount payable with respect to such termination shall not be greater than (1) the Applicable Percentage, multiplied by (2) the Affected Number of Options, multiplied by (3) (x) the sum of (i) the amount of cash paid (if any) to the Holder (as such term is defined in the Indenture) of an Affected Convertible Note upon conversion of such Affected Convertible Note and (ii) the number of Shares delivered (if any) to the Holder (as such term is defined in the Indenture) of an Affected Convertible Note upon conversion of such Affected Convertible Note, multiplied by the fair market value of one Share as determined by the Calculation Agent, minus (y) USD 1,000;
(D)     for the avoidance of doubt, in determining the amount payable in respect of such Affected Transaction pursuant to Section 6 of the Agreement, the Calculation Agent shall assume that (x) the relevant Early Conversion and any conversions, adjustments, agreements, payments, deliveries or acquisitions by or on behalf of Counterparty leading thereto had not occurred, (y) no adjustments to the Conversion Rate have occurred pursuant to any Excluded Provision and (z) the corresponding Convertible Notes remain outstanding; and
(E)    the Transaction shall remain in full force and effect, except that, as of the Conversion Date for such Early Conversion, the Number of Options shall be reduced by the Affected Number of Options.
(ii) Notwithstanding anything to the contrary in this Confirmation if an event of default with respect to Counterparty occurs under the terms of the Convertible Notes as set forth in Section 6.01 of the Indenture and results in the Convertible Notes becoming or being declared due and payable pursuant to the terms of the Indenture, then such acceleration shall constitute an Additional Termination Event applicable to the Transaction and, with respect to such Additional Termination Event, (A) Counterparty shall be deemed to be the sole Affected Party, (B) the Transaction shall be the sole Affected Transaction and (C) Dealer shall be the party entitled to designate an Early Termination Date pursuant to Section 6(b) of the Agreement.
(iii) Notwithstanding anything to the contrary in this Confirmation, the occurrence of an Amendment Event shall constitute an Additional Termination Event applicable to the Transaction and, with respect to such Additional Termination Event, (A) Counterparty shall be deemed to be the sole Affected Party, (B) the Transaction shall be the sole Affected Transaction and (C) Dealer shall be the party entitled to designate an Early Termination Date pursuant to Section 6(b) of the Agreement. “Amendment Event” means that Counterparty amends, modifies, supplements, waives or obtains a waiver in respect of any term of the Indenture or the Convertible Notes governing the principal amount, coupon, maturity, repurchase obligation of Counterparty, redemption right of Counterparty, any term relating to conversion of the Convertible Notes (including changes to the conversion rate, conversion rate adjustment provisions, conversion settlement dates or conversion conditions), or any term that would require consent of the holders of not less than 100% of the principal amount of the Convertible Notes to amend (other than, in each case, any amendment or supplement (x) pursuant to Section 10.01(1) of the Indenture that, as determined by the Calculation Agent, conforms the Indenture to the description of Convertible Notes in the Prospectus or (y) pursuant to Section 14.07 of the Indenture), in each case, without the consent of Dealer.
(iv) Within two Scheduled Trading Days following any Repayment Event (as defined below), Counterparty shall notify Dealer of such Repayment Event, including the number of Convertible Notes subject to such Repayment Event and the related settlement date for

    

22





such Repayment Event (any such notice, a “Repayment Notice”); provided that no such Repayment Notice shall be effective unless it contains the representation by Counterparty set forth in Section 8(f) hereunder as of the date of such Repayment Notice[; provided further that any “Repayment Notice” delivered to Dealer pursuant to the Base Call Option Confirmation shall be deemed to be a Repayment Notice pursuant to this Confirmation and the terms of such Repayment Notice shall apply, mutatis mutandis, to this Confirmation]30.  Notwithstanding anything to the contrary in this Confirmation, the receipt by Dealer from Counterparty of any Repayment Notice shall constitute an Additional Termination Event as provided in this Section 9(i)(iv).  Upon receipt of any such Repayment Notice, Dealer shall promptly designate an Exchange Business Day following receipt of such Repayment Notice (which in no event shall be earlier than the related settlement date for the relevant Repayment Event) as an Early Termination Date with respect to the portion of the Transaction corresponding to a number of Options (the “Repayment Options”) equal to the lesser of (A) the number of such Convertible Notes specified in such Repayment Notice [minus the number of Repayment Options (as defined in the Base Call Option Confirmation), if any, that relate to such Convertible Notes (and for purposes of determining whether any Options under this Confirmation or under the Base Call Option Confirmation will be among the Repayment Options hereunder or under, and as defined in, the Base Call Option Confirmation, the Convertible Notes specified in such Repayment Notice shall be allocated first to the Base Call Option Confirmation until all Options thereunder are exercised or terminated)]31 and (B) the Number of Options as of the date Dealer designates such Early Termination Date and, as of such date, the Number of Options shall be reduced by the number of Repayment Options.  Any payment hereunder with respect to such termination shall be calculated pursuant to Section 6 of the Agreement as if (1) an Early Termination Date had been designated in respect of a Transaction having terms identical to the Transaction and a Number of Options equal to the number of Repayment Options, (2) Counterparty were the sole Affected Party with respect to such Additional Termination Event and (3) the terminated portion of the Transaction were the sole Affected Transaction. “Repayment Event” means that (i) any Convertible Notes are repurchased (whether pursuant to Section 15.02 of the Indenture, pursuant to Section 16.01 of the Indenture or otherwise) by Counterparty or any of its subsidiaries (including in connection with, or as a result of, a Fundamental Change (as defined in the Indenture), a tender offer, exchange offer or similar transaction or for any other reason), (ii) any Convertible Notes are delivered to Counterparty in exchange for delivery of any property or assets of Counterparty or any of its subsidiaries (howsoever described), (iii) any principal of any of the Convertible Notes is repaid in full prior to the final maturity date of the Convertible Notes (other than upon acceleration of the Convertible Notes pursuant to Section 6.01 of the Indenture), or (iv) any Convertible Notes are exchanged by or for the benefit of the “Holders” (as such term is defined in the Indenture) thereof for any other securities of Counterparty or any of its affiliates (or any other property, or any combination thereof) pursuant to any exchange offer or similar transaction.  For the avoidance of doubt, any conversion of Convertible Notes (whether into cash, Shares, a combination of cash and Shares or any “Reference Property” (as defined in the Indenture)) pursuant to the terms of the Indenture shall not constitute a Repayment Event.  Counterparty acknowledges and agrees that if an Additional Termination Event has occurred under this Section 9(i)(iv), then any related Convertible Notes subject to a Repayment Event will be deemed to be cancelled and disregarded and no longer outstanding for all purposes hereunder.
(j) Amendments to Equity Definitions.
(i) Section 11.2(e)(vii) of the Equity Definitions is hereby amended by deleting the words “a diluting or concentrative” and replacing them with the words “in the commercially
30 Include in Additional Call Option Confirmation only.
31 Include in Additional Call Option Confirmation only.

    

23





reasonable judgment of the Calculation Agent, a material economic” and adding the phrase “or the Options” at the end of the sentence.
(ii) Section 12.6(a)(ii) of the Equity Definitions is hereby amended by (1) inserting “(1)” immediately following the word “means” in the first line thereof and (2) inserting immediately prior to the semi-colon at the end of subsection (B) thereof the following words: “or (2) the occurrence of any of the events specified in Section 5(a)(vii)(1) through (9) of the ISDA Master Agreement with respect to that Issuer”.
(iii) Section 12.9(b)(i) of the Equity Definitions is hereby amended by (1) replacing “either party may elect” with “Dealer may elect” and (2) replacing “notice to the other party” with “notice to Counterparty” in the first sentence of such section.
(iv) Section 12.9(b)(vi) of the Equity Definitions is hereby amended by (1) adding the word “or” immediately before subsection “(B)”, (2) deleting the comma at the end of subsection (A), (3) deleting subsection (C) in its entirety, (4) deleting the word “or” immediately preceding subsection (C) and (5) replacing the words “either party” in the last sentence of such Section with “Dealer”.
(k) No Setoff. Neither party shall have the right to set off any obligation that it may have to the other party under the Transaction against any obligation such other party may have to it, whether arising under the Agreement, this Confirmation or any other agreement between the parties hereto, by operation of law or otherwise.
(l) Alternative Calculations and Payment on Early Termination and on Certain Extraordinary Events. If (a) an Early Termination Date (whether as a result of an Event of Default or a Termination Event) occurs or is designated with respect to the Transaction or (b) the Transaction is cancelled or terminated upon the occurrence of an Extraordinary Event (except as a result of (i) a Nationalization, Insolvency or Merger Event in which the consideration to be paid to holders of Shares consists solely of cash, (ii) an Announcement Event, Merger Event or Tender Offer that is within Counterparty’s control, or (iii) an Event of Default in which Counterparty is the Defaulting Party or a Termination Event in which Counterparty is the Affected Party other than an Event of Default of the type described in Section 5(a)(iii), (v), (vi), (vii) or (viii) of the Agreement or a Termination Event of the type described in Section 5(b) of the Agreement, in each case that resulted from an event or events outside Counterparty’s control), and if Dealer would owe any amount to Counterparty pursuant to Section 6(d)(ii) of the Agreement or any Cancellation Amount pursuant to Article 12 of the Equity Definitions (any such amount, a “Payment Obligation”), then Dealer shall satisfy the Payment Obligation by the Share Termination Alternative (as defined below), unless (a) Counterparty gives irrevocable telephonic notice to Dealer, confirmed in writing within one Scheduled Trading Day, no later than 12:00 p.m. (New York City time) on the date of the Announcement Event, Merger Date, Tender Offer Date, Announcement Date (in the case of a Nationalization, Insolvency or Delisting), Early Termination Date or date of cancellation, as applicable, of its election that the Share Termination Alternative shall not apply, (b) Counterparty remakes the representation set forth in Section 8(f) as of the date of such election and (c) Dealer agrees, in its sole discretion, to such election, in which case the provisions of Section 12.7 or Section 12.9 of the Equity Definitions, or the provisions of Section 6(d)(ii) of the Agreement, as the case may be, shall apply.
Share Termination Alternative: If applicable, Dealer shall deliver to Counterparty the Share Termination Delivery Property on, or within a commercially reasonable period of time after, the date when the relevant Payment Obligation would otherwise be due pursuant to Section 12.7 or 12.9 of the Equity Definitions or Section 6(d)(ii) and 6(e) of the Agreement, as applicable, in satisfaction of such Payment Obligation in the manner reasonably requested by Counterparty free of payment.
Share Termination Delivery Property: A number of Share Termination Delivery Units, as calculated by the Calculation Agent, equal to the

    

24





Payment Obligation divided by the Share Termination Unit Price. The Calculation Agent shall adjust the Share Termination Delivery Property by replacing any fractional portion of a security therein with an amount of cash equal to the value of such fractional security based on the values used to calculate the Share Termination Unit Price.
Share Termination Unit Price: The value to Dealer of property contained in one Share Termination Delivery Unit, as determined by the Calculation Agent in its discretion by commercially reasonable means and notified by the Calculation Agent to Dealer at the time of notification of the Payment Obligation. For the avoidance of doubt, the parties agree that in determining the Share Termination Delivery Unit Price the Calculation Agent may consider the purchase price paid in connection with the purchase of Share Termination Delivery Property.
Share Termination Delivery Unit: One Share or, if the Shares have changed into cash or any other property or the right to receive cash or any other property as the result of a Nationalization, Insolvency or Merger Event (any such cash or other property, the “Exchange Property”), a unit consisting of the type and amount of such Exchange Property received by a holder of one Share (without consideration of any requirement to pay cash or other consideration in lieu of fractional amounts of any securities) in such Nationalization, Insolvency or Merger Event, as determined by the Calculation Agent.
Failure to Deliver: Applicable
Other applicable provisions: If Share Termination Alternative is applicable, the provisions of Sections 9.8, 9.9 and 9.11 (as modified above) of the Equity Definitions and the provisions set forth opposite the caption “Representation and Agreement” in Section 2 will be applicable, except that all references in such provisions to “Physically-settled” shall be read as references to “Share Termination Settled” and all references to “Shares” shall be read as references to “Share Termination Delivery Units”. “Share Termination Settled” in relation to the Transaction means that Share Termination Alternative is applicable to the Transaction.
(m) Waiver of Jury Trial. Each party waives, to the fullest extent permitted by applicable law, any right it may have to a trial by jury in respect of any suit, action or proceeding relating to the Transaction. Each party (i) certifies that no representative, agent or attorney of either party has represented, expressly or otherwise, that such other party would not, in the event of such a suit, action or proceeding, seek to enforce the foregoing waiver and (ii) acknowledges that it and the other party have been induced to enter into the Transaction, as applicable, by, among other things, the mutual waivers and certifications provided herein.
(n) Registration. Counterparty hereby agrees that if, in the good faith reasonable judgment of Dealer, the Shares (“Hedge Shares”) acquired by Dealer for the purpose of hedging its obligations pursuant to the Transaction cannot be sold in the public market by Dealer without registration under the Securities Act, Counterparty shall, at its election, either (i) in order to allow Dealer to sell the Hedge Shares in a registered offering, make available to Dealer an effective registration statement under the Securities Act and enter into an agreement, in form and substance satisfactory to Dealer, substantially in the form of an underwriting agreement for a registered secondary offering; provided, however, that if Dealer, in its sole reasonable discretion, is not satisfied with access to due diligence materials, the results of its due diligence

    

25





investigation, or the procedures and documentation for the registered offering referred to above, then clause (ii) or clause (iii) of this paragraph shall apply at the election of Counterparty, (ii) in order to allow Dealer to sell the Hedge Shares in a private placement, enter into a private placement agreement substantially similar to private placement purchase agreements customary for private placements of equity securities, in form and substance satisfactory to Dealer (in which case, the Calculation Agent shall make any adjustments to the terms of the Transaction that are necessary, in its reasonable judgment, to compensate Dealer for any discount from the public market price of the Shares incurred on the sale of Hedge Shares in a private placement), or (iii) purchase the Hedge Shares from Dealer at the then-current market price on such Exchange Business Days, and in the amounts and at such time(s), requested by Dealer.
(o) Tax Disclosure. Effective from the date of commencement of discussions concerning the Transaction, Counterparty and each of its employees, representatives, or other agents may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the Transaction and all materials of any kind (including opinions or other tax analyses) that are provided to Counterparty relating to such tax treatment and tax structure.
(p) Right to Extend. Dealer may postpone or add, in whole or in part, any Valid Day or Valid Days during the Settlement Averaging Period or any other date of valuation, payment or delivery by Dealer, with respect to some or all of the Options hereunder, if Dealer reasonably determines, in its reasonable discretion, that such action is reasonably necessary or appropriate to preserve Dealer’s reasonable hedging or hedge unwind activity hereunder in light of existing liquidity conditions or to enable Dealer to effect purchases of Shares in connection with its reasonable hedging, hedge unwind or settlement activity hereunder in a manner that would, if Dealer were Counterparty or an affiliated purchaser of Counterparty, be in compliance with applicable legal, regulatory or self-regulatory requirements, or with related policies and procedures applicable to Dealer.
(q) Status of Claims in Bankruptcy. Dealer acknowledges and agrees that this Confirmation is not intended to convey to Dealer rights against Counterparty with respect to the Transaction that are senior to the claims of common stockholders of Counterparty in any United States bankruptcy proceedings of Counterparty; provided that nothing herein shall limit or shall be deemed to limit Dealer’s right to pursue remedies in the event of a breach by Counterparty of its obligations and agreements with respect to the Transaction; provided, further that nothing herein shall limit or shall be deemed to limit Dealer’s rights in respect of any transactions other than the Transaction.
(r) Securities Contract; Swap Agreement. The parties hereto intend for (i) the Transaction to be a “securities contract” and a “swap agreement” as defined in the Bankruptcy Code, and the parties hereto to be entitled to the protections afforded by, among other Sections, Sections 362(b)(6), 362(b)(17), 546(e), 546(g), 555 and 560 of the Bankruptcy Code, (ii) a party’s right to liquidate the Transaction and to exercise any other remedies upon the occurrence of any Event of Default under the Agreement with respect to the other party to constitute a “contractual right” as described in the Bankruptcy Code, and (iii) each payment and delivery of cash, securities or other property hereunder to constitute a “margin payment” or “settlement payment” and a “transfer” as defined in the Bankruptcy Code.
(s) Notice of Certain Other Events. Counterparty covenants and agrees that:
(i) promptly following the public announcement of the results of any election by the holders of Shares with respect to the consideration due upon consummation of any Merger Event, Counterparty shall give Dealer written notice of the weighted average of the types and amounts of consideration received by holders of Shares upon consummation of such Merger Event (the date of such notification, the “Consideration Notification Date”); provided that in no event shall the Consideration Notification Date be later than the date on which such Merger Event is consummated; and
(ii) (A) Counterparty shall give Dealer commercially reasonable advance (but in no event less than one Exchange Business Day) written notice of the section or sections of the Indenture and, if applicable, the formula therein, pursuant to which any adjustment will be made to the Convertible Notes in connection with any Potential Adjustment Event, Merger Event or Tender Offer and (B)

    

26





promptly following any such adjustment, Counterparty shall give Dealer written notice of the details of such adjustment.
(t) Wall Street Transparency and Accountability Act. In connection with Section 739 of the Wall Street Transparency and Accountability Act of 2010 (“WSTAA”), the parties hereby agree that neither the enactment of WSTAA or any regulation under the WSTAA, nor any requirement under WSTAA or an amendment made by WSTAA, shall limit or otherwise impair either party’s otherwise applicable rights to terminate, renegotiate, modify, amend or supplement this Confirmation or the Agreement, as applicable, arising from a termination event, force majeure, illegality, increased costs, regulatory change or similar event under this Confirmation, the Equity Definitions incorporated herein, or the Agreement (including, but not limited to, rights arising from Change in Law, Hedging Disruption, Increased Cost of Hedging, an Excess Ownership Position, or Illegality (as defined in the Agreement)).
(u) Agreements and Acknowledgements Regarding Hedging. Counterparty understands, acknowledges and agrees that: (A) at any time on and prior to the Expiration Date, Dealer and its affiliates may buy or sell Shares or other securities or buy or sell options or futures contracts or enter into swaps or other derivative securities in order to adjust its hedge position with respect to the Transaction; (B) Dealer and its affiliates also may be active in the market for Shares other than in connection with hedging activities in relation to the Transaction; (C) Dealer shall make its own determination as to whether, when or in what manner any hedging or market activities in securities of Issuer shall be conducted and shall do so in a manner that it deems appropriate to hedge its price and market risk with respect to the Relevant Prices; and (D) any market activities of Dealer and its affiliates with respect to Shares may affect the market price and volatility of Shares, as well as the Relevant Prices, each in a manner that may be adverse to Counterparty.
(v) Early Unwind. In the event the sale of the [“Initial Securities”]32[“Option Securities”]33 (as defined in the Underwriting Agreement) is not consummated with the Underwriters for any reason, or Counterparty fails to deliver to Dealer opinions of counsel as required pursuant to Section 9(a), in each case by 5:00 p.m. (New York City time) on the Premium Payment Date, or such later date as agreed upon by the parties (the Premium Payment Date or such later date the “Early Unwind Date”), the Transaction shall automatically terminate (the “Early Unwind”), on the Early Unwind Date and (i) the Transaction and all of the respective rights and obligations of Dealer and Counterparty under the Transaction shall be cancelled and terminated and (ii) each party shall be released and discharged by the other party from and agrees not to make any claim against the other party with respect to any obligations or liabilities of the other party arising out of and to be performed in connection with the Transaction either prior to or after the Early Unwind Date; provided that Counterparty shall purchase from Dealer on the Early Unwind Date all Shares purchased by Dealer or one or more of its affiliates in connection with the Transaction at the then prevailing market price. Each of Dealer and Counterparty represents and acknowledges to the other that, subject to the proviso included in this Section 9(v), upon an Early Unwind, all obligations with respect to the Transaction shall be deemed fully and finally discharged.
(w) Payment by Counterparty. In the event that, following payment of the Premium, (i) an Early Termination Date occurs or is designated with respect to the Transaction as a result of a Termination Event or an Event of Default (other than an Event of Default arising under Section 5(a)(ii) or 5(a)(iv) of the Agreement) and, as a result, Counterparty owes to Dealer an amount calculated under Section 6(e) of the Agreement, or (ii) Counterparty owes to Dealer, pursuant to Section 12.7 or Section 12.9 of the Equity Definitions, an amount calculated under Section 12.8 of the Equity Definitions, such amount shall be deemed to be zero.
(x) Other Adjustments Pursuant to the Equity Definitions. Notwithstanding anything to the contrary in the Agreement, the Equity Definitions or this Confirmation, upon the occurrence of a Merger Date, the occurrence of a Tender Offer Date, or declaration by Counterparty of the terms of any Potential Adjustment Event, the Calculation Agent may, in its commercially reasonable discretion, adjust the Cap Price to preserve the fair value of the Options to Dealer (provided that in no event shall the Cap Price be less than the Strike Price). Solely for purposes of this Section 9(x) (x) the terms “Potential Adjustment Event,” “Merger Event,” and “Tender Offer” shall each have the meanings assigned to each such term in the Equity
32 Insert for Base Call Option Confirmation.
33 Insert for Additional Call Option Confirmation.

    

27





Definitions (in the case of the definition of “Potential Adjustment Event”, as amended by Section 9(j)(i), and in the case of the definition of “Tender Offer”, as if all references to “voting shares” in Sections 12.1(d), 12.1(e) and 12.1(l) of the Equity Definitions were instead references to “Shares”) and (y) “Extraordinary Dividend” means any cash dividend on the Shares.
(y) [U.S. Resolution Stay.  The parties acknowledge and agree that (i) to the extent that prior to the date hereof both parties have adhered to the 2018 ISDA U.S. Resolution Stay Protocol (the “Protocol”), the terms of the Protocol are incorporated into and form a part of the Agreement, and for such purposes the Agreement shall be deemed a Protocol Covered Agreement, Dealer shall be deemed a Regulated Entity and Counterparty shall be deemed an Adhering Party; (ii) to the extent that prior to the date hereof the parties have executed a separate agreement the effect of which is to amend the qualified financial contracts between them to conform with the requirements of the QFC Stay Rules (the “Bilateral Agreement”), the terms of the Bilateral Agreement are incorporated into and form a part of the Agreement, and for such purposes the Agreement shall be deemed a Covered Agreement, Dealer shall be deemed a Covered Entity and Counterparty shall be deemed a Counterparty Entity; or (iii) if clause (i) and clause (ii) do not apply, the terms of Section 1 and Section 2 and the related defined terms (together, the “Bilateral Terms”) of the form of bilateral template entitled “Full-Length Omnibus (for use between U.S. G-SIBs and Corporate Groups)” published by ISDA on November 2, 2018 (currently available on the 2018 ISDA U.S. Resolution Stay Protocol page at www.isda.org and, a copy of which is available upon request), the effect of which is to amend the qualified financial contracts between the parties thereto to conform with the requirements of the QFC Stay Rules, are hereby incorporated into and form a part of the Agreement, and for such purposes the Agreement shall be deemed a “Covered Agreement,” Dealer shall be deemed a “Covered Entity” and Counterparty shall be deemed a “Counterparty Entity.” In the event that, after the date of the Agreement, both parties hereto become adhering parties to the Protocol, the terms of the Protocol will replace the terms of this paragraph. In the event of any inconsistencies between the Agreement and the terms of the Protocol, the Bilateral Agreement or the Bilateral Terms (each, the “QFC Stay Terms”), as applicable, the QFC Stay Terms will govern. Terms used in this paragraph without definition shall have the meanings assigned to them under the QFC Stay Rules. For purposes of this paragraph, references to “the Agreement” include any related credit enhancements entered into between the parties or provided by one to the other. In addition, the parties agree that the terms of this paragraph shall be incorporated into any related covered affiliate credit enhancements, with all references to Dealer replaced by references to the covered affiliate support provider. “QFC Stay Rules” means the regulations codified at 12 C.F.R. 252.2, 252.81–8, 12 C.F.R. 382.1-7 and 12 C.F.R. 47.1-8, which, subject to limited exceptions, require an express recognition of the stay-and-transfer powers of the FDIC under the Federal Deposit Insurance Act and the Orderly Liquidation Authority under Title II of the Dodd Frank Wall Street Reform and Consumer Protection Act and the override of default rights related directly or indirectly to the entry of an affiliate into certain insolvency proceedings and any restrictions on the transfer of any covered affiliate credit enhancements.]34
[QFC Stay Rules. The parties agree that (i) to the extent that prior to the date hereof both parties have adhered to the 2018 ISDA U.S. Resolution Stay Protocol (the “Protocol”), the terms of the Protocol are incorporated into and form a part of this Confirmation, and for such purposes this Confirmation shall be deemed a Protocol Covered Agreement and each party shall be deemed to have the same status as Regulated Entity and/or Adhering Party as applicable to it under the Protocol; (ii) to the extent that prior to the date hereof the parties have executed a separate agreement the effect of which is to amend the qualified financial contracts between them to conform with the requirements of the QFC Stay Rules (the “Bilateral Agreement”), the terms of the Bilateral Agreement are incorporated into and form a part of this Confirmation and each party shall be deemed to have the status of “Covered Entity” or “Counterparty Entity” (or other similar term) as applicable to it under the Bilateral Agreement; or (iii) if clause (i) and clause (ii) do not apply, the terms of Section 1 and Section 2 and the related defined terms (together, the “Bilateral Terms”) of the form of bilateral template entitled “Full-Length Omnibus (for use between U.S. G-SIBs and Corporate Groups)” published by ISDA on November 2, 2018 (currently available on the 2018 ISDA U.S. Resolution Stay Protocol page at www.isda.org and a copy of which is available upon request), the effect of which is to amend the qualified financial contracts between the parties thereto to conform with the requirements of the QFC Stay Rules, are hereby incorporated into and form a part of this Confirmation, and for such purposes this Confirmation shall be deemed a “Covered Agreement,” Dealer shall be deemed a
34 Insert for BofA.

    

28





“Covered Entity” and Counterparty shall be deemed a “Counterparty Entity.” In the event that, after the date of this Confirmation, both parties hereto become adhering parties to the Protocol, the terms of the Protocol will replace the terms of this paragraph. In the event of any inconsistencies between this Confirmation and the terms of the Protocol, the Bilateral Agreement or the Bilateral Terms (each, the “QFC Stay Terms”), as applicable, the QFC Stay Terms will govern. Terms used in this paragraph without definition shall have the meanings assigned to them under the QFC Stay Rules. For purposes of this paragraph, references to “this Confirmation” include any related credit enhancements entered into between the parties or provided by one to the other. “QFC Stay Rules” means the regulations codified at 12 C.F.R. 252.2, 252.81–8, 12 C.F.R. 382.1-7 and 12 C.F.R. 47.1-8, which, subject to limited exceptions, require an express recognition of the stay-and-transfer powers of the FDIC under the Federal Deposit Insurance Act and the Orderly Liquidation Authority under Title II of the Dodd Frank Wall Street Reform and Consumer Protection Act and the override of default rights related directly or indirectly to the entry of an affiliate into certain insolvency proceedings and any restrictions on the transfer of any covered affiliate credit enhancements.]35
[U.S. Resolution Stay Provisions.
(i) Recognition of the U.S. Special Resolution Regimes.
(A) In the event that Goldman Sachs & Co. LLC (“GS&Co.”) becomes subject to a proceeding under (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder or (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder (a “U.S. Special Resolution Regime”) the transfer from GS&Co. of this Confirmation, and any interest and obligation in or under, and any property securing, this Confirmation, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Confirmation, and any interest and obligation in or under, and any property securing, this Confirmation were governed by the laws of the United States or a state of the United States.
(B) In the event that GS&Co. or an Affiliate becomes subject to a proceeding under a U.S. Special Resolution Regime, any Default Rights (as defined in 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable (“Default Right”)) under this Confirmation that may be exercised against GS&Co. are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Confirmation were governed by the laws of the United States or a state of the United States.
(ii) Limitation on Exercise of Certain Default Rights Related to an Affiliate’s Entry Into Insolvency Proceedings. Notwithstanding anything to the contrary in this Confirmation, GS&Co. and Counterparty expressly acknowledge and agree that:
(A) Counterparty shall not be permitted to exercise any Default Right with respect to this Confirmation or any Affiliate Credit Enhancement that is related, directly or indirectly, to an Affiliate of GS&Co. becoming subject to receivership, insolvency, liquidation, resolution, or similar proceeding (an “Insolvency Proceeding”), except to the extent that the exercise of such Default Right would be permitted under the provisions of 12 C.F.R. 252.84, 12 C.F.R. 47.5 or 12 C.F.R. 382.4, as applicable; and
(B) Nothing in this Confirmation shall prohibit the transfer of any Affiliate Credit Enhancement, any interest or obligation in or under such Affiliate Credit Enhancement, or any property securing such Affiliate Credit Enhancement, to a transferee upon or following an Affiliate of GS&Co. becoming subject to an Insolvency Proceeding, unless the transfer would result in the Counterparty
35 Insert for MS.

    

29





being the beneficiary of such Affiliate Credit Enhancement in violation of any law applicable to the Counterparty.
(iii) U.S. Protocol. If Counterparty has previously adhered to, or subsequently adheres to, the ISDA 2018 U.S. Resolution Stay Protocol as published by the International Swaps and Derivatives Association, Inc. as of July 31, 2018 (the “ISDA U.S. Protocol”), the terms of such protocol shall be incorporated into and form a part of this Confirmation and the terms of the ISDA U.S. Protocol shall supersede and replace the terms of this Section 9(y). For purposes of incorporating the ISDA U.S. Protocol, GS&Co. shall be deemed to be a Regulated Entity, Counterparty shall be deemed to be an Adhering Party, and this Confirmation shall be deemed to be a Protocol Covered Agreement. Capitalized terms used but not defined in this paragraph shall have the meanings given to them in the ISDA U.S. Protocol.
(iv) Preexisting In-Scope Agreements. GS&Co. and Counterparty agree that to the extent there are any outstanding “in-scope QFCs,” as defined in 12 C.F.R. § 252.82(d), that are not excluded under 12 C.F.R. § 252.88, between GS&Co. and Counterparty that do not otherwise comply with the requirements of 12 C.F.R. § 252.2, 252.81–8 (each such agreement, a “Preexisting In-Scope Agreement”), then each such Preexisting In-Scope Agreement is hereby amended to include the foregoing provisions in this Section 9(y), with references to “this Confirmation” being understood to be references to the applicable Preexisting In-Scope Agreement.
For the purposes of this Section 9(y), “Affiliate” is defined in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k), and “Credit Enhancement” means any credit enhancement or credit support arrangement in support of the obligations of GS&Co. under or with respect to this Confirmation, including any guarantee, collateral arrangement (including any pledge, charge, mortgage or other security interest in collateral or title transfer arrangement), trust or similar arrangement, letter of credit, transfer of margin or any similar arrangement.]36
(z) Counterparts. Delivery of an executed counterpart of a signature page of this Confirmation by telecopy, emailed pdf. or any other electronic means shall be effective as delivery of a manually executed counterpart of this Confirmation. The words “execution,” “signed,” “signature,” “delivery,” and words of like import in or relating to any document to be signed in connection with this Confirmation and the transactions contemplated hereby shall be deemed to include electronic signatures, deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.
36 Insert for GS.

    

30


image1a.jpg
Please confirm that the foregoing correctly sets forth the terms of our agreement by executing this Confirmation and returning it to Dealer.
Very truly yours,
[Bank of America, N.A.][Morgan Stanley & Co. LLC][Goldman Sachs & Co. LLC]
By:
Authorized Signatory
Name:

Accepted and confirmed
as of the Trade Date:
NeoGenomics, Inc.
By:
Authorized Signatory
Name:



EX-99.1 8 exhibit991pricingpressrele.htm EX-99.1 Document
Exhibit 99.1


image1e.jpg

NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes

Fort Myers, Florida (January 6, 2021) - NeoGenomics, Inc. (NASDAQ: NEO) (the Company), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced the pricing of concurrent underwritten public offerings of (a) 4,081,632 shares of its common stock at a public offering price of $49.00 per share (the “common stock offering”) for gross proceeds to NeoGenomics from the common stock offering of $200.0 million, before deducting the underwriting discounts and commissions and estimated common stock offering expenses payable by NeoGenomics and (b) $300,000,000 aggregate principal amount of its 0.25% convertible senior notes due 2028 (the “notes”) (the “notes offering”; collectively with the common stock offering, the “offerings”) for gross proceeds to NeoGenomics from the notes offering of $300.0 million, before deducting the underwriting discounts and commissions and estimated notes offering expenses payable by NeoGenomics. In addition, NeoGenomics has granted the underwriters of the offerings a 30-day option to purchase up to an additional (a) 612,244 shares of its common stock at the public offering price, less underwriting discounts and commissions, and (b) $45,000,000 aggregate principal amount of the notes, less underwriting discounts and commissions and solely to cover over-allotments with respect to the notes offering. The size of the notes offering was increased from the previously announced amount. The offerings of the shares and the notes are expected to close on or about January 11, 2021, subject to the satisfaction of customary closing conditions.
The notes will be senior, unsecured obligations of NeoGenomics, and will bear interest at a rate of 0.25% per year. Interest will be payable semi-annually and in arrears on January 15 and July 15 of each year, beginning on July 15, 2021. The notes will mature on January 15, 2028, unless earlier converted or repurchased.
The notes may be converted at an initial conversion rate of 15.1172 shares of NeoGenomics’ common stock per $1,000 principal amount of notes (which is equivalent to an initial conversion price of approximately $66.15 per share and represents a conversion premium of approximately 35.0% to the public offering price of NeoGenomics’ common stock in the common stock offering). Prior to the close of business on the business day immediately preceding September 15, 2027, the notes will be convertible at the option of the holders of the notes only in certain circumstances and during certain periods, and thereafter, the notes will be convertible at any time until the close of business on the second business day immediately preceding the maturity date, in either case into cash, shares of NeoGenomics’ common stock or a combination thereof, at NeoGenomics’ election.



NeoGenomics may redeem all or any portion of the notes, at its option, on or after January 20, 2025, at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest thereon, if the last reported sale price of NeoGenomics’ common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which NeoGenomics provides written notice of redemption.
Holders of notes may require NeoGenomics to repurchase their notes upon the occurrence of certain events that constitute a fundamental change under the indenture governing the notes at a purchase price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but excluding, the date of repurchase. In connection with certain corporate events or if NeoGenomics issues a notice of redemption, it will, under certain circumstances, increase the conversion rate for holders who elect to convert their notes in connection with such corporate event or during the relevant redemption period.
In connection with the pricing of the notes offering, NeoGenomics has entered into capped call transactions with certain of the underwriters and/or their respective affiliates (the “option counterparties”). The capped call transactions will cover, subject to anti-dilution adjustments substantially similar to those applicable to the notes, the number of shares of NeoGenomics’ common stock underlying the notes sold in the notes offering. The capped call transactions are generally expected to limit potential dilution to NeoGenomics’ common stock upon any conversion of the notes and/or offset some or all of any cash payments NeoGenomics is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap. The cap price of the capped call transactions is initially $85.75 per share, which represents a premium of 75% over the concurrent public offering price of the common stock offering, which was $49.00 per share, and is subject to certain adjustments under the terms of the capped call transactions.
In connection with establishing their initial hedges of the capped call transactions, NeoGenomics has been advised that the option counterparties or their respective affiliates are expected to enter into various derivative transactions with respect to NeoGenomics’ common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of NeoGenomics’ common stock. In addition, NeoGenomics expects that the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to NeoGenomics’ common stock and/or purchasing or selling shares of NeoGenomics’ common stock or other securities of NeoGenomics in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so during any observation period related to a conversion of the notes or following any repurchase or redemption of the notes). This activity could also cause or avoid an increase or a decrease in the market price of NeoGenomics’ common stock or the notes, which could affect the ability of holders of the notes to convert the notes and, to the extent the activity occurs during any observation period related to a conversion of the notes, it could affect the number of shares and the value of the consideration that holders of the notes will receive upon conversion of the notes.
2


Holders of the notes will have the right to require NeoGenomics to repurchase all or any portion of their notes at 100% of their principal amount, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date, upon the occurrence of certain fundamental changes.
BofA Securities, Morgan Stanley, Goldman Sachs & Co. LLC acted as representatives of the underwriters and book-running managers for the offerings. SVB Leerink is also acting as a book-running manager for the offering. Craig-Hallum Capital Group, Needham & Company, Raymond James and Stephens Inc. acted as co-managers for the offerings.
NeoGenomics intends to use the net proceeds from the offerings for general corporate purposes and to pay the cost of the capped call transactions described above. NeoGenomics may also use a portion of the net proceeds from the offerings to acquire or invest in complementary businesses and technologies, although NeoGenomics has no present commitments or agreements to enter into any material acquisitions or investments. If the initial purchasers exercise their option to purchase additional notes, NeoGenomics expects to use a portion of the net proceeds from the sale of such additional notes to enter into additional capped call transactions with the option counterparties.
The notes offering is being made pursuant to an automatic shelf registration statement (including a prospectus) filed with the Securities Exchange Commission ("SEC") on January 5, 2021, which became effective upon filing and is available on the SEC’s website at www.sec.gov. The common stock offering is being made pursuant to an automatic shelf registration statement (including a prospectus) filed with the SEC on May 20, 2019, which became effective upon filing; a preliminary prospectus supplement related to the common stock offering has been filed with the SEC and is available on the SEC's website at www.sec.gov. Alternatively, copies of the notes offering preliminary prospectus and the common stock offering preliminary prospectus supplement and the related final prospectus and prospectus supplement, when available, may be obtained from: BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attn: Prospectus Department or email: dg.prospectus_requests@bofa.com; Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York , NY 10014; or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-212-902-1171, facsimile: 212-902-9316 or by emailing prospectus-ny@ny.email.gs.com
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities, in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. The offerings are being made only by means of the prospectus for the notes offering and the prospectus supplement and the accompanying prospectus for the common stock offering.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services. NeoGenomics provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
3


Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.
Forward Looking Statements
Certain statements contained in this press release that are not historical, including but not limited to those regarding NeoGenomics' planned offerings of common stock and convertible senior notes and anticipated use of the net proceeds, constitute forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward-looking statements. No assurance can be given that the offerings will be consummated on the terms described above or at all. Consummation of the offerings and the terms thereof are subject to numerous conditions, many of which are beyond the control of the NeoGenomics, including: the prevailing conditions in the capital markets; interest rates; and economic, political and market factors affecting trading volumes, securities prices or demand for the Company's securities. As a result, this press release should be read in conjunction with the NeoGenomics' periodic filings with the SEC and the offering documents for the notes offering and the common stock offering.
For a discussion of risks and uncertainties, which could cause actual results to differ materially from those contained in the forward-looking statements, see "Risk Factors" in the NeoGenomics' Annual Report on Form 10-K, for the most recently ended fiscal year and in its subsequent Quarterly Reports on Form 10-Q, and the notes offering preliminary prospectus and common stock offering preliminary prospectus supplement each filed with the SEC on January 5, 2021.
For further information, please contact:
NeoGenomics, Inc.
Doug Brown
Chief Strategy and Corporate Development Officer
T: 239.768.0600 x2539
M: 704.236.2064
doug.brown@neogenomics.com

Charlie Eidson
Manager of Investor Relations and Manager of Strategy and Corporate Development
T: 239.768.0600 x2726
M: 952.221.8816
charlie.eidson@neogenomics.com

4
EX-101.SCH 9 neo-20210106.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 neo-20210106_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 neo-20210106_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 neo-20210106_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name Entity Address, Address Line Two Entity Address, Address Line Two City Area Code City Area Code Cover [Abstract] Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Amendment Flag Amendment Flag Entity Address, Postal Zip Code Entity Address, Postal Zip Code Trading Symbol Trading Symbol Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 13 neo-20210106_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 image1a.jpg begin 644 image1a.jpg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image1b.jpg begin 644 image1b.jpg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image1c.jpg begin 644 image1c.jpg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end GRAPHIC 17 image1d.jpg begin 644 image1d.jpg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end GRAPHIC 18 image1e.jpg begin 644 image1e.jpg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end GRAPHIC 19 image2a.jpg begin 644 image2a.jpg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end GRAPHIC 24 image3c.jpg begin 644 image3c.jpg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end GRAPHIC 25 image4a.jpg begin 644 image4a.jpg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end GRAPHIC 26 image4b.jpg begin 644 image4b.jpg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end GRAPHIC 27 image4c.jpg begin 644 image4c.jpg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end GRAPHIC 28 image5a.jpg begin 644 image5a.jpg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end GRAPHIC 29 image6a.jpg begin 644 image6a.jpg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

D,[H'N.*<.2EP,O.<(Z 63Y09 M:0 FYERT* 0ZIKD,<^3KQ96)C)0EP(>^6E[[0X-'>?'.0)GM+,<#-P7'AEH MXE%(E,=DC3R.[K]\9LIDC?O'%U9"2>ZMS!]62YEFM?U.8"YQC]-$M'(*XQ)W MQ(Q5G\!1 G,&.R6;E!Q( M8*8,) =FD ,)S!GLE&Q2[/< MC"Y9E SP".+-4GZ<0[QBRO-^\PX*XA_*$RC2<$7CI5-35QUE.64]RBL)N,HZ M!%B7+G1EVK(<;>*:V$72E;ZM91KG72])6^,>ZVMENOS=S8'4F-U\&7J6CRP? MUO(30=7\9@4KE]?XEP:)8N%#&]?K6,5(ISP.])%.M 9?6P2T?&WC.C]4+GI! MO(CXWT9>,:+E]4CGR,V.\WBD[?+9!3+.[5T#"-!Q\A>-$P20VAIEAN-_7,_C M: XD,$?S:$$*3NQ!M)-="R*LB\]GQ'!*0U/%OCG^BW>,^,8HH^O(IY0/:A#_ M4J%FB-.WD"_N? @(2H #9CCBMPD&?-%T?%]K/]PRN4' 8 .\=3KWSFO)-6F" M!'0#LNOB,5W7YJ3Q.9# ')]7G2DYD0-C["I0)Z*11%,$C0O,2!]'&C3B-X&. M%@K34ID19@4,-)O(E%'$R=T ,"CD3/G *&)$&%D-3(.%08&%$,#DG"^"))ST M:4]QJ>5@-JI=>3WGF.S( ,-TYVI? ME,Z !(1B0P.8@*[,.^:K8C]C\8FF8D8JWSS3MAXT;5R/ M,AR%9P6P!%W+$YN(26\ 'KA7S4P:5EM &;Y ICNSZ!0@M 4 =S$X!R0YO9 J6,G8SRHGU M-2HV$R"U)0828')O!HX IJ/!QD*2!2WF>P"3J:U=\HLM+36F/ : $:&,> MNSF0P.SFRUAG:0USNRXSEO#29,.$T=R3UAM&\MM3-HBI2HO%8I/SYISF>5TK MK\Q46K-1U9[K;;:/TCYS%$# NUH,'"-=K1QF7S R>0V M[]3.()K9PI6!(FD\#B0PQ^/3@E3F6 215NPBP+$:.8S,32VJ#"."3^B#0OLP MH4ORBH$N\)E[TKB#GF.69;@7X -,@T9L.D8[>EP#=#2H>XMK\A@X@-^<5WOM MJ%X&?M.^Y2Z!99WYNYL#"ND]8C''C,<:3#^/ M'NP75!)067P)HG742;N%>2J?LFH*C6[.:7442=NU@LQ49LJ6)G.4%Z9LN?@3 MU\*4C3DF0-*@,2=V7S3K(',_RLGC? XD,.?S8^Q_%GZ8=[1F%UF4*;6IQRH> MG<2F5-4$>JD<:'CA=\9C21YHX*B?JX#D4Y3B6Y:M' M>R(?1X;:+2_:XACEA-N?0.F:U-<5DRF=NEV+MD5>_[6C;EM<=Y3&5BE<"3DA M1%NB[7$LO9S*_,-^\[?EQEBW:UB>E7)M50*3K^E55UW51DR(FO#"5'ZG_$<) MT)577CEW35B6>,;8IX> Q04 H%;YBR#N78HD.D!4$7CL775AE" MJ$KO'G7PL[695=13EEW^!BC1')&.8WU-RA-EPG>U)FT!?([Q9=@80+D'\94 M-X@,!N$/R\6/"^'%%U_<\C3:Y BXDQ)0VG"LR^-HTK*66_I5!\P 11GM$'Z= MA-'Y$1KB'P-\(BQ$:XPB0"C?Z!R:E? #>3B2*X=/*=]: $+JX$L[CD!J M.Y /TVJV#1$6%IMYE6WGQZHMY4YZV@%L\H@4&01,FDS9'.,C\D1[#"@E?_GK MAPP2I::K\]!H(DR K-RM3SJFM4&(Y@Z+P7F UCW:< 8!$P# M&2?^TI&?12! O 1FW:9)_AMT:."N8/1)REEN:5<], D7L)6!O=&)S$3F&2T0 M1+@YEM,4'-C+2)!(4Q^!@U:,.$A@%Y(56W4X7P82&PB 5QT^P^98=J#31NGJ M 4/[ 4]9-%\)S#!A!39K2PG,:/\H8!H0[. 0L9CRU)UN)?U?]< DU(2WRVRT6X"Y5YBQ.IY92QB95V(E@6B4T"F':5B.^H*?@86I M9DX; =/JH#&!11WF9UW!RR&$XD'%<4IKKAHFI>N !7@TL?C/$IC,2WG-(YU? M###%>=*HIP 0D XY!S4X-TMHH3)N<]S%P:(??PMWPV2X,_AMH+"0AL:TL MBM5$JQJ8.I[0E!HQ.M\\BSDV:*2FQ0@]< T*_5)6E%.NJA) _P%.K"5P6NSI M,DEI6J9@!T+\]-MYYB[+09T&%@MP+!<+/@8\&X'%#@UV<4A@1B^O@J.% M'3N:TQHUQ=P,, 81+6 [CE(PZ[3* 3H"%V1>Z!%+:%K MF>.^507U1JU*XUS M-)*= YC:0 _PP&JO5ZN;%GD(.) #JGMWS?F[[KJK736.-BEO%##=OQ7AF#O+ M$QHSYI@& 5K<(,AT-R#@A2#RF)N:3EC]9448[/ F0*E,P"QW@W!NI=.JUIC, M6'NC,C5KH@T(3Q=H(ZT%&F96^:@CKL41^ &D#"2V&,-T"^U$: DI,[DF;3/' M&K0X5:8' !I,'FVC">-CI=1C'L\X:>8X[^@\34O#TFQ!HX )/ !MGAM4 S/. M R@^61FV\ 70^! D'[/=(E5MP1BT!EDND7^E'5B-<(T*KFB#1*2$!KT\0ET:XTM+KPBZGJ M@_"+IJ0QG9,F5JB!'V#+N7-9[DK]O6J!R9RSP%)NB!6=3),9V6M $5"@,GH3 M1G.C>*P!*#2!<[0M G! 9B2@$@Z6E)9YIOFN@2=9HPZ+#))9R$$$6#S,!I$ MO0!*6RF#8X%!@H;NHDF J=WF?L#*,4(;W#NM5Y+Y,_-;V=*[;P,=TUL;2Q,7 M?]RC>])>O*?=G<,WFA*8F;D6L0!>>>[7X+#::-4"4Z?K?,"I%UT $UB8>*4) MRK0C;!X_^)2/6("&>:L#1SHWR:$ ]I.6TWMXQ\L? 4:D?/3LLT^!F@CS)6RW'5 M/H3[#-(0-(T>D 9B/U4:K%IBK MK:/[O%^#CH$LM/ZTZF+RUY;&M,J>]7(2F+/>0]F^5= PG,6>^A"=O' M.6(U/O>;D$TSGSR!.?-=-'X#.4-P%>3&EK2\.9# 7-[]-Z_U7 RON>::!.8\ MKBS//PG,Y=EOG:T6)2-V,35F)WN6UB)OP7^L2I6CB2_SXB1Z2):!2QDT+ 1'-$ M&D=IQ(#Z+9@:B(1P^1\QG=$4=4CCFG(Y<_NM3/]%Q/@OS$N8E';Z+Q2L-&65 M$VECQP3MD%;YPM;BNL!D85?N1WD1Q!UM%HXA,%/2M+.?8= M4I^ 8;ORN:8NVX382%GX#2C@YV(- F\:4V\M)69;A'Y^T=)/S+0 .@[D^@M95B.S3(%VFU4Z"T M=$D+.9# 7,B3]CD@@;># 2T'J'8A((1B%@7UBL*G 0@;#2!@F #&)ENT$5 MJ7UQ8C,N^0BX1QN$DL"61%.)0Q2H+0@::#V7M-N!55<$X'8L4"^R:X#?I2FK M7@'5P*:]]M@!2NV/+3SDE499$4LIZ+G>QL/]"_AF,2!'9=*V\M+"")CQ #AI M: "/;4%8(>H%2%H>OPP"PS8[:PM=I5\)S $=#SB 9863T-M[A] 2*%J,$ (1 M8:-1:0G;D=@R ^"<(\"TBGU_(I"8E@-&V@N(ZRA_S6&RTFB77799JXD $W!$ M\P.#08. RP]$M!?SL00F,Y*6 VC M4L>8"K+_#B'H%7G=J!6 !V+F".&BR"#$C*4>8O\J)O6,-'K8#<01BH'(/0 I4L;V(\H%1 M^:XK@]FN/7[[ )_[MO%6G -X&M\]F4^:8]**I@0&$O?H?\RWF?DEL(-GJ_V8 MP!PB <#(1 TM$BNB!#O(;R!T#3%C:<40\$AGQ33F8L )7+02 CIFHGD;<]*U MV- J\D@'@(08:!#-*A\0Q'_Y:$'M9OY&.=KD?,P?:4VF;)B5S%OWJ2T(Z)C, M 1KM]S_*,T]$3/YXUXIKVAO\<3_.T:PQY_5?6[0O\M'X2?,YD,"B&[(1R8'Y'$A@SN='_DL.S 0'$I@ST0W9B.3 ? XD,.?S(_\E!V:" B PG,F>B&;$1R8#X'_A\4T(36Y^,!3 !)14Y$KD)@@@$! end GRAPHIC 20 image2b.jpg begin 644 image2b.jpg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image2c.jpg begin 644 image2c.jpg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end GRAPHIC 22 image3a.jpg begin 644 image3a.jpg MB5!.1PT*&@H -24A$4@ 1, B" 8 !\^#T$ +RDE$051X >W8 M"Y$42Q,%X+6 !BS@ 0EHP (.<( #%* QC 1[FC^_>.#=RBZI^S@/FKXSH MZ.ZJK'R"F MP^3[]^^7SY\_7SY\^'!Y]^[=Y>7EY9_KS9LWEX\?/UY^_?IUE22FD8G 1. 8 M C]^_+A\_?KU\NG3I\O[]^\O;]^^_:]/]:MW_:N7U^2JP^3GSY^7+U^^_.,\ M@0CRV[=O%T%'Z G0H)ER#@$#&>:( '.#^J@@%?*PH493MB&@!KB<1G2O?-]F M99N6IM8[^3#KKSTB5G5F0YUC!W_RX;=712[VUGQ=99@8%DG0+Q#D7B.CP.A- M.88 ?/VZ0P;WD&RMX#UO"!8RJ26;:_7KV?E_7(.7IG1I4J(&^:)?"Q,U2H^Y MJX\UM=)S:[\<,D R/,0GSGJ.COW1(+0_VI/GJ6'"N* B=!+CBJH])P!QB.$ MWS3B4LRFL3C_I*$G]L1E (@?L1#*-<)4K7J8.^^]<26,+1E3K57Z-+@U]&=HEM#DA"ZAVF(XFP5 MN=5:J W2+1&FGA\]QQ_<\./9!#_P'U;)#W8X94\]KL496+(7+J:?^./#WI+0 M46-W9WN"!W))C_9TK,EUB1N[APG'$N!X%%R""5DE3M<99ZT_0D)R12>]@B<_ MQ1.S,VMYWB,7V"EX'1J*:RWY].)(SBWN\M00^:K)D0[[9T0L8@IN[L\D<,J7 M/KGA4;@4O(/KF=QC*UQD$[ZQ;4@LU7Z+[_!]S0Z?[<>HM;]KF'#,X-)TBH.0 MDRY0G$/>1S5F"A/0#+@4)3$'V!3/^Y9<<_X6=WB)6:/+(6)MZR"AU^9A$-5: MY)=F78NOK??$E#C38%O/_^EZL&D'"1R3K_UK-#@W:/[!5UY;#>S!L M^3XZF[R3YTAOUS"1C "V2":9A'WM-.^C)(7)(-%8;3PML !$E$=+FCRXBPN> M:X.$/AW7&@E"S';@[,F]-TC.$'V/[WOIJ@4\,R3A6K'%%T/_;-[JP(_!I-XN M^+H3=W[6_BQ9PH4-@RK#:J2+1^+8XFO7,)'@WR89) $-.*-!HD#V 1W"/#+? M-+EXD4EL\E"'#,9>?/3D0J^2O:<;XH[(8IVMI3]_,D@2DWC%\$S2YBB_BEEP M/,N;U"Y6BLW"OV,-7S8YBO#1([.F1_!KFR]I6V35,TIP(YN+4Q2GB MF\YU@FX-XA9ZM3 !2?Q5 JQ2#[LXKV^M MY4/E%RC[\MHKNX8)XX:%0#*] -U>"'HFX;U)M/KYXJ8PAETOG@!HS_2OA6MM M;GT/N13J&A)[+:%;V\BH)O3DM29T@L^:;F\?7O$%;X1,@_7T_\8UC98<:W/A M$TEM8%GW]^;JK)[AJ_+4+M10XP&<"M[[JA$8:US4DA3M;F,02+,4[$OC+TW#8\DLC MN1^M#W]\N=2=O9!^%..MUN4@YVM+FKV)I^5K/\F/?/7RN^UN? MXT.];CGPKS),>DD)>O1/NYJ_!UZ(PB<][UNE MC4,\\1'?>=]JP@[$K[D$/S6?,?F*&?GD8Y>3U([Y%8K&%MK)0W G@M. M[&;H&$+RBIWVO/?\XG&.7CO\O%MW7;-1PH_1H+#.']Q[N?=RZ:U5+'OU2'[\ MP>NHJ!&,>CZ.VNR=N]DPD7QOF(2LDD,X":;I$:XW3(":XH5@/;('?'9&)'>> M+9<&%,]625.P+VYD8(\O[]&M$]^\Z21A%-HA:GBG3W$<$HF1;;4*GM:KL&&-#3C0\U[CCDZ:W3Z\1EA5^TO/[,G- M%=M+^F?VUNIQQG;.9C#"\A[RVS!1*,0"J"(A[9XB.2_X6GR)L&D-P12>;06+ M?J^ ]+,N#@UCS9DJ;+/I0OB> )8M.FG"GMYHC=^>;8W!IOUK29J1[9[ @@X< M8,B__$8BME&,;-A/S7O8T$G=V.DU6II>;'1'Q,V/-1=[8G+& M/4(GW+&6W'JUR9DM=W'A1_BVYR8I/F+Y*B%92ZI> 3-5D9@^ K4QAPK%3OQ&QYZ<^/9\ABS.IT#L\)<+J?F09R5_XMAS MAQ<_K<@-+A4_.GQKE%8JH<36BEB#'QL]_*S#+[Y[#5!U[,,F_F 6C#R3^*HX MI9;!E4[==R[XQXX[_36^LNVJW) [SL":C5R]0=GB-GIGW_G$1T\.?(LQ/MSY MK?&,;!Y=C[\>+X[:W'+NU3"1Z-XD@8=$2%.+44E&QWYM! 7E+^#S*_D,G^BW M2=#35"&Y?<_\5?'.5NPGGJISYEG#B#'VS]C*6;9@ ILJUF%7\F[BQ!6MYL1W,Z;4XQD9BII\:9"]W=C-(D@=_P<=9/OFV/A+Q MT%6OD?!%3_W6L!G9V.)G=/;5,%%HQ6L+(#")2A@P"9A^!=HZD.H:P*V[5V$+ M."E$NP^T) 8<%P+V0$JQZ+3^XS/^E@H6W;6[XK?QKIW9LL\FVT2<:@&#)0+1 ME7/%LJT?'7;AU,;-3\[2Z?F".6SI]>J@+G4(\"?N-@ZVV; GYK:6^)18Z(AG M5"]QT%D2]L55LT[.N[LBD%>,' F.;%AS;[+7D_$(V^Y M)O=>G=B@MR1\PJ7FNZ3?V]OBIW?.VJMA8@$P 3O)N8>, #H3["B0N?XO I6 MH\$XL=J. *[F8Y.A -?1D-IN^7=-MC.;BEG(O#D",QA\N0%GNE- M!.Z%P!PF]T)Z^ID(/#D"8%G>A.!>R$PA\F]D)Y^)@)/CL#_ *S$)1"' /?(FC $E%3D2N0F"" end GRAPHIC 23 image3b.jpg begin 644 image3b.jpg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